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 SUMMARY 
The potential health benefits of human milk oligosaccharides (HMO) have been studied for 
many years. It is well known that these oligosaccharides provide a protective barrier and 
nutritive support that infants with poor access to breast milk do not acquire in the first years of 
life. Human milk is considered to be unique among mammals in terms of the quantity and 
complexity of its oligosaccharides. To date, 130 chemical structures within HMO have been 
identified. No other natural resources provide access to these complex oligosaccharides in 
such large amounts, and until now, large scale synthesis of HMO has not been possible by any 
traditional organic chemistry methodology. Enzymatic synthesis is an alternative synthetic tool 
since enzymes can form the new glycosidic linkage between carbohydrates with high regio- 
and stereoselectivity. 
The objective of this thesis is to evaluate the use of Lacto-N-biosidase from Bifidobacterium 
bifidum (LnbB) as an efficient biocatalyst in the following two ways: i) the structural-functional 
study of LnbB and ii) protein engineering of LnbB to generate biocatalysts able to synthesize 
the target lacto-N-tetraose.  
Here, we have analysed the domain organization of GH20 enzymes, and accordingly, have 
defined two models of domain architectures. Model A, contains at least two domains, a non-
catalytic GH20b domain, and the catalytic GH20 which is always accompanied with an extra α-
helix. In contrast, Model B consists only of the catalytic GH20 domain. By expressing different 
truncated forms of LnbB, we have described the structural requirements for functionality of 
GH20 enzymes, and in particular for LnbB, to obtain a minimal functional unit that retains the 
enzymatic activity.  
With regard to the synthesis of lacto-N-tetraose using new engineered LnbB proteins as 
biocatalysts, we envisage two different enzymatic strategies. First, the glycosynthase strategy, 
in which the activated donor is the corresponding synthetic sugar oxazoline and the enzyme, a 
mutant on the assisting residue, is able to transfer the donor to an acceptor without hydrolysis 
of the product. Second, the enhanced transglycosidase strategy, in which, a new generation of 
mutants on the acceptor subsites of the enzyme will be able to more favourably accommodate 
a sugar acceptor instead of water, and thus, increase transglycosylation activity.  
  
III 
 
  
 
 SUMARI 
Els efectes beneficiosos que els oligosacàrids de la llet materna (OLM) confereixen a la salut 
dels lactants s'ha estudiat durant anys. Aquests oligosacàrids proporcionen una barrera 
protectora i un suport nutritiu essencials, als quals no tenen accés els nens que no prenen llet 
materna. La llet humana és considerada única respecte a la resta de llets de mamífers pel que 
fa a la quantitat i la complexitat d'oligosacàrids. Actualment, s'han identificat més de 130 
estructures químiques diferents de OLM, i no es disposa de cap recurs natural que proporcioni 
accés a aquestes estructures tan complexes i a bastament. De la mateixa manera, la síntesi 
química és complicada a causa de l'estructura tan complexa i diversa que presenten els OLM, i 
de moment, la síntesi en gran escala no ha estat possible. La síntesi enzimàtica, en canvi, es 
presenta com una eina alternativa de síntesi d'aquestes molècules complexes atès que, en la 
naturalesa els enzims són els responsables de formar enllaços glicosídics entre carbohidrats 
amb alta regio- i estéreo-selectivitat.  
L'objectiu d'aquesta tesi és avaluar l'ús de l'enzim Lacto-N-biosidasa de Bifidobacterium 
bifidum (LnbB) com un biocatalizador eficient des de dues perspectives diferents: i) l'estudi 
estructural-funcional de LnbB i ii) la generació de biocatalizadors capaços de sintetitzar 
l'oligosacàrid d'interès (lacto-N-tetraosa) mitjançant enginyeria de proteïnes en l'enzim LnbB.  
En aquesta tesi, hem analitzat l'organització dels dominis dels enzims de la família GH20, i, en 
conseqüència, hem definit dos models d'arquitectures. El Model A conté almenys dos dominis, 
un domini GH20b no catalític i el GH20 catalític, que sempre es presenta acompanyat d'una α-
hèlix extra. En canvi, el Model B consisteix únicament en el domini catalític GH20. Mitjançant 
l'expressió de diferents formes truncades de LnbB, hem descrit els requeriments estructurals 
per a la funcionalitat dels enzims GH20, i en particular per LnbB, per tal d’obtenir la unitat 
funcional mínima que conservi l'activitat enzimàtica.  
Respecte a la síntesi de la lacto-N-tetraosa usant com a biocatalizador noves proteïnes de LnbB 
obtingudes mitjançant enginyeria de proteïnes, hem contemplat dues estratègies 
enzimàtiques diferents. En primer lloc, l'estratègia de glicosintasa, en la qual l'enzim (amb 
mutació en el residu assistent) és capaç de transferir el corresponent donador activat (sucre 
sintètic derivat d’oxazolina) a un acceptor, sense hidròlisi del producte. En segon lloc, 
l'estratègia de transglicosilació millorada, en la qual, una nova generació de mutants en els 
llocs d'unió a l'acceptor seran capaços d'acomodar de manera més favorable un sucre en lloc 
d'una molècula d'aigua, i d'aquesta manera, augmentar l'activitat de transglicosilació.  
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 SUMARIO 
Los efectos beneficiosos que los oligosacáridos de la leche materna (OLM) confieren a la salud 
de los lactantes se han estudiado durante años. Estos oligosacáridos proporcionan una barrera 
protectora y un soporte nutritivo esenciales, a los que, los niños que no toman leche materna 
no tienen acceso. La leche humana se considerada única respecto al resto de leches de 
mamíferos en cuanto a cantidad y complejidad de oligosacáridos. Actualmente, se han 
identificado más de 130 estructuras químicas diferentes de OLM, y no se dispone de ningún 
recurso natural que proporcione acceso a estas estructuras tan complejas y en cantidad 
suficiente. Del mismo modo, la síntesis química es complicada debido a la estructura tan 
compleja y diversa que presentan los OLM, y por el momento, la síntesis en gran escala no ha 
sido posible. La síntesis enzimática, en cambio, se presenta como una herramienta alternativa 
de síntesis de éstas moléculas complejas dado que, en la naturaleza las enzimas son las 
responsables de formar enlaces glicosídicos entre carbohidratos con alta regio- y estéreo-
selectividad. 
El objetivo de esta tesis es evaluar el uso del enzima Lacto-N-biosidase de Bifidobacterium 
bifidum (LnbB) como un biocatalizador eficiente desde dos perspectivas diferentes: i) el 
estudio estructural-funcional de LnbB y ii) la generación de biocatalizadores capaces de 
sintetizar el oligosacárido de interés (lacto-N-tetraosa) mediante ingeniería de proteínas en el 
enzima LnbB. 
En esta tesis, hemos analizado la organización de los dominios de enzimas GH20, y, en 
consecuencia, hemos definido dos modelos de arquitecturas de dominio. El Modelo A contiene 
al menos dos dominios, un dominio GH20b no catalítico y el GH20 catalítico, que siempre se 
presenta acompañado de una α-hélice extra. Por el contrario, el Modelo B consiste 
únicamente en el dominio catalítico GH20. Mediante la expresión de diferentes formas 
truncadas de LnbB, hemos descrito los requerimientos estructurales para la funcionalidad de 
las enzimas GH20, y en particular para LnbB, de modo que se obtenga la unidad funcional 
mínima que conserve la actividad enzimática. 
Respecto a la síntesis de la lacto-N-tetraosa usando como biocatalizador nuevas proteínas de 
LnbB obtenidas mediante ingeniería, hemos contemplado dos estrategias enzimáticas 
diferentes. En primer lugar, la estrategia de glicosintasa, en la que el enzima (un mutante en el 
residuo asistente) es capaz de transferir el correspondiente dador activado (azúcar sintético 
derivado de oxazolina) a un aceptor, sin hidrólisis del producto. En segundo lugar, la estrategia 
de transglicosilación mejorada, en la que, una nueva generación de mutantes en los sitios de 
unión al aceptor serán capaces de acomodar de manera más favorable un aceptor de azúcar 
en lugar de una molécula de agua, y de este modo, aumentar la actividad de transglicosilación. 
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CHAPTER 1. LITERATURE REVIEW 
 
1.1 GLYCOBIOLOGY OF HUMAN MILK 
Human milk is considered the gold standard for infant nutrition. It is defined as a very complex 
mixture that apart from providing complete postnatal nutrition, delivers bioactive components 
for the growth and development of the intestinal and immune system of the infants. Its 
composition is dynamic, and varies within a feeding, diurnally, over lactation, and between 
mothers and populations, but in general terms, it is consist of essential nutrients such as; 
lactose, fatty acids and proteins, micronutrients such as; nucleotides, vitamins and minerals, 
and a wide variety of bioactive molecules, which include immunoglobulins, like IgA, 
antimicrobial agents such as lactoferrin and lysozyme, and human milk glycoconjugates 
(Garrido et al., 2013; Smilowitz et al., 2014).   
Glycans in milk can be found as free human milk oligosaccharides (HMO), or conjugated to 
peptides, proteins or lipids. One of the most striking features of breast milk is the diversity and 
abundance of complex glycans. Large quantities of mucins and glycosaminoglycans are present 
in its composition, and almost all of the milk proteins are glycosylated (Dallas et al., 2012). 
However, the major glycans in milk are lactose and HMO, representing approximately 6 and 1 
% of the total milk, respectively (Figure 1.1). In contrast to other milk components like fatty 
acids, oligosaccharides do not depend on the nutritional status of the lactating mother, they 
are controlled by genetics mechanisms (Hennet et al., 2014). Several of these glycans are not 
absorbed by the small intestine and transit through the colon, poorly contributing to infant 
nutrition. Although their impact and biological activities are not entirely understood, they play 
a role in the protection and stimulation of development of the nurslings (Newburg, 2013).  
 
Figure 1.1 Human milk composition. 
General molecular classes given in percentage of total mass. Image adapted from Hennet et al., 2014. 
1.1 HUMAN MILK OLIGOSACCHARIDES (HMO) 
Human milk oligosaccharides (HMO) are a group of unconjugated structurally complex glycans 
that are unique to human milk.  HMO are the third largest solid component of human milk, 
after lactose and lipids, and they are exclusively synthesised in the mammary glands, and only 
during lactation. Oligosaccharide composition vary between women and over lactation period 
with levels of >20 g/L in colostrum and 5-14 g/L in mature milk  (Bode, 2012; Coppa et al., 
1999; Kunz et al., 2000).  
87.2% 
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HMO are consider unique among other mammal oligosaccharides with regard to the quantity 
and the structural complexity exhibit in milk composition (Garrido et al., 2012; Kunz et al., 
2000; Urashima et al., 2012a).  
1.2.1 HISTORICAL ASPECTS OF HMO 
Interest in breast milk benefits started at the beginning of the 20th century when infant 
mortality rates were as high as 30% in the first year of the infants’ life. By this time it was 
observed that breast-fed infants had 7 times more chances of survival than formula-fed infants 
(Kunz, 2012). 
 
Research in HMO was driven by scientists with two different perspectives and interests. 
Chemists were trying to characterize the wide variety of oligosaccharides found in milk, while 
paediatricians and microbiologists were keen on the benefits that were observed in breast 
feeding (Bode, 2012).  
 
In 1886, Theodor Escherich published the relationship between intestinal bacteria and the 
physiology of digestion in infants, being considered the pioneer researcher in this area 
(Escherich, 1886; Kunz, 2012). Inspired from this fact, by 1900 Herni Tissier and Ernst Moro, 
independently found differences in the composition of gut flora of breast-fed infants 
compared to formula-fed ones (Tissier, 1900; Weirich and Hoffmann, 2005). In 1926, Herbert 
Schönfeld reported that the whey fraction of human milk contains growth-promoting factors 
for Lactobacillus bifidus, later classified as Bifidobacterium bifidum, and named it Bifidus factor 
(Schönfeld, 1926).  
 
At the same time, in 1888, Eschbach was the first who found that human and bovine milks did 
not contain the same type of lactose. Shortly after, Deniges observed that apart from lactose, 
human milk also contained an additional unknown carbohydrate fraction (reviewed in Kunz, 
2012). Forty years later, Michael Polonowski and Albert Lespagnol established a method to 
characterize this carbohydrate fraction, which was insoluble in methanol, and they called it 
Gynolactose (Polonovski and Montreuil, 1954). 
 
It was in 1950, when Paul György and Richard Kuhn established the connection between the 
Gynolactose and the Bifidus factor, and confirmed that the composition of the Bifidus factor 
was indeed oligosaccharides containing N-acetylglucosamine (Gyorgy et al., 1954).  
 
With the development of new analytical techniques, the identification and characterization of 
new structures of HMO had been achieved. Heinz Egge was one of the leading pioneers in this 
field (Egge et al., 1983). Another milestones in HMO research were done by Akira Kobata, 
elucidating the ABO (blood type system) and secretor pathway of HMO (Kobata, 2003), and 
Clemens Kunz, studying the nutritional and biological properties of HMO (Kunz et al., 2000). 
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1.2.2 STRUCTURES AND COMPOSITION OF HMO 
HMO consist of a pool of soluble oligosaccharides with a degree of polymerization of 3-15. 
They are composed of five monosaccharides: glucose (Glc), galactose (Gal), N-
acetylglucosamine (GlcNAc), fucose (Fuc) and sialic acid (Sia), with the predominant form of N-
acteylneuraminic (Neu5Ac) (Figure 1.2).  
All HMO are characterised by terminal lactose in their reducing end, which can be fucosylated 
or sialylated to render human milk trisaccharides commonly included as HMO. The 
modification with fucose can occur at the terminal Gal in α-1,2 linkage to yield 2’-
fucosyllactose, or at the reducing end of Glc in a α-1,3 linkage to generate 3’-fucosyllactose. 
The modifications with sialic acid are done at the terminal Gal in α-2,3 linkage to generate 3’-
sialyllactose or in α-2,6 linkage to form 6’-sialyllactose. In addition, lactose can be further 
elongated and branched with lacto-N-biose (LNB; Galβ1-3GlcNAc) or N-acetyllactosamine 
(LacNAc; Galβ1-4GlcNAc) in β-1,3 and β-1,6 linkages to render two of the building blocks of the 
HMO structures. These core structures are the tetrasaccharides Lacto-N-tetraose (LNT; Galβ1-
3GlcNAcβ1-3Galβ1-4Glc) core type 1, and Lacto-N-neotetraose (LNnT; Galβ1-4GlcNAcβ1-
3Galβ1-4Glc) core type 2 (Bode, 2012; Garrido et al., 2013; Kobata, 2010; Kunz et al., 2000). 
 
 
 
Figure 1.2 An example of the structural diversity of human milk oligosaccharides. 
(A) Structural composition of HMO. If n = 0, the lactose backbone is either sialylated or fucosylated to form human 
milk trisaccharides such as 2’-fucosyllactose (B). If n>0, complex HMO are formed that can be branched and also 
modified like the sialylated and fucosylated iso-lacto-N-decaose (C). Glycan structures are depicted according to the 
recommendations of the Consortium of Functional Glycomics (http://www.functionalglycomics.org). Image from 
Bode and Jantscher-Krenn, 2012. 
HMO are structurally classified into 11 more core groups that are built from core type 1 and 
type 2 (Table 1.1). These backbone structures can be further decorated with Fuc residues in α-
1,2, α-1,3 and α-1,4 linkages, or with Neu5Ac in α-2,3 or α-2,6 linkages to achieve the wide 
complexity and diversity of HMO (Urashima et al., 2013). 
The β-1,6 linkages introduce branched chains, and branched oligosaccharides are designated 
as iso-HMO. The rest of them generate linear chains, and linear ones are named as para-HMO. 
HMO can be further classified as acidic or neutral oligosaccharides, depending on the presence 
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of sialic acid or not. The carboxylate group of sialic acid is deprotonated at physiological pH 
and confers the net negative charge of the oligosaccharide in which is present (Bode, 2012; 
Garrido et al., 2013). 
 
Table 1.1 The 13 core structures that occur in HMO.  
(Table from Urashima 2013). 
 
 
 
Due to the nature of chemical structures of HMO, a single molecular weight can be assigned to 
several structural isomers. Those variations of structures can range from linkage isomers (α-1,2 
or α-1,3 or α-1,4) to variations in branching and positional isomers. The number of isomers can 
be up to 10 in some cases, with many of the isomers in relatively equal abundance (Zivkovic et 
al., 2011). An example is shown in Figure 1.3, in which Wu et al. (2011) determined a mass of 
1511.6 which corresponded to one Fuc and one NeuAc on a lacto-N-hexaose (FS-LNH) or lacto-
N-neohexaose core (FS-LNnH). This molecular weight was assigned to seven different isomers 
that were separated into different fractions using standard HPLC. The selected fractions were 
then analysed by Chip/TOF MS (Figure 1.3 a-g), and their structures were determined using 
standards (Figure 1.3 c-g) or by tandem MS and targeted exoglycosidase digestion (Figure 1.3 
a-b). 
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Figure 1.3 Isomeric structures of FS-LNH in human milk. 
First image shows the extracted ion chromatogram (EIC) with neutral mass 1511.6 (m/z 756.8 (+2), MS inset). 
Images a–b show new structures with no assigned nomenclature. Image from Wu et al., 2011. 
In terms of composition of HMO, there are important intra- and interpersonal variations, 
although oligosaccharide synthesis follows the cited general rules. In 2003, Kobata published a 
comparative study on HMO profiles of individual human milk, and revealed the presence of 
three different patterns that correspond with different blood types of those individuals. 
Different women, then, synthesise different subsets of oligosaccharides, and this fact depends 
on women’s Secretor and Lewis blood group status (Kobata, 2003). 
 
Lewis group blood types are named because of the fucose containing glycans found on the 
surfaces of erythrocytes and in glycoproteins of secreted fluids. Lewis motifs are found on the 
surfaces of cells and have been implicated in many diseases, from cancer to infection. It has 
been shown, for example, that Lewis b exhibits preferential binding to pathogens, specifically 
Helicobacter pylori. Lewis-related antigens have prognostic value for diseases as diverse as 
cancer and celiac disease. The Lewis structures are not synthesized in erythroblasts but are 
believed to be produced in the gut epithelium where they are shed into the digestive tract. 
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Then they are digested, reabsorbed, and transported as glycolipids into the plasma where they 
are, then, absorbed onto red blood cells (Zivkovic et al., 2011). 
 
The addition of fucose is dependent of at least three different fucosyltransferases in a 
genetically determined process (Bode and Jantscher-krenn, 2012; Kunz et al., 2000). Lewis and 
Secretor genes have dominant alleles (Le and Se) that codify for two fucosyltransferases, and 
recessive alleles (se and le) that are not functional. Lewis gene codifies for the 
fucosyltransferase 3 (FUT3) that adds Fuc to subterminal GlcNAc of Type 1 chains in α-1,4 
linkage, generating the Lewis a antigen in non-secretor individuals (Le a+ b) (Table 1.2). 
Secretor gene codifies for the fucosyltransferase 2 (FUT2) that connects Fuc to terminal Gal of 
previously FUT3 modified type 1 chain in α-1,2 linkage. Individuals expressing Se gene are 
classified as secretors, and generate Lewis b antigens (Le a- b+). There is a third type of Lewis 
phenotypes corresponding to people that are Lewis recessive and can be either secretors or 
non-secretors (Le a-b-). In this case, it has been found that they possess oligosaccharides 
carrying Fuc in α-1,3 linkage to the reducing end Glc or internal GlcNAc of type 2 chains. Those 
results suggest that there is a third unknown gene, independent from Se and Le genotype, 
which codifies for a α-1,3-fucosyltranferase (FUTx).  
 
Table 1.2 The Lewis and Secretor gene-related groups of HMO. 
The Le and Se epitopes, which are characteristic for the Le phenotype in red blood cells and in human milk, are 
synthesized by the listed fucosyltransferases (FUT). The Le and Se genes code for the active FUT in presence of at 
least 1 functional allele (heterozygous with Lele or Sese, homozygous with LeLe or SeSe). The prevalence of the Le 
phenotypes is conferred to Europeans. Adapted from Blank et al., 2012 and Bode and Jantscher-Krenn, 2012.  
Group Epitope 
Lewis 
phenotype, 
prevalence 
Active 
fucosyltransferase 
 
Secretor, 
Lewis positive 
Se+Le+ 
 
Le a-b+ 
72% 
FUT 3 α1-3/4 
FUT 2 α1-2   
 
Nonsecretor, 
Lewis positive 
Se-Le+ 
 
Le a+b- 
22% 
FUT 3 
α1-3/4 
Secretor, 
Lewis negative 
Se+Le- 
 Le a
-b- 
6% 
 
FUT 2  
α1-2   
 
Nonsecretor, 
Lewis negative 
Se-Le- 
  
------- 
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Based on the expression of these fucosyltransferases, 4 different HMO groups can be 
distinguished, as is observed in Table 1.2. According to fucosylation, women with a SeLe 
phenotype secrete milk with the most complex oligosaccharides, while women with sele 
phenotype secrete the least complex HMO (Blank et al., 2012; Bode and Jantscher-krenn, 
2012; Kobata, 2003; Kunz et al., 2000). 
 
In terms of sialylation, Tsuchida and coworkers reported that sialylation in α-2,6 of subterminal 
GlcNAc of oligosaccharides could be facilitated by two novel identified α-2,6-sialyltransferases, 
called ST6GalNAc V and VI (Tsuchida et al., 2003). However, little knowledge has been 
obtained for sialyltransferases that are responsible for α-2,3 sialylation . Variations in sialylated 
oligosaccharides among individuals may be due to differential expression and regulation of 
sialytransferases more than an all-or-nothing expression system (Bode, 2012; Bode and 
Jantscher-krenn, 2012). 
 
Besides HMO variation among women, there are also differences in different periods of 
lactation from the same individual. The largest amounts of HMO are observed at early stages 
and they decrease over the course of lactation (Kunz et al., 2000). Furthermore, women 
delivering preterm have much wider variation (both between women and for a given woman 
over time) in the percentage of HMOs that contain fucose or sialic acid than women who 
deliver at term (Underwood et al., 2015). 
 
1.2.2.1 The predominance of Type 1 oligosaccharides in human milk 
 
The general trend of quantitative data of HMO reveals specific patterns for human milk and 
colostrum compare to other mammals. HMO are determined in higher quantities and 
complexity, with more diversity, and with longer structures than oligosaccharides in other 
mammals.  
 
In terms of total oligosaccharide amounts, HMO concentrations arise at 12-13 g/L in mature 
milk, and 22-24 g/L in colostrum. While, for example in bovine milk, only traces of 
oligosaccharides have been detected (see Table 1.3) (Kunz et al., 2000; Ninonuevo et al., 
2006). The only exception is the amount of oligosaccharides in elephant milk, which is higher 
than in humans, and may reflect the relative importance of these components in neonatal host 
defence, in endothelial leucocyte interactions or in brain development (Kunz et al., 1999). 
 
Table 1.3 Oligosaccharides detected in human milk and cow’s milk. 
(Table adapted from Kunz 2000). 
 Human Bovine 
Protein (g/L) 8 32 
Fat (g/L) 41 37 
Lactose (g/L) 70 48 
Oligosaccharides (g/L) 5-15 0.05 
     Number of identified oligosaccharides >150 ~40 
     % fucosylated 50-80% ~1% 
     % sialylated 10-20% ~70% 
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To date, more than 200 different structures of milk oligosaccharides have been identified in a 
pooled human milk sample (Urashima et al., 2012b) containing mostly neutral and fucosylated 
glycans (Ninonuevo et al., 2006). Consensus data estimates that the proportion of fucosylated, 
sialylated, and nonfucosylated neutral HMOs in term breast milk is 35–50%, 12–14%, and 42–
55%, respectively (Smilowitz 2014). It is important to emphasize that the main quantitative 
component of HMOs includes 20 to 25 oligosaccharides, while the remaining oligosaccharides 
constitute only minimal amounts (Gabrielli et al., 2011). Furthermore, only 50 structures 
represent 99% of the abundance oligosaccharides in human milk (Smilowitz et al., 2014). 
 
Among all glycogonjugates present in human milk, type 1 chains, containing LNT structure, 
predominate over those chains containing LNnT structure. The predominance of type 1 
oligosaccharides is observed in different ethnic population and independently of Le and Se 
phenotype (Urashima et al., 2012a). 
 
Studies in other mammals revealed that their oligosaccharides differ in structure, complexity 
and quantity compared to HMO (Boehm and Stahl, 2007). On one hand, type 2 
oligosaccharides are the most predominant glycans in domestic animals, and in some cases, 
the only ones detected (Kunz et al., 1999; Urashima et al., 2001).  On the other hand, in the 
acidic fraction of animal milk oligosaccharides, two forms of sialic acid are present, N-
acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc), while only Neu5Ac is 
present in human milk. Sialyllactose is the major component detected in caw milk. And finally, 
in the neutral fraction of oligosaccharides, linkages to Fuc are very rare in oligosaccharides 
from domestic animals’ milk (Kunz et al., 2000). 
 
Besides studies in domestic animals, Urashima reported a study with new and old monkeys 
and primates, in which confirmed that the predominance of type 1 oligosaccharide is a human 
specific feature rather than a primate or hominoid feature (Urashima et al., 2012a). The 
comparison of milk oligosaccharide profiles across evolution did not exactly match the primate 
phylogeny showing a non-sequential developmental pattern (Jeong et al., 2012) 
 
The identification and structural assignment of HMO has been achieved using a variety of 
techniques. In 1996, Thurl and coworkers reported the first quantification of representative 
neutral and acidic HMO. They and other researchers used pH anion exchange chromatography 
with pulse amperometry detection system for separation of HMO (Coppa et al., 1999; Kunz et 
al., 1999; Thurl et al., 1996). Nowadays, capillary electrophoresis associated with magnetic 
resonance spectroscopy (NMR) and mass spectrometry (MS) techniques have been used for 
chemically structure determination (Kogelberg et al., 2004; Wu et al., 2011). And  the recent 
development of matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron 
resonance mass spectrometry (MALDI-FTICR MS) has allowed the accurate identification and 
quantification of HMO (Barboza et al., 2009; LoCascio et al., 2007).  
 
Despite these methodological advances, there are some variations in terms of total HMO 
quantification among published data. One reason may be the different lactation stages at 
which the samples were obtained. In addition, there may be differences between the samples 
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from different donors, some of whom may be non-secretors, as well as, variation depending 
on their ethnic origins. Moreover, these quantitative results are also affected by the 
methodological differences among the studies as is shown in Table 1.4 (Urashima et al., 
2012a). There are large differences among the values obtained by these authors. Nevertheless, 
it is clearly evidenced the predominance of type I oligosaccharides in HMO (Urashima et al., 
2012a). 
Among these complex oligosaccharides, the major secreted ones in human milk include lacto-
N-tetraose (LNT) and lacto-N-neotetraose (LNnT). Lacto-N-hexaose (LNH) is usually identified 
as one of the most abundant. In addition, fucosylated molecules such as fucosyllacto-N-
hexaoses (LNDFH I) and lacto-N-fucopentaoses I, II and III (LNFP I, II and III), which are 
fucosyllacto-N-tetraoses, are among the most abundant neutral HMO, apart from the 
trisaccharides 2’-fucosyllactose (2’FL), 3’-fucosyllactose (3’FL) (Chen, 2015; Garrido et al., 
2015).  
Finally, sialyl-lacto-N-tetraose (LSTa), 3’- sialyllactose (3’SL) and 6’-sialyllactose (6’SL) are the 
most abundant acidic HMO, although their concentrations do not arrive to 0.3 g/L  (Garrido et 
al., 2015; Kunz et al., 2000). 
 
Table 1.4 Concentrations of neutral HMO from 5 different studies.  
Thurl et al. 1996, Kunz et al. 1999, and Coppa et al. 1999, used high pH anion exchange chromatography with a 
pulse amperometry detection system for the separation of HMO without any prior derivatization. Chaturdevi et al. 
2001, determined the concentrations of neutral HMO at several lactation periods using reverse-phase HPLC 
following O-benzoyl derivatization of the HMO fraction. And, Asakuma et al., used reverse-phase HPLC after 
derivatization with 2-aminopyridine or 1-phenyl-3-methyl-5-pyrazolone. (d) means day of lactation.  
2’-FL, Fucα1-2Galβ1-4Glc; 3’-FL, Galβ1-4[Fucα1-3]Glc; LDFT, Fucα1-2Galβ1-4[Fucα1-3]Glc; LNDFH I, Fucα1-2Galβ1-
3[Fucα1-4]GlcNAcβ1-3Galβ1-4)Glc; LNDFH II, Galβ1-3[Fucα1-4GlcNAcβ1-3Galβ1-4[Fucα1-3]Glc; LNT, Galβ1-
3GlcNAcβ1-3Galβ1-4Glc; LNnT, Galβ1-4GlcNAcβ1-3Galβ1-4Glc; LNFPI, Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc; 
LNFPII, Galβ1-3[Fucα1-4]GlcNAcβ1-3Galβ1-4Glc; LNFP III, Galβ1-4[Fucα1-3)]GlcNAcβ1-3]Galβ1-4Glc; LNH, Galβ1-
3GlcNAcβ1-3[Galβ1-4GlcNAcβ1-6]Galβ1-4Glc. (Table adapted  from Urashima 2012). 
 
 
 
1.2.3 BIOSYNTHESIS OF HMO 
As has previously been described, all HMO carry a lactose molecule in the reducing end of their 
chains. Accordingly, biosynthesis of HMO is suggested to be an extension of lactose synthesis 
that occurs in the Golgi (Blank et al., 2012; Bode, 2012). Lactose synthase, a complex of β-1,4-
galactosyltransferase I (β-1,4GalT) and α-lactalbumin (α-LA), catalyses the formation of lactose 
from uridine diphosphate galactose (UDP-Gal, activated donor) and  Glc (acceptor) by 
transglycosylation (See Figure 1.4) (Castanys-Muñoz et al., 2013). 
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Figure 1.4 Biosynthesis of lactose. 
The monosaccharide Uridine-diphosphate galactose (UDP-Gal) is transferred to glucose (Glc) by the action of 
Lactose synthase activity. Image from Castanys-Muñoz et al., 2013. 
β-1,4GalT is constitutively expressed to transfer UDP-Gal to terminal GlcNAc during 
glycoconjugates synthesis, while α-LA is only expressed in the mammary gland of mammals 
under the expressions of lactation hormones. In the presence of α-LA, β-1,4GalT shifts the 
acceptor specificity from GlcNAc to Glc and allows the attachment of activated UDP-Gal to Glc 
to yield lactose. Thus, α-LA is the key to the presence of oligosaccharides in milk, and besides, 
it is also known that regulates the rate of lactose synthesis (Rudloff, 2006; Urashima et al., 
2011). 
 
The biosynthetic steps for extending lactose to form LNT and LNnT remain poorly understood. 
The hypothetical pathway is presented in figure 1.5 and suggests that this extension could be 
carried out by the action of N-acetylglucosaminyltransferases (GlcNAcT) and 
galactosyltransferases (GalT). They might occur as membrane-bound glycoproteins which act 
by sequentially addition of single activated (UDP-bound) monosaccharides (Kobata, 2003). 
  
As reported in 1.1.2, HMO fucosylation and sialylation provide further complexity to HMO 
structures. They involve the addition of fucose and sialic acid sugar via α-1,2/3/4 linkages and 
α-2,3/6 respectively. The heterogeneity of fucosylated oligosaccharides strongly depends on 
the expression of specific glycosyltransferases in correlation to the mothers’ Lewis blood group 
and secretor status, while HMO sialylation remains poorly understood.  
 
In general, the study of the biosynthesis of HMO remains incomplete due to the high variation 
of amount and composition that is observed in human milk. Furthermore, animal models have 
limited success because the huge differences in oligosaccharide complexity compared to 
humans, meaning less enzymes implicated in the synthesis. None of the cell lines studied 
synthesised HMO or lactose, even most of them do not express α-LA enzyme (Bode, 2012). 
 
 
α-LA
12 
 
CHAPTER 1. LITERATURE REVIEW 
 
 
Figure 1.5 Biosynthesis of neutral complex human milk oligosaccharides (HMO). 
The assumed biosynthetic pathway starts from the activated monosaccharides. N-acetylglucosaminyltransferases 
(GlcNAcT) attach N-acetylglucosamine (GlcNAc) in the β-1,3 position to terminal galactose (Gal), Iβ6GlcNAcT 
attaches GlcNAc in β-1,6 position to terminal Gal. Galactosyltransferases (GalT): b3GalT attaches Gal in the β-1,3 
position to GlcNAc and b4GalT attaches Gal in the β-1,4 position to GlcNAc. Fucosyltransferases (FucT): α2FucT 
attaches fucose (Fuc) in the α-1,2 position to terminal Gal, secretor (Se) enzyme,α3FucT attaches Fuc in the a1–3 
position to GlcNAc, α3/4FucT attaches Fuc in the α1–3/4 position to GlcNAc and in the α1–3 position to Glc of the 
lactose core, Lewis (Le) enzyme .The no entry signs mean that no further elongation takes place. Fucosylation is 
indicated exemplarily for terminal type 1 and type 2 chains. Glycan structures are depicted according to the 
recommendations of the Consortium of Functional Glycomics. Image from Blank et al., 2012.  
1.2.4 PHYSIOLOGICAL PROPERTIES OF HMO 
Lactose is hydrolysed to Glc and Gal by the enzymatic activity of β-1,4-galactosidase lactase (EC 
3.2.1.108) which is located in the microvilli in the brush border of the small intestinal epithelial 
cells. The released monosaccharides are then absorbed to be used as energy source by the 
infant (Urashima et al., 2012a). In contrast, milk oligosaccharides have no nutritional value for 
humans. HMO tolerate the acidic conditions of the upper gastrointestinal tract, and they do 
not suffer from hydrolysis in the intestine owing to the lack of locally-expressed glycosidases. 
They reach the distal small intestine and colon in an intact form, and they are excreted with 
infants’ feces (Engfer et al., 2000). However, at least some ingested HMO are absorbed intact 
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into the circulation and excreted in the urine. Their concentrations in these fluids correlate 
with levels of the corresponding mothers’ milk. Although relative fractions of absorbed HMO 
are low, these levels have been shown to have biological effects in cell cultures, and could 
explain some of the postulated benefits of human milk (Goehring et al., 2014).  
 
Since the very first beginning of HMO research, these oligosaccharides have been associated 
with their “bifidogenic” or prebiotic effect. However, since the last two decades, there is 
striking evidence suggesting a wide spectrum of health benefits for the neonates by these 
complex oligosaccharides. HMO are antiadhesive antimicrobials that serve as soluble decoy 
receptors, prevent pathogen attachment to infant mucosal surfaces and lower the risk for 
viral, bacterial and protozoan parasite infections. In addition, HMO may modulate epithelial 
and immune cell responses, reduce excessive mucosal leukocyte infiltration and activation, 
lower the risk for necrotizing enterocolitis, and provide the infant with sialic acid as a 
potentially essential nutrient for brain development and cognition (reviewed in Lane and 
Hickey, 2014). 
 
Figure 1.6 Overview of HMO metabolism and potential functions in human milk-fed infants. 
The numbers 1 to 4 indicate specific functions, i.e. (1) influence on the microbiota composition and/or activity, (2) 
prevention of pathogen adhesion, (3) direct effects on epithelial cells and (4) systemic effects. Image from Lane and 
Hickey, 2014. 
1.2.4.1 Prebiotic effect 
Although there are some suggestions that infants could be exposed to bacteria prior to birth 
(Perez et al., 2007) is generally accepted that, in normal conditions, the human gastrointestinal 
tract is sterile at birth (German et al., 2008). Several factors can modulate the development of 
intestinal microflora, like the type of birth, the environmental contamination, sanitary 
conditions and geographical distributions. However, the type of feeding is the main factor for 
an optimal development of gut flora (Coppa et al., 2006b). 
As has already been reported above, human milk is a mixture of interacting factors. In 
particular, the prebiotic effect has been assigned to a low concentration of proteins and 
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phosphate, the presence of lactoferrin, lactose and oligosaccharides. However, Table 1.5 
clearly shows that oligosaccharides represent the main substances to promote the prebiotic 
effect. 
 
Table 1.5 Features of milk components proposed as prebiotics. 
The analysis of the literature shows that oligosaccharides undoubtedly represent the main substances able to 
promote a bifidobacteria-dominant microflora in infants. (Adapted from Coppa et al., 2006.) 
Component In vitro effects Resistance to digestion Clinical trials Prebiotic effect 
Phosphates ? ? - No 
Proteins ± + - Minor 
Lactoferrin ? ++ ± Possible 
Nucleotides + ? ± Uncertain 
Lactose + ± - Minor 
Oligosaccharides +++ ++ +++ Documented 
 
 
The most recent definition of prebiotics describes them as “selectively fermented ingredients 
that allow specific changes, both in the composition and/or activity in the gastrointestinal 
microbiota that confers benefits upon host well-being and health”. This definition requires that 
prebiotics are resistant to gastric acidity, hydrolysis by host enzymes and gastrointestinal 
absorption (Roberfroid, 2007). Prebiotics stimulate the growth of beneficial bacteria including 
bifidobacteria, genus generally predominant in infants’ microbiota. In breast-fed infants, 
lactobacilli and bifidobacteria represent up to 90% of total gut flora, whereas in formula-fed 
infants these two genera represent 40-60% of total intestinal flora  (Coppa et al., 2006b).  
 
Since the pioneering research of Herni Tissier and Ernst Moro in 1900, who found different 
bacterial composition in breast-fed and formula-fed infants’ colon, and the research of György 
in 1954, who first showed that B. bifidum was uniquely able to grow on human milk glycan 
fractions, human milk has been thougth to have a prebiotic effect.  
 
More recently, a large gene cluster, composed of several glycosidases and specific transporters 
for HMO metabolism in the genome of B. longum subsp. infantis (Sela et al., 2008), has been 
found. In fact, Marcobal and coworkers reported that B. longum subsp. infantis can use HMO 
as a sole source of carbon, whereas other intestinal bacteria were unable to assimilate HMO 
(Marcobal et al., 2011). The localization of HMO degrading enzymes have been identified in 
some but not all bifidobacterial strains. B. infantis consumes HMO entirely over time, including 
mono- and disaccharide degradation products. B. bifidum, in comparison, grows slower on 
HMO and leaves some monosaccharide degradation products. In contrast, B. longum subsp. 
longu and B. breve hardly grow on HMO, and metabolize only LNT, but not LNnT (Asakuma et 
al., 2011). The assumption of “bifidogenic” effect of HMO, is therefore incorrect, since not all 
bifidobacteria are able to grow using HMO. 
 
In addition, a unique sugar metabolic pathway for bifidobacteria has been found. It confirms 
the ability of some species of this genus to metabolize HMO (Fushinobu, 2010; Wada et al., 
2008a). This specific pathway is called the GNB/LNB pathway and is reviewed in more detail in 
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paragraph 1.3.1. The presence of external glycosidases, fucosidases, lacto-N-biosidases and 
specific transporters for LNB explains why bacteria use HMO in different ways. It is understood 
that the bifidobacterial strains that grow well on HMO have acquired these specific genetic 
adaptations for select growth on human milk glycans (Sela et al., 2008). In addition, supporting 
the prebiotic concept of HMO, certain HMO species promoted bifidobacterial growth within in 
vitro fecal enrichment assays (Yu et al., 2013). 
With regard to acidic HMO studies, 3’-sialyllactose, as a single oligosaccharide, has been found 
to influenced the intestinal microbiota composition of mice (Fuhrer et al., 2010). 
Furthermore, the growth of beneficial bacteria produces other positive biological effects in the 
infant. The growth of lactobacilli may inhibit the growth of harmful bacteria, stimulate immune 
functions and enhance thre absorption of minerals. Bifidobacteria, produce short chain fatty 
acids (SCFA), acetate and lactate as metabolic end products, which decrease intestinal pH, and 
contribute to lowering blood cholesterol and ammonia levels, and help to absorb minerals. 
Both strains produce group B vitamins and act as immunomodulators (Gibson and Roberfroid, 
1995). In addition to the direct prebiotic effect, HMO also produced a unfavourable 
environment for the growth of pathogenic bacteria such us Shigella sp, Escherichia coli, 
Streptococcus faecalis and Clostridium sp (Bode, 2006). Moreover, the SCFA produced by 
bifidobacteria are absorbed in the large bowel providing nutrition for the neonate. Therefore, 
most of the energy contained in human milk oligosaccharides is finally available for the breast-
fed infant (Miller and McVeagh, 1999).  
Although there are is striking evidence of the overall prebiotic effect of HMO, more studies are 
needed regarding absorption, metabolism and physiological function in infants in order to 
decide which compound, and in which concentration or combination, it should be used for the 
development of a desire beneficial gut flora. 
 
1.2.4.2 Antiadhesive antimicrobials 
The adhesion of bacterial, many viral and protozoan pathogens involves a ligand-receptor 
interaction between structures on the pathogen surface and homologous structures on host’s 
mucosal surface. Most commonly, the pathogen adhesion is initiated by lectin-glycan 
interactions (Bode, 2015; Smilowitz et al., 2014; Kunz et al., 1999).  
Human-milk glycans are often part of the carbohydrate-binding determinants, suggesting that 
they are innate anti-adhesion agents that protect the breast-fed child by preventing pathogens 
from adhering to host ligands. HMO have structural homology to host cell receptors and thus 
can act as “receptor decoys” to prevent the adhesion of such pathogens from binding to the 
host cell-surface glycans (Morrow et al., 2005; Kobata, 2003).  
 
The most extended data on HMO acting as antiadhesive agents has been reported with regard 
to Campylobacter jejuni infections, which are the most common cause of bacterial diarrhoea 
and infant mortality. C. jejuni binds to type 2 H-antigen exposed in the surface of epitheal cells, 
which is 2’-fucosyllactose structure. α-1,2-fucosylated HMO inhibits C. jejuni colonization of 
mice in vivo and human intestinal mucosa ex vivo (Ruiz-Palacios et al., 2003). Indeed, this 
antiadhesive effect has been confirmed in a prospective clinical study in which C. jejuni 
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diarrhoea occurred significantly less often in infants whose mothers’ milk contain high 
amounts of 2’-fucosyllactose (Morrow et al., 2005). 
Besides, some microorganisms express glycans to bind to host’s lectins, instead of the vice 
versa process cited above. Human immunodeficiency virus (HIV) uses a glycoprotein (gp120) to 
bind to human dendritic cells (DC). A strong gp120-DC interaction is needed for HIV entry 
through mucosal barriers during HIV mother-to-child transmission via breast-feeding. HMO 
contain Lewis blood group antigens that compete with gp120 for binding to DC in vitro. Thus, a 
possible explanation for the inefficient transmission of HIV via breast-feeding (10-20% of the 
infants get infected) would be that mucosal surfaces are covered with high concentrations of 
HMO, and these might block HIV entry via DC (Bode, 2015 and 2012). 
Other examples of in vitro assays to determine the antiadhesion effect of HMO have been 
reported. The inhibition of adhesion of Escherichia coli, Vibrio cholera and Salmonella fyris to 
Caco-2 cells, when HMO were present in the culture media, was revealed (Coppa et al., 
2006a). Moreover,  a reduction of Entamoeba hystolitica attachment and cytoxicity to the 
host’s colonic mucosa in HT-29 cells was also reported (Jantscher-Krenn et al., 2012a). 
The antiadhesive effect of HMO may not only be relevant for enteric infections. Breast-fed 
infants are less likely to develop otitis media caused by Streptococcus pneumonia, 
Pseudomonas aeruginosa or Haemophilus influenza. In addition, they are also at lower risk of 
developing respiratory syncytial virus infection (RSV). These microbial pathogens employ 
lectin-glycan interactions to initiate infection, and HMO have shown to in vitro block their 
attachment. Human milk covers the mucosal surfaces in the infants’ nasopharyngeal regions 
and occasionally reaches the upper respiratory tract during episodes of aspiration allowing 
HMO to reach those areas.  (Andersson et al., 1986). Similarly, HMO are absorbed and 
excreted with the urine, and they reduce uropathogenic E. coli-induced hemagglutination, 
suggesting that HMO also reduce urinary tract infections (Martín-Sosa et al., 2002).  
In conclusion, it has been confirmed that some HMO are potential decoy receptors for 
pathogenic microorganism relevant to infections of the gastrointestinal, urogenital and 
respiratory tract and reduce the risk of infections (Lane and Hickey, 2014).  
1.2.4.3 Modulators of intestinal epithelial cell and immune responses 
Different studies have shown that HMO are absorbed intact into the circulation and excreted 
in the urine. Their concentrations in these fluids correlate with levels of the corresponding 
mothers’ milk. Although the detected levels of HMO were low, these levels have shown to be 
enough to have biological effects in vitro, and could explain some of the postulated benefits of 
human milk (Goehring et al., 2014; Martín-Sosa et al., 2002).  
It seems likely that HMO may also have systemic effects such as influencing the adhesion of 
leukocytes to endothelial cells, the interaction of platelets with neutrophils, or influencing 
systemic infectious, inflammatory and immune processes. 
Recent studies have demonstrated the effects of HMO on the glycosylation pattern of 
epithelial cells, on cell proliferation, differentiation, and apoptosis as well as on cell signalling 
pathways (Lane and Hickey, 2014). In this sense, Kuntz and coworkers have confirmed that 
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HMO induce growth inhibition in intestinal cells through two different mechanisms. Firstly, by 
suppressing cell cycle progression through induction of differentiation and/or, secondly, by 
influencing apoptosis. As the development and maturation of digestive and absorptive 
processes depend on differentiation, HMO seem to be effective at influencing various stages of 
gastrointestinal development in vitro (Kuntz et al., 2008). Subsequent studies showed the 
effects of pooled HMO on cell cycle regulation, suggesting  that oligosaccharides from human 
milk inhibited intestinal cell proliferation and altered cell cycle dynamics by affecting 
corresponding regulator genes and mitogen-activated protein kinase signalling (Kuntz et al., 
2009). In an in vitro study with human intestinal epithelial cell line, a differential expression of 
glycosylation-related genes and cell surface glycome changes with 3’-sialyllactose were 
observed. These results suggest that 3’-sialyllactose may influence cell surface glycosylation 
and thereby reduce the susceptibility of pathogenic bacteria by orally administrated HMO 
(Angeloni, 2004). This published data strongly indicates that HMO can directly interact with 
infant epithelial cells, affect gene expression and reprogram the cell cycle as well as cell 
surface glycosylation. Whether those results are translated into in vivo models or, ultimately, 
into human babies remains to be investigated (Bode, 2015 and 2012). 
With regard to immune system modulation, the involvement of intestinal epithelial cells in 
inflammatory processes of the gastrointestinal tract is widely recognized (Green-Johnson, 
2012). The secretion of proinflammatory cytokines in response to bacterial lipopolysaccharides 
or dietary components is a well-known concept in on-going intestinal inflammation and its 
progression. Therefore, it is of interest to know to what extent HMO affects the initial step of 
an inflammatory process in intestinal cells by inhibiting the secretion of proinflammatory 
cytokines (Lane and Hickey, 2014). 
The neutral HMO fraction, LNFP III and LNnT, which are two of the most abundant 
oligosaccharides in human milk, have been shown to influence peritoneal macrophages, 
capable of suppressing naive CD4+ Tcell responses. LNFP III also stimulated macrophage 
activity in vitro and increased secretion of prostaglandin E2, IL-10, and TNFα (as reviewed in 
Lane and Hickey, 2014). 
Likewise, sialylated and fucosylated HMO influenced leukocyte infiltration and activation in an 
in vitro flow model with TNFα-activated human umbilical vein endothelial cells and isolated 
human leukocytes. Moreover, a reduced platelet neutrophil complex formation and neutrophil 
activation in the presence of sialylated and fucosylated HMO was observed in an ex vivo model 
with fresh human blood (Bode et al., 2004). 
1.2.4.4 Protection against necrotizing enterocolitis 
A special mention is required for HMO protection against necrotizing enterocolitis (NEC). NEC 
is one of the most common and lethal diseases in preterm infants However, it is still poorly 
understood. NEC happens when tissue in the small or large intestine is damaged and it is 
characterised by mucosal or even deeper intestinal necrosis. More than 25% of infants with 
NEC die, and survivors are often faced with severe neurological complications. The ethology is 
unknown and the treatment is limited to surgical resection of the necrotic intestine which 
often comes with long term complications associated with short bowel syndrome. Thus, 
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prevention appears to be the primary strategy for dealing with this disease (Kosloske and 
Musemeche, 1989).   
Improper establishment of the neonatal gastrointestinal (GI) microbiota has been implicated 
as one of several contributing factors to necrotizing enterocolitis (NEC) (Hoeflinger et al., 
2015). Furthermore, the risk of developing NEC is up to 10 times less frequent in breast-fed 
infants than in formula-fed ones. The significant differences between formula milk and human 
milk led to the hypothesis that HMO can protect against NEC (Lucas and Cole, 1990). There is 
still no confirmed evidence of this hypothesis in humans due to the lack of available HMO 
required for a well-controlled design. However, studies on an established rat model of NEC 
showed that HMO indeed protect against the disease, and it seemed that a single 
oligosaccharide, diasyllactose-N-tetraose (DSLNT, Neu5Acα-2-3-Galβ-1-3-[α-Neu5Acα-2-
6]GlcNAcβ-1-3-Galβ-1-4-Glc), was responsible for NEC protection, suggesting  a highly 
structure-specific host-receptor effect (Jantscher-Krenn et al., 2012b).  
Further studies are needed to establish by which mechanism sialylated HMO protect infants 
from NEC. Needless to say, these results seem to be encouraging. 
1.2.4.5 Nutrients for brain development 
There are some indications that dietary carbohydrates may be important for normal brain 
composition. Evidence suggests that brain development and cognition in part depend on sialic 
acid-containing gangliosides and poly-sialic acid containing glycoproteins (reviewed in Wang, B. 
et al., 2009). Post-mortem analysis on human neonates showed that concentrations of 
ganglioside and proteins bound to sialic acid are significantly higher in the brains of breast-fed 
infants compared to infants fed with formula. Human milk is a rich source of sialic acid. The 
amount of sialic acid from HMO is 2 to 3 times higher than the amount from glycoproteins, and 
sialic acid in glycolipids accounts for only about 1% of the total sialic acid in human milk (Wang, 
2009). It remains to be investigated whether sialylated HMO are the primary sialic acid carrier 
that provides the developing brain with this seemingly essential nutrient and in they 
contribute to superior  developmental scores and intelligence quotients in breast-fed infants 
(Bode, 2012). 
Lactose-derived oligosaccharides, and in particular their Gal moieties, may play a role in the 
development of the infant brain. Galactocerebroside, with Gal as its polar head group, is the 
predominant glycolipid in myelin. The liver may not be capable of providing the entire Gal 
needed by young mammals during this period of myelination and brain development. Taking 
into account that oligosaccharides are not completely excreted via feces, but are to some 
extent absorbed in the digestive tract, a possible role of milk oligosaccharides is to provide 
infants with sufficient Gal levels. This hypothesis is supported by the fact that the 
oligosaccharide pattern in the milk of elephants is even more complex than that of human 
milk. Both species show similar patterns of postnatal ontogeny; they both grow slowly, have 
relatively large and highly developed central nervous systems developing mainly after birth, 
are highly intelligent, and exhibit a high degree of learned behaviour. The degree of 
encephalization is considerably higher in humans and  elephants than in nonhuman primates, 
reflecting the differences in milk oligosaccharide concentrations (Kunz et al., 2000). 
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Furthermore, with regard to neutral oligosaccharides, Vazquez and coworkers reported that a 
diet with 2’-fucosyllactose (2’-FL) increased the expression of a molecular brain function 
marker in conscious rats and enhanced memory consolidation, spatial learning and associative 
learning. Dietary 2’-FL exerts a positive effect on learning and memory in rodents while dietary 
L-fucose showed no measurable effects. Then, 2’-FL could contribute to improved cognitive 
abilities in breast-fed babies, although the mechanism of action by which this is achieved, has 
not been elucidated (Vázquez et al., 2015).  
1.2.5 PRODUCTION OF HMO 
Due to the relevant biological effects assigned to HMO, and, given that they are obviously not 
amenable to large scale production, there is an urgent need for alternative sources from which 
to obtain a diverse mixture of complex human milk-like oligosaccharides, which resemble as 
much as possible or even reproduce the variety of complex oligosaccharides in human milk. 
1.2.5.1 Recovery from natural sources 
The importance of the structure-function relationship of HMO suggests that oligosaccharides 
from (farmed) animal milk could be the first choice for an acceptable and available source for 
molecules with structures close to those of human milk oligosaccharides. Both, HMO and 
MMO (other mammals’ milk oligosaccharides) are branched structures that contain the five 
structural elements: Gal, Glc, Fuc, Sia and GlcNAc. MMO have been studied over the years, but 
no animal milk matches the high amount and high structural diversity of human milk 
oligosaccharides. Oligosaccharide concentrations in the milk of most farm animals (including 
cows, goats, sheep and pigs) are 100-1.000 times lower than in human milk, with a lower 
number of different oligosaccharides, a higher abundance of sialylated and a lower abundance 
of fucosylated oligosaccharides (Urashima et al., 2001, 2012b).  
 
Figure 1.7 The structural features of free milk oligosaccharides among mammals. 
Human milk contains large amounts of fucose and highly branched structures, with lower levels of sialic acid in 
comparison to primates and other mammals. Glycan structures are depicted according to the recommendations of 
the Consortium of Functional Glycomics (http://www.functionalglycomics.org). Blue square: GlcNAc, yellow circle: 
Gal, red triangle: Fuc, purple diamond: Neu5Ac and blue diamond: Neu5Gc. Image from Ruhaak and Lebrilla 2012. 
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Among other milks from domestic animals, goat milk is especially rich in lactose-derived 
oligosaccharides. Interestingly, it is found that goat milk oligosaccharides (GMO) are present in 
higher amounts than bovine milk oligosaccharides (BMO), and contain fucosylated species. 
Goat milk contains a large variety of acidic and galactosyllactose together with N-
acetylglucosaminyllactose as the major neutral oligosaccharides. The similarities found 
between human and goats’ milk oligosaccharides in terms of the presence of neutral 
(galactosyl-lactose and lacto-N-hexaose) and sialylated (3-, 6-sialyl-lactose and disialyl-lactose) 
structures suggest that GMO could carry out some of the physiological activities described for 
HMO (Martinez-Ferez et al., 2006).  
Until now, among farm animals, there is not one type of milk which has been found to contain 
the proportion of oligosaccharides resembling that found in human milk, both in quantity and 
composition. The development of analytical methodologies demonstrates that milk from 
farmed animals contains a much larger variety of complex oligosaccharides than previously 
thought. Therefore, farmed animal milk is a highly attractive source of bioactive 
oligosaccharides, which, once extracted, can be potentially used in medical and functional 
foods. To justify their use, additional studies on their biological functions are required. The 
advanced knowledge on their structural composition will certainly help to gain new insights 
into the complex biochemical pathways underlying their potential health promoting properties 
(Albrecht et al., 2014). 
1.2.5.2 Chemical synthesis 
The chemical synthesis of long chains of oligosaccharides remains challenging. Conventional 
chemical methods of synthesis of these compounds require many protection and deprotection 
steps due to the similar reactivity of the hydroxyl groups of monomer units as well as the 
requirements for the stereo- and regio-selective control of glycosidic bond formation. 
Accordingly, there are a lot of synthetic steps which render low productivity and, in some 
cases, result in the presence of some harmful chemicals in the final product used within the 
process (Wang and Davis, 2013). 
 
Figure 1.8 General issues in chemically glycoside synthesis. 
Image adapted from Wang and Davis, 2013. 
A small number of HMO have recently been chemically synthesized and are registered in 
different patents. See Table 1.6 for detailed information.  
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Table 1.6 Patented synthesis methods for HMO.  
 
Chemically synthesised HMO Reference 
Lacto-N-difucohexaose I (LNDFH I) WO2013185780 A1 
2'-Fucosyllactose (2'FL) WO 2010/115935 
Lacto-N-neotetraose (LnNT) WO 2011/100980  
6'-Sialyllactose (6'SL) WO 2011/100979 
2'-FL polymorphs WO 2011/150939 
 
It is noteworthy that the development in 2001 of automated solid-phase oligosaccharide 
synthesis (Plante, 2001) enables the fast and efficient production of HMO like sugars. In solid-
phase synthesis, the synthesised oligosaccharides are linked to an insoluble material (beads or 
resins) that allows the fast separation of reaction products from excess reagents, soluble 
reaction by-products, and solvents. For example, the synthesis of complex oligosaccharides, 
such as Lewisy hexasaccharide and Ley-Lex nonasaccharide (which are tumor markers that are 
currently being evaluated as cancer vaccines), took more than 1 year using conventional 
synthesis. Applying solid-phase methodology, the synthesis was accomplished in 1 day 
(Castagner and Seeberger, 2007). This methodology opens the gate to the chemical synthesis 
of some complex HMO. However, achieved yields by solid-phase synthesis are in the mg scale, 
very far from industrial purposes. 
More recently, in 2014, a one-pot procedure to synthesise LNFP I and its α-1,2-fucosylated 
LNnT analog in high yields was reported. A galactose thioglycoside was coupled 
chemoselectively to a phthalimide-protected glucosamine thioglycoside. The resulting 
disaccharide was then coupled to the 3-position in lactose. However, it was not possible to 
extend the one-pot process to the synthesis of the corresponding 3-linked structures (Arboe 
Jennum et al., 2014). 
In conclusion, chemical synthesis has reported the production of 15 different HMOS and 
derivatives with 3–11 monosaccharide units (Chen, 2015). However, synthesised HMO 
according to methods mentioned above, may still be contaminated with small residues, 
organic or protic solvents used in the procedure. In order to use the HMO in nutritional and 
therapeutic formulations for mammals (especially for humans but particularly for infants), it 
would be necessary to substantially reduce such residual contaminants (Andreas et al., 2013). 
1.2.5.3 Enzymatic synthesis 
Enzymatic synthesis is an alternative strategy that overcomes synthetic limitations since 
enzymes offer a perfect control of stereo- and regio-selectivity and usually high efficiency in 
transformations for glycan assembly in aqueous solution without the need for protecting 
groups (Faijes and Planas, 2007; Moracci et al., 2001; Wang and Davis, 2013).  
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Figure 1.9 General issues in enzymatic glycoside synthesis. 
UDP-Gal as donor for glycosyltransferase synthesis, and OR-Gal for glycosidase synthesis. Enzymatic synthesis of 
carbohydrates offers high regio and stereoselectivity. Image adapted from Wang and Davis, 2013. 
Furthermore, the application of enzymes enables the utilization of side-products from the food 
industry which would provide a double benefit. It generates a product and, at the same time, 
avoids the disposal of biomass. The use of the enzymes in the production process would 
ensure that no harsh chemicals are produced and this would ensure safer products for infants. 
In nature, condensation reaction can be provided by two types of enzymes: 
glycosyltransferases and glycosidases. Glycosyltransferase enzymes are responsible for 
glycoside bond formation in nature, catalysing the transfer of a monosaccharide from a sugar 
nucleotide donor (in Leloir type) to an acceptor. However, the use of glycosyltransferases for 
production purposes is still limited since the enzymes are difficult to solubilize and express and 
also the nucleotide donor is expensive. In contrast, glycosidase enzymes are normally 
hydrolytic enzymes. However, they can also perform reversal reaction, leading to glycosidic 
bond formation in specific conditions. Oligosaccharide synthesis may be achieved either by 
displacing the equilibrium towards glycosidic bond formation (thermodynamically controlled 
synthesis) or by using activated glycosyl donors (kinetically controlled transglycosylation). In 
any case, these methodologies only achieve yields of up to 40-50%  (Faijes and Planas, 2007; 
Moracci et al., 2001; Wang and Davis, 2013; Wang and Huang, 2009). 
Regarding enzymatic synthesis, several HMO have been obtained and is explained as follows. 
LNB 
LNB production from sucrose and GlcNAc was developed via one-pot enzymatic reaction on an 
industrial scale and cost-effective process. Four kinds of enzymes, including sucrose 
phosphorylase (SP) from Bifidobacterium longum, UDP-glucose-hexose-1-phosphate 
uridylyltransferase (GalT), UDP-glucose-4-epimerase (GalE), and lacto-N-biose phosphorylase 
(LNBP) from B. bifidum were applied to the LNB production to yield kilograms of LNB with an 
approximate 83% reaction yield. The overall reaction is described in Figure 1.10.  
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Figure 1.10 Reaction scheme for LNB production.  
SP: Sucrose phosphorylase from Bifidobacterium longum, GalT: UDP-glucose-hexose-1-phosphate 
uridylyltransferase, GalE: UDP-glucose-4-epimerase, LNBP: lacto-N-biose phosphorylase, Suc: sucrose, Glc1P: α-
glucose 1-phosphate, Fru: fructose, LNB: Lacto-N-biose. Image from Nishimoto and Kitaoka, 2007. 
 
Sucrose is phosphorolysed into α-glucose 1-phosphate (Glc1P) and fructose by SP. Glc1P is 
converted into UDP-Glc concomitantly with the conversion of UDP-Gal into Gal1P by GalT. 
UDP-Glc is converted into UDP-Gal by GalE, and the resulting UDP-Gal is consumed in the 
reaction of GalT. Finally, LNB is synthesized from Gal1P and GlcNAc by LNBP. Phosphate and 
UDP-Glc are recycled during the reaction system (Nishimoto and Kitaoka, 2007).  
In the same way, GNB was easily produced using a one-pot enzymatic reaction, but in this 
case, the starting material was sucrose and GalNAc (Nishimoto and Kitaoka, 2009).  
As an alternative process, LNB was synthesized from p-NP-β-Gal and GlcNAc by a β-
galactosidase from Bacillus circulans, β-Gal-3. The transglycosylation was achieved in mg scale 
in the presence of 1-butyl-3-methylimidazolium hexafluorophosphate ([Bmim][PF6]), an ionic 
solvent with a 90% of yield (Bayón et al., 2013). This methodology was used in this project for 
the production of LNB, and it is further explained in chapter 2.  
LNT 
The enzymatic synthesis of lacto-N-tetraose (type 1) was first described by Murata et al., 1999 
(Figure 1.11). It consisted of consecutive additions of N-acetylglucosamine and galactose to 
lactose. Firstly, the β-1,3-N-acetylglucosaminyltransferase from bovine serum transferred N-
acetylglucosamine from UDP-GlcNAc to lactose to obtain the trisaccharide lacto-N-triose. In 
the next step, the β-galactosidase from B. circulans ATCC31382 transglycosylated o-
nitrophenyl galactoside to the trisaccharide to achieve the lacto-N-tetraose derivative 
(regiosomer β-1,3) and the regiosomer β-1,6 with an overall yield of 19% (Murata et al., 1999). 
In addition, Murata and coworkers assayed the transglycosylation reaction with partially 
purified lacto-N-biosidase from Aureobacterium sp. strain L-101. This enzyme was able to 
condense p-nitrophenyl-lacto-N-biose as the donor and lactose as the acceptor yielding the 
lacto-N-tetraose with a 3.7% yield. Some years later, Wada and coworkers demonstrated that 
LnbB from Bifidobacterium bifidum was also capable of preforming the same 
transglycosylation reaction. The catalytic efficacy was also very low, <4% of yield. However, 
these results suggest that LnbB is a good candidate for enzymatic synthesis of LNT (Murata et 
al., 1999; Wada et al., 2008a).  
Suc Glc1P UDP-Glc UDP-Gal Gal1P LNB
SP GalT GalE GalT LNBP
(UMP unit)
Fru
Pi
GlcNAc
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Figure 1.11 Enzymatic conversion of lactose into LNT and LNnT. 
Image adapted from Murata et al., 1999. 
LNT-II and LNnT 
Recently, Lacto-N-triose II (LNT-II) and Lacto-N-neotetraose (LNnT) were successfully 
synthesised in large quantities using sequential “onepot” multienzyme (OPME) systems (Figure 
1.12). In these systems, free monosaccharides were added one by one to each of the “one-
pot” systems containing multiple enzymes responsible for catalyzing monosaccharide 
activation, followed by transfer processes. The overall yields of both HMO were 95% (1.36 g) 
for LNT-II, and 92% (1.16 g) for LNnT (Yu et al., 2014).  
LNT-II and LNnT were synthesized from the inexpensive disaccharide lactose and the 
monosaccharide GlcNAc by using a one-pot four-enzyme GlcNAc activation and transfer 
system containing Bifidobacterium longum N-acetylhexosamine-1-kinase (NahK), Pasteurella 
multocida N-acetylglucosamine uridyltransferase (PmGlmU), Pasteurella multocida inorganic 
pyrophosphatase (PmPpA), and Neisseria meningitidis β-1,3-N-acetylglucosaminyltransferase 
(NmLgtA) (Figure 1.12).  
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Figure 1.12 Sequential one-pot multienzyme (OPME) synthesis of Lacto-N-triose (LNT-II) and  lacto-N-neotetraose 
(LNnT).  
Image from Yu et al., 2014. 
Sialylated HMO 
For the enzymatic synthesis of sialyllactose, sequential enzymatic reactions and a nucleotides 
recycle system were performed with substrates in a one-pot reaction (Figure 1.13). The 
process started with the production of NeuAc from GlcNAc, GlcNAc 2-epimerase and Neu5Ac 
aldolase. GlcNAc 2-epimerase converts GlcNAc to N-acetyl-D-mannosamine (ManNAc), which 
then reacts with pyruvate to form Neu5Ac through the enzymatic action of Neu5Ac aldolase. 
To date, mammalian GlcNAc 2- epimerase and mammalian and E. coli Neu5Ac aldolases have 
been used to produce Neu5Ac (Li et al., 2008).   
 
 
Figure 1.13 Scheme for the coupled enzymatic synthesis of sialyllactose. 
Substrate molecules are in the box. The oval frame represents the intermediate molecules to be recycled. 
Discontinuing arrows represent the alternative cytidine triphosphate (CTP) recycle pathway. PPK, polyphosphate 
kinase; PolyPn, polyphosphate. Image from Han et al., 2012. 
26 
 
CHAPTER 1. LITERATURE REVIEW 
Then NeuAc was converted to CMP-NeuAc via the cytidine triphosphate (CTP) regeneration 
system using acetate kinase, cytidine monophosphate (CMP) kinase, and polyphosphate kinase 
enzymes. CTP was synthesized from an inexpensive substrate CMP in a high yield of more than 
97% via cytidine diphosphate (CDP) by CMP-kinase and acetate kinase (Woo et al., 2014).  
A fusion protein of NmCSS and Neisseria meningitides α-2,3-sialyltransferase (Nmα2–3ST) was 
used in a sugar nucleotide regeneration reaction for the synthesis of 3’-SL (68 g in a partially 
purified solid form, 68% yield) from lactose, Neu5Ac, phosphoenolpyruvate, and catalytic 
amounts of ATP and CMP (Sallomons et al., 2013). 
Both 6’SL and 6’SLN were synthesized from CMP-Neu5Ac and lactose using a Pasteurella 
dagmatis α-2,3-sialyltransferase double mutant that was completely switched to an α-2,6-
sialyltransferase (Schmölzer et al., 2015). Although they are promising results, this approach is 
still in laboratory scale evaluation (72% yield, 0.72 mM). 
A sequential 2-step synthesis of sialyl T-antigens and derivatives, including α-2,3-sialylated 
LNB, was also reported. During the first step, galactose was enzymatically converted to LNB via 
a one-pot reaction with galactokinase and LNB phosphorylase. The resulting LNB was 
successively transformed to an α-2,3-sialylated LNB using a one-pot 3-enzyme sialylation 
process employing Pasteurella multocida sialic acid aldolase, N. meningitidis CMP-sialic acid 
synthetase, and P. multocida α-2,3-sialyltransferase. Yields were above 70% in all cases for 
semi-preparative scale production (< 100 mg in each case) (Lau et al., 2011).  
Fucosylated HMO 
Classical enzymatic fucosylation of sugars requires GDP-L-fucose as a substrate donor and a 
fucosyltransferase enzyme. Various fucosyltransferases have been identified in mammals, 
most of which are located in the Golgi apparatus, with α-1,2, α-1,3/4 and α-1,6 activity, and in 
different bacteria with α-1,2, α-1,3/4 activity (Han et al., 2012). 
The enzymatic synthesis of 2’-fucosyllactose was examined using α-1,2-fucosyltransferase from 
H. pylori (FucT2), GDP-L-fucose and lactose as the starting materials to trisaccharide with 65% 
yield at mg scale (Albermann et al., 2001). 
Synthesis of the lacto-N-difucohexaose I using GDP-β-L-fucose and two fucosyltransferases has 
been reported  with an overall yield of 6% at mg scale (Miyazaki et al., 2010). Starting from 
LNT, produced using Murata and coworkers methodology, human fucosyltransferase I (FUT1) 
transferred Fuc  from GDP-Fuc to the Gal residue of LNT with an α-1,2 linkage. The resulting 
LNFP-I was subsequently reacted with GDP-β-L-fucose and commercial fucosyltransferase III 
(FUT3) to generate Lacto-N-difucohexaose I (LNDFH-I) (Figure 1.14). 
27 
 
CHAPTER 1. LITERATURE REVIEW 
 
Figure 1.14 Enzymatic synthesis of lacto-N-difucohexaose I. 
Human fucosyltransferase I (FUT1) transferred Fuc  from GDP-Fuc to the Gal residue of LNT with an α-1,2 linkage. 
The resulting LNFP-I was subsequently reacted with GDP-β-L-fucose and commercial fucosyltransferase III (FUT3) to 
generate Lacto-N-difucohexaose I (LNDFH-I).  Image from (Han et al., 2012). 
As is cited in detailed in Chapter 4, one of the most striking advances in glycosynthesis was the 
development of the glycosynthase technology in 1998 (Mackenzie et al., 1998; Malet and 
Planas, 1998). Glycosynthases are engineered glycosidases devoid of hydrolase activity but are 
able to efficiently catalyse the formation of glycosidic bonds in high yields when using an 
activated glycosyl donor. Glycosynthase methodology, then, is postulated as a powerful 
enzymatic tool for the synthesis of oligo- and polysaccharides (Planas et al., 2015; Armstrong 
and Withers, 2013). According to glycosidases mechanism, glycosynthases can be obtained for 
retaining and inverting mechanisms. 
Concerning HMO synthesis, to date, the unique case of glycosynthase technology strategy has 
been reported by Wada and coworkers for the production of 2′-fucosyllactose. An inverting 
1,2-α-L-fucosidase from B. bifidum was converted to a 1,2-α-L-fucosynthase, redesigning its 
hydrolytic activity to  the synthesis of 2′-fucosyllactose from a β-L-fucosyl fluoride donor and 
lactose acceptor. Even though these approaches opened the way to easily produce α-1,2-
fucosyl linkages on galactose residues at the non-reducing ends of sugar chains, the chemical 
instability of these beta-fucosyl-fluoride donor molecules needs to be solved for an enhanced 
conversion yield (Wada et al., 2008b).  
In spite of the reported data, to date, the developed enzymatic methods for producing 
fucosylated oligosaccharides have obtained a very limited number and quantity of 
fucooligosaccharides.  
1.2.5.4 Prokaryotic biotechnology approach 
 
Recently, promising new strategies for oligosaccharides production have been developed using 
metabolically engineered bacteria. These methods are based on the utilization of recombinant 
whole cells that overexpress the glycosyltransferase genes that are naturally involved in the 
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synthesis of oligosaccharides from sugar-nucleotides and on systems that allow a sugar-
nucleotide recycling by these whole cells. 
 A coupled microbial method was first developed by the Kyowa Hakko Kogyo Company. A 
Corynebacterium ammoniagenes strain was engineered to produce and regenerate UTP from 
inexpensive substrate by coupling this strain with two recombinant Escherichia coli. One of the 
strains was used to overexpress the genes of sugar nucleotides biosynthesis and the other 
strain to overexpress a glycosyltransferase gene. The Kyowa researchers were able to produce 
different oligosaccharides, such as globotriose, lactosamine, and sialyllactose in very high 
yields (Endo and Koizumi, 2000). The whole cell-based methodology takes advantage of the 
metabolic machinery of the microorganism used. However, the design of the reactions are 
limited by the capability of those molecules to get transported into the cell or synthesized in 
vivo. To facilitate passive circulation of the substrates, the method described above requires a 
permeabilization of the bacteria with xylene (reviewed in Han et al., 2012; Priem et al., 2002).  
Metabolic engineering overcomes coupled microbial method concerns. To date, the 
oligosaccharides are produced in single growing bacteria, usually E. coli that overexpresses the 
enzyme or enzymes of interest. Up to now, the range of oligosaccharides that could be 
produced by this in vivo method is limited because most of the glycosyltransferases of interest 
require specific acceptors that are not naturally present in the bacterial cytoplasm. 
Small oligosaccharides have been produced by whole-cell systems. However, there are some 
important bottlenecks in producing HMO at high rates in cells. On the one hand is the massive 
intracellular enrichment of the produced oligosaccharides and nucleotide by-products, and on 
the other hand is the extraction of the produced oligosaccharides. Due to intracellular 
enrichment, the products of the synthesis reaction may gradually develop a product-inhibitory 
effect on the synthetic enzymes. The purification of the target oligosaccharide from this 
complex mixture is costly, and thus for most oligosaccharides, not economical. Under these 
circumstances, biotechnical oligosaccharide production is not efficient enough and hard to 
control, especially since known biotechnological oligosaccharide production is performed using 
batch culturing, which, from an economical point of view, is highly unsatisfactory.  
Despite these difficulties, several HMO have been obtained and is explained as follows.  
LNT-II and LNnT 
Priem and coworkers reported the same strategy of using living E. coli JM109 cells (lacY+ lacZ-) 
engineered to overexpress Neisseria meningitidis β-1,3-N-acetylglucosaminyltransferase 
(NmLgtA) for large-scale production of LNT-II (6 g/L, 73% yield). In the case of LNnT production 
(5g/L) E. coli cells co-expressing NmLgtA and Neisseria meningitidis β-1,4GalT (NmLgtB) were 
used. In both cases, lactose was transported into the cell by the β-galactoside permease LacY. 
Intracellular lactose, which could not be degraded because the cell is devoid of β-galactosidase 
activity, was glycosylated into LNT-II by LgtA using the endogenous pool of UDP-N-
acetylglucosamine. Glycerol provides the carbon and energy source required for bacterial 
growth, lactose transport, and LNT-II and LNnT synthesis (Figure 1.15) and LNnT synthesis 
(Priem et al., 2002). 
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Figure 1.15 Production scheme of the trisaccharide LNT-II by E. coli.  
Cells expressing the N. meningitidis lgtA gene that encodes a β-1,3-N-acetylglucosaminyltransferase. Image from 
Priem et al., 2002. 
LNT 
Large-scale production of LNT in whole-cell was achieved in 2014. E. coli strain LJ110 (lacY+ 
lacZ-) chromosomally integrated with Neisseria meningitidis β-1,3-N-
acetylglucosaminyltransferase (NmlgtA) and Escherichia coli O55:H7 β-1,3-
galactosyltransferase (wbgO) genes were used. When glucose was used as the carbon source, 
LNT-II was the major product and only about 5% of the lactose was converted to LNT (See 
Figure 1.16). Nevertheless, by substituting the glucose with galactose, the yield of LNT 
production was improved 3.6-fold (Baumgärtner et al., 2015). Further studies revealed that 
fed-batch cultivation with galactose further improved the efficiency and produced 12.72 g/L of 
LNT (Baumgärtner et al., 2014). 
Fucosylated HMO 
Several fucose-containing lactooligosaccharides have been produced by single cell method. 
With regard to LNT and LNnT synthesis, the aditional expression of different 
fucosyltransferases (FutA, FutB, FutC and FutT14) led to different fucosylated lacto-N-
neotetraoses.  
Following LNnT synthesis, the use of Helicobacter pillory α-1,3-fucosyltransferase (FutA) 
produced Lacto-N-neodifucohexaose-II at a concentration of 1.7 g/L. The same fermentation 
driven by another α-1,3-fucosyltransferase (FutB) led to equal amounts of both lacto-N-
neofucopentaose-V and lacto-N-neofucopentaose-II produced at 280 and 260 mg/L, 
respectively  (Dumon et al., 2004; Priem et al., 2002). Sequential feeding of glucose and lactose 
in a fed-batch fermentation, using H. pylori α-1,2-Fucosyltransferase (FutC) produced 3 g/L of 
oligosaccharide mixture which was composed of 57%2’-fucosyllactose and 23% lacto-N-
fucopentaose I (LNFP I). Moreover, the same E. coli strain just expressing FutC (without the 
lgtA and lgtB expression) and with the addition of more lactose, produced 11 g/L of 2’-
fucosyllactose (Drouillard et al., 2006).  
And following LNT synthesis, the additional expression of a recombinant GDP-L-fucose salvage 
pathway together with a bacterial fucosyltransferase, lacto-N-tetraose is further converted 
into the respective fucosylated compounds (Figure 1.16). The expression of the α-1,2-
fucosyltransferase (FutC) in the lacto-N-tetraose producing E. coli strain led to the formation of 
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lacto-N-fucopentaose I (271.6 mg/L). While the expression of the α-1,4- fucosyltransferase 
(FucT14) mainly led to the conversion of lacto-N-difucohexaose II (133.7 mg/L).  The salvage 
synthetic method was developed using L-fucose for fucosyllactose production. E. coli was 
engineered to overexpress E. coli K12 L-fucose transporter (FucP) and Bacteroides fragilis 
fucose kinase/fucose-1-phosphate guanylyltransferase (Fkp) under the control of the T7 
promoter. To block the L-fucose metabolism for cell growth, its chromosome was more 
modified by disruption of the fucA gene encoding fuculose-1-phosphate aldolase. This 
recombinant E. coli strain was able to convert L-fucose to 369 μM GDP-fucose (Baumgärtner et 
al., 2015). 
 
Figure 1.16 In vivo synthesis of fucosylated lacto-N-tetraoses using Leloir glycosyltransferases and intracellularly 
generated nucleotide-activated sugars. 
Abbreviations are as follows: ATP; adenosine triphosphate, Fuc.LNT; fucosylated lacto-N-tetraose, GDP; guanosine 
diphosphate, GDP-Fuc; guanosine 5’-diphospho-β-L-fucose, GTP; guanosine triphosphate, L-Fuc; L-fucose, LNT II; 
lacto-N-triose II, LNT; lacto-N-tetraose, UDP-Gal; uridine 5’-diphosphogalactose, UDP-GlcNAc; uridine 5’-diphospho-
N- acetylglucosamine, Fkp; bifunctional L-fucose kinase / L-fucose-1-phosphate guanylyltransferase, FucP; L-fucose 
permease, FucT; α-1,2- or α-1,4-fucosyltransferase, LacY; lactose permease, LacZ; β- galactosidase, LgtA; β-1,3-N-
acetylglucosaminyltransferase, PTS; phosphotransferase system, WbgO; β-1,3-galactosyltransferase. Image from 
Baumgärtner et al., 2015. 
Sialylated HMO 
Sialyllactose or complex sialylated oligosaccharides can be produced in living E. coli cells either 
with synthesis of NeuAc from glucose via the de novo synthetic pathway (Priem et al., 2002) or 
with its uptake from medium via the salvage method (Figure 1.17) (Fierfort and Samain, 2008) . 
For the salvage synthesis method, Neu5Ac was transported into the cell by NanT permease 
and it was protected from degradation because of aldolase (nanA) inactivation (Drouillard et 
al., 2010). And for the the novo synthesis, the pathway for CMP-Neu5Ac biosynthesis had to be 
introduced into E. coli strain K12 derivatives, since the E. coli strain which is able to produce 
CMP-Neu5Ac in nature is a pathogenic strain K1, and consequently, unsuitable for 
biotechnological use.  In both systems, lactose was internalized by LacY permease and 
sialylated by a glycosyltransferase, using CMP-Neu5Ac, which was constantly regenerated by 
the enzymatic machinery of the living cells (Priem et al., 2002). To accomplish the synthesis of 
3’-sialyllactose, the α-2,3-sialyltransferase gene from Neisseriameningitidis was coexpressed 
with Campylobacter jejuni genes encoding N-acetylglucosamine-6-phosphate-epimerase 
(neuA), sialic acid synthase (neuB) and CMP-Neu5Ac synthetase (neuC). Simultaneously, 
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Neu5Ac aldolase, ManNAc kinase, and β-galactosidase activities were eliminated to ensure a 
higher yield of sialyllactose. Sialyllactose concentration of 25 g/L was obtained with continuous 
lactose feed in the high cell density culture of the recombinant E. coli cells (Fierfort and 
Samain, 2008) 
 
Figure 1.17 Engineered metabolic pathways for the production of sialyllactose. 
From an endogenous synthesis of NeuAc from glucose (A) or with its uptake from medium (B). Overexpressed genes 
are marker with a blue star. Discontinued arrows represent the enzymatic activities that have been eliminated. 
Glycerol provides the carbon and energy source required for bacterial growth, lactose transport, and sialyllactose 
synthesis. Image from Han et al., 2012. 
This system was further extended with the addition of the appropriate glycosyltransferase 
genes to produce gangliosides GD3, GM2 and GM1 ( reviewed in Han et al., 2012). 
To date, a limited number of HMO have been synthesized by whole-cell synthesis and 
engineered E. coli living-cell factory approaches. Despite of some limitations of the technology, 
the use of genetically modified organisms (GMO) is regulated by the Novel Food Regulation of 
the European Comission Regulation (EC) No 1829/2003 on genetically modified food and feed. 
This regulation does not cover the use of GMO derivatives in infant formula (European 
Commission, 2013), and to date, there is no infant food with the GMO special label in Europe. 
 
1.2.5.5 Eukaryotic cell based assays 
Eukaryotic cell based assays are being developed for understanding HMO biosynthesis rather 
than HMO production.  
 
To date, immortalized or transformed human mammary gland epithelial cells have been 
studied with limited success. None of the cell lines studied synthesized HMO, not even lactose. 
Most of them did not even express α-lactalbumin, essential for lactose synthesis (Bode, 2012). 
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1.2.5.6 Transgenic animal production 
Some research has been done with transgenic animals regarding the role of HMO in the health 
of infants rather than HMO production. 
Prieto et al., achieved the production of healthy transgenic animals and healthy progeny 
expressing transgene-encoded glycosyltransferases. The transgenic mice containing cDNA 
encoding the human alpha 1,2-fucosyltransferase, synthesised 2’-fucosyllactose. Nevertheless, 
transgenic rabbits generated using the same fusion gene used to produce transgenic mice did 
not produce enough milk suggesting that the human alpha 1,2-fucosyltransferase arrested the 
lactation process and apparently modulated the differentiation of the mammary gland (Prieto, 
2012).  
1.2.6 ALTERNATIVES TO HMO  
As previously cited, different methodologies have been developed for the synthesis of HMO 
which have provided single structures in sufficient quantity to perform clinical studies for 
formula supplemented with those oligosaccharides. However, there is no available 
methodology for large scale production of HMO at reasonable prize to introduce them in 
commercial formula for infants. Furthermore, the human mammary gland produces not only 
one or two HMO, but more than one hundred different oligosaccharides, so it is needed a mix 
of structurally more complex oligosaccharides composition to confer the wide spectrum of 
health benefits given by HMO for the formula-fed infants.  
Due to the difficulties in the production of HMO, much simpler structures, such as fructo-
oligosaccharides (FOS) and galacto-oligosaccharides (GOS) are introduced as supplements in 
infant formula (Sela and Mills, 2010).  
 
Figure 1.18 Structural comparison of different oligosaccharides. 
Galactooligosaccharides (GOS), inulin, human milk oligosaccharides (HMO) and bovine milk oligosaccharides (BMO). 
Whereas FOS and GOS are linear chains, HMO and BMO are branched structures and contain the structural 
elements fucose, sialic acid, and N-acetylglucosamine that are completely absent in FOS and GOS. Furthermore, 
they do not exhibit the inherent structural complexity that is characteristic of HMO and BMO that results from the 
large number of possible β and α glycosidic linkages present in these oligosaccharides. Glycan structures are 
depicted according to the recommendations of the Consortium of Functional Glycomics 
(http://www.functionalglycomics.org). Image adapted from Zivcokic et al., 2011. 
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FOS are composed of glucose at their reducing end bound to repetitive units of fructosyl 
residues in β 2-1 or β 2-6 linkages. They derived from inulin commonly extracted from chicory 
or other plant sources through hydrolysis by an endoinulinase to form oligomers of a degree of 
polymerization of 5 . As an alternative, FOS can be also enzymatically synthesised from sucrose 
(Boehm et al., 2005). GOS, composed of β 1-3/4/6 linked oligo-galactose with lactose at their 
reducing end, are produced from lactose by β-galactosidase (Intanon et al., 2014). It is 
important to note that FOS and GOS do not naturally occur in human milk. In fact, the fructose 
monomer itself is not found in human milk. Besides, neither GOS nor FOS are fucosylated nor 
sialylated (See Figure 1.18).  
These simpler oligosaccharides do not contain the structural complexity and diversity of HMO; 
thus, most of them do not resemble epithelial cell surface glycans, and may not be recognized 
by these lectins or bind to other lectins that trigger a different cell response. Even prebiotic 
effects may, to a certain extent, be structure dependent (Ninonuevo and Bode, 2008). 
However, FOS and GOS are reported to mimic the prebiotic effects of human milk and 
promote a bacterial microflora that closely resembles that of breast-fed infants (Ninonuevo 
and Bode, 2008).  
To date, GOS, FOS or inulin represent a reasonable and inexpensive way to supplement infant 
formula with prebiotic oligosaccharides. In the future, better sources of complex 
oligosaccharides that more closely mimic the structures and functions of HMO are needed to 
improve upon the existing supplementation strategy (Zivkovic and Barile, 2011). 
1.2 LACTO-N-BIOSIDASE  
Lacto-N-biosidase (EC 3.2.1.140) was first found in Streptomyces sp. strain 142, a soil 
actinomycete, in the course of the preparation of an α-fucosidase batch (Sano et al., 1992). In 
2008, Wada et al. identified the second lacto-N-biosidase gene from B. bifidum JCM1254, and 
classified it as an exo-β-N-acetylhexosaminidase that acts upon the terminal Galβ-1,3GlcNAc 
residues of HMO to release LNB (Wada et al., 2008a). While the role of Lacto-N-biosidase in B. 
bifidum is clearly located in the metabolism of the HMO, the role of this enzyme in 
Streptomyces sp. is yet to be fully elucidated (Hattie et al., 2012).   
1.3.1 Occurrence and physiological role in bifidobacteria 
Bifidobacteria are Gram-positive anaerobic bacteria that naturally occur in the human 
intestinal tract. They are considered to be beneficial commensals for human health because 
they prevent the growth of pathogenic bacteria by lowering the intestinal pH and stimulate the 
host’s immune system to enhance anti-pathogenic and anti-carcinogenic activities (Miwa et al., 
2010). After a week of birth, breast-fed infants guts are colonized by bifidobacteria, in 
particular B. breve, B. longum subsp. longum/infantis and B. bifidum, in comparison with those 
of formula-fed infants, which gut flora is more similar to adults (Harmsen et al., 2000).  
The lower gastrointestinal tract is an environment poor in mono- and disaccharides because 
these sugars are consumed by the host. In order to survive, bifidobacteria have different 
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extracellular glycosidases and a unique sugar metabolic pathway for LNB and GNB (galacto-N-
biose) called The GNB/LNB pathway, as it is represented in Figure 1.19 (Fushinobu, 2010).  
 
 
Figure 1.19 GNB/LNB Pathway and Extracellular Glycosidases of Bifidobacteria. 
Domain organization of extracellular glycosidases and the GNB/LNB transporter. The crystal structures of enzymes 
(or proteins) shown as hatched boxes have been determined. EngBF was isolated from B. longum JCM1217, 
whereas the other extracellular glycosidases were isolated from B. bifidum JCM1254. Image from Fushinobu et al., 
2010.  
 
LNB is a building unit of type 1 HMO, and GNB is a core 1 disaccharide of O-glycans of mucin 
glycoproteins that are present in the human intestines and milk (Wada et al., 2008a). The 
GNB/LNB pathway involves the following five proteins required for the uptake and degradation 
of the disaccharides: GNB/LNB transporter, lacto-N-biose phosphorylase (LnpA), N-
acetylhexosamine 1-kinase (NahK), UDP-glucose-hexose 1-phosphate uridylyltransferase 
(GalT), and UDP-galactose epimerase (GalE). It is likely that LNB and GNB are first imported by 
GNB/LNB transporter into the cytoplasm through a specific ABC-type transporter and 
phosphorolyzed by galacto-N-biose/lacto-N-biose phosphorylase (GNLBP), and finally 
metabolized in the glycolytic and aminosugar metabolic pathways (Kiyohara et al., 2009; Wada 
et al., 2008a).  
Based on the dominance of LNB-containing oligosaccharides in HMO and the presence of the 
GNB/LNB pathway in bifidobacteria, Kitaoka et al. 2005, hypothesized that the LNB residues in 
HMO act as the bifidus factor in breastfed infants (Kitaoka et al., 2005). Xiao et al. 2010, in a 
study of LNB as a sole source of carbon for 208 strains of bifidobacteria, confirmed that all the 
strains that naturally and predominantly colonize the infant gastrointestinal tract grew when 
LNB was used as sole carbohydrate source, while the strains that are found in adult 
gastrointestinal tract, human dental caries, and the guts of domestic animals are not able to 
utilize LNB (Xiao et al., 2010). 
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Since no free form of LNB is present in HMO, extracellular glycosidases responsible for the 
cleavage and release of LNB from HMO and the release of GNB from mucin glycoprotein have 
to be present in the gastrointestinal tract.  
1.3.2 Characteristics of Lacto-N-biosidase from B.bifidum  
The release of LNB from HMO is the most important step of type 1 HMO degradation. The 
discovery of GNB/LNB pathway presupposed the presence of lacto-N-biosidase in 
bifidobacteria. 
Bifidobacterial lacto-N-biosidase (LnbB) was first identified by Wada et al., 2008 in 
Bifidobacterium bifidum JCM 1254, and since then, it has also been found in different strains of 
B. bifidum and B. longum. The gene (lnbB) encoding for LnbB from B. bifidum was isolated 
using degenerated primers based on the amino acid sequence of LnbB from Streptomyces sp. 
strain 142, and the recombinant protein was characterised. LnbB consists of 1112 amino acids 
and contains an N-terminal signal sequence and a C-terminal membrane anchor. LnbB exhibits 
38% amino acid identity to Streptomyces sp protein. In terms of catalytic classification, LnbB 
belongs to the GH20 family of glycosyl hydrolases (CAZY database, (Cantarel et al., 2009)) since 
it presents a GH20 catalytic domain (Ito et al., 2013; Wada et al., 2008a). GH20 enzymes 
operate by substrate-assisted catalysis meaning the enzyme does not present the nucleophilic 
amino acid and the N-acetamido group of the substrate acts as the nucleophile to generate an 
oxazolinium intermediate. Most characterized GH20 enzymes are β-N-acetylhexosaminidases 
(EC 3.2.1.52), which release a monosaccharide, GlcNAc or GalNAc, from the non-reducing end 
of oligosaccharides. However, as it is observed in Figure 1.20, LnbB releases a disaccharide 
(LNB), implying that this enzyme has an extended -2 subsite, compared to the rest of GH20 
enzymes that only present -1 subsite (Ito et al., 2013). 
 
Figure 1.20 Hydrolytic reaction of lacto-N-tetraose catalyzed by B. bifidum lacto-N-biosidase. 
 
Lacto-N-biosidase exhibits a very specific activity releasing LNB from lacto-N-tetraose (LNT) 
(Figure 1.20). LnbB shows strict preference for the unmodified β-linked LNB structure, 
indicating that cleavage of the fucose and sialic acid modifications of HMO is prerequisite for 
activity (Wada et al., 2008a).  
Due to the relevant characteristics of LnbB, this thesis envisages LnbB as a promising 
biocatalyst for HMO synthesis. Accordingly, a deeper characterization of LnbB has been 
achieved and is revealed in the following chapters.  
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1.5 GLYCOSIDASES AS TOOLS FOR IMPROVED GLYCOSIDE SYNTHESIS 
In nature, glycosidic bond formation is mainly synthesized by two different types of enzymes, 
which are glycosyltransferases (GTs) and glycosidases (glycoside hydrolases, GHs). GTs catalyse 
the transfer of a monosaccharide sugar nucleotide donor to an acceptor, producing the new 
sugar. They are the main catalyst in vivo, but the large-scale use in vitro is limited. GTs are 
often membrane bound proteins, hard to isolate and purify, and unstable once they are 
isolated. In addition, these enzymes require activated glycosyl donor as substrates, which are 
not readily available and increases the already high cost of the reaction. Therefore, the use of 
glycosyltransferases is still considered as a general tool for in vitro micro-scale carbohydrate 
synthesis (Planas et al., 2015; Wang and Davis, 2013). With regard to HMO synthesis, some 
simple HMO are produced in vitro using the corresponding GTs as previously cited (section 
1.2.5.3). However, a deeply understanding of the synthetic pathways of HMO is required for a 
complete benefit of this methodology. 
 
Alternatively, GHs are degrading enzymes involved in glycan metabolism which hydrolyse 
glycosidic linkages in a stereospecific manner. Glycoside hydrolases fall into two mechanistic 
categories, according to the stereochemical outcome of the bond cleavage: inverting enzymes, 
which hydrolyse the glycosidic bond with inversion of configuration, and retaining enzymes, 
which do so with net retention of the anomeric configuration. Inverting GHs operate by a 
single-step mechanism in which a water molecule (with general base catalysis) affects a direct 
displacement at the anomeric center with protonic assistance by the general acid residue on 
the departing glycosidic oxygen (Figure 1.21C). While retaining GHs follow a double 
displacement reaction via formation and hydrolysis of a glycosyl–enzyme intermediate. In the 
first step (glycosylation), the amino acid residue acts as the general acid and protonates the 
glycosidic oxygen while the deprotonated carboxylate functions as the nucleophile and attacks 
the anomeric centre leading to a covalent glycosyl–enzyme intermediate. The second step 
(deglycosylation) involves the attack by a molecule of water assisted by the conjugate base of 
the general acid residue, which renders the free sugar (Figure 1.21A). Some retaining 
glycosidases catalysing glycoside bond hydrolysis in 2-acetamido sugars follow a variation of 
the retaining mechanism (Figure 1.21B). In this case, the N-acetyl group of the substrate acts 
as an internal nucleophile, forming an oxazolinium intermediate, which is then attacked by a 
water molecule assisted by the conjugate base of the general acid residue to yield the product. 
Instead of a nucleophile residue, an auxiliary amino acid hydrogen bonds with the –NH of the 
acetamido group assisting the formation of the oxazolinium intermediate (Planas et al., 2015).  
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Figure 1.21 Glycosidase mechanism.  
 (A) Retaining glycosidase with enzyme nucleophile, via a glycosyl–enzyme intermediate in the two-step 
displacement mechanism. (B) Retaining glycosidase by substrate-assisted catalysis, via an oxazolinium ion 
intermediate (C) Inverting glycosidase. 
 
GHs hydrolytic activity can be reverted to the synthesis of glycans through transglycosylation 
reactions under appropriate conditions. GHs are applied as efficient biosynthetic tools due to 
the easy access and stability of the enzymes, and the use of glycosyl donors that are cheap and 
relatively simple to produce in large scale. Classical approaches are based on the reversal of 
their hydrolytic activity. This is achieved either by displacing the equilibrium towards glycoside 
bond formation (thermodynamically controlled synthesis) or by using activated glycosyl donors 
(kinetically controlled transglycosylation). However, since these enzymes are still hydrolytically 
active and reactions are run in water, the product of transglycosylation is always hydrolysed 
reducing yields. In any case, these methodologies only achieve yields up to 40-50% (Bissaro et 
al., 2015; Planas et al., 2015; Wang and Huang, 2009). 
Improvement of transglycosylation efficiency of natural GHs can also be achieved by protein 
engineering. The strategies for engineering glycosidases generally consist of rational design on 
the basis of available structural information as well as directed evolution with use of powerful 
screening approaches. In site-directed mutagenesis, the mutations play a role in either 
B
A 
C
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disfavouring the positioning of hydrolytic water molecule or favouring binding of incoming 
carbohydrate molecule in the aglycon subsite, thereby increasing transglycosylation activity. 
Directed evolution, on the other hand, can be used for improving transglycosylation activity 
without prior knowledge of structure-function relationships.  
Progress in enzymatic synthesis was achieved in 1998, when the glycosynthase technology was 
developed (Mackenzie et al., 1998; Malet and Planas, 1998). Glycosynthases are nucleophile 
mutants of retaining glycosidases that efficiently catalyse the synthesis of the glycosidic linkage 
by condensing an activated glycosyl fluoride donor with a suitable acceptor sugar. They can 
efficiently catalyse glycoside bond formation and achieve good yields, since they are 
hydrolytically inactive. As shown in Figure 1.22A, the α-glycosyl fluoride donor mimics the 
glycosyl-enzyme intermediate in the active site of the nucleophile-less mutant of a β-
glycosidase. This enzyme transglycosylates this donor to the acceptor and the product formed 
is unable to be hydrolyzed by the mutant enzyme, so transglycosylation yields are very high 
(Planas et al., 2015; Armstrong and Withers, 2013).  
The glycosynthase technology has thereafter been applied in a wide variety of glycosynthases. 
The initial concept developed in mutated retaining glycosidases using glycosyl fluoride donors 
(Figure 1.22B), was then extended to other approaches including the in situ generation of an 
activated glycosyl donor with an external nucleophile (Figure 1.22B), glycosynthases derived 
from glycosidases acting by substrate-assisted catalysis (Figure 1.22C), and glycosynthases 
derived from inverting glycosidases (Figure 1.22D) (Armstrong and Withers, 2013; Planas et al., 
2015).  
The applicability of enzymes from thermophilic organisms is limited because of the instability 
of the glycosyl fluoride donor at high temperatures. The in situ generation of the glycosyl 
donor in the active site of the glycosynthase mutant is used as an alternative strategy. Then, 
the  activity on an aryl glycoside substrate can be rescued by an exogenous nucleophile such as 
formate or azide and condensation to an acceptor can occur (Trincone et al., 2000).  
It has also been developed glycosynthases acting via substrate-assisted mechanism. In this 
case, the glycosyl donor for transglycosylation is an activated oxazoline sugar, which binds the 
enzyme to directly form the reaction intermediate. The first glycosynthase acting via substrate-
assisted catalysis was an endo-β-N-acetylglucosaminidase (Endo-M) of GH85 family proteins, 
and was further extended to other GH85 enzymes (Endo-A and Endo-D) (Wang and Huang, 
2009; Yamamoto, 2013) and also to GH18 family proteins (Huang et al., 2012; Martinez et al., 
2012). 
The action of inverting enzymes on glycosyl fluorides with an opposite anomer was first 
mentioned by Honda and coworkers. As inverting glycosidases operate by a single 
displacement mechanism, enzyme engineering for glycosynthesis in this case is based on a 
similar but slightly different concept. Inverting glycosynthases transfer the glycosyl fluoride of 
the opposite anomer of the substrate (e.g. inFigure 1.24, α-glycosyl fluoride by a β-glycoside-
hydrolyzing enzyme) to the acceptor molecule. However, although the normal hydrolytic 
process is substantially slowed, is still significant (Honda and Kitaoka, 2006). As regards HMO 
synthesis, 1,2-α-L-Fucosidase (AfcA) from Bifidobacterium bifidum was engineered to 
condense a fucose moiety to a lactose to form 2’-fucosyllactose (Wada et al., 2008b).  
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Figure 1.22 Glycosynthase enzymes.  
(A) Nucleophile mutant of a retaining GH with glycosyl fluoride donor. (B) Nucleophile mutant of a retaining 
glycosidase (thermophilic) with in situ generation of the glycosyl donor by and exogenous nucleophile. (C) Mutant at 
the assisting residue of a retaining glycosidase acting by substrate-assisted catalysis and a sugar oxazoline donor. (D) 
Glycosynthase-like mutant derived from an inverting glycosidase. 
 
To date, more than 50 glycosynthases have been developed covering a wide repertoire of 
sugar moieties and glycosidic linkages (Planas et al., 2015) but still, no glycosynthase exists to 
synthesize any core structure of HMO sugars.  
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1.5 AIM OF THE THESIS 
Human milk oligosaccharides (HMO) are of current interest due to the short and long term 
beneficial effects they provide to the infant. To date, large scale synthesis of HMO has not 
been possible by any synthetic methodology. Consequently, HMO are not available in infant 
formulas. Enzymatic synthesis is an alternative strategy that overcomes chemical synthetic 
limitations since enzymes can form the new glycosidic linkages with high regio- and stereo-
selectivity. In particular, glycosidases, which mainly catalyse the hydrolysis of oligo- and 
polysaccharides in vivo, have been shown to be effective biocatalysts when they are converted 
to glycosynthases.  
Using structural-functional knowledge of glycosidase enzymes and rational redesign, this 
project aims to develop new biocatalysts to achieve the large scale synthesis of type 1 
oligosaccharides. 
Recently, the Lacto-N-biosidase from Bifidobacterium bifidum (LnbB) was identified. LnbB 
specifically hydrolyses the Lacto-N-tetraose (type 1 HMO) compound into two disaccharides, 
lacto-N-biose and lactose, via substrate-assisted mechanism.  
On this basis, the present thesis tackles two main objectives to address the use of LnbB as an 
efficient biocatalyst: i) the structural-functional study of LnbB and ii) protein engineering of 
LnbB to generate biocatalysts able to synthesize the target lacto-N-tetraose. Modulation of the 
transglycosylation/hydrolysis activity of LnbB will be evaluated using two different strategies: 
the glycosynthase-like and the enhanced transglycosylation strategies. 
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 OBJECTIVES 
Given the important role of HMO in infant development, and the lack of an efficient synthetic 
approach for large scale production of these complex molecules, the current thesis envisages 
the chemo-enzymatic synthesis of lacto-N-tetraose (LNT, core type 1), one of the most 
abundant HMO. With the aim of engineering Lacto-N-biosidase form B. bifidum (LnbB) as an 
efficient biocatalyst for LNT synthesis, four main objectives are outlined in this thesis.  
1. Synthesis of the key disaccharide Lacto-N-biose (LNB) and subsequent substrate 
donors. The 4-nitrophenyl (p-NP) derivative of LNB (p-NP-LNB) for the enhanced 
transglycosylation strategy, and 1,2-oxazoline derivative of LNB (oxa-LNB) for the 
glycosynthase strategy.  
 
2. Kinetic characterization of Lacto-N-biosidase from B. bifidum, and identification of the 
catalytic residues. 
 
3. Structural-functional analysis of GH20 enzymes to evaluate the minimal functional unit 
of LnbB that retains the enzymatic activity. 
 
4. LnbB engineering, either as a glycosynthase-like or a transglycosidase, for the 
enzymatic synthesis of LNT. 
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CHAPTER 2. SYNTHESIS OF SUBSTRATES 
2.1 INTRODUCTION 
Chemo-enzymatic glycosylation has become a powerful tool for stereo- and regio-selective 
synthesis of glycosidic bonds in carbohydrate chemistry. The chemo-enzymatic strategy mainly 
consists of two steps. The first one involves the synthesis of an activated glycosyl donor. And 
the second one consists of the subsequent enzyme-catalysed transglycosylation of that 
glycosyl donor to an acceptor (Noguchi et al., 2009).  
The improvement of transglycosylation efficiency of natural glycosides can be achieved by 
protein engineering. Reaction engineering will modify reaction to enhance probability of 
acceptor condensation instead of water and also reduce of water activity. The strategies for 
protein engineering consist of rational design based on the structural information available of 
the active site of the enzyme, as well as directed evolution with using screening resources. 
Both strategies aim to modify the reaction and favour transglycosylation over hydrolysis to 
achieve efficient carbohydrate synthesis.  
In this context, we aim the chemo-enzymatic synthesis of lacto-N-tetraose (LNT, Galβ-
1,3GlcNAcβ-1,3Galβ-1,4Glc) using engineered Lacto-N-biosidase (LnbB) as biocatalyst. Which 
consists of, firstly, synthesizing the glycosyl donors (activated LNB) and, secondly, producing a 
generation of LnbB mutants which are believed to condense these donor disaccharides and the 
acceptor sugar, lactose, to achieve the target lacto-N-tetraose. 
 
Subsequently, the generation of LnbB mutants are addressed to two different LNT synthesis 
approaches. The first one consists of enhancing transglycosylation activity by engineering 
reaction conditions and using p-NP-LNB as the activated glycosyl donor and also, performing 
mutations in acceptor recognition residues of LnbB. While the second one is based on the 
glycosynthase methodology, and consists of generating glycosynthase-like LnbB and providing 
the corresponding activated donor (oxa-LNB) to the new enzyme.  
 
First we present the enzymatic synthesis of the key disaccharide LNB using a β-galactosidase 
from Bacillus circulans. β-Gal-3 is able to synthesise the target disaccharide (LNB) in high yields 
in a reaction mixture of ionic liquids in water solution.  
 
Secondly, we evaluate the synthesis of donor substrates, p-NP-LNB and oxa-LNB, via two 
different synthetic procedures. The total synthesis 1 scheme (Figure 2.1) starts with the 
enzymatic production of Galβ-1,3GlcNAc (3) from p-NP-β-Gal (1) (donor) and GlcNAc (2) 
(acceptor) mediated by a β-galactosidase from Bacillus circulans (β-Gal-3) (Bayón et al., 2013). 
Subsequent substrate activation involves chemical synthesis.  p-NP-LNB (7) synthesis starts 
from the peracetylated LNB converted into the corresponding glycosyl chloride, followed by  
glycosylation with 4-nitrophenol, and further deacetylation. oxa-LNB (15) synthesis is 
performed directly from LNB by using a newly designed dehydrative condensing agent. By 
contrast, the total synthesis 2 scheme (Figure 2.2) consists of the enzymatic synthesis of the 
substrates using β-Gal-3 as biocatalyst and the corresponding monosaccharides. In the case of 
p-NP-LNB (7) synthesis, p-NP-β-Gal (1) as donor and p-NP-GlcNAc (8) as acceptor were used. 
And with regard to oxa-LNB (15) synthesis, p-NP-β-Gal (1) as donor and oxa-GlcNAc (14) as 
acceptor were used. 
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Figure 2.1 Total synthesis 1 scheme. 
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Figure 2.2 Total synthesis 2 scheme. 
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2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Solvents 
Cyclohexane, chloroform and dichloromethane (DCM) were distilled over CaCl2. In some cases 
DCM and DCE was distilled a second time over P2O5 for a higher desiccation. Ethyl acetate was 
distilled over K2CO3. Pyridine was distilled over KOH. 1,2-dichloroethane (DCE) was first dried 
with MgSO4, further distilled over P2O5 and immediately stored with freshly activated 
molecular sieves. MeOH was distilled over I2 (1 g/L of methanol) and Mg (5 g/L of methanol). 
Molecular sieves were activated in the oven at 450 °C for 3 - 4 hours.  
Reactants 
Tetrabutylammonium hydrogen sulphate (TBAHS) was recrystallized from acetone. Sodium 
methoxide in methanol was prepared from Na (2.23 g, 1M) and anhydrous MeOH (100 mL). 
Amberlite® IR-120 (H+) resin was washed with MeOH until it was colourless. 
Substrates 
4-Nitrophenyl β-D-galactopyranoside (p-NP-Gal, ref N0616) and 4-Nitrophenyl 2-Acetamido-2-
deoxy-β-D-glucopyranoside (p-NP-GlcNAc, ref N0866) were purchased from TCI America. N-
acetil-β-D-glucosamina (GlcNAc, Ref. A8625) was purchased from Sigma-Aldrich. 
2.2.2 General methods 
Monitoring the reactions 
Thin-layer chromatography (TLC) was used to follow the reactions. TLC was performed in 
aluminium sheets coated with regular silica gel (Merck 60 F254) or with silica gel modified with 
aliphatic hydrocarbons ((Merck 60 RP-18 F254). Once the products are eluted, TLC was analysed 
under uv light (254 and 360 nm) and then, revealed with the mixture H2O/MeOH/H2SO4 
(4.5:4.5:1) at 125 °C. 
NMR 
1H and 13C NMR, COSY and HSQC spectra were recorded in a Varian Gemini 400 MHz 
spectrometer operated at 298 K. For 1H NMR, chemical shifts were referenced to internal TMS 
(δH=0 ppm) for solutions in CDCl3 (δH= 7.26 ppm) and in D2O (δH=4.79 ppm). For 13C NMR, the 
central peak of the CDCl3 triplet (δ=77.16 ppm) was used as a reference. Chemical shifts (δ, 
ppm) are indicated followed by the type of signal: s=singlet, d=doublet, t: triplet, dd: double 
doublet, ddd= double of doublets and m= multiplet. Spin-spin- coupling (J, Hz) and the number 
of protons according to electronic integration was also indicated. 
Lyophilisation 
The samples were frozen at -80 °C and then maintained at -50°C and under vacuum conditions 
to be lyophilised in the Cryodos-45 TELSTAR equipment. 
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2.2.3 Expression and purification of β-Gal-3 from Bacillus circulans ATCC 31382 
Recombinant cultures of E.coli BL21 were grown in LB medium with kanamycin at final 
concentration of 30µg/ml for 16 hours, 250 rpm at 37 °C. Protein expression was induced 
adding IPTG at final concentration of 1mM and after 5 hours of incubation at 250 rpm and 37 
°C. Cells were harvested by centrifugation (4,000xg, 15 min at 4 °C), resuspended in 100 mM of 
phosphate buffer at pH 6 (50 mM Na2HPO4, 50 mM NaH2PO4), and disrupted by ultrasonic 
disruption (25 cycles, 10 s on and 35 s off, 50% amplitude). Cell free extracts were centrifuged 
(14000xg, 4C, 15 min) and the supernatant was applied into a 5mL Ni2+-charged HiTrap 
chelating column (Bio-Scale™ Mini Profinity™ IMAC Cartridges, Bio-Rad) chromatography. 
Proteins were purified to homogeneity according to manufacturer’s protocol (ref. 10005455, 
Bio-Rad). Fractions were monitored by absorbance at 280 nm, pooled and concentrated and 
desalted in an Amicon ultracentrifuge filter (Millipore). The protein concentration was 
determined by the Bradford method using BSA as standard (Bradford, 1976). 
2.2.4 Synthesis of lacto-N-biose by transglycosilation using β-Gal-3 
Reaction conditions involved 85 mM of p-NP-Gal (donor), 425 mM of GlcNAc (acceptor) and 
2.5 µM of protein in a final volume of 200 mL (splitted in 4x50 mL volumetric flasks). The 
reactions took place in 100mM of phosphate buffer at pH 6 (50 mM Na2HPO4, 50 mM 
NaH2PO4) with 30 % of ionic liquid ([BMIN][PF6]) at 37 °C. Aliquots were withdrawn at regular 
time intervals (1, 2, 2.5 and 3 hours) by heating at 80 °C for 10 min, diluted 1:10 in water and 
analysed by HPLC-ELSD.  The reaction was stopped after 3 hours by heating at 80 °C for 30 min. 
The crude was centrifuged (4 cycles of 15 min at 8000 rpm) to recover the aqueous phase 
(containing carbohydrate compounds), which was, then, lyophilized to eliminate the water. 
The yield in the crude reaction crude was 90% (27 g).  
Analysis of the reaction was performed by HPLC (Jasco 2000) using an amino column (NH2P50-
4E, Asahipak, Japan) and two detectors: ELSD (Evaporative Light Scattering) and UV at 317 nm. 
Chromatographic conditions were 10 µL injection, flow rate of 0.8 mL/min of an isocratic 
elution ACN (80%) and H2O (20%) at 50 °C. Detector conditions regarding ELSD were nebulizer 
at 60 °C, evaporation at 50 °C and gas pressure of 1.6 SLM. Each experimental assay was 
determined at least three times with a coefficient of variation of < 5%. 
2.2.5 Purification of lacto-N-biose from the previous reaction using charcoal-Celite 
Chromatography was performed on a mixture of charcoal (ref. 242276, Sigma-Aldrich) and 
Celite-503 (Merck) (50%, w/w). A mixture of 20:1 ratio (w/w), dry charcoal-Celite mixture: 
crude fraction was poured into the column and was packed by vacuum. Column was pre-
eluted with H2O at a flow rate of 1mL/L for an overnight. Then, the crude fraction was 
dissolved in a small amount of H2O and loaded into the column. Products were eluted with 
milliQ water in linear gradient of ethanol (from 0% to 20%, v/v). Disaccharide enriched 
fractions were collected in 10% or 15% ethanol; samples were pooled, solvent was removed 
and then lyophilized, purity of the solid powder was analysed by HPLC. The yield of pure 
disaccharide (3) after purification through the charcoal-Celite column (compared with initial p-
NP-LNB) was 90%, although the total chromatographic yield was 60%. Purity of the solid 
powder was analysed by NMR and HPLC-MS.  
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Compound 3. 
1H NMR (400 MHz, D2O) δ 5.19 (d, J = 3.5 Hz, 1H, H1Iα), 4.76 (d, J = 8.2 Hz, 0H, H1Iβ), 4.13 – 
2.95 (H2, H3, H4, H5 and H6), 2.04 (s, 3H, Ac). 
13C NMR (100 MHz, D2O) δ 174.45 (C=O,COCH3), 103.48/103.35 (C1 β/αII), 94.63 (C1βI), 90.95 
(C1αI), 82.52/80.08 (C3β/αII), 75.37, 75.20, 75.15, 72.47, 72.44, 71.14, 70.64, 70.60 (C5I, C5II, 
C3II, C2II), 68.63, 68.59, 68.47, 68.45 (C4I,C4II), 60.92, 60.66, 60.49 (C6I,C6II), 55.54 (C2β), 52.81 
(C2α), 22.17/21.92(CH3CO). 
2.2.6 Purification of lacto-N-biose from the previous reaction crude using silica-gel 
Flash chromatography was performed on Merck Silica gel (40–63 µm) in a 60:1 dry silica 
gel:crude ratio (w/w). Column was pre-eluted with the corresponding solvent previously mixed 
with triethylamine (Et3N) (1mL/L). The crude fraction was dissolved in a small amount of 
solvent and loaded into the column. The crude fraction was acetylated, purified using flash 
chromatography and finally deacetylated. 
Acetylation of the crude  
Crude fraction (5 g) was reacted with acetic anhydride (Ac2O, 5 mL, 52.5 mmol), pyridine (2.5 
mL, 30 mmol) and 4-dimethylaminopyridine (DMAP, 2.5 mg, 0.02 mmol). The reaction was 
stirred at room temperature for 18 hours. Then, MeOH (1.5 vol of Ac2O) was poured into the 
mixture once cold. A fter concentration and dilution with chloroform, the organic layer was 
washed with saturated aq. NaHCO3 and water, dried over MgSO4 and the organic solvent was 
evaporated under vacuum. In order to remove pyridine residues, the crude was co-evaporated 
with toluene. Per-O-acetated mixture (8.2 g) was obtained. 
Silica-gel column chromatography 
The per-O-acetated crude fraction was dissolved in a small amount of solvent (CH2Cl2) and 
loaded into the column. p-NP was first eluted with AcOEt/Cy 4:1. Then, elution was changed to 
AcOEt/Cy 10:1. And, Ac-GlcNAc (fractions 76-88) (12) and Ac-LNB (16) (fractions 92-208) were 
independently eluted). Disaccharide enriched fractions were pooled and solvent was removed 
by evaporation to dryness in vacuo. Ac-LNB (16) structure was confirmed by NMR. 
Chromatographic yield was 98%. 
Compound 16 
1H-RMN (400 MHz, CDCl3): δ 6.07 (d, J = 3.7 Hz, 0.65H,H1Iα), 5.85 (d, J = 7.9 Hz, 0.35H, H1Iβ), 
5.76 (d, J = 8.8 Hz, 0.35H, NHα), 5.47 (d, J = 9.7 Hz, 0.65H, NHβ), 5.37 (dd, J = 3.3, 1.2 Hz, 1H, 
H4I), 5.12-4.89 (m, 3H, H2II, H3II,H5I), 4.62 (dd, J = 7.6, 3.5 Hz, 0.65H, H2αI), 4.54 (ddd, J = 10.4, 
9.7, 3.7 Hz, 1H, H1II), 4.31-3.88 (m, 8H,H6I, H4II, H5I, H6II, H3I, H2βI), 2.25-1.90 (m, 24H, CH3CO). 
13C-RMN (100 MHz, CDCl3): δ 171.3-168.2 (COCH3), 100.9/100.8 (C1β/αII) ,91.7 (C1βI) ,91.2 
(C1αI), 75.7 (C3βI), 72.7 (C3αI), 70.8, 70.3, 69.8, 69.0, 68.1 ( C5αI, C5II, C3II, C5βI, C2II) , 66.6 (C4I), 
64.4 (C4II) , 61.8 , 60.8, 60.4 ( C6I,C6II), 54.4 (C2β), 51.1 (C2α) , 23.45-20.2 (CH3CO). 
2.2.6.1 Zemplen deacetylation of Ac-LNB (16) 
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Freshly prepared sodium methoxide (1M in methanol, 100 µL) was added to a stirred solution 
of peracetylated LNB (16) (Ac-LNB) in anhydrous methanol. Reaction conditions are detailed in 
Table 2.2 (section 2.3.2.1). Reactions were neutralized with Amberlite® IR-120 (H+) resin, 
filtered and analysed by TLC (ACN:H2O, 7:3 as eluent). 
2.2.6.2 Methanolic amonia deacteylation of Ac-LNB (16) 
 
Peracetylated LNB (16) (Ac-LNB, 100 mg, 0.14 mmol) or peracetylated GlcNAc (12) (Ac-GlcNAc, 
100 mg, 0.24 mmol) were suspended with methanolic ammonia (NH3/MeOH, 2mL) and 
methanol (2 mL). The solutions were stirred at room temperature for 50 hours. The reaction 
mixtures were then evaporated to dryness in vacuo and analysed by TLC (ACN:H2O, 7:3 as 
eluent). 
2.2.7 Enzymatic synthesis of 4-nitrophenyl 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-
β-D-glucopyranoside (7) using β-Gal-3  
Reaction with free enzyme 
Reaction conditions involved 85 mM of p-NP-Gal, 425 mM or 850 mM of p-NP-GlcNAc 
(donor:acceptor molar ratio, 1:5 or 1:10) and 2 nM of protein in a final volume of 100 µL. The 
reactions took place in 100 mM of phosphate buffer at pH 6 (50 mM Na2HPO4, 50 mM 
NaH2PO4) with different amounts of ionic liquids at 37 °C. At different time intervals, 1 and 3 
hours, 20 µL of samples were analysed using HPLC as described in section 2.2.4.  
Reaction with immobilised enzyme 
Immobilization was carried out with 0.5 mg (7.4 nmol) of enzyme diluted in 5 mL of 100 mM of 
NaHCO3 buffer at pH 10. In order to avoid conformational changes in the protein due to the 
high pH, a stabilizing agent was added to the solution (50% of PEG-600 (Polyethyleneglycol). 
Then, 1 g of 10 % glyoxyl-agarose was added to the solution and was stirred at 25 °C for 30 
min. The immobilization was finished adding 5 mg of NaBH4 and the solution was further 
stirred for 30 min at 25 °C. The final mixture was filtered and washed with 50 mM of 
phosphate buffer at pH 6.0. 
Enzymatic synthesis of p-NP-LNB (7) using glyoxyl-agarose immobilised enzyme consisted of 85 
mM of p-NP-Gal, 425 mM of p-NP-GlcNAc (1:5 donor:acceptor molar ratio), and 30 mg of 
immobilised enzyme (0.03 mg of protein) in a final volume of 100 µL (4.4 µM of protein). 
Enzymatic reactions were performed in 100 mM phosphate buffer pH 6.0 with or without 30% 
of BMIN [PF6] at 37 °C. At different time intervals, 1 and 3 hours, 20 µL of samples were 
analysed using HPLC as described in section 2.2.4. 
2.2.8 Enzymatic synthesis 1,2-oxazoline derivative of 2-acetamido-2-deoxy-3-O-(β-D-
galactopyranosyl)-β-D-glucopyranose (15) 
Reactions containing 85 mM of p-NP-Gal and 425 mM oxa-GlcNAc (donor:acceptor molar ratio, 
1:5) were performed in 100 mM phosphate buffer at different conditions (pH 7.5 and 10 in the 
presence or absence of PEG and of BMIN [PF6]) in a final volume of 200 µL and at 37 °C. At 
different time intervals (10 and 30 min, and 1 and 3 hours) 20 µL aliquots were analysed using 
HPLC-ELSD. 
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2.2.9 Chemical synthesis of 4-nitrophenyl β-N-acetyl-D-glucosamine (8) 
Anomeric carbon activation via chlorination 
N-acetyl-D-glucosamine (2) (5 g, 22.5 mmol) was reacted with acetyl chloride (30mL, 420 mM) 
in a three-necked volumetric flask with a CaCl2 tube. The reaction was kept at stirring 
conditions and under nitrogen atmosphere for 24 hours. The reaction was diluted with DCM 
(50 mL), washed with aq satd NaHCO3 (4x100 mL) and water (3x100mL). The organic layer was 
dried with MgSO4, filtered and concentrated. Yellow oil was obtained. It corresponded with a 
mixture of 60:40 fully acetylated α-chloride (9) and α-per-O-acetated N-acetyl-D-glucosamine 
(10) (5.3 g, 55% yield). This mixture was used directly for the glycosylation reaction with 4-
nitrophenol. 
1H-RMN (400 MHz, CDCl3): 6.19 (d, J= 3.7 Hz, 1H, Cl-GlcNAc), 6.17 (d, J  = 3.7 Hz, 1H, Ac-
GlcNAc), 5.81 (d, J = 8.7 Hz, 1H, NH-Cl-GlcNAc), 5.56 (d, J = 8.9 Hz, 1H, NH-Ac-GlcNAc), 3.89 – 
5.34(m, 12H, H2- H6), 1.90-2.25 (m, 27H, CH3CO). 
4-nitrophenol glycosylation 
A mixture of fully acetylated α-chloride (9) and α-per-O-acetated N-acetyl-D-gucosamine (10) 
(1.15 g, considering 60% of 9, 0.68 mg, 1.82 mmol), anhydrous DCM (5 mL), TBAHS (635.6 mg, 
1.82 mmol), 4-nitrophenol (520.8 mg, 3.74 mmol) and NaOH 1M (5 mL) was stirred at room 
temperature for 3 hours. The resulting crude was diluted with anhydrous DCM (50 mL) and 
washed with NaOH (200mL) and water (1 L) to get rid of unreacted 4-nitrophenol. The organic 
layer was dried with MgSO4, filtered and concentrated. The crude was recrystallized from 
MeOH, and p-NP per-O-acetated N-acetyl-D-gucosamine (11) was obtained as a white solid in 
57% yield (390 mg). 
1H-NMR (400 MHz, CDCl3): δ 8.23 (d, J = 9.3 Hz, 1H, Ar-H), 7.29 (d, J = 9.2 Hz, 1H, Ar-H), 5.77 (d, 
J = 8.4 Hz, 1H, H1), 5.48-5.43 (m, 2H,H1,H3), 5.15 (dd, J = 9.9, 9.2 Hz, 1H, H4), 4.29 (dd, J = 12.3, 
5.6 Hz, 1H, H6a), 4.17-4.14 (m, 1H, H6b), 4.13-4.11 (m, 1H, H2), 3.94 (ddd, J = 9.9, 5.6, 2.5 Hz, 
1H, H5), 2.08-1.84 (12H, CH3CO ), 1.96 (s, 3H, NHCOCH3). 
Zemplen deacetylation 
Freshly prepared sodium methoxide (1M in methanol, 100 µL) was added to a stirred solution 
of p-NP per-O-acetated N-acetyl-D-gucosamine (11) (1g, 2 mmol) in anhydrous methanol (25 
mL), and the mixture was stirred at RT for 18 hours. A white solid and a yellow solution were 
obtained. The white solid was filtered, and the yellow solution was neutralized with 
Amberlite® IR-120 (H+) resin and filtered. White powder was then lyophilized to give 4-
Nitrophenyl 2-Acetamido-2-deoxy-β-D-glucopyranoside (8) in quantitative yield.  
1H NMR (400 MHz, Methanol-d4) δ 8.22 (d, J = 9.3 Hz, 1H, Ar-H), 7.19 (d, J = 9.3 Hz, 1H, Ar-H), 
5.22 (d, J = 8.4 Hz, 1H, H1), 4.04 – 3.88 (m, 2H), 3.76 – 3.22 (m, 9H), 1.99 (s, 3H). 
13C-NMR (100 MHz, Methanol-d4): δ 169.8 (COCH3), 125.7-116.0 (Ar-C), 98.8 (C1), 77.8 (C3), 
74.3 (C5), 71.5 (C4), 61.9 (C6), 55.7 (C2), 23.5 (NHCH3CO). 
 
62 
 
CHAPTER 2. SYNTHESIS OF SUBSTRATES 
2.2.10 Chemical synthesis of 4-nitrophenyl 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-
β-D-glucopyranoside (7) 
Anomeric carbon activation via chlorination 
2-Acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-glucopyranose (3) (LNB, 380 mg, 0.99 
mmol) was reacted with acetyl chloride (4mL, 56.7 mM) in a three-necked volumetric flask 
with a CaCl2 tube. The reaction was kept at stirring conditions and under nitrogen atmosphere 
for 22 hours. The reaction was diluted DCM (20 mL), washed with aq satd NaHCO3 (4x40 mL) 
and water (3x40mL). The organic layer was dried with MgSO4, filtered and concentrated. 
Brown oil was obtained. It corresponded with a mixture of 50:50 fully acetylated α-chloride (4) 
and α-per-O-acetated (5) LNB (404 mg, 53% yield).  
1H-NMR (400 MHz,CDCl3): 6.04 (d, J=3.7 Hz, 1H, αH1I Cl-LNB), 6.00 (d, J= 3.7 Hz, 1H, αH1I Ac-
LNB), 5.80 (d, J= 8.9 Hz, 1H, NH-Cl-LNB), 5.76 (d, J=8.9 Hz, 1H, NH-Ac-LNB ), 4.75-3.83 (m, 10 H, 
H2-H6), 2.23 (m, 42 H, CH3CO), 1.78 (s, 3H, CH3CONH). 
13C-RMN (100 MHz, CDCl3): δ 171.3-168.2 (COCH3), 100.9/100.8 (C1β/αII),91.7 
(C1βI),91.2(C1αI), 75.7 (C3βI), 72.7 (C3αI), 70.8, 70.3, 69.8, 69.0, 68.1 ( C5αI, C5II, C3II, C5βI, C2II), 
66.6 (C4I), 64.4 (C4II), 61.8, 60.8, 60.4 ( C6I,C6II), 54.4 (C2β), 51.1 (C2α), 23.45-20.2 (CH3CO). 
4-nitrophenol glycosylation 
A mixture of fully acetylated α-chloride (4) and α-per-O-acetated (5) 2-acetamido-2-deoxy-3-O-
(β-D-galactopyranosyl)-D-glucopyranose (404 mg, considering 50% of 4, 202 mg, 0.55 mmol), 
anhydrous DCM (1.4 mL, 18.38 mmol), TBAHS (187.42 mg ,0.55 mmol), 4-nitrophenol (153.7 
mg, 1.104 mmol) and NaOH 1M (1.4 mL, 49.5 mmol) was stirred at room temperature for 3 
hours. The resulting crude was diluted with anhydrous DCM (10 mL) and washed with NaOH 
(40 mL) and water (200 mL) to get rid of unreacted 4-nitrophenol. The organic layer was dried 
with MgSO4, filtered and concentrated. The crude was recrystallized from MeOH, and 4-
nitrophenyl 2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-β-D-glucopyranoside (6) was obtained as a white solid in 49% yield (197.9 
mg, 0.25 mmol). 
1H-NMR (400 MHz,CDCl3): δ 8.21-8.16 (m, 2H, Ar-H), 7.10-7.04 (m, 2H, Ar-H), 6.04 (d, J=3.7 Hz, 
1H, αH1I Cl-LNB), 6.00 (d, J= 3.7 Hz, 1H, αH1 I, Ac-LNB), 5.80 (d, J= 8.9 Hz, 1H, NH-Cl-LNB), 5.76 
(d, J=8.9 Hz, 1H, NH-Ac-LNB ), 4.75-3.83 (m, 10 H, H2-H6), 2.23 (m, 42 H, CH3CO), 1.78 (s, 3H, 
CH3CONH).  
13C-RMN (100 MHz, CDCl3): δ 170.7-169.1 (COCH3), 161.4 (NHAc), 100.9/100.8 (C1β/αII), 125.7-
116.5 (Ar-C), 91.7 (C1βI), 91.2 (C1αI), 75.7 (C3βI), 72.7(C3αI), 70.8, 70.3, 69.8, 69.0, 68.1 ( C5αI, 
C5II, C3II, C5βI, C2II), 66.6 (C4I), 64.4 (C4II), 61.8, 60.8, 60.4 (C6I,C6II), 54.4 (C2β), 51.1(C2α), 
23.45-20.2 (CH3CO).  
Zemplen deacetylation 
Freshly prepared sodium methoxide (1M in methanol, 100 µL) was added to a stirred solution 
of 6 (157 mg, 0.2 mmol) in anhydrous methanol (4 mL), and the mixture was stirred at RT for 
18 hours. A white solid and a yellow solution were obtained. The white solid was filtered, and 
the yellow solution was neutralized with Amberlite® IR-120 (H+) resin and filtered. The white 
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powder was lyophilized to give 4-Nitrophenyl 2-acetamido-2-deoxy-3-O-(β-D-
galactopyranosyl)-β-D-glucopyranoside (7) (43,7 mg, 0.18 mmol) in 75% yield.  
1H NMR (400 MHz, D2O) δ 8.16 – 8.11 (m, 1H, Ar-H), 7.11 – 7.05 (m, 1H, Ar-H), 5.24 (d, J = 8.5 
Hz, 1H,H-1), 4.35 (d, J = 7.7 Hz, 1H), 4.06 (dd, J = 10.4, 8.5 Hz, 1H), 3.87 – 3.77 (m, 2H), 3.73 – 
3.38 (m, 6H), 2.09 (s, 11H), 1.88 (s, 1H, NHCOCH3).  
2.2.11 Synthesis of 1,2-oxazoline derivative of N-acetyl-D-glucosamine (14) 
2.2.8.3.1 Synthesis of 1,2-oxazoline derivative of N-acetyl-D-glucosamine (14) starting from the 
peracetylated sugar 
 
To a solution of N-acetyl-D-glucosamine (2) (2 g, 9 mmol) was added acetic anhydride (Ac2O, 
2 mL, 21 mmol), pyridine (1 mL, 12 mmol) and 4-dimethylaminopyridine (DMAP, 1 mg, 
0.008 mmol). The reaction was stirred at room temperature for 18 hours. Then, MeOH (1.5 vol 
of Ac2O) was poured into the mixture once cold. A fter concentration and dilution with 
chloroform, the organic layer was washed with saturated aq. NaHCO3 and water, dried over 
MgSO4 and the solvent was evaporated at reduced pressure. In order to remove pyridine 
residues, the crude was co-evaporated with toluene. Per-O-acetated N-acetyl-D-glucosamine 
(12) (2.7 g, 4.4 mmol) was obtained as a white powder in 90% yield. 
1H-RMN (400 MHz, CDCl3): δ  6.16 (d, J = 3.4 Hz, 1H, H1α), 5.68 (d, J = 8.8 Hz, 0.09H, NHβ), 5.58 
(d, J = 8.8 Hz, 0.91H, NHα), 5.27-5.15 (m, 2H, H3, H4), 4.52-4.43 (m, 1H, H2), 4.24 (dd, J = 12.5, 
4.1 Hz, 1H, H6a), 4.06 (dd, J = 12.5, 2.4 Hz, 1H, H6b), 4.02-3.96 (m, 1H, H5), 2.17 (dd, J = 10.3, 
0.4 Hz, 6H, CH3CO), 2.12-2.01 (m, 10H), 1.93 (d, J = 0.4 Hz, 3H, NHCOCH3).  
13C-RMN (100 MHz, CDCl3): δ 171.7-168.6 (COCH3), 90.7 (C1β), 70.7 (C3), 69.7 (C5), 67.4(C4), 
61.5 (C6), 51.0 (C2), 23.0-20.5 (CH3CO). 
Using trimethylsilyl bromide and boron trifluoride: Per-O-acetated N-acetyl-D-glucosamine (12) 
(120 mg, 0.3 mmol) was dissolved in anhydrous DCE (10 mL), and then trimethylsilyl bromide 
(TMSBr) (197 μL, 1.5 mmol), BF3·Et2O (163 μL, 1.5 mmol) and 2,4,6-collidine (187 μL, 1.5 
mmol) were added sequentially under nitrogen atmosphere. The mixture was stirred at room 
temperature for 12 h and then diluted with chloroform. The organic layer was washed with 
saturated aq. NaHCO3 and water, dried over MgSO4 and evaporation of the solvent under 
reduced pressure. Reaction was followed by TLC (AcOEt). 
Using trimethylsilyl trifluoromethanesulfonate: A solution of per-O-acetated N-acetyl-D-
glucosamine (12) (1g, 2.6 mmol) in 31 mL of DCE was heated at 50 °C under nitrogen 
atmosphere, followed by the dropwise addition of trimethylsilyl trifluoromethanesulfonate 
(TMSOTf, 550 µl, 3.03 mmol). After 20 h, the reaction was neutralised by slowly adding 
triethylamine (Et3N, 1 mL) at 0 °C and stirring conditions for 10 min. A fter concentration and 
dilution with chloroform, the organic layer was washed with saturated aq. NaHCO3 and water, 
dried over MgSO4 and evaporation of the solvent under reduced pressure. Per-O-acetated 1,2-
oxazoline derivative of N-acetyl-D-glucosamine (13) as an orange-ish oil was obtained (1.8 g). 
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1H-RMN (400MHz, CDCl3): δ 5.97 (d, J = 7.4 Hz, 1H, H1oxa), 5.27 (t, J = 2.5 Hz, 1H, H3), 4.94 
(ddd, J = 9.3, 2.1, 1.2 Hz, 1H, H4), 4.19-4.17 (m, 2H,H2, H6a), 4.14 (ddq, J = 6.0, 3.1, 1.6 Hz, 
1H,H6b), 3.65 – 3.57 (m, 1H, H5), 2.19 – 2.01 (m, 12H,CH3CO). 
13C-RMN (100 MHz, CDCl3): δ 170.6-166.6 (COCH3), 99.4 (C1oxa), 70.4 (C3), 68.4 (C5), 67.5 
(C4), 64.9 (C6), 63.3 (C2), 20.9-13.9 (CH3CO). 
Zemplen deacetylation 
Freshly prepared sodium methoxide (1M in methanol, 450 µL) was added to a stirred solution 
of 13 (1g) in anhydrous methanol (100 mL), and the mixture was stirred at 0 °C for 1 hour (final 
5 mM NaOMe concentration). Solvent was removed by evaporation in vacuum without 
previous neutralization, and the oil obtained was dissolved in water and lyophilised. An orange 
solid corresponding to 1,2-oxazoline derivative of N-acetyl-D-glucosamine (14) was obtained 
with an overall yield of 60% (1 g, 4.9 mmol). 
1H-RMN (400MHz, D2O):) δ 6.10 (d, J = 7.3 Hz, 1H, H1oxa), 4.14 (dddd, J = 7.3, 3.8, 1.8, 1.2 Hz, 
1H, H3), 3.99 (dd, J = 3.8, 3.3 Hz, 1H, H4), 3.83 (dd, J = 12.4, 2.5 Hz, 1H, H6b), 3.68 (dd, J = 12.4, 
6.6 Hz, 1H, H6a), 3.62 (ddd, J = 9.0, 3.3, 1.2 Hz, 1H,H2), 3.40 (dddd, J = 9.0, 6.5, 2.5, 0.6 Hz, 1H, 
H5), 2.07 (d, J = 1.7 Hz, 3H, CH3CO). 
13C-RMN (100 MHz, D2O): 168.0 COCH3 , 100.4 (C1oxa), 72.9 (C3), 71.6 (C5), 68.6 (C4), 65.8 
(C6), 61.6 (C2), 12.9 (CH3CO). 
2.2.8.3.2 Synthesis of 1,2-oxazoline derivative of N-acetyl-D-glucosamine (14) starting from the 
unprotected sugar 
 
Using 2-chloro-1,3-dimethylimidazolinium chloride (DMC): N-acetyl-D-glucosamine (2) (100 mg, 
495 µmol) with Et3N (620 µL, 4.4 mmol) were dissolved in 1.98 mL of 10% D2O in water at 0 °C 
and stirring conditions. Then DMC (251 mg, 1.5 mmol) was added and let to react for 15 min. 
NMR analysis showed the formation of 1,2-oxazoline derivative of N-acetyl-D-glucosamine (14) 
in 90% yield. DMI product (that comes from DMC after reaction) was also present in the final 
product since it was not possible to be removed.  
Using 2-chloro-1,3-dimethyl-1H-benzimidazol-3-ium chloride (CDMBI): a solution of N-acetyl-D-
glucosamine (2) (20 mg, 94.6 µmol) with Na3PO4 (128 mg, 709 µmol) in 630 µL of 10% D2O in 
water, CBMBI (61.5 mg, 238.6 µmol) was added. The solution was stirred at room temperature 
for 1 h, then, centrifuged to removed DMBI (product from CDMBI reaction), and finally, 
lyophilized to give 1,2-oxazoline derivative of N-acetyl-D-glucosamine (14) in 80% yield (16 mg, 
77.12 µmol). There was no DMBI in the final crude, but an excess of salt remained in the final 
product. Before further transglycosylation reactions, solution of oxa-LNB should be dropwise 
neutralized with HCl to decrease Na3PO4 resultant basic pH. 
1H-RMN (400MHz, D2O):) δ 6.10 (d, J = 7.3 Hz, 1H, H1oxa), 4.14 (dddd, J = 7.3, 3.8, 1.8, 1.2 Hz, 
1H, H3), 3.99 (dd, J = 3.8, 3.3 Hz, 1H, H4), 3.83 (dd, J = 12.4, 2.5 Hz, 1H, H6b), 3.68 (dd, J = 12.4, 
6.6 Hz, 1H, H6a), 3.62 (ddd, J = 9.0, 3.3, 1.2 Hz, 1H,H2), 3.40 (dddd, J = 9.0, 6.5, 2.5, 0.6 Hz, 1H, 
H5), 2.07 (d, J = 1.7 Hz, 3H, CH3CO). 
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13C-RMN (100 MHz, D2O): 168.0 COCH3, 100.4 (C1oxa), 72.9 (C3), 71.6 (C5), 68.6 (C4), 65.8 
(C6), 61.6 (C2), 12.9 (CH3CO). 
2.2.12 Synthesis of 1,2-oxazoline derivative of 2-acetamido-2-deoxy-3-O-(β-D-
galactopyranosyl)-β-D-glucopyranose (15) 
Using 2-chloro-1,3-dimethyl-1H-benzimidazol-3-ium chloride (CDMBI): a solution of 2-
acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-glucopyranose (3) (LNB, 16 mg, 41 µmol)  
with Na3PO4 (55.7 mg, 307.5 µmol) in 800 µL of 10% D2O in water, CBMBI (27 mg, 123 µmol) 
was added. The solution was stirred at 4 °C for 90 min. After that, reaction was centrifuged to 
removed DMBI (product from CDMBI reaction), and finally, lyophilized to give 1,2-oxazoline 
derivative of LNB (15) in 80% yield (13 mg, 33.3 µmol). There was no DMBI in the final crude, 
but an excess of salt remained in the final product. Before further transglycosylation reactions, 
solution of oxa-LNB should be dropwise neutralized with HCl (5N) to decrease Na3PO4 
resultant basic pH. 
1H NMR (400 MHz, D2O) δ 6.13 (d, J = 7.4 Hz, 0.8H, H1I-oxa), 5.28 (d, J = 3.6 Hz, 0.2H, 1HI-α), 
4.61 (d, J = 7.9 Hz, 1H, H1II), 4.19 (ddd, J = 7.2, 3.3, 1.7 Hz, 1H), 4.04 (t, J = 3.0 Hz, 1H), 3.83 – 
3.50 (m, 11H), 3.28 – 3.22 (m, 1H), 1.95 (t, J = 2.0 Hz, 2H). 
2.2.13 Stability studies of 1,2-oxazoline derivative of N-acetyl-β-D-glucosamine 
Different solutions of 14 in 50 mM citrate-phosphate buffer with 10% D2O in a pH range of 3.5-
9.0 were studied. At WET_1D NMR conditions, three signals were followed to determine the 
evolution of the hydrolysis of the oxazoline ring. oxa-GlcNAc is followed with the signal at 5.95 
ppm (J = 7.4 Hz ), and the α-GlcNAc and β-GlcNAc formed due to hydrolysis were followed at 
5.05 ppm (J = 3.7 Hz )  at 4.50ppm (J = 8.9 Hz ) respectively (see Figure 2.12). 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Enzymatic synthesis of LNB by β-Gal-3 
 
LNB (3) was prepared as starting material for the synthesis of the target activated donors p-NP-
LNB (7) and oxa-LNB (15) according to the total synthesis scheme 1. The reaction was catalysed 
by β-galactosidase (β-Gal3) from Bacillus circulans ATCC 31382 using p-NP-Gal (as donor) and 
GlcNAc (as acceptor) to yield LNB (Galβ-1,3GlcNAc). 
 
Figure 2.3 Enzymatic synthesis of Lacto-N-biose (3) by β-Gal-3 transglycosilation. 
 
β-Gal-3 was first identified by Ito and coworkers. This enzyme, with a molecular size of 67 kDa, 
belongs to the family GH35 glycosyl hydrolases. β-Gal-3 hydrolyses β-1,3 linkages, but also 
performs transglycosylation (Fujimoto et al., 1998). By using different ionic liquids, Hernáiz and 
coworkers reported the synthesis of LNB mediated by β-Gal-3 transglycosylation with yields of 
99 % (Bayón et al., 2013).  
With the collaboration of Dr. Hernáiz (Department of Organic and Pharmaceutical Chemistry, 
Faculty of Pharmacy, Complutense University of Madrid), β-Gal3 was successfully expressed to 
obtain N-terminally His-tagged recombinant protein in a yield of 10 mg of protein per litre of 
culture.  
The transglycosylation reaction was performed at 85 mM of p-NP-Gal, 425 mM of GlcNAc and 
2.5 µM of protein in 100 mM phosphate buffer pH 6.0 and 30% of [BMIN][PF6] at 37 °C. 
Reaction was followed by HPLC using two detectors: ELSD (Evaporative Light Scattering) and 
UV at 317 nm. Final recovery of 27 grams of dried crude was obtained. 
Figure 2.4 shows the chromatograms at different reaction times. According to standards, peaks 
before 3 min corresponds to [BMIN][PF6] and salts. The peak at 4 min corresponds to p-NP-
Gal, which decreases while the reaction evolves. The peak at 10 min corresponds to GlcNAc, 
which is fully saturated during the whole analysis due to the high amount added to the 
reaction (5-fold excess of acceptor compared to the donor). During the reaction, a new peak 
appears at 17 min, which corresponds to LNB. As is observed, the LNB peak is maximum at 2.5 
hours and, from then, p-NP-Gal had completely reacted and the enzyme hydrolysed the 
disaccharide product. For this reason, reaction yield of this scale-up reaction was 78% instead 
of the reported 98% (Bayón et al., 2013). 
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Figure 2.4 Transglycosylation reaction followed using HPLC-ELSD. 
 
Purification of Lacto-N-biose from the enzymatic crude 
It was expected that the enzymatic crude was composed of LNB, GlcNAc and p-NP in a ratio of 
1:4:1 according to reaction conditions. In addition, TLC analysis confirmed traces of Gal and 
impurities.  
Two different strategies were used for the purification of the Lacto-N-biose. The first one was 
directly performed with the crude that contained unprotected sugars using a charcoal-celite 
column. The second one was performed with the acetylated sugars and involved three steps, 
sugar acetylation, purification using a silica-gel column, and deacetylation. 
Purification of Lacto-N-biose using charcoal-celite 
The crude was dissolved in water (<2% of the total volume of the column) and loaded into the 
charcoal-celite column. The elution was performed as Table 2.1 indicates. LNB, eluted with 5% 
of ethanol, could be purified from GlcNAc and impurities, and it was identified by TLC analysis 
(ACN:H2O, 80:20). Enriched carbohydrate fractions were lyophilised and stored at -20 °C.  
Table 2.1 Elution gradient of charcoal-celite chromatography. 
 
Eluent Recovered 
product 
Elution 
volume (L)  
H2O GlcNAc 3 
1% EtOH - 1 
2% EtOH Impurities 0.5 
5% EtOH LNB 3 
20% EtOH Impurities 1 
 
Column recovery was 60% of the total crude loaded into the column. LNB recovery yield was 
70 %, since at least, p-NP did not elute from the column due to the hydrophobic properties of 
the charcoal-celite stationary phase. The structure of LNB was confirmed by the characteristic 
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signals using NMR analysis (δ 5.19 ppm (d, J = 3.5 Hz, 1H, H1Iα)), and by MS analysis (MS m/z 
384 [M+H]+; 406 [M+Na]+) . 
Purification of Lacto-N-biose using silica-gel 
The enzymatic crude was acetylated in quantitative yield. Flash chromatography was 
performed on silica-gel using a gradient of AcOEt/Cy as eluent in 95-98% yield.  The elution 
was as it follows: p-NP, peracetylated GlcNAc (Ac-GlcNAc) and peracetylated LNB (Ac-LNB). 
Carbohydrate enriched fractions were evaporated and stored at -20 °C. The corresponding 
structures were confirmed by NMR analysis (see the experimental section).  
Deacetylation with NaOMe/MeOH was performed to deacetylate the peracetylated LNB. 
Standard reaction conditions involving low NaOMe/Ac-LNB molar ratio (< 1), 24 hours of 
reaction and at room temperature (Table 2.4, entries 1 and 2), rendered hydrolysis of the 
disaccharide to yield the corresponding monosaccharides. These results were not expected, 
since these conditions are extensively used for deacetylation of β-1,3 and β-1,4 sugars. It 
suggests that oligosaccharides with β-1,3  linkages and an acetamide group in C-2 position are 
not stable at high basic conditions. Subsequently, different reaction conditions were studied: 
NaOMe concentrations, Ac-LNB/NaOMe molar ratio, temperatures and reaction time. 
Reactions were analysed by TLC. Detail conditions are shown in Table 2.2.  
Table 2.2 Screening of Zemplen reaction of compound 16. 
 
 
 
When performing a similar NaOMe/Ac-LNB molar ratio conditions (< 1) and at 0°C (entries 3 
and 4), reactions did not evolved. In contrast, at high NaOMe/Ac-LNB molar ratio (entries 4-11) 
and shorter time of reaction (<2.5 h) (entries 5-12), partial deacetylation of the disaccharide 
was observed in all cases, and also another compound, most probably O-methyl disaccharide 
Reaction 
number 
[Ac-LNB] 
(mM) 
[NaOMe] 
(mM) 
NaOMe/Ac-LNB 
molar ratio 
(mM) 
Reaction 
 time  
(h) 
Temperature 
1 50.4 24 0.5 20 R.T. 
2 26.2 10 0.4 20 R.T 
3 8.2 0.4 0.05 4 0 °C 
4 9.2 1 0.1 20 0 °C 
5 4.5 29.1 6.5 0.5 R.T 
6 4.5 29.1 6.5 1 R.T 
7 4.4 38.5 8.7 1.5 R.T 
8 4.4 47.6 10.8 2 R.T 
9 4.4 47.6 10.8 2.5 R.T 
10 4.5 19.6 4.3 0.5 R.T 
11 4.5 19.6 4.3 1 R.T 
12 4.5 29.1 6.5 1.5 R.T 
13 4.5 29.1 6.5 2 R.T 
14 81.7 23.1 0.3 1 R.T 
15 81.7 23.1 0.3 1.5 0°C 
16 39.7 23.1 0.6 6 0°C 
69 
 
CHAPTER 2. SYNTHESIS OF SUBSTRATES 
derivative. Best conditions for deacetylation of the Ac-LNB were found at low NaOMe/Ac-LNB 
molar ratio (< 1) and shorter time of reaction (Table 2.4, entries 14-16). Best conditions at 0°C 
(entry 15) rendered total deacetylation of the disaccharide with a minor amount of O-methyl 
disaccharide derivative. 
Given the difficulties due to the NaOMe basic conditions, a milder strategy using methanolic 
ammonia (NH3/MeOH) was used (Neilson and Werstiuk, 1971). Reactions of peracetylated LNB 
and GlcNAc (as control) were performed and followed by TLC. 
According to literature, after 3 h of reaction, deacetylation should be complete. However, in 
our hands, peracetylated products were present at 3 h of reaction, and after 50 h, 
deacetylation was complete, but a minor amount of sugar with the OMe group at the C-1 
position were also found. 
Considering these results, purification of the enzymatic crude with unprotected sugars and 
using the charcoal-celite column was chosen.  
2.3.2 Synthesis of p-nitrophenyl β-lacto-N-bioside (p-NP-LNB) 
 
Since the transglycosylation strategy for the synthesis of LNT involves p-NP-LNB (7) as 
substrate, different syntheses of this compound were evaluated. Total synthesis 2 scheme 
proposes the enzymatic synthesis of p-NP-LNB from monosaccharides, and in total synthesis 1 
scheme it is developed the chemical synthesis from LNB. 
 
2.3.2.1 Enzymatic synthesis of p-nitrophenyl β-lacto-N-bioside via β-Gal-3 transglycosylation 
 
β-Gal-3 enzyme was evaluated as biocatalyst of the reaction between p-NP-Gal (as donor) and 
p-NP-GlcNAc (as acceptor) to yield p-NP-LNB (p-NP-Galβ-1,3GlcNAc) (7). 
 
Figure 2.5 Enzymatic synthesis of compound 7 using β-Gal-3 transglycosylation. 
  
The transglycosylation activity was assayed using 2 nM of protein, 85 mM of p-NP-Gal and of p-
NP-GlcNAc at 1:5 or 1:10 donor:acceptor molar ratio in a final volume of 100 µL. Enzymatic 
reactions were performed in 100 mM phosphate buffer pH 6.0 at 37 °C and different amounts 
of ionic liquids. At different times, 1 and 3 hours, 20 µL of samples were taken and analysed 
using HPLC-ELSD-UV. Specific reaction details are listed in Table 2.3. 
 
 
 
 
Β-Gal-3+O
OH
HO
OH
OH
O
NO2
1
O
HO
HO
NHAc
HO
O
NO2
8
O
OH
HO
OH
OH
OHO
O
AcHN
OH
O
NO2
7
70 
 
CHAPTER 2. SYNTHESIS OF SUBSTRATES 
Table 2.3 Screening of different ionic liquids for transglycosylation reactions using β-Gal-3 and p-NP-GlcNAc as 
acceptor. 
BMIN [PF6]: 1-Butyl-3-methylimidazolium hexafluorophosphate, TROMA [NTF2]: methyltrioctylammoniumbis 
(trifluoromethylsulfonyl)-imide, BMIN [NTF2]: 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfony1) imide. 
 
Reaction 
number 
Ionic liquid Final amount 
used (v/v) 
Molar ratio 
donor : acceptor 
1 BMIN [PF6] 30% 1:5 
2 BMIN [PF6] 30% 1:10 
3 TROMA [NTF2] 30% 1:5 
4 BMIN [NTF2] 30% 1:5 
5 GC12 43% 1:5 
6 GC9 49% 1:5 
 
In Figure 2.6, chromatograms obtained after 1 hour of reaction are shown. Figure 2.6A shows 
p-NP-LNB as standard. Figures 2.6B-G show peaks before 3 min, which corresponds to ionic 
liquids and buffer, and peak at 4 min to the substrates p-NP-Gal and p-NP-GlcNAc. While 
reactions evolved, new peaks at higher retention times appeared. Peak at 5.9 min corresponds 
to p-NP-LNB and peaks at 7.7 and 8.7 correspond to p-NP derivatives since they absorbed at 
UV (317 nm). It is known that β-Gal-3 can also formed β -1,6 linkages when GlcNAc was used as 
acceptor (Bayón et al., 2013). Here, using p-NP-GlcNAc as acceptor might change the 
regiospecifity of the enzyme, and peaks at 7.7 and 8.7 min could correspond to the β-1,4 and 
β-1,6 isomers of LNB, but they were not further identified. 
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Figure 2.6 HPLC-ELSD chromatograms of the transglycosylation reaction of p-NP-LNB at 1 hour.  
(A) p-NP-LNB standard in phosphate and reactions in the presence of (B) BMIN [PF6] 1:5 (C) BMIN [PF6] 1:10 (D) 
BMIN [NTF2] 1:5  (E) GC 9 (F) GC 12 (G ) TROMA [NTF2].  
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The same products were obtained in all six reactions, regardless of the ionic liquid used.  
However, p-NP-LNB was never the major product obtained. Transglycosylation in the presence 
of BMIN [NTF2], GC12 and GC9 (Figure 2.6E-G) was very low, while the best conditions were 
obtained in the presence of BMIN [PF6] (Figure 2.6B). In this case, LNB was obtained in 32% of 
the total products formed. In addition, transglycosylation was not increased when a higher 
excess of acceptor was used (Figure 2.6C), suggesting that p-NP-GlcNAc could act as inhibitor. 
Moreover, increasing the reaction time to 3 hours, products were hydrolysed. As is shown in 
Figure 2.7, peaks at 5.9, corresponding to p-NP-LNB and peak at 8.7 min decreased from 1 
hour of reaction (Figure 2.7B) to 3 hours of reaction (Figure 2.7C). 
 
Figure 2.7 HPLC-ELSD chromatograms of the transglycosylation reaction of p-NP-LNB using BMIN [PF6]. 
(A) (A) p-NP-LNB standard in phosphate. Reactions LNB using 30% BMIN [PF6] and 1:5 molar ratio (donor:acceptor) 
at  (B)1 hour of reaction (C) 3 hour of reaction. 
 
Moreover, transglycosylation reaction between p-NP-Gal and p-NP-GlcNAc was also evaluated 
with immobilised β-Gal-3. Immobilisation of the enzyme can offer several advantages such as 
repeated recycle of the enzyme, simple separation of reaction products from the biocatalyst 
and enhance enzyme stability (Hernaiz and Crout, 2000a). In some cases, even changes in 
regioselectivity have been observed. For example, immobilised β-galactosidase from B. 
circulans (Biolacta N5) showed a specific regioselectivity for β-1,4 N-acetyllactosamine (Galβ-
1,4GlcNAc), while the free form of the enzyme yielded β-1,4 and β-1,6 isomers (Hernaiz and 
Crout, 2000b). 
In collaboration with Dr. Hernáiz group, β-Gal-3 was immobilised with glyoxyl-agarose in order 
to assess whether the regioselectivity of the enzyme could be modified. Glyoxyl agarose is 
constituted by thick agarose fibres containing a large number of very stable aldehyde groups 
attached to the support by short spacer arms. Under alkaline conditions, the protein is 
immobilised. After borohydride reduction  the enzyme remains attached to the support by 
means of very stable secondary amino groups (Mateo et al., 2006). 
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Figure 2.8 Immobilization strategy with glyoxyl-agarose. 
 
The transglycosylation activity was assayed using 30 mg of immobilised enzyme (0.03 mg of 
protein), 85 mM of p-NP-Gal and 425 mM of p-NP GlcNAc (1:5 donor:acceptor molar ratio)  in 
a final volume of 100 µL. Enzymatic reactions were performed at 37 °C and 100 mM phosphate 
buffer pH 6.0 in the absence or the presence of 30% of BMIN [PF6]. 
 
Figure 2.9 HPLC-ELSD Chromatograms of the transglycosylation reaction of p-NP-LNB using immobilised β-Gal-3 at 
1 hour of reaction. 
(A) p-NP-LNB standard, (B) 100 mM phosphate buffer, (C) phosphate buffer and BMIN [PF6]. 
 
In Figure 2.9, chromatograms after 1 hour of reaction are shown.  In addition to the peaks at 3 
and 4 min corresponding to BMIN [PF6], salts and substrates (p-NP-Gal and p-NP-GlcNAc), two 
new peaks, at 5.9 and 8.7 appeared. None of the reaction conditions assayed were satisfying. 
In the absence of BMIN [PF6], other regioisomer than β-1,3 was mainly formed, and in the 
presence of BMIN [PF6] transglycosylation yield was very low. In conclusion, the catalytic 
efficiency of immobilised β-Gal-3 when using p-NP-GlcNAc as acceptor was decreased 
compared to the free enzyme. These results are in agreement with the literature, since 
immobilised β-Gal-3 also showed a reduction in catalytic efficiency when GlcNAc was used as 
acceptor to synthesise LNB. In the presence of phosphate buffer without ionic liquid, 
transglycosylation yield using immobilised β-Gal-3 was reduced from 51% to 31%, and in the 
presence of BMIN [PF6], the yield was decreased from 99% to 55% (Carlos Bayón Sánchez, 
2013).  
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2.3.3.2 Chemical synthesis of p-nitrophenyl β-lacto-N-bioside 
Since the chemical synthesis of p-NP-LNB was not reported by the time of this study, the 
approach was done based on the synthesis of p-NP-GlcNAc from GlcNAc (Chen and Withers, 
2007; Hattie et al., 2012; Sauerzapfe et al., 2008). As total synthesis 1 scheme shows, this 
involves the activation of the anomeric carbon via chlorination, followed by p-NP glycosylation, 
and further deacetylation. More details are presented in Figure 2.10. 
 
 
Figure 2.10 Synthesis of the substrate 7. 
Anomeric carbon activation by chlorination, further 4-nitrophenol glycosylation and finally sugar deprotection.  
 
LNB (3) was reacted with acetyl chloride at room temperature to give a mixture of both sugars, 
the fully acetylated α-chloride (4, 50%) and the α-per-O-acetate (5, 50%). MS (m/z 676 
[M+Na]+ of Cl-LNB; 700 [M+Na]+ of Ac-LNB) and NMR analysis confirmed the presence of both 
products (δ 6.04 ppm (d, J=3.7 Hz, 1H, αH1I Cl-LNB)) and 6.00 ppm (d, J= 3.7 Hz, 1H, αH1I Ac-
LNB)). This mixture, without further purification, was used for the phase transfer glycosylation 
reaction with 4-nitrophenol (p-NP). After several aqueous ammonium carbonate washing 
steps, the crude was treated under Zemplen conditions to remove the acetyl protecting 
groups. The sugar crystallised during deacetylation and was washed after filtration with MeOH 
to give pure p-NP-LNB (7, 11% yield). MS (m/z 527.2 [M+Na]+) and NMR analysis confirmed the 
structure of compound 7 (8.20  ppm (d, J = 9.2 Hz, 2H, Ar-H), 7.18 ppm (d, J = 9.2 Hz, 2H, Ar-H), 
5.24 ppm (d, J = 8.5 Hz, 1HI). 
The same reaction was performed with GlcNAc (2) to obtain p-NP-GlcNAc (8). Contrary to 
compound 7, compound 8 was obtained in 65% of yield. The low yield obtained in p-NP-LNB 
synthesis was mainly due to the workup after glycosylation. Later, Thiem and coworkers 
reported the synthesis and substituted the workup step for a chromatography step increasing 
the yield up to 33% (Böttcher and Thiem, 2014). 
2.3.3 Synthesis of 1,2-oxazoline derivatives 
Since the glycosynthase strategy for the synthesis of LNT involves oxa-LNB (15) as substrate, 
different syntheses of this compound were evaluated. Total synthesis 2 scheme proposes the 
enzymatic synthesis of oxa-LNB from monosaccharides and total synthesis 1 scheme, the 
chemical synthesis from LNB. 
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2.3.3.1 Chemical synthesis of 1,2-oxazoline derivative of GlcNAc 
 
β-Gal-3 enzyme was evaluated as biocatalyst for the synthesis of the oxazoline derivative of 
Lacto-N-biose (oxa-LNB). The reaction involved p-NP-Gal (as donor) and the oxazoline 
derivative of GlcNAc (oxa-GlcNAc, as acceptor) to yield p-NP-LNB (p-NP-Galβ-1,3GlcNAc). 
Oxazoline ring formation of N-acetylglucosamine (14) was evaluated using two different 
methodologies. It was first attempted by acetylation followed by treatment of (10) with TMSBr 
and boron trifluoride in the presence of collidine as  reported by Huang et al., 2009. Other side 
reaction products were seen and should be separated by a chromatographic step, therefore, 
and other methodology was applied. 
Then, the synthesis of 14 was prepared essentially as originally reported in Shoda et al., 2002. 
Compound 2 was acetylated, followed by oxazoline ring formation with trimethylsilyl 
trifluoromethanesulfonate (TMSOTf). Finally, the acetyl groups were removed by NaOMe in 
MeOH. Typical neutralization with Amberlite® IR-120 (H+) resin was not applied, since this 
acidic condition opens the oxazoline ring. The characteristic NMR signal of the proton of the 
anomeric carbon (5.95 ppm, J = 7.3 Hz) confirmed the structure of 14. Pure compound 14 was 
obtained with an overall yield of 60%.  
 
Figure 2.11 Synthesis of compound 14.  
Acetylation, followed by oxazoline ring formation with trimethylsilyl trifluoromethanesulfonate (TMSOTf) and 
further deacetylation. 
 
pH-dependence study of 14 
Stability of the oxazoline ring at different pHs was evaluated in order to perform further 
transglycosylation reactions. Hydrolysis rates of 14 were studied by NMR using Water 
Suppression Enhanced analysis (WET_1D) (Figure 2.12). The WET method uses selective pulses, 
applied on the solvents resonance, followed by pulsed field gradients to dephase residual 
solvent magnetization.  Oxazoline ring is more stable if the amide group is deprotonated. 
When it is protonated, the oxazoline ring is opened via hydrolysis, and GlcNAc (2) is obtained. 
At WET_1D NMR conditions, proton of the anomeric carbon of the oxazoline derivative can be 
observed at 5.95 ppm (J = 7.4 Hz) and the corresponding to α-GlcNAc and β-GlcNAc appeared 
at 5.05 ppm (J = 3.7 Hz) and 4.50ppm (J = 8.9 Hz), respectively.  
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Figure 2.12 NMR analysis of compound 14 after 16 h in 50 mM citrate-phosphate buffer at pH 7. 
Characteristic signals are highlighted. 1:  proton of the anomeric carbon when the oxazoline ring is formed (d, J = 7.4 
Hz), 2: proton of the anomeric carbon when the oxazoline ring is opened in an alpha conformation (d, J = 3.7 Hz) 
and 3: proton of the anomeric carbon when the oxazoline ring is opened in an beta conformation (d, J = 8.9 Hz). 
 
Below pH 4.5 the oxazoline ring was immediately hydrolysed. In Figure 2.13A the evolution of 
the stability of the oxazoline ring at different pHs is shown. Oxazoline ring suffered a fast 
hydrolysis rate at pH 4.5, 5.0 and 6.0. In contrast, at pH 6.5 and 7.0 the hydrolytic rate was 
slower, and the complete hydrolysis occurred after 24 h. Above pH 7.5 the oxazoline ring 
remained stable for at least 48 h. 
 
Figure 2.13 pH-dependence study of compound 14. 
(A) Hydrolysis of the oxazoline ring of 14 at different pHs. (B) Kinetic profile of the hydrolysis of the oxazoline ring of 
14. 
 
As shown in Figure 2.13B, when hydrolytic rates at different pHs are plotted, an estimated pKa 
value of 5.4 was obtained. When the amide group of the oxazoline is protonated, the nitrogen 
has a positive charge, favouring oxazoline ring opening. In conclusion, enzymatic reactions with 
oxazoline derivative substrates are recommended to be performed at pH above 6.5.  
2.3.3.2 Enzymatic synthesis of 1,2-oxazoline derivative of Lacto-N-biose by β-Gal3 
 
β-Gal-3 was also evaluated as biocatalyst for the synthesis of the oxazoline derivative of Lacto-
N-biose (oxa-LNB). As total synthesis 2 scheme shows, the reaction using p-NP-Gal as donor, 
and oxa-GlcNAc as acceptor to yield oxa-LNB (15) was explored. Oxa-GlcNAc was synthesised 
following the procedure cited in section 2.3.3.1. 
1
2
3
77 
 
CHAPTER 2. SYNTHESIS OF SUBSTRATES 
 
Figure 2.14  Enzymatic synthesis of compound 15 by β-Gal-3 transglycosylation. 
 
β-Gal-3 remains active (>80%) in a pH range of 5-8. At higher pH values, addition of 50% PEG-
600 to the reaction media stabilised the protein, and it remained still catalytically active 
(>60%) at pH 10 for 120 min (Carlos Bayón Sánchez, 2013).  
Considering pH dependence stability of the oxazoline ring and the catalytic activity of β-Gal-3 
at basic conditions, transglycosylation reactions for oxa-LNT synthesis were set at pH 7.5 and 
10. 
Final reaction conditions involved 2 nM of protein, 85 mM of p-NP-Gal and 425 mM oxa-
GlcNAc (donor:acceptor molar ratio, 1:5)  in a final volume of 200 µL and at 37 °C. Enzymatic 
reactions were performed in 100 mM phosphate buffer and in the presence or absence of PEG 
and BMIN [PF6].  
Table 2.4 Different screening conditions for transglycosylation reactions using β-Gal-3 and oxa-GlcNAc as the 
acceptor. 
 
Reaction 
number pH 
PEG 
(v/v)  
BMIN [PF6] 
(v/v) 
1 7.5 - - 
2 7.5 50% - 
3 7.5 - 30%  
4 10 50% - 
 
Transglycosylation was not observed in any of the reaction conditions checked. Product 
formation was not observed by HPLC-ELDS. Since the oxazoline ring was stable at these 
conditions, it is concluded that β-Gal-3 did not recognize oxa-GlcNAc as acceptor. 
2.3.3.3 Chemical synthesis of 1,2-oxazoline derivative of Lacto-N-biose 
When the same methodologies described for the monosaccharide 12 using TMSOTf or TMSBr 
and boron trifluoride (reported in section 2.3.3.1) was applied to the peracetylated 
disaccharide LNB (16), reactions rendered the hydrolysis of the disaccharide. Although these 
reactions were successfully reported in the literature for β-1,4 linked oligosaccharides, here we 
can confirm that are not applicable to  β-1,3 bound disaccharides. 
Alternatively, the synthesis of oxa-LNB (15) was assayed directly with LNB (3) and  2-chloro-
1,3-dimethylimidazolinium chloride (DMC)  in aqueous media as reported by Noguchi et al., 
2009 (Figure 2.15). 
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Figure 2.15 Synthesis of compound 15 by using DMC. 
 
The mechanism of oxazoline ring formation in water involves the preferential attack of the 
hydroxyl group of the beta anomer to the 2-position of DMC to give a reactive intermediate 
with β-configuration (Figure 2.16). Then, an intra-molecular attack of the carbonyl oxygen of 
the 2-acetamido group, followed by the abstraction of the amide proton by triethylamine, 
render a sugar oxazoline and 1,3-dimethyl-2-imidazolidinone. The hydroxyl group of the α-
anomer, which is in equilibrium with the β one, may also react with DMC to form an R-adduct. 
However, the resulting intermediate is immediately hydrolysed by the attack of water, 
regenerating the starting free sugar, because intra-molecular ring formation from the R-adduct 
is sterically prohibited. In addition, a considerable amount of DMC was decomposed by the 
attack of H2O before being converted to the intermediate (glycosyl dimethylimidazolinium 
salt) giving rise to the hydrolysed reagent, 1,3-dimethyl-2-imidazolidin-2-one (DMI). 
 
Figure 2.16 Plausible Mechanism for sugar oxazoline formation by DMC. 
 
Synthesis of the disaccharide 15 and monosaccharide 14 (used as control) were successfully 
achieved in high yields (90%). However, products were not pure since DMI was not easy to 
remove and appeared in the final product. Other disadvantages concerning the use of DMC 
involved that it was extremely hygroscopic. Moreover, DMI can strongly inhibit enzymatic 
reactions according to literature (Noguchi et al., 2009). 
Thus, an alternative synthesis of the sugar oxazoline derivatives was performed by using a 
newly designed dehydrative condensing agent, 2-chloro-1,3-dimethyl-1H-benzimidazol-3-ium 
chloride (CDMBI) (Figure 2.17). In this case, the existence of the benzene ring decrease the 
solubility of the 1,3-dimethyl-1H-benzimidazol-2-one produced (DMBI) as a result of oxazoline 
formation and can be removed by filtration (Noguchi et al., 2012). 
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The synthesis of compound 15 and 14 (used as control) were prepared directly from the 
corresponding 2-acetamido-2-deoxy sugars in aqueous media by using CDMBI and Na3PO4 to 
yield 80% in both cases. During the reaction DMBI precipitated. NMR analysis confirmed the 
structure of oxa-LNB (6.13 ppm (d, J = 7.4 Hz, 0.8H, H1I-oxa)) with a minor presence of LNB 
(5.28 ppm (d, J = 3.6 Hz, 0.2H, 1HI-α)).  In this case, there was no side product (DMBI) in the 
final crude, but an excess of salt remained in the final product. Before its use in 
transglycosylation reactions, the solution of oxa-LNB was neutralised with HCl to decrease the 
pH around 7. 
 
Figure 2.17 Synthesis of compound 15 by using CDMBI. 
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2.4 CONCLUSIONS 
The synthesis of LNB using β-Gal-3 transglycosylation with p-NP-Gal and GlcNAc and further 
purification with charcoal/celite chromatography successfully rendered LNB. By contrast, LNB 
could not be obatined when silica-gel purification was performed after acetylation and 
followed by Zemplen reaction. Deacetylation on peracetylated LNB under standard conditions 
yielded hydrolysis meaning high lability of the β-1,3 linkage when an acetamide group in 
position 2 is present. Best deacetylation reaction conditions were low sodium 
metoxide/peracetylated LNB ratio, low temperature and short time reaction. 
 
The synthesis of oxa-LNB, substrate for the glycosynthase approach, was achieved from LNB 
via chemical oxazoline ring formation using a newly designed dehydrative condensing agent, 
CDMBI, in water solution. By contrast, transglycosylation reaction between p-NP-Gal and oxa-
GlcNAc using β-Gal-3 as biocatalyst did not occur. 
The synthesis of p-NP-LNB, substrate for the transglycosylation approach, was afforded via 
chemical synthesis with chlorination step, phase transfer glycosylation and deacetylation with 
a yield of 11%. Using β-Gal-3 transglycosylation with p-NP-Gal and p-NP-GlcNAc, the reaction 
was not regioselective and β-1,3, and others isomers were formed.   
p-NP-LNB and oxa-LNB are ready to be used for the kinetic study of the enzyme lacto-N-
biosidase, and for the subsequent enzyme-catalysed transglycosylation using lacto-N-biosidase 
mutants to achieve the target lacto-N-tetraose. 
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3.1 INTRODUCTION 
Bifidibacterium bifidum Lacto-N-biosidase (LnbB) is a critical enzyme in the selective promotion 
of the growth of bifidobacteria in the infant gut ecosystem. It has recently been found that 
bifidobacteria assimilate HMO as their sole carbon source, since they possess a unique 
metabolic pathway specific for Lacto-N-biose (LNB) called the GNB/LNB pathway. In particular, 
LnbB is the responsible of the hydrolysis of the lacto-N-tetraose (LNT, 19) into lacto-N-biose 
(LNB, 3)  and lactose (18) disaccharides (Figure 3.1) (Wada et al., 2008).  
 
Figure 3.1 Hydrolysis of Lacto-N-tetraose catalysed by Lacto-N-biosidase to yield lacto-N-biose and lactose. 
 
LnbB consists of 1112 amino acids and contains a signal peptide, a catalytic GH20 domain, a 
carbohydrate-binding module (CBM) from family 32, a bacterial Ig-like domain, and a 
membrane anchor according to Wada and coworkers (Wada et al., 2008).  
LnbB is classified as a member of family 20 glycosyl hydrolases (GH20), and as other members 
of this family, it has been shown to use a two-step catalytic mechanism involving substrate-
assisted catalysis. 
In terms of substrate specificity, it is known that LnbB does not hydrolyse the fucosylated 
forms of lacto-N-tetraose (lacto-N-fucopentaose I and II) or lacto-N-neotetraose (LNnT, type 2 
chain), indicating that LnbB specifically releases LNB from the non-reducing end of unmodified 
type 1 oligosaccharides. In addition, among the para-nitrophenyl (p-NP) sugars tested, the 
enzyme is more active toward p-NP-LNB and less active toward p-NP-GNB (30% compared to 
p-NP-LNB), and did not hydrolyse α-linked disaccharides. The LnbB protein does not act on β-
linked p-NP monosaccharides, including p-NP-GlcNAc and p-NP-GalNAc. With respect to pyridyl 
amino (PA)  oligosaccharides, the enzyme acts on lacto-N-tetraose, but not on the ganglioside 
structure with a β-linked GNB (Wada et al., 2008).  
Due to the relevant characteristics of LnbB, we envisage LnbB as a promising biocatalyst for 
HMO synthesis. In this chapter, we report the kinetic characterization of the recombinant LnbB 
and the identification of its catalytic residues. 
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3.2 MATERIALS AND METHODS 
3.2.1 Bioinformatics 
Protein sequences were retrieved from UniProt (http://www.uniprot.org). Assignment of 
protein domains were obtained from different databases (Pfam, Superfamily, PSI-BLAST and 
CAZY) and also using predicting online tools; Jpred3 (Cole et al., 2008) and HHpred (Söding et 
al., 2005)Sequence alignment was performed with PROMALS (Pei and Grishin, 2007) and 
ClustalW with default options.  
3.2.2 General materials and experimental procedures 
3.2.2.1 Materials 
 
All reagents are from Sigma-Aldrich unless otherwise designated. 
Bacterial strains 
Escherichia coli DH5α (Invitrogen) was used as host strains for regular cloning experiments. 
Escherichia coli BL21 (DE3) (Invitrogen) was used for protein expression. 
Plasmids 
pET 24b and pET 28a+ (Novagen) were used for cloning and protein expression.  
Oligonucleotides 
The oligonucleotides used in this work were purchased from Stab Vida Laboratories. 
LB broth (Luria-Betrani) 
10 g/L bacto-tryptone, 5 g/L bacto-yeast extract and 10 g/L NaCl, pH 7.2 
To prepare solid medium, 15 g/L bacto agar was added to LB and poured on Petri dishes. 
Kanamycin stock solutions 
Kanamycin (Kan) stock solutions (30 mg/mL) were prepared in distilled sterile water and 
filtered with 0.2 μm syringe filters.  
Final concentration at culture media was 30 µg/mL. 
 
Autoinduction media 
LB media supplemented with; 25mM Na2HPO4, 25mM K2HPO4, 50mM NH4Cl, 5mM Na2SO4, 
2mM MgSO4, 0.5% (w/v) glycerol, 0.05% (w/v) glucose and 0.2% (w/v) lactose. 
 
Protease inhibitor cocktail (PMSF) solutions 
PMSF stock solutions (100mM) were prepared in isopropanol. 
 
DNA loading buffer (6X) 
360 mM Tris-base at pH 8.8, 9% (w/v) SDS, 0.9% (w/v) bromophenol blue, 15% (v/v) β-
mercaptoethanol and 30% (w/v) glycerol. 
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TAE buffer (50X) 
2M Tris-base, 50mM EDTA and 17.5% (v/v) glacial acetic acid. 
 
Agarose gel for DNA analysis 
0 1% (w/v) of agarose in TAE buffer (1X). Heat the solution on hot plate until rolling boil, let 
cool for 10 minutes, and add ethidium bromide to a final concentration of 0.5 µg/mL before 
pouring gel in the container. 
 
Running gel solution for SDS-PAGE analysis  
125 mM Tris-base at pH 6.8, 0.1% (w/v) SDS, 10-20% (w/v) ammonium persulfate, 0.1% (v/v) 
TEMED and 8-16% (v/v) acrylamide. 
 
Stacking gel solution for SDS-PAGE analysis  
375 mM Tris-base at pH 8.8, 0.1% (w/v) SDS, 10-20% (w/v) ammonium persulfate, 0.1% (v/v) 
TEMED and 4% (v/v) acrylamide. 
 
Running buffer for SDS-PAGE analysis 
25 mM Tris-base, 190 mM glycine and 0.1% (w/v) SDS, at pH 8.3. 
 
Protein loading buffer (5X) 
63 mM Tris-base at pH 6.8, 10% (w/v) glycerol, 2% (w/v) SDS, 5% (v/v) ß-mercaptoethanol and 
0.0025% (w/v) bromophenol blue. 
 
Buffer A for enzyme purification 
20 mM Na2HPO4, 150 mM NaCl at pH 7.5. 
 
Buffer B for enzyme purification (Affinity purification) 
20 mM Na2HPO4, 150 mM NaCl, 500 mM imidazole at pH 7.5. 
 
Buffer C for enzyme kinetics 
25 mM Na2HPO4, 25 mM citric acid at pH 4.5 
 
Glycine buffer for enzyme kinetics 
500 mM glycine at pH 11 
 
Buffer D for enzyme purification (HPSEC) 
20 mM Na2HPO4, 300 mM NaCl at pH 7.5. 
 
3.2.2.2 General methods 
 
Bacterial growth in LB medium 
The cells were grown overnight at 37 °C, 250 rpm in LB medium and diluted 200 fold to obtain 
starting main culture. If proceed, LB medium was complemented with the appropriate 
antibiotic for cell selection, 30 µg/mL of kanamycin. 
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Preparation of heat shock competent cells 
A single colony of E. coli was inoculated into 2 ml LB medium and incubated at 37 °C overnight 
250 rpm. The overnight culture was then used to inoculate 500 ml LB. Cells were grown to 
OD600 of around 0.4, placed on ice for 20 min and then harvested by centrifugation at 3000 g 
for 10 min at 4 °C. Cell pellets were gently resuspended in 30 ml of ice-cold 100mM CaCl2 and 
incubated on ice for 30 min. Cells were harvested by centrifugation as described above and 
gently resuspended in 8 ml 100 mM CaCl2,containing 15% glycerol. The aliquots (100 µL) were 
stored at -80 °C. 
Plasmid DNA isolation 
Plasmidic DNA was isolated by following the GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich).  
A single colony of E. coli DH5α, previously transformed with the target plasmid, was inoculated 
into 5 ml LB medium and incubated at 37 °C overnight, 250 rpm. The o/n culture was then 
used following the manufacturer’s instructions.  
 
 
Oligonucleotides 
Primers used for PCR amplification of fragments were designed following standard rules: the 
length of most primers was ranged from 18-25 nucleotides with a >50% of guanine/cytosine 
(GC) content greater than 50% in order to result in a melting temperature (Tm) from 50-65 ˚C. 
Primers for site-directed mutagenesis were designed following instructions of Liu et al., 2008. 
Each primer pair contains non-overlapping sequences at their 3' end and primer-primer 
complementary (overlapping) sequences at the 5' end. The mismatching nucleotides for the 
mutation are located at the centre of the overlapping region. It was considered to introduce as 
less mismatched nucleotides as possible for a desired mutated amino acid, taking into account 
the codon usage for E. coli. 
Oligonucleotide stock solutions (100 µM) were prepared in nuclease-free sterile water and 
diluted to working solution (1 µM).  
Final concentration at PCR reaction was 0.05-0.02 µM. 
 
Enzymatic digestion    
The corresponding DNA (1 µg) was digested with appropriate endonucleases, 10 U/µg of DNA, 
following the manufacturer’s instructions (New England Biolab, NEB). To inhibit restriction 
enzymes, the digested mixtures were heated at 65 °C for 10 min in the case of heat labile 
enzymes. For heat resistant enzymes, the DNA fragments resulting from the digestion were 
purified from an agarose gel after electrophoresis. PCR products were mixed with 6x DNA 
loading buffer and electrophoresed on a 1% agarose gel.  
PCR products purification 
The corresponding DNA was purified using a commercially available purification kit: Gen Elute 
gel extraction kit (Sigma-Aldrich) after electrophoretic separation in 1% agarose gel. 
Ligation  
Ligation was carried out in a 20 μL final volume reaction mixture containing nuclease-free 
water, corresponding vector and insert DNA (50 ng vector), 2 μL of 10x ligation buffer (NEB), 
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and 2.5 U/μL T4 DNA polymerase (NEB). The ligation reaction was incubated o/n at 16 °C or 30 
min at room temperature, depending on laboratory timing. A control ligation was set up 
without insert. DNA ligase inactivation was performed by heating the reaction mixture for 10 
min at 65 °C. 
The correct vector-insert molar ratio might has to be experimentally determined to adjust the 
molar ratios from anywhere between 1:1 to 1:5 vector to insert, respectively. 
Heat shock transformation 
Competent cells (100 µL) were incubated on ice for 30 min with 20 μL of ligation reaction. 
Then, they were heat shocked at 42 °C for 2 min. Tubes were placed back on ice for a further 5 
min. 500 μL of LB media was added and cells were incubated for 1 h at 37 °C, in stirring 
conditions (250 rpm). Transformation mixtures were spread onto LB agar plates containing 30 
µg/mL of Kan for transformant selection. Plates were incubated o/n at 37 °C.  
Colony screening by PCR 
To screen for recombinant plasmids, colony PCR was performed. Amplification was carried out 
in a 20 μL final volume reaction mixture containing 0.05-0.02 µM T7 forward and reverse 
primers, nuclease-free water, REDTaq PCR Reaction Mix (ReadyMix™, Sigma-Aldrich). With a 
20 µL pipette, freshly transformed colony was picked and mixed thoroughly in the reaction 
mixture. PCR conditions were a 3 min initial denaturation at 95 °C followed by 34 cycles: 95 °C 
15 s, 50 °C 15 s (corresponding annealing temperature), 72 °C 50 s or 4 min depending on the 
amplicon, and a 10 min final extension at 72 °C. PCR were carried out using a thermocycler 
PTC-200 (MJ research). 
 
DNA sequencing 
Plasmidic DNA of the new clones was sent to Technical and Scientific Services of University of 
Barcelona or to StabVida Laboratories to be automatically sequenced by the fluorescent 
Sanger method. T7 forward and reverse primers were used. 
 
SDS-PAGE analysis 
6 mL of running gel solution and 1.5 mL of stacking gel solution were placed in the 
electrophoresis apparatus according to the manufacturer’s instructions (Mini-protean Tetra 
Vertical Electrophoresis Cell, Bio-Rad). Protein samples were mixed with an appropriate 
amount of protein loading buffer and heated for 10 min at 95 °C before loading into the gel. 
The gels were run in running buffer at 100 V for 90 min. After electrophoresis, gels were 
washed three times with water, stained with the Bio-safe Coomassie from Bio-Rad for 30 min, 
and finally, rinsed several times with water before visualizing protein bands in them. 
 
Protein concentration quantification Protein concentration was determined by Bradford 
(Bradford, 1976) at Abs 595 nm using BSA as standard. 
3.2.2.3 Design and cloning LnbB 
 
A synthetic gene of Lacto-N-biosidase from Bifidobacterium bifidum (LnbB), codon-optimized 
for the expression in Escherichia coli were produced by GenScript (GenScript, NJ, USA). The 
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LnbB-FL gene (37-1064) was cloned into the pET24b plasmid (Novagen, Madison, WI, USA) 
using the restriction sites NdeI and XhoI to obtain the plasmid pET 24b-LnbB-FL-Cter. 
LnbB-FL gene with N-terminal His-tag was also obtained by PCR reaction and cloned into a 
pET28a+ plasmid (Novagen, Madison, WI, USA) using NdeI and Bpu1102 as flanking regions to 
obtained the plasmid pET 28a-LnbB-FL-Nter. 
Amplification was carried out with iProof High-Fidelity DNA Polymerase from Bio-Rad IProof 
polymerase (0.04 U/µL, Bio-Rad) in a 20 μl final volume reaction mixture containing plasmidic 
DNA (50-100 ng), sense primer (0.05 µM), antisense primer (0.05 µM), nuclease-free water and  
I-proof PCR master mix (10 µL). A 3 min initial denaturation at 95°C was followed by 30 cycles: 
95°C 30 s, 30 s of the corresponding annealing temperature for the different primers, 72°C 2.5 
min and a 10 min final extension at 72°C. The following forward and reverse primers were used 
(restriction site are underlined):  
 
Full-length N-his sense  5’-GGAATTCCATATGGCTGATGACTCCGCAGCAGGC-3’ 
Full-length N-his antisense 5’-TAATAGCTCAGCTTCGGTGCCCGG-3’ 
 
PCR were carried out using a thermocycler PTC-200 (MJ research). 
PCR products were purified with Gen Elute gel extraction kit (Sigma-Aldrich). Vector pET28a+ 
(Novagen) and purified PCR products were digested with the specific endonucleases.  After 
ligation, LnbB-FL gene was cloned into the pET28a+ vector with NdeI and Bpu1102 as flanking 
restrictions sites. Both proteins mentioned above were design to be purified using affinity 
chromatography (IMAC) with Ni2+-charged columns. 
3.2.2.4 Site-directed mutagenesis of active site mutants of LnbB 
 
Mutagenesis of specific catalytic residues of LnbB was carried out using modified QuikChange 
site-directed mutagenesis protocol (Liu and Naismith, 2008). For each single mutant, a 
sense/antisense primer pair was designed. Each primer pair contains non-overlapping 
sequences at their 3' end and primer-primer complementary (overlapping) sequences at the 5' 
end. The mismatching nucleotides for the mutation are located at the centre of the 
overlapping region.  
It has been tried to introduce as less mismatched nucleotides as possible for a desired mutated 
amino acid, taking into account the codon usage for E. coli. 
Primers used are list below (mutated nucleotides are underlined, and codons affected are 
lowercase letter): 
 
D320A sense 5’-TGGGCGCGgcgGAATACATGATTGGTACC-3’ 
D320A antisense 5’-CATGTATTCcgcCGCGCCCATGTGCCAATATTTCG-3’ 
E321A sense 5’-GCGCGGATgcgTACATGATTGGTACCTCG-3’ 
E321A antisense 5’-AATCATGTAcgcATCCGCGCCCATGTGCCAATATTTCG-3’ 
 
Plasmid pET 24b-LnbB-FL-Cter, which encodes for full length C-terminal LnbB was used as 
template for mutagenesis. PCR were carried out using IProof polymerase (0.04 U/µL, Bio-Rad) 
90 
 
CHAPTER 3. LACTO-N-BIOSIDASE CHARACTERIZATION 
and a thermocycler PTC-200 (MJ research). Amplification was carried out in a 50-20 μl final 
volume reaction mixture containing plasmidic DNA (50-100 ng), sense primer (0.05-0.02 µM),  
antisense primer (0.05-0.02 µM), nuclease-free water and  I-proof PCR master mix (10-25 µL) 
(Ref. 1725310, Bio-Rad). A 3 min initial denaturation at 95°C was followed by 30 cycles: 95°C 
30 sec, 30 sec of the corresponding annealing temperature for the different primers, 72°C 4 
min, and a 10 min final extension at 72°C. After PCR reaction, the samples were digested with 
DpnI for 1 hour at 37 °C, and then, transformed into E. coli DH5α. Positive transformants were 
confirmed by DNA sequencing and the final constructs were used to transform E. coli DH5α 
and BL21 (DE3) cells. 
 
3.2.2.5 Protein expression trials 
 
The protein expression levels were optimized by adjusting temperature and time of 
expression, either with IPTG or with autoinduction medium.   
 
The cells were grown overnight at 37° C, 250 rpm in LB medium and diluted 200 fold to obtain 
starting main culture. In the case of IPTG induction, the starting cultures were induced at OD600 
0.5-0.6 and OD600 1 at 25 °C, 30 °C and 37 °C, for 3, 6 and 14 hours of induction. In the case of 
autoinduction media, cells were allowed to grow for 12, 24, 48 and 60 hours at 22 °C, 30 °C 
and 37 °C. 1 mL of culture was taken from each experiment. Cells were harvested by 
centrifugation (4000g, 15 min, 4°C), resuspended in buffer A (Na2HPO4 20mM, NaCl 150mM, 
pH 7.5) and disrupted by sonication (2 μm probe, 50% amplitude, 15 sec on, 45 sec off for 3 
cycles) (Brandson). After centrifugation of the lysate (16000rpm, 1 h at 4 °C), the supernatant 
and the pellet were analysed by SDS-PAGE.  
3.2.2.6 Expression and purification of recombinant Lacto-N-biosidase enzymes  
 
Expression of both LnbB was performed either with IPTG or with autoinduction medium. 
IPTG induction: recombinant cultures of E.coli BL21 were grown in LB medium with kanamycin 
at final concentration of 30µg/ml for 16 hours, 250 rpm at 37 °C. Protein expression was 
induced adding IPTG at final concentration of 1mM and after 3hours of incubation at 250rpm 
and 37 °C, cells were harvested by centrifugation (4000xg, 15 minutes). 
Autoinduction media: recombinant cultures of E. coli BL21 (DE3) star cells were grown 
following an autoinduction protocol (Studier, 2005) in LB medium with 30 µg/mL kanamycin, 
25mM Na2HPO4, 25mM K2HPO4, 50mM NH4Cl, 5mM Na2SO4, 2mM MgSO4, 0.5% glycerol, 
0.05% glucose and 0.2% lactose at 250 rpm and 30 °C. After 24 h cells were harvested by 
centrifugation (4000xg, 15 minutes). 
Purification was carried out as follows: harvested cells were resuspended in buffer A (Na2HPO4 
20mM, NaCl 150mM, pH 7.5) and disrupted by French press (1200 psi). Cell free extracts were 
centrifuged (20000xg, 4 °C, 1 hour) and the supernatant was applied into a 1mL Ni2+-charged 
HiTrap chelating column chromatography. Proteins were purified to homogeneity by a linear 
gradient of Buffer B (Na2HPO4 20mM, NaCl 150mM, imidazole 500mM, pH 7.5) at flow rate of 
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1 mL/min, and appropriate fractions were collected. The protein concentration was 
determined by Bradford measuring Abs 595 nm using BSA as standard  
3.2.2.7 Purification of Lacto-N-biosidase enzymes using FPLC 
 
Both proteins were purified further using an XK16/60 Superdex 200 column (GE Healthcare), 
preequilibrated with buffer A. The calibration curve was obtained with 1-2 mg/mL of standards 
(Dextran Blue (>2000kDa), Alcohol dehydrogenase (150kDa), BSA monomer (66 kDa), Carbonic 
anhydrase (29kDa), Cytochrome C (12.4 kDa), Aprotinin (6.5 kDa) Sigma-Aldrich). All 
purifications were done in an ÄKTA FPLC (GE Healthcare). 
 
1-2 mL of concentrated proteins (standards or samples) from affinity purification was loaded 
into the Superdex 200 column by loop injection. Elution was done with buffer A at a flow rate 
of 1 mL/min. SDS-PAGE analysis was performed for all fractions collected, and fractions 
containing the protein of interest were pooled, concentrated with a 10 kDa cut-off membrane 
centricon (Merck-Millipore) and stored at 4 °C. In general, the elution yielded a single peak of 
the target protein with >95% of purity. 
 
3.2.2.8 Protein Identification 
 
Since LnbB has a higher molecular mass which is out of the range of detection of the Bruker 
Daltonics spectrometer, it was analysed by peptide mass fingerprint. Pure proteins obtained 
from acrylamide gel bands were digested with trypsin (Trypsin Gold Mass Spectrometry Grade, 
Promega) and peptides were identified using Mascot (Matrix Science, London UK) by search on 
NCBInr database.  
 
Protein size was determined using dynamic light scattering in a Nano ZS Nanosizer (Malvern 
Instruments Ltd., UK) with a laser light wavelength of 632.8 nm and a scattering angle of 173 
degrees. Temperature was set at 25°C. Protein solutions in buffer A were measured without 
previous dilution. 
 
3.2.2.9 Kinetics of the hydrolase activity 
 
Lacto-N-biosidase activity assays with p-nitrophenyl β-lacto-N-bioside (p-NP-LNB, synthesised 
in this thesis, Chapter 2) were performed at 30 °C in a volume of 0.1 mL using 96-wells 
microtiter plates using a Bravo liquid handling Robot (Agilent). Enzymatic reactions were 
performed in a reaction mixture containing the substrate and Buffer C (25mM of citrate-25mM 
phosphate buffer, pH 4.5). After pre-incubation for 5 min at 30 °C, reactions were initiated by 
addition of the enzyme (20 nM), specific concentration is determined in each experiment). At 
regular time intervals, reactions were quenched by the addition of 0.15 mL of quenching buffer 
(0.5 M of glycine, pH 11) and p-nitrophenol release was measured by absorbance at 400 nm 
with a microplate-reader MRX (Cultek). Triplicate measurements at each concentration were 
performed. 
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Substrate concentration to determine Michaelis-Menten kinetic parameters was between 0-1 
mM. Substrate concentration for specific activity was at 0.25 mM (according to Km and kcat 
values of 68 µM and 89 s-1 of Wada et al., 2008, it was performed at saturated conditions. 
 
Initial rates (vow) were obtained from the linear progress curve of release of p-NP, and they 
were expressed as vow/[E] in s-1. Kinetic parameters kcat, KM, and kcat/KM were calculated by 
nonlinear regression to the Michaelis–Menten equation. 
 
3.2.2.10 pH-activity profile dependence with p-NP-LNB  
 
The pH dependence of enzyme activity was studied using p-NP-LNB (synthesised in this thesis, 
Chapter 2). The assays were performed at standard conditions: at 30 °C, pH values ranging 
from 3 to 8.5 and final volume of 0.1 mL. After pre-incubation of 20nM of the full length 
protein for 15 min in the appropriate buffer, addition of 0.25 mM substrate initiated the 
reaction. At regular time intervals, reactions were quenched by the addition of 0.15 mL of 
quenching buffer (0.5 M of glycine, pH 11) and p-nitrophenol release was measured by 
absorbance at 400 nm with a microplate-reader MRX (Cultek). Triplicate measurements at 
each concentration were performed. The molar extinction coefficients of p-nitrophenol at 405 
nm were calculated at each pH and substrate stability was also measured at each pH. Initial 
rates values were plotted against pH according to Equation 3.1. 
Vo = 𝐾𝐾𝑐𝑐𝑐𝑐𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙1 + (10𝑝𝑝𝑝𝑝𝑝𝑝1−pH) + (10pH−𝑝𝑝𝑝𝑝𝑝𝑝2) 
Equation 3.1 
 
3.2.2.11 Temperature-activity dependence with p-NP-LNB  
 
The temperature-activity dependence of enzyme activity was studied using p-NP-LNB 
(synthesised in this thesis, Chapter 2). The assays were performed at standard conditions in a 
volume of 0.1 mL at 50mM of citrate-phosphate buffer pH 4.5 (Buffer C). The temperature 
range assayed was from 25-50 °C. After pre-incubation of 20nM of the full length protein for 
15 min at the appropriate temperature, addition of 0.25 mM substrate initiated the reaction. 
At regular time intervals, reactions were quenched by the addition of 0.15 mL of quenching 
buffer (0.5 M of glycine, pH 11) and p-nitrophenol release was measured by absorbance at 400 
nm with a microplate-reader MRX (Cultek). Triplicate measurements at each concentration 
were performed. The molar extinction coefficients of p-nitrophenol at 400 nm were calculated 
at each temperature and substrate stability was also measured at each temperature. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Analysis of domain structure and cloning of Lacto-N-biosidase enzyme 
Lacto-N-biosidase form B. bifidum consists of 1112 amino acids and, according to Wada and 
coworkers, contains a signal peptide, a catalytic GH20 domain, a carbohydrate-binding module 
(CBM) from family 32, a bacterial Ig-like domain, and a membrane anchor (Wada et al., 2008). 
However, this domain assignment only covers around 65% of the total amino acids contained 
in LnbB. Therefore, it suggested that some domains are missing in this description. 
In order to predict secondary structure of LnbB and further assignment of the domains, 
prediction and sequence alignment online tools were used, since the crystal structure of the 
protein was not solved by the time of this study. 
Jpred3 (Cole et al., 2008) was used to predict LnbB secondary structure. Sequence alignment 
of all known structure GH20 proteins was performed with PROMALS with default options (Pei 
and Grishin, 2007). The amino acidic sequence of LnbB showed less than 25% of similarity with 
the rest of the GH20 proteins. However, in terms of secondary structure, region 1-528 residues 
of LnbB presented a very similar structure to the others GH20 proteins.  
Pfam and Supfam databases assigned region 784-932 and 962-1064 residues of LnbB as 
CBM32 and Iglike domains, respectively. Nevertheless, region 528-776 residues of LnbB were 
not assigned and HHpred was used, in this work, to predict the structure. The software is 
based on identifying homologous sequences with known structure to be used as a template 
(Söding et al., 2005). Results showed that this region was structurally very similar to a lectin 
domain (ricin-like). 
Using data integration from different databases (Pfam, Superfamily, SCOP, PSI-BLAST and 
CAZY), and the results from the cited online tools (Jpred3, Promals and HHpred), a model of 
the domain architecture of LnbB was built (Figure 3.2). 
 
 
Figure 3.2 Schematic representation of the modular structure of LnbB. 
Each box represents the different domains of LnbB. Numbers indicate the amino acids involved in the domain and E-
value determines the significance of the assignment. 
 
LnbB is formed by five domains (Figure 3.2). Domains I and II are the GH20b and GH20 ones. 
Domain III (residues 546-700) is similar to a lectin domain according to an HHpred search. 
Domain IV (784-932) has sequence homology to CBM32 (Supfam), and domain V (962-1041) is 
described as a Immunoglobulin-like domain in PFam. In addition, LnbB presents an N-terminal 
secretion signal peptide and a C-terminal cell wall anchoring sorting signal motif. This indicates 
that the protein is secreted to the outside of the cell. 
N’ C’
GH20b Lectin CBM 32 Ig likeGH20 α
Signal
peptide
Membrane
anchor
E-value 5.4 e-20 E-value 1.5 e-44 E-value 5.47e-22 E-value 2.7 e-18 E-value 1.3 e-14 1082-11081-34
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In particular, Domain I and II are characteristic domains of glycoside hydrolase family 20. 
GH20b domain is a non-catalytic domain, which is conserved in most GH20 enzymes although 
with unknown function. GH20 domain is actually the catalytic domain composed of a (β/α)8-
barrel (TIM-barrel) architecture, with the active site located at the C-terminal face of the β-
barrel (Henn-Sax et al., 2001). Lectin and CBM32 are two different carbohydrate binding 
domains. And the Ig-like domain, which is frequently found in the surface-located enzymes of 
bacteria, has no assigned function in LnbB.  
 
The design of the gene encoding for LnbB protein was thought to avoid trasnmembrane 
regions. Accordingly, recombinant LnbB (34-1064 amino acids) lacks the signal peptide and the 
membrane anchor compared to the B. bifidum protein.  
A synthetic gene encoding the LnbB from B. bifidum, codon-optimized for the expression in E. 
coli, was produced. It was supplied in a pUC57 and in pET24b vector between NdeI and XhoI 
restriction sites to generate a C-terminal His-tagged protein. By PCR reaction, the gene of the 
N-terminal His-tagged LnbB protein was also obtained to evaluate the effect of the terminal 
tag. E.coli DH5α and BL21 (DE3) were transformed with the different plasmids.  
3.3.2 Expression and purification of Lacto-N-biosidase enzymes 
Two different protein induction methods were performed, IPTG induction and autoinduction in 
a supplemented LB media. Expression trials were performed at different temperatures and 
different times of induction. The trials carried out with autoinduction system showed higher 
levels of protein expression in the soluble fraction (23 mg/L), compared to IPTG induction (7 
mg/L). 
 
 
 
Figure 3.3 C-terminal His-tagged LnbB protein purification. 
(A) Chromatogram of affinity chromatography (IMAC). Single peak of full-length was eluted with 50 mM Imidazole 
in buffer A. (B) Chromatogram of size exclusion chromatography on a Superdex 200 column. Single peak of full-
length eluted with buffer A. (C) SDS-PAGE of fractions from size exclusion chromatography. Pure bands of full-length 
(112kDa) are observed.  
 
Final conditions for the expression of the LnbB proteins (either N- or C-terminal His-tagged) 
involved growing recombinant cells at 30 °C for 24 h with autoinduction medium. After cell 
lysis, the soluble fraction obtained was purified by affinity chromatography (Figure 3.3A). SDS-
PAGE analysis revealed that full-length migrated with an approximate molecular mass of 112 
B
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kDa, which agrees with its respective theoretical molecular mass (Figure 3.3C). Fractions 
containing the protein were pooled and concentrated before being purified on a Superdex 200 
column (GE Healthcare) (Figure 3.3B). After the gel filtration column, fractions were pooled 
and concentrated with a 10 kDa cut-off membrane centricon (Merck-Millipore). Final protein 
concentration was determined spectrophotometrically by Bradford method measuring Abs 
595 nm using BSA as standard (Smith et al., 1985). Average yields of 23 mg of full-length 
protein per litre of culture were obtained. Both His-tagged LnbB proteins were expressed and 
purified by following the same protocol and were obtained as soluble proteins with similar 
yields. 
C-terminal His-tagged LnbB protein solutions were also analysed by mass spectrometry 
(MALDI-TOFF MS) and analytical size-exclusion chromatography (HPSEC).The identification of 
peptides after enzymatic digestion of wild type LnbB was done, and the molecular mass 
estimation of the protein in solution was consistent with a monomeric 112 kDa protein. 
Protein size was determined using dynamic light scattering in a Nano ZS Nanosizer (Malvern 
Instruments Ltd., UK). The full-length protein showed a single peak for monodisperse particles 
of 10 nm and PDI 0.30, which agrees with monomeric species (Figure 3.4).  
 
Figure 3.4 Molecular mass and oligomerization state analysis of the C-terminal His-tagged LnbB protein. 
(A) MALDI-TOF spectrum of enzymatic digestion of LnbB. (B) Size distribution plot by Dynamic Light Scattering. 99.9 
% of the particles of the assayed sample presented a unique size particle of LnbB. 
 
3.3.3 Biochemical characterization of Lacto-N-biosidase from Bifidobacterium bifidum 
3.3.3.1 Kinetic analysis of LnbB using p-NP-Galβ1,3GlcNAc as substrate 
 
Lacto-N-biosidase hydrolytic activity was characterised using p-NP-LNB as substrate (7) and the 
C-terminal His-tagged enzyme. 
 
 
 
Figure 3.5 Hydrolytic reaction of p-NP-LNB mediated by LnbB. 
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Conditions: 20 mM of LnbB, different p-NP-LNB substrate concentrations (0-1 mM), 50 mM citrate-phosphate 
bufferat pH 4.5 and 30 °C. 
 
Hydrolytic rates at constant LnbB concentration (20 nM) and different substrate 
concentrations 0-1 mM), showed that the reaction followed saturation kinetics (Figure 3.6) 
with an apparent kcat value of 25±3 s-1 and Km of 162±34 µM, then kcat / Km of 154·103 M-1·s-1.  
 
 
 
Figure 3.6 Michaelis-Menten kinetics of LnbB. 
Reaction conditions involved 20 nM of protein, p-NP-LNB substrate (0-1 mM), 50 mM citrate-phosphate buffer at 
pH 4.5 and 30 °C. 
 
Compared to literature (Table 3.1), these results are in the range of Ito’s et al. Results from 
Wada et al., and Hattie et al., which were determined at pH 4.5 and 37 °C, and showed higher 
catalytic efficiency.  
Table 3.1 Kinetic parameters of the hydrolytic reaction of Lacto-N-biosidase from B. bifidum.  
(Hattie et al., 2012; Ito et al., 2013; Wada et al., 2008) 
 
 
k
cat 
 (s
-1
) KM (µM) kcat/KM  (M
-1
·s
-1
) 
Present study 25 ± 3 162 ± 34 154· 10
3
 
Wada et al. 2008 89 68 1300· 10
3
 
Hattie et al. 2012 78± 6 71 ± 11 1000· 10
3
 
Ito et al. 2013 15 ± 1 99 ± 11 150· 10
3
 
 
The hydrolytic activities of the C-terminal and the N-terminal LnbB proteins (20 nM) were 
determined in order to evaluate the effect of the tag. The reaction mixture contained 0.25 mM 
of p-NP-LNB and 50mM of citrate-phosphate buffer at pH 4.5 (Buffer C) and at 30 °C. Both 
LnbB proteins, N- and C-terminal His-tagged, showed a specific activity of 27.2 ± 3.5 s-1, 
indicating that the His-tag has no effect on the catalysis rates. 
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3.3.3.2 pH-activity profile and temperature dependence with p-NP-Galβ1,3GlcNAc as 
substrate 
 
pH dependence of LnbB was analysed using 20 nM of enzyme and 0.25 mM of p-NP-LNB in a 
pH range of 3-8.5 of 50 mM citrate-phosphate buffer and at 30 °C. At different time intervals, 
the reactions were stopped by addition of 0.5 M of glycine at pH 11. The release of p-NP was 
measured at 405 nm, and the initial rates were determined. These initial rates values were 
plotted against pH and an approximately bell-shaped profile was obtained (Equation 3.1). 
 
Figure 3.7 pH dependence of LnbB. 
Initial hydrolytic rates vs pH using p-NP-LNB as substrate and 50 mM citrate-phosphate buffer at 30 °C. Profile is 
fitted to Equation 3.1. 
Although the enzyme remained active in a wide pH range, an environment more acidic than pH 
3 and more basic than pH 7, results in a loss of activity. Maximum activity was registered at pH 
4.5 which is in agreement with other authors (Sano et al., 1992; Wada et al., 2008).  
Temperature dependence of LnbB was analysed using 20 nM of enzyme and 0.25 mM of p-NP-
LNB, in 50 mM citrate-phosphate buffer at pH 4.5 and in a temperature range of 25-50 °C. The 
Arrhenius plot is obtained by plotting the logarithm of the rate constant, k, versus the inverse 
temperature, 1/T (Figure 3.8). As before, reactions were stopped at different times and 
released p-NP was measured. 
 
Figure 3.8 Temperature dependence of LnbB. 
(A) Temperature dependence of LnbB and  (B) Arrhenius plot. Hydrolytic reactions were done at temperature range 
of 25-50 °C. 
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Hydrolytic activity of LnbB increased linearly till 50°C. And it showed a linear Arrhenius plot for 
the reaction with p-NP-LNB substrate in the temperature range of 25-50 °C. Hydrolytic 
reactions were always done at 30 °C, although as shown in Figure 3.8, it is not the optimal 
temperature for catalysis.  
3.3.4 Lacto-N-biosidase active site mutants  
The catalytic mechanism of GH20 family proteins is a modification of the classical double- 
displacement process used by retaining glycosidases, and has been described very thoroughly 
(Mark and James, 2002). GH20 family β-N-acetylhexosaminidases operate via substrate-
assisted catalysis, sometimes also called anchimeric assistance (neighbouring group 
participation), wherein the 2-acetamido substrate moiety acts as a nucleophile to form an 
oxazolinium ion intermediate (Figure 3.9).  
 
Figure 3.9 Catalytic mechanisms for β-N-acetylhexosaminidases. 
Double-displacement retaining mechanism of GH20 family proteins: the nucleophile is not provided by the enzyme 
but by the substrate 2-acetamido group, leading to the formation of an oxazoline intermediate. Image from 
Slámová et al., 2010.  
The active site of GH20 enzymes contains a highly conserved pair of catalytic residues Asp-Glu. 
It has been proposed that the conserved Asp residue plays a role in orientating the 2-
acetamido group, and ultimately promoting the nucleophilic attack of this 2-acetamido group 
at the anomeric position to form the oxazolinium ion intermediate, which is in turn attacked by 
water to release the hydrolysis product with net retention of the anomeric stereochemistry. 
Experiments with mutated hexosaminidases have provided evidence that this aspartate 
stabilizes the oxazoline transition state and also assists in correctly orienting the 2-acetamido 
moiety for catalysis. For example, Glu314 and Asp313 are the corresponding essential residues 
in β-N-acetylhexosaminidase from Streptomyces plicatus (SpHex). E314Q mutant reduced its 
Vmax 296-fold, and its KM 7-fold, implying that Glu314 is the proton donor in the catalytic 
reaction of SpHex (Mark et al., 1998). The catalytic role of Asp313 was determined by Williams 
et al., obtaining D313A and D313N variants. D313A showed a decrease in the catalytic 
efficiency of 70-fold, where D313N presented a decrease of 5·106-fold. These results were 
consistent with the important role for Asp313 in carefully positioning the 2-acetamido group in 
a favourable geometry to act as a nucleophile (Williams et al., 2002). 
With regard to LnbB protein, Hattie and coworkers confirmed that LnbB uses a mechanism 
involving substrate-assisted catalysis of the 2-acetamido group of the substrate using 2-
acetamido analogues bearing differing degrees of fluorine substitutions (Hattie et al., 2012). 
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The highly electronegative fluorine substituent decreases the basicity of the carbonyl group, 
and the effect of such substitution is that there is a dramatic decrease in rate for enzymes 
using anchimeric assistance.  
The identification of Asp and Glu catalytic residues of LnbB was based on sequence alignment 
between LnbB and different members of the GH20 family (Figure 3.10). 
 
Figure 3.10 Promals multiple alignment of GH20 domain of LnbB and its homologues.  
The numbering starts at the initiation of codon of each protein. Conserved catalytic residues are marked by a blue 
star. The organisms are as follows: Hex1T, N-acetylhexosaminidase from Paenibacillus sp; SpHex, N-
acetylhexosaminidase from Streptomyces plicatus; LnbB, Lacto-N-biosidase from B-bifidum; NahA, N-
acetylhexosaminidase from Arthrobacter aurescens; SmCHB, chitobiose from Serratia marcescens; DspB, N-
acetylhexosaminidase from Aggregatibacter actinomycetemcomitans; GcnA, N-acetylhexosaminidase from 
Streptococcus gordonii; HexB and HexA, N-acetylhexosaminidase from Homo sapiens. Full image at Appendix 
section. 
As observed in Figure 3.10 the two catalytic residues (Asp and Glu) are completely conserved 
among all predicted members of GH20 family. Accordingly, the two corresponding catalytic 
residues of Lacto-N-biosidase are Asp320 and Glu321. Asp320 corresponds to the assisting 
residue that orientates the 2-acetamido group, and Glu321 acts as the acid/base residue. 
Based on this identification, the explanation of the possible catalytic mechanism of LnbB is 
represented in Figure 3.11. The first step of the reaction (cyclization) proceeds via attack of the 
2-acetamido carbonyl oxygen on the anomeric carbon to form a covalent bicyclic oxazoline 
intermediate. This step is facilitated by polarization of the 2-acetamido moiety by Asp320. 
Departure of the aglycone is facilitated by general acid catalysis provided by Glu321 in the 
enzyme active site. In the second step (ring opening) the oxazoline intermediate is opened by 
the general base-catalysed attack of a water molecule on the anomeric carbon. Both steps 
occur with inversion of stereochemistry at the anomeric centre such that the overall reaction 
proceeds with net retention of stereochemistry. 
 
Figure 3.11 Catalytic mechanism of LnbB involving substrate-assisted catalysis. 
R1: Galactose, R2: Lactose. 
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Mutants of the catalytic residues of LnbB were designed. Both residues (Asp and Glu) were 
substituted for alanine (Ala) to generate D320A and E321A mutant proteins. The change to Ala 
removed the side-chain and the charge from the wild type residue in order to abolish its 
catalytic capacities.  
3.3.4.1 Cloning, expression and purification of Lacto-N-biosidase active site mutants 
Mutated proteins were successfully obtained by site-directed mutagenesis using wild type Full-
length pET24b construct as template (C-terminal His-tagged). Mutations were confirmed by 
DNA sequencing. Finally, E. coli BL21 (DE3) cells were transformed with the final vectors for the 
expression and purification of mutant recombinant proteins. 
Purification of the mutated proteins was performed as described for the wild type LnbB. The 
protein concentration was determined by Bradford (Bradford, 1976) using BSA as standard. 
Average yields of 3-7 mg of proteins per litre of culture were obtained. All proteins were 
considered to be >90% pure by Coomassie staining after SDS-PAGE (Figure 3.12). 
 
Figure 3.12 SDS-PAGE analysis of the wild type, D320A and E321A mutated proteins. 
Lane 1: full-length protein, M: marker, Lane 2: D320A protein, Lane 3: E321A protein. Molecular masses in kDa. 
 
3.3.4.2 Kinetics of Lacto-N-biosidase active site mutants 
The hydrolytic activities of the mutated proteins and a new batch of wild type LnbB (as control) 
were also evaluated as described above. Briefly, the hydrolytic activity of the soluble proteins 
(20 nM) was performed in a reaction mixture containing p-NP-LNB (0.25 mM) as substrate in 
50 mM citrate-phosphate buffer at pH 4.5 and at 30 °C. The reaction was stopped at different 
interval times and the release of p-NP was measured.  
Table 3.2 Kinetic parameters of the hydrolytic reaction of wild type and mutated proteins. 
The reactions were performed at 20 nM of proteins, 0.25 mM of substrate, 30 °C in buffer C at pH 4.5. 
 
Protein Specific activity (s-1) 
Wild type 31 
D320A 0.01 
E321A 0.8  
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Both mutated proteins showed decreased hydrolytic activity compared to the wild type LnbB 
(Table 3.2). In the case of the D320A mutant, a 3500-fold decrease was observed. This result is 
consistent with the corresponding D313A mutant of SpHex (Williams et al., 2002), indicating 
that D320 is the candidate to be the assisting residue. Mutation of the proposed acid/base 
catalytic residue Glu321 to Ala (E321A mutant) yielded a 38-fold less active enzyme. This 
mutation was expected to abolish the hydrolytic activity of the enzyme but in this case, and in 
general in GH20 enzymes, the mutation to Ala slightly decreases the activity (E314A of SpHex 
showed 70-fold decrease). For a retaining β-glycosidase, replacement of the acid/base catalytic 
residue with a non-ionisable residue should substantially reduce the catalytic efficiency of the 
mutant enzyme. However, it has a less pronounced effect for substrates bearing good leaving 
groups that do not benefit significantly from general acid catalysis (Vallmitjana et al., 2001). 
The substitution of Glu321 to Ala321 had little effect and maybe p-NP-LNB does not require 
general acid assistance since p-NP is quite good leaving group. 
 
Figure 3.13 Stereoviews of LNB bound to the active site of LnbB. 
Catalytic residues, residues forming hydrogen bonds, and residues forming hydrophobic interactions are shown in 
magenta, green, and white, respectively. Hydrogen bonds are shown as red dashed lines. (PBD entry 4H04).  Image 
from Ito et al., 2013. 
 
These results are consistent with the crystal structure of LnbB in complex with the product LNB 
(Ito et al., 2013), in which, the role of these catalytic positions was confirmed. A clear electron 
density for ligands at the centre of the barrel domain is observed (Figure 3.13). The two 
catalytic residues, Asp320 (assisting residue) and Glu321 (acid/base catalytic residue), form 
hydrogen bonds with the amide nitrogen of the 2-acetamido group and the O1-hydroxyl, 
respectively (Ito et al., 2013).  
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3.4 CONCLUSIONS 
Using data integration from different databases, and the results from structure prediction 
online tools, a model of the domain architecture of LnbB was built. LnbB is formed by five 
domains, GH20b and GH20 catalytic domains, a lectin domain, a CBM32 and an 
Immunoglobulin-like. In addition, LnbB presents an N-terminal secretion signal peptide and a 
C-terminal cell wall anchoring sorting signal motif.  
LnbB has been successfully cloned to obtain N-terminal and C-terminal His-tagged 
recombinant proteins. The study of the catalytic capacity of both proteins indicated that the 
terminal tag has no effect on catalysis.  
The behaviour of the hydrolytic reaction followed saturation kinetics, with an apparent kcat 
value of 25±3 s-1 and Km of 162±34 µM, the a catalytic efficiency of kcat / Km of 154·103 M-1·s-1. 
 
The pH profile for the hydrolytic activity of the wild type enzyme using p-NP-LNB resembled a 
bell-shaped curve with the optimum catalytic efficiency at a pH of 4.5. In addition, LnbB 
remained catalytically active in a wide range of temperatures (from 25°C to 50 °C).  
 
The catalytic residues, D320A and E321A, were identified using sequence alignment between 
LnbB protein and crystallised GH20 proteins. D320A and E321A mutants showed decreased 
hydrolytic activity compared to the wild type enzyme, 3500-fold and 39-fold decrease, 
respectively. 
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CHAPTER 4. STRUCTURAL FUNCTIONAL ANALYSIS OF GH20 FAMILY ENZYMES 
4.1 INTRODUCTION 
N-acetyl-β-hexosaminidases, classified in CAZY families GH3, GH20 and GH84 (Carbohydrate 
Active Enzymes database, www.cazy.org (Cantarel et al., 2009)) catalyse the hydrolysis of β-
linked GlcNAc or GalNAc from the non-reducing end of glycoproteins, glycosaminoglycans, 
glycolipids, chitin and other oligosaccharides. They are widely distributed in nature, and they 
have recently gained a lot of attention, not only for their implication in human physiology and 
diseases, but also for their potential as biosynthetic tools for carbohydrate and glycomimetic 
synthesis (Liu et al., 2012; Slámová et al., 2010). Enzymes from these three families share some 
basic features in terms of protein structure and catalytic mechanism, but show no sequence 
homology. GH20 hexosaminidases are the most numerous of them, they are well distributed in 
different microorganisms, animals, and plants, and they are also involved in many important 
physiological and pathological processes, such as cell structural integrity, energy storage, 
pathogen defence, cellular signalling, fertilization, inflammatory events, and lysosomal storage 
diseases (Intra et al., 2008). However, these enzymes show a broad range of different 
functions depending on the organism but also on the localization of the enzyme within the 
organism. From the biotechnological point of view, hexosaminidases, together with chitinases, 
are important enzymes for industrial chitin degradation, the most abundant polysaccharide 
after cellulose (Slámová et al., 2010). In insects, because of the important role of chitin, these 
enzymes are considered potential targets for insect control, acting as biopesticides (Dowd et 
al., 2007). In humans, the two lysosomal hexosaminidases HexA and HexB are responsible for 
the hydrolysis of GlcNAc and GalNAc residues of glycosphingolipids such as ganglioside GM2 
and their dysfunction is linked to neurodegenerative disorders known as Tay-Sachs and 
Sandhoff diseases (Gloster and Vocadlo, 2012; Shane Rountree et al., 2009). Recent data 
suggests that lysosomal exoglycosidases, together with many other factors may participate in 
the progression of development of glial tumours (Wielgat et al., 2006). In plants, β-N-
hexosaminidases have been detected in germinating seeds, suggesting their role in the storage 
of glycoproteins (Intra et al., 2008). In addition, some bacterial hexosaminidases contribute to 
the virulence of some infections in humans, as in the case of Actinobacillus 
actinomycetemcomitans, an organism that colonizes the human oral cavity and causes 
periodontitis and Streptococcus pneumoniae infections (Slámová et al., 2010).  
Family GH20 has been mechanistically well characterized; it is known that they catalyse 
hydrolysis with retention of anomeric configuration with substrate participation mechanism. 
The 2-acetamido group of the substrate is used for nucleophilic attack at the anomeric carbon 
to create an oxazoline intermediate (Vocadlo and Davies, 2008).  
 
 
 
Figure 4.1 Retaining glycosidase by substrate-assisted catalysis, via an oxazolonium ion intermediate.  
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Moreover, protein folding of the catalytic domain is highly conserved among GH20 enzymes; 
the common feature of all known structures is the (β/α)8-barrel (TIM-barrel) architecture, 
which consists of eight parallel β-sheets forming a cylindrical form, surrounded by the eight α-
helices. The active site is located at the C-terminal face of the β-barrel and within the loops 
that connect the β-strands with the subsequent α-helices (Henn-Sax et al., 2001). 
 
 
 
Figure 4.2 The (βα)8-Barrel Fold. 
(A) View onto the C-terminal ends of the eight β-strands, which form a cylindrical parallel β-sheet. This β-barrel is 
surrounded by the eight α-helices. β) Topologic diagram of the eight (βα) modules. The active site residues of all 
known (βα)8-barrel enzymes are located at the C-terminal ends of the β-strands and in the loops that connect the 
β-strands with the subsequent α-helices. Image from Henn-sax et al., 2001. 
 
GH20 enzymes comprise not only β-N-acetylhexosaminidases (EC.3.2.1.52), catalysing the 
removal of terminal non-reducing N-acetylhexosamine residues, but also lacto-N-biosidases 
(EC.3.2.1.140), hydrolysing the terminal lacto-N-biosyl residues from the non-reducing end of 
oligosaccharides such as human milk oligosaccharides (HMO).  
 
To date, the structures of thirteen GH20 enzymes are known. Their domain organization is 
diverse as they present several accompanying domains apart from the catalytic GH20 domain. 
In addition, some of them exist as dimeric proteins.  
 
Due to their great potential as biocatalysts for biotechnology and biomedical applications, our 
aim has been to define the minimal functional domain architecture for enzymatic activity in 
these GH20 family enzymes.  
 
The large B. bifidum lacto-N-biosidase (LnbB) protein has been chosen due to its biological 
importance in the metabolism of human milk oligosaccharides and also, because of its complex 
domain organization. The LnbB gene encodes for a membrane-anchored extracellular enzyme 
of 1112 amino acid residues. Recently, it was cloned and the recombinant full-length protein 
was characterized confirming that this enzyme catalyses the hydrolysis of the tetrasaccharide 
Galβ1,3GlcNAcβ1,3Galβ1,4Glc to lacto-N-biose (Galβ1,3GlcNAc) and lactose (Hattie et al., 
2012; Wada et al., 2008).  
 
We here report the structural requirements for functionality of GH20 enzymes to obtain a 
minimal functional unit that retains the enzymatic activity. 
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4.2 MATERIALS AND METHODS 
4.2.1 Bioinformatics: GH20 structures and sequences retrieval and analysis 
The list of currently available 3D structures of GH20 enzymes was retrieved from CAZY 
database (http://www.cazy.org). Protein structures were downloaded from the Protein Data 
Bank (http://www.pdb.org). Protein sequences were retrieved from UniProt 
(http://www.uniprot.org). Assignment of protein domains were obtained from different 
databases (Pfam, Superfamily, SCOP, PSI-BLAST and CAZY) and also using predicting online 
tools; Jpred3 (Cole et al., 2008) and HHpred (Söding et al., 2005). Protein structures were 
analysed and visualized with VMD (Humphrey et al., 1996). Structure alignment was 
performed with MultiSeq (Roberts et al., 2006) restricting the alignment region to GH20b and 
GH20 domains only. Sequence alignment was performed with PROMALS (Pei and Grishin, 
2007) and ClustalW with default options.  
 
Table 4.1 PDB entries of the proteins used in the analysis of the GH20 structures. 
 
Enzyme Organism PDB 
β-N-acetylhexosaminidase 
(SpHex) 
Streptomyces plicatus 1HP5 
β-N-acetylhexosaminidase 
(ScHex) 
Streptomyces coelicolor A3(2) 4C7G 
β-N-acetylhexosaminidase 
(Hex1T) 
Paenibacillus sp. 3GH5 
Chitobiase  
(SmCHB) 
Serratia marcescens 1QBB 
Lacto-N-biosidase  
(LnbB) 
Bifidobacterium bifidum 4JAW 
β-N-acetylhexosaminidase 
(NahA) 
Arthrobacter aurescens 3RCN 
β-N-acetylhexosaminidase 
βf3009) 
Bacteroides fragilis 4PYS 
β-N-acetylhexosaminidase 
(HexA) 
Homo sapiens 2GK1  
 
β-N-acetylhexosaminidase 
(HexB) 
Homo sapiens 1NP0 
β-N-acetylhexosaminidase 
(OfHex1) 
Ostrinia furnacalis 3OZO 
β-N-acetylhexosaminidase 
(GcnA) 
Streptococcus gordonii 2EPN 
β-1,6-N-acetylglucosaminidase 
Dispersin B (DspB) 
Aggregatibacter 
actinomycetemcomitans 
1YHT 
β-N-acetylhexosaminidase 
(StrH) 
Streptococcus pneumoniae R6 3RPM 
 Streptococcus pneumoniae 
TIGR4 
2YL8 
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4.2.2 General materials and experimental procedures 
All reagents are from Sigma-Aldrich unless otherwise designated. 
General material and methods are detailed in Chapter 3. 
Specific substrates for both enzymatic approaches (p-NP-LNB and oxa-LNB) were synthesised 
according to Chapter 2 (see experimental section).  
4.2.3 Design and cloning of the different genes of LnbB 
The Construct A gene (40-528) of Lacto-N-biosidase from Bifidobacterium bifidum (LnbB), 
codon-optimized for the expression in Escherichia coli were produced by GenScript (GenScript, 
NJ, USA). Construct A gene (40-528) was cloned into the pET28a+ plasmid (Novagen, Madison, 
WI, USA) using the restriction sites NdeI and Bpu1102. Constructs B (176-497) and Bα (176-
528) genes were obtained by PCR reaction using construct A as template, and constructs C (40-
667), D (40-776), E (546-667), and F (546-776) genes were carried out using the wild type LnbB 
C-terminal His-tagged gene. The following forward and reverse primers were used (restriction 
site are underlined):  
 
Construct B and Bα sense 5’-GGAATTCCATATGAAGCCGAAATATAAAGAACGT-3’ 
Construct B antisense 5’-TAATAGCTCAGCGGCGTCAAC-3’ 
Construct Bα antisense 5’-TAATAGCTCAGCACGGGAGTCACTCCA-3’ 
Construct C and D sense 5’-GCGTATCCATGGCTGATGACTCCGCAGCAGGCTA-3’ 
Construct C and E antisense 5’-GCGTATCTCGAGCAGCGCGTTGTCGC-3’ 
Construct D and F antisense 5’-GCGTATCTCGAGCAGGCTGCCGGTCAGC-3’ 
Construct E and F sense 5’-GCGTATCCATGGTGGATGCGGGTATC-3’ 
 
Amplification was carried out with iProof High-Fidelity DNA Polymerase (2U/µL) from Bio-Rad 
in a 50-20 μl final volume reaction mixture containing plasmidic DNA (~150 ng), 0.02- 0.05 µM 
of sense primer, 0.02-0.05 µM of antisense primer, nuclease-free water and  I-proof PCR 
master mix (Ref. 172-5310, Bio-Rad). A 3 min initial denaturation at 95°C was followed by 30 
cycles: 95°C 30 sec, 30 sec of the corresponding annealing temperature for the different 
primers, 72°C 50 sec or 2.5 min depending on the amplicon, and a 10 min final extension at 
72°C. Cloning primers incorporated restriction sites for directed cloning. 
PCR were carried out using a thermocycler PTC-200 (MJ research). 
PCR products were purified with Gen Elute gel extraction kit (Sigma-Aldrich), and vector 
pET28a+ (Novagen) and purified PCR products were digested with the specific endonucleases.  
After ligation, all constructs were cloned into the pET28a+ vector with NdeI and Bpu1102 as 
flanking restrictions sites, except for construct D and F that were flanked by NcoI and XhoI 
sites.  
All proteins mentioned above were design to be purified using affinity chromatography (IMAC) 
with Ni2+-charged columns. 
Construct F with Strep-tag sequence was obtained by PCR reaction using LnbB gene as 
template using cloning primers that incorporated streptavidin sequence and restriction sites 
for directed cloning.  
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The gen was inserted in pET28a+ among NcoI and Bpu1102 restriction sites. The following 
primers were used (restriction site are underlined and Strep-tag sequence is bold): 
 
Construct F Strep-tag sense 5’-GCGTATCCATGGTGGATGCGGGTATC-3’ 
Construct F Strep-tag antisense 5’TAATAGCTCAGCCTATTTTTCAAATTGAGGATGTGACCAC
GCGCCCAGGCTGCCGGTCAGCGCAACCG-3’ 
E. coli DH5α cells were transformed with the different plasmids and positive transformants 
were verified by DNA sequencing. Afterwards, E.coli BL21 (DE3) (Stratagene, La Jolla, CA, USA) 
were also transformed for protein production. Both strains were cultivated in LB-medium 
under selective conditions (final concentration of kanamycin 30µg/ml). 
4.2.4 Site-directed mutagenesis of loop mutants of LnbB 
Mutagenesis of specific residues of loop 573-575 of LnbB was carried out using modified 
QuikChange site-directed mutagenesis protocol (Liu and Naismith, 2008). For each single 
mutant, a sense/antisense primer pair was designed. Each primer pair contains non-
overlapping sequences at their 3' end and primer-primer complementary (overlapping) 
sequences at the 5' end. The mismatching nucleotides for the mutation are located at the 
centre of the overlapping region.  
It has been tried to introduce as less mismatched nucleotides as possible for a desired mutated 
amino acid, taking into account the codon usage for E. coli. 
Primers used are list below (mutated nucleotides are underlined, and codons affected are 
lowercase letter): 
 
H573A sense 5’-GGTTCAAAAgcgCTGGATGTCGTTACCCAAG-3’ 
H573A antisense 5’-CGACATCCAGcgcTTTTGAACCGGTAAACAGTGCC-3’ 
L574A sense 5’- CAAAACAT gcgGATGTCGTTACCCAAGTGG-3’ 
L574A antisense 5’-GTAACGACATCcgcATGTTTTGAACCGGTAAACAGTGCC-3’ 
L574R sense 5’-CAAAACATcgcGATGTCGTTACCCAAGTGG-3’ 
L574R antisense 5’-GTAACGACATcgcGATGTTTTGAACCGGTAAACAGTGCC-3’ 
D575A sense 5’-AAACATCTGgcgGTCGTTACCCAAGTGGGTGC-3’ 
D575A antisense 5’-GGTAACGACcgcCAGATGTTTTGAACCGGTAA-3’ 
H573A-L574A-D575A sense 5’-GGTTCAAAAgcggcggcgGTCGTTACCCAAGTGGGTGC -3’ 
H573A-L574A-D575A 
antisense 
5’- GGTAACGACcgccgccgcTTTTGAACCGGTAAACAGT-3’ 
 
 
Plasmid pET 24b-LnbB-FL, which encodes for wild type C-terminal His-tagged LnbB was used as 
template for mutagenesis. PCR were carried out using IProof polymerase (Bio-Rad) and a 
thermocycler PTC-200 (MJ research). Amplification was carried out in a 20-50 μl final volume 
reaction mixture containing plasmidic DNA (~150 ng), 0.02- 0.05 µM of sense primer, 0.02-0.05 
µM of antisense primer, nuclease-free water and  I-proof PCR master mix (Ref. 172-5310, Bio-
Rad). A 3 min initial denaturation at 95 °C was followed by 30 cycles: 95 °C 30 s, 30 s of the 
corresponding annealing temperature for the different primers, 72 °C 4 min, and a 10 min final 
extension at 72°C. After PCR reaction, the samples were digested with DpnI for 1 hour at 37 °C, 
and then, transformed into E. coli DH5α. Positive transformants were confirmed by DNA 
sequencing and the final constructs were used to transform E. coli DH5α and BL21 (DE3) cells. 
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4.2.5 Protein expression trials  
Construct A, B and Bα expression levels were optimized by adjusting the temperature and the 
time allowed for expression, either with IPTG or with autoinduction medium.  
 
The cells were grown in overnight at 37° C, 250 rpm in LB medium and diluted 200 fold to 
obtain starting main culture. In the case of IPTG induction, the starting cultures were induced 
at OD600 0.5-0.6 and OD600 1 at 25 °C, 30 °C and 37 °C, for 3, 6 and 14 hours of induction.  
In the case of autoinduction media, cells were allowed to grow for 12, 24, 48 and 60 hours at 
22 °C, 30 °C and 37 °C in LB media supplemented with25mM Na2HPO4, 25mM K2HPO4, 50mM 
NH4Cl, 5mM Na2SO4, 2mM MgSO4, 0.5% glycerol, 0.05% glucose and 0.2% lactose. 
 1 mL of cultures was taken from each experiment. Cells were harvested by centrifugation 
(4000g, 15 min, 4°C), resuspended in buffer A (Na2HPO4 20mM, NaCl 150mM, pH 7.5) and 
disrupted by sonication (2 μm probe, 50% amplitude, 15 sec on, 45 sec off for 3 cycles) 
(Brandson). After centrifugation (16000rpm, 1 h at 4 °C), supernatant and pellet were analysed 
by SDS-PAGE.  
4.2.6 Expression and purification of wild type and mutants forms of Lacto-N-biosidase 
enzymes with His-tag in Escherichia coli 
Recombinant cultures of E. coli BL21 (DE3) star cells were grown following an autoinduction 
protocol (Studier, 2005) in LB medium with 30 µg/mL kanamycin, 25mM Na2HPO4, 25mM 
K2HPO4, 50mM NH4Cl, 5mM Na2SO4, 2mM MgSO4, 0.5% glycerol, 0.05% glucose and 0.2% 
lactose at 250 rpm and 30 °C for 24 h. Cells were harvested by centrifugation (4000g, 15 min, 4 
°C), resuspended in buffer A (Na2HPO4 20mM, NaCl 150mM, pH 7.5) and disrupted by passing 
once through a cell disrupter (20000 psi) (Constant Systems, UK). After centrifugation (20000g, 
4 °C, 2 h), the supernatant was loaded into a 1mL Ni2+-charged HiTrap chelating column 
chromatography (GE Healthcare). Proteins were purified to homogeneity by a linear gradient 
of 50 mL of Buffer B (20 mM Na2HPO4, 150 mM NaCl, 500 mM imidazole at pH 7.5) at a flow 
rate of 1 mL/min (Na2HPO4 20 mM, NaCl 150 mM, imidazole 500mM, pH 7.5). Collected 
fractions were analysed by SDS-PAGE (8%-12% acrylamide) and fractions containing the 
proteins were combined and dialyzed against buffer A with a 10 kDa cut-off membrane 
centricon (Merck-Millipore). 
4.2.7 Expression and purification of truncated Lacto-N-biosidase with Strep-tag in Escherichia 
coli 
Recombinant cultures of E. coli BL21 (DE3) star cells were grown following an autoinduction 
protocol, cited above. Once the cells were disrupted, the lysate was centrifuged and the pellet 
was discarded. The clarified lysate was loaded onto 1 mL Strep-Taq column (GE Healthcare). 
The protein was eluted with 2.5 mM d-desthiobiotin in Buffer A (Na2HPO4 20mM, NaCl 
150mM, pH 7.5). Collected fractions were analysed by SDS-PAGE (12-16% acrylamide) and 
fractions containing the proteins were combined and dialyzed against buffer A with a 10 kDa 
cut-off membrane centricon (Merck-Millipore). 
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4.2.8 Purification of Lacto-N-biosidase enzymes using FPLC 
 
All proteins, except loop mutants and the Strep-tagged construct F, were purified further using 
an XK16/60 Superdex 200 column (GE Healthcare), preequilibrated with buffer A. The 
calibration curve was obtained with 1-2 mg/mL of standards (Dextran Blue (>2000kDa), 
Alcohol dehydrogenase (150kDa), BSA monomer (66 kDa), Carbonic anhydrase (29kDa), 
Cytochrome C (12.4 kDa), Aprotinin (6.5 kDa) Sigma-Aldrich). All purifications were done in an 
ÄKTA FPLC (GE Healthcare). 
1-2 mL of concentrated proteins from affinity purification was loaded into the Superdex 200 
column by loop injection. Elution was done with buffer A (Na2HPO4 20mM, NaCl 150mM, pH 
7.5) at a flow rate of 1 mL/min. SDS-PAGE analysis was performed for all fractions collected, 
and fractions containing the protein of interest were pooled, concentrated with a 10 kDa cut-
off membrane centricon (Merck-Millipore) and stored at 4°C. In general, the elution yielded a 
single peak of the target protein with >95% of purity. 
4.2.9 Protein Identification 
Construct A solution was analyzed by mass spectrometry (MALDI-TOFF MS) for molecular mass 
determination in a Bruker Daltonics spectrometer with 2,5-dihydroxybenzoic acid as matrix. 
Reflectron, positive ion mode, 19 kV acceleration voltage, and 20 kV reflector voltage were 
used.  
Other soluble proteins were analysed by peptide mass fingerprint. In those cases, pure 
proteins obtained from acrylamide gel bands were digested with trypsin (Trypsin Gold Mass 
Spectrometry Grade, Promega) and peptides were identified using Mascot (Matrix Science, 
London UK) by search on NCBInr database.  
 
Protein size was determined using dynamic light scattering in a Nano ZS Nanosizer (Malvern 
Instruments Ltd., UK) with a laser light wavelength of 632.8 nm and a scattering angle of 173 
degrees. Temperature was set at 25°C. Protein solutions in buffer A were measured without 
previous dilution. 
 4.2.10 Size exclusion chromatography (HPSEC) 
HPSEC analyses to determine molecular mass estimation of the protein in solution were 
performed on an Agilent 1100 HPLC system (Agilent) equipped with a UV detector. 10 µL of 
each sample or standard was injected into a Shodex-803KW column (8.0 x 300 mm) 
thermostated at 25°C, and Buffer D (50mM Na2HPO4, 300mM NaCl, pH 7.0) as eluent at a flow 
rate of 0.8 mL/min. The calibration curve was obtained with 1-2 mg/mL of standards (Dextran 
Blue (>2000kDa), Alcohol dehydrogenase (150kDa), BSA monomer (66 kDa), Carbonic 
anhydrase (29kDa), Cytochrome C (12.4 kDa), Aprotinin (6.5 kDa) Sigma-Aldrich). 
All samples were filtered with PVDF 0.45 µm filters (Teknokroma) prior to be injected into the 
column. 
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4.2.11 Kinetics of the hydrolase activity 
Lacto-N-biosidase activity assays with p-nitrophenyl β-lacto-N-bioside (Toronto Research 
Chemicals Inc.) were performed at 30 °C in a volume of 0.1 mL using 96-wells microtiter plates 
measuring p-nitrophenol concentration at 405 nm. Enzymatic reactions were performed in a 
reaction mixture containing 0.25 mM substrate and Buffer C (50mM of citrate-phosphate 
buffer, pH 4.5). After pre-incubation for 5 min at 30 °C, reactions were initiated by addition of 
the enzyme (20 nM-4 µM, specific concentration is determined in each experiment). At regular 
time intervals, reactions were quenched by the addition of 0.15 mL of quenching buffer (0.5 M 
of glycine, pH 11) and p-nitrophenol release was measured by absorbance at 400 nm with a 
microplate-reader MRX (Cultek). Triplicate measurements at each concentration were 
performed. The molar absorption coefficient of p-nitrophenol at 405 nm was 5117 M-1·cm-1 at 
pH 4.5 at 30 °C. 
Initial rates (vo) were obtained from the linear progress curve of release of pNP, and they were 
expressed as vo/[E] in s-1. 
 
4.2.12 Kinetic complementation assays 
Enzymatic reactions with constructs A and F were performed using standard conditions 
mentioned in C2.2.11 in a Bravo liquid handling Robot (Agilent). After pre-incubation of 
construct A (50 nM) and F (25 nM-500 nM) for 5 min at 30 °C, addition of the substrate (0.25 
mM of p-nitrophenyl β-lacto-N-bioside) initiated the reaction. Triplicate measurements at each 
concentration were performed.  
Enzymatic activities of construct A (50 nM) in the presence of BSA at 1:1, 1:4 and 1:10 ratio 
were also analysed using standard conditions. 
4.2.13 Differential scanning fluorimetry (ThermoFluor assay) 
ThermoFluor assay to assess the stability of proteins was performed. 5 µM of protein solution 
in Buffer A (Na2HPO4 20mM, NaCl 150mM, pH 7.5) was added to 200X SYPRO Orange dye at 
50 µl of final volume. The scan of the fluorescence was done at 492nm/516nm, 
excitation/emission, by increasing 1 °C each min, from 25 °C to 75 °C. Temperature and 
fluorescence were followed using qPCR equipment, Rotor- Gene 3000 (Corbett Research). 
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4.3 RESULTS AND DISCUSSION  
According to CAZY classification (Cantarel et al., 2009), the GH20 family is mainly composed of 
both prokaryotic and eukaryotic β-N-acetylhexosaminidases with different substrate 
specificities, EC.3.2.1.52 and EC.3.2.1.140. This family is very wide, with more than 2000 
proteins identified. However, only thirteen of them have the 3D structure solved (Figure 4.3). 
Their domain organization is quite diverse, being the catalytic module assigned to a GH20 
domain (PFAM code PF00728).  
Among known structure GH20 proteins, the catalytic GH20 domain appears to be a single 
domain, as it is shown in Dispersin B from A. actinomycetemcomitans. Or it can be 
accompanied by other domains with quite diverse functionalities, such as; a non-catalytic 
domain (commonly called GH20b) which is conserved in most GH20 enzymes although with 
unknown function, several lectin domains, different carbohydrate binding domains (CBM), and 
other domains of unknown function. In addition, the oligomerization state of the different 
hexosaminidases is also varied, from monomeric to dimeric proteins. 
Several studies on the structure-function relationships at the active site have been performed 
(Mark et al., 2001; Pluvinage et al., 2011; Prag et al., 2000; Sumida et al., 2012; Williams et al., 
2002) but only a few of them have addressed the structural organization of these enzymes (Ito 
et al., 2013; Mark et al., 2001; Sumida et al., 2009).  
In this thesis a detailed analysis of the structure-function relationships among GH20 enzymes is 
reported. 
4.3.1 Structural domains organization of GH20 enzymes 
Using data integration from different databases (Pfam, Superfamily, SCOP, PSI-BLAST and CAZY 
databases), a consensus organization for the known structure GH20 enzymes has been created 
(Table 4.2). Regardless of the number of accompanying domains, in this study two different 
models of organization are n proposed (Table 4.2): Model A, comprising of proteins with at 
least both GH20b and GH20 domains, which is characterized by a GH20b-GH20-α architecture, 
where GH20 is always accompanied by GH20b at the N-terminus and followed by an extra α-
helix after the GH20 (β/α)8-barrel, and Model B with proteins that only present the GH20 
domain without GH20b, or the α-helix . 
To date, eleven of the thirteen GH20 enzymes structures fit into Model A (Figure 4.3). As 
summarized in Table 4.2, five of them are monomeric proteins in solution (SpHex, ScHex, 
Hex1T, SmCHB, and LnbB), whereas other four are dimeric proteins (HexA, Hex B, OfHex1, and 
GcnA). The oligomerization state of the Arthrobacter aurescens (NahA) and Bacteroides fragilis 
(Bf3009 a) enzymes remains unknown. 
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Table 4.2 Domain organization of GH20 β-N-acetylhexosaminidases.  
Data obtained using integration from different databases (Pfam, Superfamily, SCOP, PSI-BLAST and CAZY databases). 
PDB structure accession code and chain identifier used for structural analysis are indicated and domains actually 
present in the PDB structure are underlined.1.*: Oligomerization state in solution is unknown. 
Model A 
 
Enzyme Organism Length 
(aa) 
PDB Domains1 GH20b-GH20-α 
location (aa) 
Monomeric      
β-N-acetylhexosaminidase 
(SpHex) 
Streptomyces plicatus 506 1HP5[A] GH20b-GH20-α 19-494 
β-N-acetylhexosaminidase 
(ScHex) 
Streptomyces coelicolor 
A3(2) 
535 4C7G[A] GH20b-GH20-α 11-511 
β-N-acetylhexosaminidase 
(Hex1T) 
Paenibacillus sp. 978 3GH5[A] GH20b-GH20-α-Lectin-CBD 15-493 
Chitobiase  
(SmCHB) 
Serratia marcescens 885 1QBB[A] CHB_HEX-GH20b-GH20-α-CHB_HEX_C 215-814 
Lacto-N-biosidase  
(LnbB) 
Bifidobacterium bifidum 1112 4JAW[A,B] GH20b-GH20-α-Lectin-CBM32-Iglike 34-515 
β-N-acetylhexosaminidase 
(NahA) * 
Arthrobacter aurescens 540 3RCN[A] GH20b-GH20- 5-506 
β-N-acetylhexosaminidase 
βf3009) * 
Bacteroides fragilis 518 4PYS[A,B] GH20b-GH20-α 21-498 
Heterodimeric      
β-N-acetylhexosaminidase 
(HexA) 
Homo sapiens 529/556 2GK1  
[A,B,C,D,E,F,G] 
GH20b-GH20-α     α:23-510  
    β:56-540 
Homodimeric      
β-N-acetylhexosaminidase 
(HexB) 
Homo sapiens 556/556 1NP0[A,B] GH20b-GH20-α 56-540 
β-N-acetylhexosaminidase 
(OfHex1) 
Ostrinia furnacalis 593/593 3OZO[A] GH20b-GH20-α 65-574 
β-N-acetylhexosaminidase 
(GcnA) 
Streptococcus gordonii 627/627 2EPN[A,B] GH20b-GH20-α-Domain III 2-414 
Model B 
 
Enzyme Organism Length 
(aa) 
PDB Domains1 GH20 domain 
location 
Monomeric      
β-1,6-N-acetylglucosaminidase 
Dispersin B (DspB) 
Aggregatibacter 
actinomycetemcomitans 
361 1YHT[A] GH20 20-342 
β-N-acetylhexosaminidase 
(StrH) 
Streptococcus 
pneumoniae R6 
1312 3RPM[A,B] GH20-GH20-G5-G5 190-538 
635-972 
Streptococcus 
pneumoniae TIGR4 
1312 2YL8[A] GH20-GH20-G5-G5 190-538  
2YL9[A,B,C, D] GH20-GH20-G5-G5 635-972 
 
For the monomeric proteins, SpHex and ScHex share 94% sequence identity, and their 
architectures contain the GH20b domain followed by the catalytic GH20 domain (Mark et al., 
2001; Thi et al., 2014). Hex1T consists of four domains -GH20b and GH20, and domains III and 
IV-. Domains III and IV are described as concanavalin A-like lectin and cellulose-binding 
domains respectively, according to the Superfamily database (Supfam). The Hex1T crystal 
structure is a truncated form (residues 1-502), with only the GH20b and GH20 domains. 
Additional domains could help to interact with lipophilic substrates (Sumida et al., 2009). 
SmCHB was the first GH20 structure to be reported (Tews et al., 1996). It is also made up of 
four domains, where the N-terminal domain (CHB_HEX) is annotated as a carbohydrate 
binding module (although its function remains unknown) and the C-terminal domain 
(CHB_HEX_C) as an immunoglobulin-like fold domain (Supfam). The central domains 
correspond to GH20b and GH20 domains (Prag et al., 2000). LnbB (which exhibits less than 
25% amino acid sequence identity to all the characterised GH20 enzymes (Wada et al., 2008)) 
is formed by five domains. Domains I and II are the GH20b and GH20 ones. Domain III (residues 
N’ C’
GH20b GH20 α
N’ C’
GH20
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546-700) is similar to a lectin domain according to a PSI-Blast search. Domain IV (784-932) has 
sequence homology to CBM32 (Supfam), and domain V (962-1041) is described as a 
Immunoglobulin-like domain in PFam. The recent crystal structure of this enzyme corresponds 
to a C-terminal truncated form (41-663) with the GH20b, GH20 and part of the lectin-like 
domain (Ito et al., 2013). Finally, NahA and Bf3009, with unknown oligomerization state but 
included in the group of monomeric proteins in Table 4.2, present only the GH20b and GH20 
domains. 
For the dimeric proteins, each subunit of HexA, HexB (Lemieux et al., 2006; Mark et al., 2003a) 
and OfHex1 (Liu et al., 2011) have only the two domains, GH20b and GH20, while the GcnA 
structure contains an additional domain III, which is predominantly α-helical and is reported to 
form a significant part of the dimer interface (Langley et al., 2008).  
In general, these accompanying domains are non-catalytic domains involved in binding and 
substrate specificity but still the mechanism by which this occurs remains uncertain (Cuskin et 
al., 2012; Drickamer and Fadden, 2002). 
 
Figure 4.3 Crystal structures of GH20 β-N-acetylhexosaminidases. 
(A) Structures according to model A architecture. (B) Structures according to model B architecture. GH20b domains 
are coloured in orange, GH20 domains in blue, α-helix in green, and the rest of accompanying domains in yellow 
and purple. Loop 2 from GH20 domain is in red. Dimer counterparts follow the same colouring scheme but with 
lower intensity. 
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The remaining two GH20 enzymes present structures that are assigned to Model B (Figure 
4.3B). These are Dispersin B from Aggregatibacter actinomycetemcomitans (DspB) and the β-
hexosaminidases from Streptococcus pneumoniae (StrH). Both are monomeric proteins in 
solution. DspB presents only one domain, the unique GH20 domain (Ramasubbu et al., 2005), 
and StrH consists of four domains, where the N-terminus is a tandem repeat of two GH20 
domains, called GH20-1 and GH20-2, and the C-terminus is a tandem repeat of two domains 
tentatively designated as G5 with unknown function (Pfam). Truncated forms containing a 
single GH20-1 and GH20-2 domains of S. pneumoniae were crystallized (Jiang et al., 2011). The 
GH20-1 and GH20-2 domains are quite similar although specific features confer differential 
substrate specificities.  
4.3.2 B. bifidum Lacto-N-biosidase truncated forms: Construct A, B and Bα 
Due to the diversity in the GH20 hexosaminidase domain organization, several questions are 
raised. Are all the accompanying domains essential for activity? Would the GH20 catalytic 
domain alone be functional? And, what is the importance of GH20b? 
In order to answer these questions, B. bifidum Lacto-N-biosidase was truncated according to 
the two different models of structure organization proposed. As the crystal structure of LnbB 
was not solved by the time of this study, prediction and sequence aligning online tools were 
used to predict secondary structure of LnbB and, subsequently, determine the different 
truncations.  
LnbB consists of five domains: GH20b and GH20 catalytic domains, lectin-like domain (residues 
546-700), CBM32 domain (784-932) and Immunoglobulin-like domain (962-1041), as has been 
detailed in Chapter 3. 
According to the domain architecture of LnbB, and the proposed model organization of GH20 
enzymes (section 3.3.1), three different truncated proteins were designed: construct A, B and 
Bα (Table 4.3). The truncation location was designed in areas of transition from one domain to 
the next, without secondary structure, as the Jpred3 prediction revealed. 
Table 4.3 Truncated forms of B.bifidum Lacto-N-biosidase; construct A, B and Bα. 
 
 Domain architecture Residues 
Wild type protein 
 
35-1064 
Construct A 
 
40-528 
Construct B  176-497 
Construct Bα 
 
176-528 
 
N’ C’
GH20b Lectin CBM 32 Ig likeGH20 α
N’ C’
GH20b GH20 α
N’ C’
GH20
N’ C’
GH20 α
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Construct A (residues 40-528) follows the architectural organization of Model A enzymes and is 
composed of the GH20b and GH20 domains always followed by the extra α-helix. This 
construct would be expected to be active since several enzymes of model A exhibit just these 
two domains alone in the wild-type protein (such as SpHex structure and HexA, HexB and 
OfHex1 subunits). Furthermore, a truncated form of Hex1T (encoding the GH20b-GH20-α 
domains alone) is reported to be active (Sumida et al., 2009). 
Construct B (residues 176-497) mimics Model B enzymes and is formed by the single catalytic 
GH20 domain alone.  
Lastly, construct Bα (residues 176-528) was designed to tackle the open question of whether 
the accompanying GH20b domain can be removed in Model A enzymes. This construct 
encodes the catalytic GH20 domain with the extra α-helix at the C-terminus. Both constructs, B 
and Bα, were designed for the study of the behaviour of the GH20 catalytic domain in model A 
proteins. 
Construct A gene was produced as a synthetic gene with codon optimised sequence for E. coli 
expression. It was cloned into a pET28a+ vector and was used as template for PCR 
amplification of construct B and Bα. The three genes of the constructs genes were successfully 
obtained and cloned into a pET28a+ vector with NdeI and Bpu1102 as flanking regions to 
generate N-terminally His-tagged truncated proteins. E.coli DH5α and BL21 (DE3) were 
transformed and expression trials were performed. 
Expression trials were performed for construct A, B and Bα with both IPTG and autoinduction 
methods, at different temperatures and different times of of induction (see an example of 
Autoinduction trials in Figure 4.4). The trials carried out with autoinduction system showed 
higher levels of protein expression in the soluble fraction, compare to IPTG induction. 
 
 
 
Figure 4.4 SDS-PAGE analysis of autoinduction expression trials for construct A, B and Bα.  
12% SDS-PAGE with Coomassie stain analysis reveals that construct B and Bα are always observed in the insoluble 
fraction, independently of the temperature or time of expression, while construct A is always present in the soluble 
fraction in all conditions. 
 
37C 26C 20C
A B Bα A B Bα A B Bα
A B Bα A B Bα A B Bα
37C26C20C
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Final conditions for the expression of construct A were growing recombinant cells at 30 °C for 
24 h with autoinduction medium. After cell lysis, the soluble fraction obtained was purified by 
Ni2+-charged HiTrap chelating column chromatography. The chromatogram (Figure 4.5A) 
revealed a single peak of construct A eluted with 100 mM of imidazole (which corresponds to 
20% of buffer B). SDS-PAGE analysis revealed that construct A migrated with an approximate 
molecular mass of 57 kDa, which agrees with the theoretical molecular mass (Figure 4.5C) 
Fractions containing construct A were pooled, concentrated, and further purified on a 
Superdex 200 column (GE Healthcare). In this case the chromatogram also showed a single 
peak at 71.5 mL (Figure 4.5B). According to protein standards this elution volume corresponds 
to molecular masses higher than 60-100kDa, so this would indicate that construct A was 
eluting as a dimer. 
Fractions, previously analysed by SDS-PAGE, were again pooled and concentrated with a 10 
kDa cut-off membrane Centricon (Merck-Millipore). Final protein concentration was 
determined spectrophotometrically by the BCA method measuring Abs 590 nm using BSA as 
standard (Smith et al., 1985). An average yield of 27mg of construct A was obtained per litre of 
culture. 
 
Figure 4.5 Schematic representation of the purification of Construct A.  
(A) Chromatogram of affinity chromatography (IMAC). Single peak of construct A eluted with 500 mM Imidazole gradient. (B) 
Chromatogram of size exclusion chromatography on a Superdex 200 column. Single peak of construct A eluted with buffer A. (C) 
12% SDS-PAGE of fractions from size exclusion chromatography shows pure bands of construct A (57kDa).  
 
Construct A in solution was also analysed by mass spectrometry (MALDI-TOFF MS) and 
analytical size-exclusion chromatography (HPSEC). By contrast to gel filtration, the molecular 
mass estimation of the protein in solution was consistent with a monomeric 57 kDa protein 
using HPSEC. Protein size was determined using dynamic light scattering in a Nano ZS 
Nanosizer (Malvern Instruments Ltd., UK). Construct A solutions in buffer A were measured 
without previous dilution and showed a single peak for monodisperse particles of 7 nm and 
PDI 0.85, which is also consistent with monomeric species (Figure 4.6).  
Peptide mass fingerprint obtained after tryptic digestion by MALDI-TOF mass spectrometry 
confirmed the presence of peptides from construct A. 
Taking into account all the results obtained, it was concluded that construct A was a monomer 
in solution, and the resolution of the Superdex 200 column was not suitable for molecular 
mass determination in a range of 60-100 kDa. 
A
B
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Figure 4.6 Construct A identification analysis.  
(A) MALDI-TOF spectrum of construct A in solution and identification of peptides from digested construct A protein. 
(B) Size distribution plot by Dynamic Light Scattering. 99.7 % of the particles of the assayed sample presented a 
unique size particle of construct A.  
 
On the other hand, constructs B and Bα, with a predicted molecular masess of 44 kDa and 40 
kDa respectively, were only present in the insoluble pellet and no soluble protein was achieved 
after the different expression conditions mentioned above (see an example in Figure 4.7). 
 
Figure 4.7. Expression trials with IPTG for construct A, B and Bα.  
12% SDS-PAGE with Coomassie stain. Gel in the left for insoluble fractions, and gel in the right for soluble fractions. 
A, B and Bα lines correspond to the respective truncated proteins charged in a gel after 1mM IPTG induction for 3 
hours at 25°C and 37°C. Overexpressed construct B (44kDa) and Bα (40kDa) present in gel for insoluble fraction, 
while overexpressed construct A (57kDa) is present in the gel for soluble fractions. 
 
This seems to indicate that the single GH20 catalytic domain of LnbB, with or without the extra 
α-helix, is not stable enough and yields insoluble aggregates. Thus, GH20b domain at the N-
terminus of GH20 is required for LnbB expression and stability. This domain is present in all 
model A enzymes, and the relative orientation of GH20b and GH20 catalytic domain is also the 
same in all structures (Figure 4.3). The number of β-strands of the GH20b domain varies (for 
example five in GcnA, six in HexA and HexB and seven in SpHEx and LnbB) but the interface 
between both domains is well conserved: two loops (residues 54-60 of loop 1 and residues 
127-130 of loop 4 in LnbB) and three helices (residues 82-99, 146-163 and the extra α-helix of 
the GH20 domain which is oriented toward an hydrophobic pocket). GH20b domain is not only 
found in GH20 enzymes but also in some GH84 hexosaminidases and GH67 glucoronidases 
MW                A   B   Bα A   B   Bα
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annotated in Pfam as GH20b and GH67N (Nurizzo et al., 2002) respectively, always located at 
the N-terminus of the catalytic domain.  
Considering this scenario, it is concluded that GH20b-GH20-α architecture of model A enzymes 
cannot be reduced to that of model B. 
4.3.3 Kinetics of the hydrolase activity of construct A 
In order to determine whether construct A was the minimal functional unit or not, the catalytic 
activity of the truncated protein was assayed. Hydrolytic activity assay were performed in 
saturated substrate conditions: 0.25 mM of substrate, at pH 4.5 at 30 °C. Once the reaction 
was over, it was quenched with 1.5 volumes of 0.5 M glycine buffer at pH 11, and released p-
nitrophenol was measured at 400 nm in a plate reader spectrophotometer. 
The hydrolytic activity of the soluble construct A was assayed using 0.25 mM of p-NP-LNB as 
substrate. Enzymatic reactions were performed using different protein concentrations (20 nM, 
100 nM, 1 µM and 4,5 µM) in a wide range of pH (3.5-7.5) of 50 mM citrate-phosphate buffer, 
and at 25°C and 30°C. However, construct A was catalytically inactive at the assayed 
conditions. 
In conclusion, GH20b-GH20-α architecture of LnbB is enough to guarantee protein expression, 
but this architecture does not correspond to the minimal functional unit maybe requiring 
other accompanying domains from the C-terminus for the enzyme to be active.  
4.3.4 Structural requirements in the GH20 domain for functionality 
While this minimal GH20b-GH20-α architecture assures the activity of SpHex and Hex1T (Mark 
et al., 1998; Sumida et al., 2009) and also of dimeric proteins such as HexA, HexB and OfHex1 
(Liu et al., 2011; Mahuran et al., 1985), it is not enough for LnbB. 
While construct A was being studied, in 2013 Ito and co-workers presented an LnbB truncation 
study in which a truncated protein (37-520) equivalent to construct A also exhibited no 
catalytic activity. However, a longer truncated protein (37-663) composed of GH20b-GH20-α 
and a part of the lectin-like domain was reported to be as active as the full-length (Ito et al., 
2013). The accompanying lectin domain turned out to be the missing element required in 
construct A to be fully active. 
In this thesis, the interaction of the catalytic GH20 domain with other C-terminus domains was 
carefully analysed in all crystallized protein structures of model A (Figure 4.9). Exploring the 
structure, important structural features can be assigned. The lectin domain interacts with the 
catalytic GH20 domain, providing a remote element that folds on the active site (Figure 4.8A). 
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Figure 4.8 Detailed view of the remote elemt of LnbB interaction with the cavity. 
Colour assignment: red: loop 2, yellow: lectin domain and blue: catalytic GH20 domain. 
 
This element (residues 570-578) consists of a beta-turn, in which Leu574 completes the 
substrate binding cavity favouring a hydrophobic interaction with the hydroxymethyl group of 
the galactose moiety of the substrate. In addition, Leu574 is positioned between two 
conserved amino acids Gln190 and Asp467 of subsites –1 and –2 forming further interactions 
between this turn and the active site (Figure 4.8). For instance, through a water mediated 
hydrogen bond, the backbone nitrogen atom of Leu574 favours the orientation of Gln190 
towards the O4 of the galactose unit of the disaccharide ligand. Engineered forms of LnbB in 
which part of the C-terminus of the lectin domain were even shorter (Ito et al., 2013) or 
completely removed as in our construct A, showed an important decrease in activity of the 
enzyme, indicating that the interactions observed in the structure between the remote lectin 
domain and the substrate binding site are essential for catalysis.  
Interestingly, it has been detected that this pattern is reproduced in all proteins of model A. 
There is always a remote element assisting in the definition of the substrate binding cavity by 
means of direct interactions with conserved amino acids directly involved in protein–substrate 
interactions. Figure 4.9 shows the three model architectures found in GH20 model A enzyme 
with regard to the remote element.   
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Figure 4.9 Different remote elements and their key residues that complement the active site of GH20 β-N-
acetylhexosaminidases.  
(A) B. bifidum lacto-N-biosidase. (B) S. plicatus and (C) S. gordonii N-acetylhexosaminidases. Dot lines represent 
interactions between residues of the remote element and the active site as indicated in Table 4.4. 
 
Table 4.4 summarizes the exact localization of these remote elements for each member of 
model A and the interactions it forms with conserved active site residues. In general, this 
remote element is provided by a long loop of the GH20 domain itself (loop 2). In the cases 
where this loop is too short, the remote element comes from an accompanying domain (such 
as the lectin domain in the case of LnbB) or from the C-terminus of the other monomer in the 
case of dimeric proteins. 
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Figure 4.10 Multiple sequence alignment of loop 2 region of β-N-acetylhexosaminidases of known structure from 
family GH20. 
Domains distribution is shown as coloured boxes on top. Accompanying domains are not shown. Sequences were 
downloaded from UniProt entry names: SpHex (O85361_STRPL), ScHex (Q9L068), Bf3009 (Q5LAT3) NahA 
(A1RBZ5_ARTAT), Hex1T (D2KW09_9BACL), SmCHB (CHB_SERMA), LnbB B3TLD6_BIFBI), HexA (HEXA_HUMAN), 
HexB (HEXB_HUMAN), OfHex1 (Q06GJ0_OSTFU), GcnA (Q6ST21_STRGN), DspB (Q840G9_AGGAC), StrH_R6 
(Q8DRL6_STRR6), StrH_TIGR4 (STRH_STRPN). Alignment was performed with PROMALS. Conserved positions are 
coloured according to ClustalW colour scheme. Only the sequence fragments covering GH20b, GH20 domains and 
extra α-helix were considered in this alignment. Full image at Appendix section. 
 
In detail, structures of SpHex, ScHex, NahA, Bf3009, SmCHB and Hex1T present this remote 
element coming from the extended loop 2 of the GH20 domain itself (Figure 4.10). This loop 
positions a hydrophobic residue, such as Val214 in SpHex (equivalent to Leu574 in LnbB), into 
the second shell of the subsite  –1 cavity just behind the conserved arginine and aspartate in 
all known GH20 hexosaminidases, Arg 162 and Asp444 (equivalent to Gln190 and Asp467 in 
LnbB, see alignment in Figure 4.10). These amino acid residues can form hydrophobic 
interactions between their side-chains and also, a hydrogen bond between the backbone NH 
group of Val214 and the carbonyl group of the backbone of Arg162 (Figure 4.9B). These 
interactions between residues of the remote element and the conserved arginine and 
aspartate of subsite –1, are present in all the structures with long loop 2 (Table 4.4). ScHex 
presents Val243 of loop2 next to Arg191 and Asp473 in the same way. NahA and SmCHB show 
the longest loops 2 as seen in the alignment. They provide the remote elements next to the 
corresponding arginines, Arg146 and Arg349, and aspartates, Asp456 and Asp739 respectively. 
One arginine of the remote element, Arg196 in NahA and Arg399 in SmCHB, is hydrogen-
bonded to the backbone of the active site arginine. Similarly, Bf3009 presents Gln209 of loop2 
next to Arg153 and Asp450. In Hex1T, Val222 from the remote element is positioned behind 
Arg170 and Asp443 and the backbone NH group of this valine donates a hydrogen bond to the 
arginine carbonyl oxygen atom. Interestingly, a truncated form of Hex1T with only the GH20b 
and GH20 domains has been reported to be active (Sumida et al., 2009). Consistent with the 
explanations given in this study, this truncated form does not affect the definition of the active 
site, because this construct keeps the long loop 2 in the GH20 domain.  
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Table 4.4 Remote element and conserved interactions with the active site of model A GH20 β-N-
acteylhexosaminidases. 
 *Residue in LnbB substituting the function of the conserved arginine but in subsite -2. 
Enzyme Loop 2 length Remote element 
GH20 conserved 
Arg/Asp or Glu at 
subsite –1 
Remote element interactions 
with conserved Arg/Asp 
non-polar 
interactions 
polar 
interactions 
SpHex Long G209-T223 Loop 2 R162 V214 V214 
  E444 V214 - 
ScHex  Long G238-T252 Loop 2 R191 V243 V243 
  E473 V243 - 
NahA Long G193-T219 Loop 2 R146 - R196 
  E456 - - 
Bf3009 Long G200-S214 Loop 2 R153 - Q209 
  D450 -  
Hex1T Long G217-T231 Loop 2 R170 V222 V222 
  E443 V222 - 
SmCHB Long G396-S425 Loop 2 R349 Y413 R399 
  E739 Y413 - 
LnbB Short T231-T236 Lectin G570-T578 Q190* L574 S233 
  D467 L574 - 
HexA Short αG225-αT235 C-terminus subunit β 
A543-N552 
αR178 βA548 βG549 
  αE462 βY547 - 
HexA Short βG258-βT267 C-terminus subunit α 
A514-E523 
βR211 αV519 αG520 
  βE491 αV519 - 
HexB Short G258-T267 C-terminus dimer 
A514-E523 
R211 A548 G549 
  E491 Y547 - 
OfHex1 Short G267-T276 C-terminus dimer 
A577-S594 
R220  P582 E583 
  E526 P582 - 
GcnA Short G136-T143 C-terminus dimer 
S622-T627 
R95 - T627 
  D376 T627 - 
 
By contrast, when loop 2 is short, this remote element comes from the accompanying 
domains, as in LnbB, or from the C-terminus domains of the other monomer in dimeric 
structures, such as, GcnA, HexA, HexB and OfHex1. For example, in the homodimeric structure 
of GcnA, domain III forms a significant part of the dimer interface (Langley et al., 2008). The C-
terminus of domain III of chain B (622-627) winds back into the structure and contacts the 
catalytic GH20 of chain A (Figure 4.9C). Specifically, the C-terminus amino acid residue Thr627 
projects into subsite –1 and it is adjacent to the conserved arginine and aspartate (Arg95, 
Asp376) and is part of the active-site pocket of the dimer partner. Besides, the carboxyl group 
of this C-terminal Thr627 and the Arg95 side-chain are at less than 3 Å distance, establishing 
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electrostatic interactions. As in LnbB, any truncated form of this C-terminus domain III is 
believed to be inactive. In the dimeric structures of HexA, HexB and OfHex1 (Lemieux et al., 
2006; Liu et al., 2011; Mark et al., 2003), dimerization occurs exclusively between the GH20 
catalytic domains. Dimerization is essential for catalysis since residues of one subunit 
structurally complete the active site of the other one. For example, Tyr456 of subunit β is part 
of the active site of subunit α in HexA. In addition, the C-terminus of subunit β provides this 
remote element very close to the subsite-binding cavity of subunit α and vice versa (Table 4.4). 
Particularly, the hydrophobic residue Ala548 (subunit β) of this element in HexA forms part of 
the second shell of the cavity behind the conserved Arg178 (subunit α) and Asp462 (subunit α), 
and the backbone nitrogen atom of Gly549 (subunit β) interacts by hydrogen bond with the 
carbonyl oxygen atom of Arg178 (subunit α). The equivalent interactions between subunits are 
also seen in HexB and OfHex1 crystal structures (Table 4.4).  
Therefore, all GH20 structures of model A clearly show the presence of a remote element 
folding on the substrate-binding cavity providing amino acid residues that either complete the 
active site, as in the extended subsite –1 of the S. gordonii hexosaminidase or in subsite –2 of 
the LnbB, or participate in the second shell of this cavity behind the conserved arginine and 
aspartate residues in subsite –1 of hexosaminidases.  
4.3.5 B. bifidum Lacto-N-biosidase truncated forms: Construct D and F 
Further studies are presented in this work to determine the details of the minimum 
requirement for LnbB to be catalytically active. Four new constructs of LnbB were analysed 
(Table 4.5).  
Construct C (residues 40-663) is equivalent to the active truncated protein of Ito and co-
workers (residues 37-663). It contains the non-catalytic GH20b domain, the catalytic GH20 
domain and a part of the lectin domain, which they named the C-terminal domain. According 
to the HHPred prediction studies reported in Chapter 3, the lectin-like domain consists of 
residues 546 to 776. Then, the truncated protein of Ito and collaborators (residues 37-663) 
does not contain the entire lectin domain in its sequence. 
Construct D (residues 40-776) is similar to construct C, but longer. This construct contains the 
non-catalytic GH20b domain, the catalytic GH20 domain and the entire lectin domain as is 
predicted.  
Construct E (residues 546-663) contains the amino acids that are lacking in construct A to be 
active. Construct A (residues 40-528) and the truncated protein of Ito and collaborators 
(residues 37-663) differ in 135 amino acids that correspond to the C-terminal domain 
designated by Ito and co-workers. This C-terminal domain contains the remote element, but 
does not consist of an entire domain, according to the HHPred results. Construct E was 
designed to mimic C-terminal domain from Ito and co-workers.  
Construct F (residues 546-776) contains the complete sequence of amino acids for the entire 
lectin domain predicted by HHpred. Both constructs, E and F, contains the remote element 
needed for catalysis. 
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Table 4.5 Truncated forms of B.bifidum Lacto-N-biosidase; construct C, D, E and F. 
 
 Domain architecture Residues 
Wild type 
protein  
35-1064 
Construct C 
 
40-663 
Construct D  40-776 
Construct E 
 
546-663 
Construct F  546-776 
 
Engineered constructs C, D, E and F were designed as C-terminal His-tagged proteins while 
constructs A, B and Bα were designed as N-terminal His-tagged proteins. The position of the 
His-tags was located according to the proximity of the active centre, in the sense of having the 
His-tag far away from the active centre of the protein. Then, in the constructs C, D, E and F  the 
His-tag was located in the C-terminal region of the protein since the active centre and the tag 
are enough distant to each other. In contrast, the GH20 catalytic domain is located in C-
terminal of the truncated proteins A, B and Bα, so the His-tag was located in N-terminal of 
these constructs sequences.  
Constructs C, D, E and F were successfully obtained by PCR using wilt type LnbB C-terminal His-
tagged DNA as template. They were cloned into a pET28a+ vector with NdeI and Bpu1102 as 
flanking regions to obtain C-terminally His-tagged truncated proteins. DH5α and BL21 (DE3) 
were transformed with the different plasmids and the expression trials for the autoinduction 
method were performed. 
Constructs C, D and F were also expressed and purified by following the same procedure as for 
the wild type protein (see Chapter 3). Construct C, D and F were expressed as soluble proteins 
and SDS-PAGE analysis revealed that they migrate with approximate molecular masses of 
72kDa, 83 kDa and 28kDa respectively (Figure 4.11 for constructs D and F). These results are in 
line with their theoretical molecular masses. Average yields of 17 mg of construct C, 20 mg of 
construct D and 15 mg of construct F per litre of culture were obtained. 
N’ C’
GH20b Lectin CBM 32 Ig likeGH20 α
N’ C’
GH20b LectinGH20 α
N’ C’
Lectin
N’ Lectin C’
N’ C’
GH20b LectinGH20 α
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Figure 4.11 Purification and SDS-PAGE analysis of construct D and F.  
(A) Chromatogram of affinity chromatography (IMAC). Single peak of construct D eluted with 50 mM Imidazole. (B) 
Chromatogram of size exclusion chromatography on a Superdex 200 column. Peak at 71.4 mL of construct D eluted 
with buffer A as a monomer. (C) 12% SDS-PAGE of fractions from size exclusion chromatography, pure bands of 
construct D (83kDa) are observed. (D) Chromatogram of affinity chromatography (IMAC). Single peak of construct F 
eluted with 100 mM Imidazole gradient. (E) Chromatogram of size exclusion chromatography on a Superdex 200 
column. Single peak at 84.1 mL of construct F eluted with buffer A. (F) 16% SDS-PAGE of fractions from size 
exclusion chromatography. Pure bands of construct F (28kDa) are observed. Molecular masses in kDa. 
 
By contrast, construct E was not expressed in any of the conditions performed in the 
expression trials (Figure 4.12). This data would confirm that residues 546-633 do not 
correspond to a complete domain. At this point, constructs C and E were no longer being 
considered for this study. 
 
 
Figure 4.12 Expression trials for construct E and F. 
16% SDS-PAGE of the expression of construct E (gel in the left) and F (gel in the right) at different temperatures by 
following the autoinduction protocol. (SN) for the soluble fraction, (P) for the insoluble fraction. A clearly 
overexpression of construct F at 30°C and 37°C in the soluble fraction can be observed, while no overexpression is 
observed for construct E. Molecular masses in kDa. 
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4.3.6 Kinetics of the hydrolase activity of wild type LnbB and construct D 
The hydrolytic activity of the soluble proteins (20 nM) was performed in a reaction mixture 
containing 0.25 mM of p-NP-LNB and 50mM of citrate-phosphate buffer, pH 4.5 at 30 °C. Wild 
type protein showed a specific activity of 27.2 ± 3.5 s-1 and construct D was active with the 
same specific activity range as the wild type enzyme on the same substrate, 23.3 ± 1.0 s-1.  
Therefore, both the C-terminal domains in LnbB, the CBM32 and the Ig-like domains are not 
important for the catalytic activity, and construct D is the minimal functional unit of LnbB 
containing the entire domains.  
4.3.7 Complementation assays of construct A and F 
If construct A (composed of the GH20b and GH20-α domains) is inactive because of the lack of 
the remote element, would the addition of the lectin domain (as a single protein) reconstitute 
the active site and restore activity?  
 
4.3.7.1 Complementation assay analysed by hydrolytic activity 
 
To provide experimental evidence of the requirement of this remote element in LnbB to be 
active, a complementation assay was designed. The complementation experiment was assayed 
by adding construct F (the single lectin domain) into the inactive construct A solution. After 
pre-incubation of construct A (50 nM) and F (25 nM-500 nM) for 5 min at 30 °C, the addition of 
the substrate initiated the reaction. At regular time intervals, reactions were stopped and 
released p-nitrophenol was measured by absorbance at 400 nm.  
Activity was restored in a concentration-dependent manner when increasing the 
concentrations of construct F (Figure 4.13). 
 
Figure 4.13 Complementation assay of construct A with construct F at different molar ratios. 
The relative standard deviation for this kinetic data was less than 15%. 
 
130 
 
CHAPTER 4. STRUCTURAL FUNCTIONAL ANALYSIS OF GH20 FAMILY ENZYMES 
At a F:A molar ratio of 6:1 activity arrived at saturation at level rates of 2.9 ± 0.07 s-1, which is 
11% of the hydrolytic activity of the wild type enzyme. The activity was calculated taking into 
account the concentration of construct A (50 nm), which holds the catalytic centre.  
To exclude non-specific interactions, complementation assay was performed with construct A 
and BSA at different concentration ratios and no activity was recovered.  
Then, the restoration of the activity when the lectin domain is added to inactive construct A, 
indicates that the lectin domain carries the remote element needed for the structural 
conformation of the active cavity and therefore for LnbB being active. 
4.3.7.1 Complementation assays using preparative chromatography 
 
The complementation assay between construct A and F was followed by preparative size 
exclusion chromatography in order to identify the AF complex formation. 
First, the wild type protein and constructs A, D and F were analysed by preparative size 
exclusion chromatography (Figure 4.14). Proteins (50-250 µM) were loaded to a Superdex 200 
column pre-equilibrated with buffer A and calibrated with protein standards. Pure fractions 
were analysed by SDS-PAGE. 
 
Figure 4.14 Preparative size exclusion chromatography of the wild type protein and the different constructs of 
Lacto-N-biosidase from B.bifidum. 
(A) Chromatogram of the wild type LnbB: FL (black) and constructs A (blue), D (green) and F (red). (B) 12 % 
acrylamide SDS-PAGE of the eluted proteins. Molecular masses in kDa. 
 
As observed in Figure 4.14A, construct A and D elute in the same elution volume, while in the 
SDS-PAGE gel of Figure 4.14B, the four proteins clearly show different molecular masses, which 
correlates with the theoretical masses. These results indicate that the resolution of the column 
with Superdex 200 is not enough for molecular masses from 57-90kDa, as was previously 
shown in section 4.3.2. 
Construct A (42 µM), Construct F (245 µM), and the mixture of construct A and F were loaded 
into the Superdex 200 column. Eluted fractions were recovered for further SDS-PAGE analysis 
(Figure 4.15C and D). As was expected, due to the weak resolution of the column, no extra 
peak of the complex formed appears in the chromatogram (Figure 4.15A) when construct A 
and F are loaded together. According to column calibration with protein standards, the first 
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peak (71.4 mL) of the chromatogram in Figure 4.15A corresponds to proteins around 57-90 
kDa, which includes molecular masses of construct A (57kDa) and the expected AF complex 
(85kDa). The second peak of the chromatogram (84.1 mL) corresponds to the molecular mass 
of construct F (28kDa). When the recovered fractions from the interaction between construct 
A and F are analysed by SDS–PAGE, both proteins, constructs A and F can be seen in the first 
peak of elution (Figure 4.15C). This means that construct A and F are interacting with each 
other, and the complex elutes with the corresponding molecular mass (85kDa). From fraction 
J15 to K6 (69.4-76.7 mL) both proteins are visible at the SDS-PAGE, but not in an equimolar 
ratio. It is believed that not all of protein A is interacting with F. So in these fractions, free 
construct A (57kDa) and complex AF (85 kDa) are eluting together. In fractions K7-K9 (76.3-
78.4 mL), the elution of the AF complex in a 1:1 molar ratio can be observed. And in factions 
K11-L4 (80.4-88.7 mL) just free construct F is observed (Figure 4.15D). This means that just a 
small amount of them are forming the complex and there is still free construct A and F in the 
analysed mixture. 
 
Figure 4.15 Size exclusion chromatography of the complementation assay in a ratio 1:6 of constructs A and F. 
(A) Chromatogram of constructs A (blue), F (red), and the interaction between both (A:F) in a 1:6 molar ratio(lilac). 
(B) (A) Chromatogram of the eluted fractions: absorbance at 280nm (-), hydrolase activity (•••). The relative 
standard deviations for the molecular masses and activities were less than 2% and 15% respectively. (C and D) 12 % 
acrylamide SDS-PAGE gels of the different fractions; J11-J15, K1-K15, and L1-L10. Molecular masses in kDa. 
 
The hydrolase activity of the collected fractions were analysed (Figure 4.15B). Reaction rates 
were determined following the procedure cited in Materials and Methods 2.2.11. The 
hydrolase activity recovered in fractions J14-K9 and the presence of lectin in these fractions 
(seen in SDS-PAGE in Figure 4.15B, C and D) demonstrate that the complex between A and F is 
formed and it is active. However, as was previously mentioned, not all of the construct A 
protein forms a complex with construct F. By densitometry analysis of the SDS-PAGE gel in 
Figure 4.15B, it is determined that lectin eluted in fractions J14-K9 represents 10% of total 
protein in the mixture. Assuming a 1:1 interaction, just 10% of Construct A is in complex with 
Construct F.  
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4.3.7.3 Complementation assays using analytical chromatography 
 
Since preparative size exclusion chromatography did not afford the desired resolution, new 
experiments were performed using analytical size exclusion chromatography (HPSEC). Proteins 
(5-200 µM) were injected into a Shodex-803KW column, previously calibrated with protein 
standards, and eluted with buffer D (Figure 4.16).  
 
Figure 4.16 Analytical size exclusion chromatography of the wild type protein and the different constructs of 
Lacto-N-biosidase from B.bifidum.  
(A) Chromatogram of the wild type protein (FL) and constructs A, D and F. (B) Chromatogram of constructs A, F, and 
the interaction between them in a molar ratio 1:1.  
 
In this case, the column resolution was good enough for the analysis of the proteins as it is 
observed in Figure 4.16A. Each protein shows a single peak of elution; 10.2 min for wild type, 
11.2 min for construct D, 11.7 min for construct A and 12.1 min for construct F, that 
corresponds to their theoretical molecular masses (112 kDa, 83 kDa, 57 kDa and 28 kDa, 
respectively), according to calibration with protein standards. 
In Figure 4.16B, construct A and F were mixed in a molar ratio 1:1 (50 µM). In the same plot 
(Figure 4.16B) chromatograms of construct A and F were overlapped. The appearance of a new 
third peak, at 11.2 min, was observed. According to protein standards calibration, this elution 
time corresponds to 85 kDa, which clearly demonstrates that a complex among both proteins 
is formed. Again, the complex formation did not consume the total amount of the different 
constructs, since the corresponding peaks (11.7 min for construct A and 12.1 min for construct 
F) also appear in the chromatogram.  
A saturation assay of the complementation of construct A and F was also performed by HPSEC 
(Figure 4.17). Construct A (14 µM) and construct F (14-140 µM) were incubated for 5 minutes 
at room temperature before being loaded into a Shodex-803KW, previously calibrated with 
protein standards.  
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Figure 4.17 Saturation assay of the complementation of construct A and F analysed by HPSEC. 
(A) Chromatogram of saturation assay. (B) Zoom of the chromatogram of saturation assay. 
 
The absorbance of the peak corresponding to the AF complex (11.2 min) increases while 
increasing concentrations of construct F (12.1 min) are added to the reaction, at these 
conditions. Concentration of construct A is always constant (14 µM) and it can be observed in 
Figure 4.17B that the peak decreases while the complex is forming. In this case, saturation is 
not achieved at 1:10 molar ratio of construct A:F. 
A peak at 13 min can be observed in Figure 4.17 impurity peak areas are constant during the 
assay. Figure 4.18A shows an injection of purified construct F alone, and the peak at 13 min 
appears. When purified fractions of construct F are analysed by SDS-PAGE (Figure 4.18B), a 
smaller band than 21 kDa is observed. It may correspond to the impurity peak observed at 13 
min of elution time. 
 
Figure 4.18 Evidence of the presence of an impurity in construct F purification. 
(A) Chromatogram of construct F. (B) SDS-PAGE of fractions from construct F purification. Molecular masses in kDa. 
4.3.8 Isolation of the complex formed by construct A and F 
At this point, pure AF complex has not been obtained yet. In previous reactions, a mixture with 
free proteins of construct A and F were always present together with the complex. In order to 
characterize the AF complex, an isolation assay of the complex was designed. 
A different tag purification strategy was designed for isolating the AF complex. Taking 
advantage of affinity purification methodology, a different two tag strategy, His and Strep tags, 
was proposed for AF complex isolation (Figure 4.19A). While maintaining the same construct A 
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as for the rest of the experiments cited (N-terminal His-tagged truncated protein), a new 
recombinant protein of construct F was obtained, in this case with a Strep tag in the carboxyl 
terminus. Briefly, the strep-tag was introduced by PCR using construct F gene with C-terminal 
His-tag as the template and the reverse primer carrying the streptavidin sequence. PCR 
product was introduced into a pET28a+ vector with NdeI and Bpu1102 as flanking regions. 
E.coli DH5α and BL21 (DE3) were transformed with a positive sequenced plasmid. Cells were 
grown at 30°C for 24 h in autoinduction medium. After cell disruption, the clarified lysate was 
loaded onto 1 mL Strep-Taq column (GE Healthcare). The protein was eluted with 2.5 mM d-
desthiobiotin buffer. Collected fractions were analysed by SDS-PAGE (16% acrylamide) that 
revealed a protein migrating at, approximately, 28kDa of molecular mass. Fractions containing 
the proteins were pooled and concentrated before being purified on a Superdex 200 column 
(GE Healthcare). Fractions were then pooled again and concentrated with a 10 kDa cut-off 
membrane centricon (Merck-Millipore). Final protein concentration was determined 
spectrophotometrically by the BCA method measuring A590 nm using BSA as standard (Smith 
at al., 1985). The yield of the purification was 17mg of construct F (Strep-tagged) per litre of 
initial culture. 
The idea was to obtain pure AF complex from the mixture of construct A and F tagged with His 
and Strep tag, respectively. When proteins interacted with each other, the complex was 
formed carrying both tags. Sequential different affinity purifications, with a HiTrap and a 
StrepTrap column, allowed the pure AF complex to be obtained. In Figure 4.19A, a detailed 
scheme of the process is shown. Starting from pure construct A and F, both proteins are mixed 
in a 1:10 molar ratio (26 µM:254 µM, construct A:F, respectively). In the reaction tube there 
were N-terminal His-tagged construct A, C-terminal Strep-tagged construct F and N-terminal 
His-tagged and C-terminal Strep-tagged AF complex. After the HiTrap purification with 
imidazole elution, Strep-tagged construct F (which was not interacting in the complex) was 
removed. N-terminal His-tagged construct A and N-terminal His-tagged and C-terminal Strep-
tagged AF complex were eluted together. Collected fractions were then loaded into a 
StrepTrap column. In this case, N-terminal His-tagged construct A, which was not interacting in 
the complex, was removed, and pure AF complex was obtained after the elution with d-
desthiobiotin. 
Proteins eluted after every step of the scheme was analysed by SDS-PAGE (Figure 4.19B). Lane 
1 and 2 correspond to pure N-terminal His-tagged construct A and pure C-terminal Strep-
tagged construct F, respectively. The mixture of both proteins was charged in lane 3 and lane 4 
(1:4 dilution of lane 3). And pure complex, obtained after sequential HiTrap and StrepTrap 
affinity purifications, was loaded into lane 5. 
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Figure 4.19 Design of AF complex isolation. 
(A) Diagram of the design of the assay. (B) SDS-PAGE analysis of the different steps of the diagram; 1: pure construct 
A after first His purification, 2: pure construct F after first Strep purification, 3 and 4: mix of pure construct A and F, 
5: pure complex after second His and Strep purification. Molecular masses in kDa. 
 
The pure AF complex solution (shown in line 5) was concentrated with a 10 kDa cut-off 
membrane centricon (Merck-Millipore) and the concentration was analysed by BCA. A solution 
of 7.5 µM of pure AF complex was obtained. 
The hydrolytic activity was analysed with 100 nM of AF complex and 0.25 mM of p-NP-LNB as 
substrate at 30°C. At regular time intervals, reactions were stopped with quenching buffer and 
released p-nitrophenol was measured by absorbance at 400 nm. A specific activity of 0.73 ± 
0.19 s-1 was obtained. This specific activity represents 3% of the wild type protein.  
This new result differs from the specific activity of 2.9 ± 0.07 s-1, which was determined at 1:6 
A:F interaction. In that case, the specific activity was calculated taking into account the overall 
amount of construct A added into the reaction (50 nM), but at that time, there was no data 
about how much complex was formed.  
By contrast, the specific activity of 0.73 ± 0.19 s-1 was measured with the pure complex. 
Although, at the time of measuring the concentration of the complex, it was possible that the 
equilibrium with the free forms of construct A and construct F would be established. 
Nevertheless, it can be confirmed that specific activity is at least 0.73 ± 0.19 s-1. 
It is concluded that pure AF complex can be obtained. It seems that the interaction between 
both proteins has low affinity, resulting in a low KD (dissociation constant). Despite having 
excess of both, construct A and F, a small amount of AF complex is formed.  
4.3.9 LnbB loop mutants  
Different mutants were designed to explore the interactions between the remote element of 
the lectin domain and the active site. The remote element (residues 570-578) consists of a 
beta-turn which folds on the active site of LnbB (Figure 4.20). Leu574 completes the substrate 
binding cavity interacting with the hydroxymethyl group of the galactose moiety of the 
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substrate, at -2 subsite, and it is positioned between two conserved amino acids in the GH20 
domain, Gln190 and Asp467, forming further interactions between this turn and the active 
site. Residues His573 and Asp575 are also interacting with the cavity by backbone interactions 
(Table 4.4), while the rest of the remote element (570-578) is providing the structure needed 
for the interactions to be done.  
 
Figure 4.20 Residues involve in remote element and cavity interactions in LnbB.  
Colour representation; GH20b and GH20 domains in transparent blue, lectin domain in transparent yellow, loop 2 in 
solid red and remote element in solid yellow. 
 
4.3.9.1 Cloning of LnbB loop mutants  
 
Four single mutants and one double mutant were constructed. His573, Leu574 and Asp575 
were mutated to alanine to remove possible side-chain interactions. The double mutant to 
alanine was produced by the methodology in residues Leu574 and Asp575. In addition, Leu574 
was also mutated to arginine in order to introduce a positive charge that creates repulsion 
between the remote element and the cavity.  
Mutagenesis was carried out by site-directed mutagenesis using wild type pET24b construct as 
a template (C-terminal His-tagged). Mutations were confirmed by DNA sequencing and the 
final constructs were used to transform E. coli BL21 (DE3) cells for the expression and 
purification of mutant recombinant proteins (detailed sequence primers and procedure are 
cited in section 3.2.4). 
4.3.9.2 Expression and purification of LnbB loop mutants  
 
C-terminal His-tagged mutated proteins were obtained growing recombinant cells at 30°C for 
24 h with autoinduction medium. Purification was done by HiTrap chromatography using 
imidazole as eluent. SDS-PAGE analysis revealed that all mutants migrated with an 
approximate molecular mass of 112 kDa, which agrees with the theoretical molecular mass. 
Fractions containing the mutants were pooled and concentrated with a 10 kDa cut-off 
membrane centricon (Merck-Millipore). Final protein concentration was determined 
spectrophotometrically by the BCA method measuring Abs 590 nm using BSA as standard 
(Smith at al., 1985). Expression and purification were very similar for all the mutated proteins, 
and the average yields were 19-21 mg of protein per litre of culture. All proteins were 
considered to be >90% pure by Coomassie staining after SDS-PAGE (Figure 4.21). 
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Figure 4.21 SDS-PAGE analysis of the wild type and loop mutant proteins.  
Lane 1: wild type protein, Lane 2: H573A protein, Lane 2: L574A protein, Lane 4: L574R protein, Lane 5: D575A 
protein, Lane 6: L574A_D575A protein. 
 
4.3.9.3 Differential scanning fluorimetry (Thermofluor) 
 
Protein stability of the mutated proteins was evaluated by ThermoFluor assay. Fluorescence-
based thermal stability assay or differential scanning fluorimetry (DSF) (Pantoliano et al., 2001) 
is a temperature-based assay to assess the stability of proteins. The methodology takes 
advantage of the fact that the fluorescence of many non-specific protein-binding dyes 
increases with increasing hydrophobicity of their environment. It is based on the detection of 
changes in the exposure of hydrophobic areas upon heat denaturation. The dye is quenched in 
aqueous solutions, but when the aromatic moieties of the dye intercalates into a hydrophobic 
pocket, it regains its fluorescence. A sharp sigmoidal curve allows for the calculation of a 
melting temperature (Tm), which corresponds to the temperature where the protein is 50% 
unfolded (Niesen et al.; Vivoli et al., 2014). A positive shift in the melting temperature ΔTm can 
be coupled to an increase in structural order and a reduced conformational flexibility, whereas 
a negative ΔTm, indicates that induced protein structural changes lead to a more disordered 
protein conformation (Boivin et al., 2013). 
 
 
Figure 4.22 Typical thermal denaturation assay using Thermofluor. 
Image from Boivin et al., 2013.  
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Different dyes can be used, and in this case SYPRO orange dye was chosen, which has a 
maximal absorption at 470 nm and maximal emission at 569 nm (Boivin et al., 2013). 
SYPRO Orange dye was added to the corresponding proteins (5 µM), wild type LnbB and loop 
mutant proteins. Once the reactions were over, the results of fluorescence were plotted as a 
function of temperature (Figure 4.23). 
 
Figure 4.23 Graphical representation of the analysis by differential scanning fluorimetry of wild type LnbB and 
loop mutant proteins.  
(A) Denaturation curves fitting two state model. (B) Tm corresponds to different melting temperatures, and Δ Tm are 
related to wild type protein Tm. 
All proteins followed the expected shapes of a thermal denaturation profile. The characteristic 
sigmoidal shape of the raw data shows a progressive rise in fluorescence to a maximum, where 
the protein is denatured. As soon in Figure 4.23B, melting temperatures of the mutated 
proteins do not significantly differ from the wild type LnbB which means that the structural 
stability of the protein is not affected by the exchange of the amino acids.  
These minor differences in temperature support a well-folded structure for the mutant 
proteins, and hence, changes of the catalytic properties can be assigned to the replacement of 
the target amino acid residues, and not to a different folding of the mutated proteins 
4.3.9.4 Kinetics of LnbB loop mutants  
 
The hydrolytic activity of all mutants was analysed with 50 nM of protein and 0.25 mM of 
substrate.  
All mutated proteins exhibited hydrolytic activity (Table 4.6), with rates lower than wild type 
protein. While mutants to alanine reduce their specific activity at maximum of 10 times less 
than the wild type protein, the mutation of Leu574 to arginine resulted in a significant 
decrease of the specific activity (118-fold less) compared to the wild type. This means that the 
introduction of a positive charge in the side chain of the residue (Arg) instead of the 
hydrophobic existing side chain of Leu disturbs the interaction between the remote element 
and the active centre, and then, a significantly decrease of the catalytic activity is shown. 
139 
 
CHAPTER 4. STRUCTURAL FUNCTIONAL ANALYSIS OF GH20 FAMILY ENZYMES 
Table 4.6 Kinetic parameters of the wild type LnbB and loop mutant proteins.  
The reactions were done at 20 nM of wild type and 50 nM of loop mutants, 0.25 mM of substrate, 30 °C in buffer C 
at pH 4.5. 
 
Protein Specific activity (s-1) 
Wild type 27.2 ± 3.5  
H573A 6.0 ± 1.32 
L574A 2.8 ± 1.89 
L574R 0.23 ± 0.09 
D575A 3.78 ± 0.97 
L574A_D575A 4.53 ± 0.75 
 
It is concluded that the implication of the remote element is not strictly dependent on the 
specific interaction of residues 573-575 within the active centre, but it depends on the overall 
structure of the entire lectin domain.  
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4.4 CONCLUSIONS 
This structural-functional analysis allows us to come to different conclusions. First, it has been 
identified two levels of domain organization in GH20 enzymes: model A with GH20b-GH20-α 
architecture and model B with the single catalytic GH20 domain alone. As Lacto-N-biosidase 
from B. bifidum constructs show, model A enzymes cannot be reduced to model B, since 
GH20b domain is a structural requirement in the N-terminus of GH20 to assure protein 
stability. Secondly, GH20b-GH20-α architecture is not always the minimal functional unit since 
the isolated model A domain of LnbB is inactive. Based on these results and analysis of the 
structures of GH20 enzymes, it has been proposed a broader mechanism by which important 
interactions in the substrate binding cavity of the catalytic GH20 domain are provided by a 
remote element in all structures, which must be preserved to ensure a proper definition of the 
active site. The remote element can directly be provided by a long loop 2 of the GH20 domain 
itself. In this case, GH20b-GH20-α can act as a minimal functional unit and large multidomain 
enzymes can be engineer to reduced forms with a minimal model A architecture. In other 
circumstances, when loop 2 is short, proteins dimerize or present an accompanying domain in 
the C-terminus of GH20 that provide this remote element. 
In this thesis the remote element of LnbB has been studied, and in this case, loop 2 from GH20 
domain is not long enough to act as the remote element, and this element is provided by the 
consecutively C-terminal domain, a lectin like domain. It has been restored the hydrolytic 
activity of construct A (inactive truncated form of LnbB) when the lectin domain (construct F, 
which contains the remote element) was added to the reaction. It is confirmed that the lectin 
domain assists in the definition of the substrate binding cavity providing an essential loop 
(remote element) to shape the active site.  
Moreover, a mutational study of the residues directly implied in the interactions of the remote 
element with the catalytic GH20 domain was also performed. Although mutations of the 
remote element did not yield a complete inactive enzyme, there was an important decrease of 
the activity for L574R mutant. This suggests that modifications in the interaction area of both 
domains yield less active proteins.  These overall results confirm that the lectin structure of the 
lectin is required for the catalytic activity of Lacto-N-biosidase.  
This work suggests that protein engineering of GH20 enzymes must be designed according to 
the remote element. The proposed model can stimulate further studies on other members of 
the superfamily. 
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5.1 INTRODUCTION 
There is a potential commercial use of HMO, specially, for supplementation of infant formulas, 
and to date, access to HMO, in a large-scale use, has not been possible by any synthetic 
methodology. By use of biocatalytic approaches, some simple HMO have been produced. 
However, the use of HMO as bioactive substances in infant food, pharmaceuticals or for 
clinical trials is still limited by the ability to synthesise more complex structures and, in 
sufficient quantity and purity (Bode, 2015; Kobata, 2003; Kunz et al., 2000).  
 
In contrast to conventional chemical synthesis, enzymatic glycosylation is proposed to tackle 
the challenge of glycosynthesis of these complex molecules since offers many advantages. 
Enzymatic synthesis, without the need of protecting groups, is characterized by a high catalytic 
activity, lack of undesirable side-reactions, mild reaction conditions, and high regio- and 
stereoselectivity (Planas et al., 2015; Armstrong and Withers, 2013).  
 
In this context, we aim to engineer Bifidibacterium bifidum Lacto-N-biosidase (LnbB) activity to 
be able to modulate the transglycosylation/hydrolysis ratio and synthesise our target Lacto-N-
tetraose (type 1 HMO core). Two rational-design strategies have been considered. An 
enhanced transglycosylation strategy in which a new generation of mutants on the acceptor 
subsites of the enzyme will be able to favourably accommodate a sugar acceptor to compete 
with water, and then, increase transglycosylation activity. In addition, reaction will be engineer 
to favour the transglycosylation reaction, and p-NP-LNB will be used as substrate. And a 
glycosynthase-like strategy in which a new mutant on the catalytic residue of the enzyme will 
be able to exhibit transglycosylation activity without further hydrolysis of the product. Since 
LnbB, classified as a member of family 20 glycosyl hydrolases, uses a two-step catalytic 
mechanism involving substrate-assisted catalysis (Figure 5.1A). Thus, the glycosyl donor for the 
glycosynthase technology is an activated sugar oxazoline, which binds the enzyme to form a 
new glycosidic linkage by transglycosylation (Planas et al., 2015). 
Therefore, we explore the feasibility of these new engineered LnbB proteins as biocatalysts for 
the glycosynthase strategy using oxa-LNB (Figure 5.1C) and lactose as substrates, or for the 
transglycosylation strategy using p-NP-LNB and lactose (Figure 5.1B) to achieve the target 
lacto-N-tetraose.  
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Figure 5.1 Lacto-N-biosidase mechanism via substrate-assisted mechanism.  
(A) Wild type LnbB catalytic mechanism (B) enhanced transglycosidase approach using p-NP-LNB as donor (C) 
glycosynthase approach using oxa-LNB as donor (B). R1: galactose, R2: lactose. 
 
  
B. Enhance transglycosylation approach
C. Glycosynthase-like approach
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5.2 MATERIALS AND METHODS 
5.2.1 Bioinformatics 
Protein sequences were retrieved from UniProt (http://www.uniprot.org). Sequence alignment 
was performed with PROMALS (Pei and Grishin, 2007) and ClustalW with default options.  
5.2.2 General materials and experimental procedures 
All reagents are from Sigma-Aldrich unless otherwise designated. 
General material and methods are detailed in Chapter 3. 
Specific substrates for both enzymatic approaches (p-NP-LNB and oxa-LNB) were synthesised 
according to Chapter 2 (see experimental section).  
5.2.3 Site-directed mutagenesis of active site mutants of LnbB  
Plasmid pET24b-LnbB-FL, which encodes for wild type full length LnbB with C-terminal His-
tagged was used as template for mutagenesis. PCR reactions were carried out using IProof 
polymerase (2 units/µL, Bio-Rad) and a thermocycler PTC-200 (MJ research). Amplification was 
carried out in a 20-50 μl final volume reaction mixture containing plasmidic DNA (~150 ng), 
0.02- 0.05 µM of sense primer, 0.02-0.05 µM of antisense primer, nuclease-free water and  I-
proof PCR master mix (Ref. 172-5310, Bio-Rad). A 3 min initial denaturation at 95 °C was 
followed by 30 cycles: 95 °C 30 s, 30 s of the corresponding annealing temperature for the 
different primers, 72 °C 4 min, and a 10 min final extension at 72°C. After PCR reaction, the 
samples were digested with DpnI for 1 hour at 37 °C, and then, transformed into E. coli DH5α. 
Positive transformants were confirmed by DNA sequencing and the final constructs were used 
to transform E. coli DH5α and BL21 (DE3) cells. 
Following are listed primers used are list below for D320E and Y419F mutant proteins 
(mutated nucleotides are underlined, and codons affected are lowercase letter): 
 
D320E sense 5’- TGGGCGCGgaaGAATACATGATTGGTACC-3’ 
D320E antisense 5’-CATGTATTCttcCGCGCCCATGTGCCAATATTTCG-3’ 
Y419F sense 5’-AGGCTCTGttcTGGTCACGTTCGGCACAAG-3’ 
Y419F antisense 5’-ACGTGACCAgaaCAGAGCCTGCGTTGCATTCATCAGG-3’ 
5.2.4 Expression and purification of enzymes  
Proteins were expressed and purified as described in Chapter 3. Protein concentration was 
determined by Bradford (Bradford, 1976)using BSA as standard. 
5.2.5 Kinetics of the hydrolase activity 
Hydrolytic activity of soluble enzymes was performed as described in Chapter 3. Briefly, 
activity assays were performed in a reaction mixture containing 0.25 mM substrate in citrate-
phosphate buffer at pH 4.5. After pre-incubation for 5 min at 30 °C, reactions were initiated by 
addition of the enzyme (20 nM). At regular time intervals, reactions were quenched by the 
addition of 0.15 mL of quenching buffer (0.5 M of glycine, pH 11) and p-nitrophenol release 
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was measured by absorbance at 400 nm with a microplate-reader MRX (Cultek). Triplicate 
measurements at each concentration were performed. 
Initial rates (vo) were obtained from the linear progress curve of release of p-NP, and they 
were expressed as vo/[E] in s-1.  
5.2.6 Stopping method of enzymatic reactions  
The following stopping method was implemented for HPLC analysis. After performing 
hydrolytic reaction at standard conditions, reactions were stopped with different volumes of 
50%  1-propanol in water at different time intervals, 30 and 60 min. Different dilutions were 
studied:  1:2, 1:4, 1:6 and 1:8 ratio (reaction:1-propanol (v/v)). At 30 min one of the stopped 
duplicates was quenched with 100µL of glycine buffer pH 11. At 60 min the rest of the 
reactions were quenched with 100µL of glycine buffer pH 11. Release of p-nitrophenol was 
measured at 400 nm with a microplate-reader MRX (Cultek). The molar extinction coefficients 
of p-nitrophenol at 400 nm were also determined with the addition of 50% 1-propanol in 
water.  
5.2.7 Glycosynthase reaction  
Glycosynthase reaction conditions involved 1 mM of oxa-LNB (donor), 2 mM of p-NP-lactose 
and 1 µM of protein in a final volume of 1 mL. The reactions took place in 50mM of citrate-
phosphate buffer at 30 °C. At different times (0-10 min every minute, and then, at 1, 2, 3, 6 
and 24 hours), reaction samples of 20 µL were stopped by adding 60 µL volumes of 1-propanol 
(stored at 4°C), and then, were injected for HPLC-UV analysis. 
Analysis of the glycosynthase reactions was performed using HPLC-UV (Agilent-1200 with a 
Nova-Pak® C18 column (Waters), 2 μL injection, and isocratic elution of 14% methanol in water 
at 25 °C. The detection of the p-NP-glycosids was done by UV at 300 nm. The validation of the 
method was done using p-NP-GlcNAc as standard. The limit of detection (LOD) and the limit of 
quantification (LOQ) for them were 1.5 µM and 5 µM respectively, and coefficient of variation 
was 8%. 
5.2.8 DMSO tolerance analysis  
Lacto-N-biosidase hydrolytic activity was determined with p-NP-LNB as substrate in the 
presence of DMSO. The DMSO tolerance was analysed from 0 to 15 % (v/v). Reactions 
containing 0.25 mM substrate in citrate-phosphate buffer at pH 4.5, and the corresponding 
amount of DMSO were pre-incubated for 5 min at 30 °C. Then, reactions were initiated by 
addition of the enzyme (20 nM). At regular time intervals, reactions were quenched by 
addition of 0.15 mL of quenching buffer (0.5 M of glycine, pH 11) and p-nitrophenol release 
was measured by absorbance at 400 nm with a microplate-reader MRX (Cultek). Triplicate 
measurements at each concentration were performed. 
5.2.9 Transglycosylation reaction  
Reaction conditions involved 2.5 mM of p-NP-LNB (donor), 0.25 M of lactose and 500 nM of 
protein in a final volume of 300 µL. The reactions took place in 50mM of citrate-phosphate 
buffer, pH 4.5 (Buffer C) with 15% of DMSO at 30 °C. At different times (0-16 h), reaction 
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samples of 20 µL were stopped by adding 60 µL volumes of 50% 1-propanol in water (stored at 
4°C). LNT standard dilutions (0.005-0.5 mM) were injected in each analysis. 
The analysis was performed using HPLC-MS (Agilent Infinity 1260 HPLC) with a XBridge UPLC 
BEH Amide 1.8 µm 2.1x100 mm Column (Waters). Chromatographic conditions involved 1 μL 
sample injection, gradient elution of acetonitrile/water with 0.1% formic acid at 50 °C and at a 
flow rate of 0.3 ml/min. 
Table 5.1 Gradient elution conditions for HPLC.MS analysis 
 
Time (min) Acetonitrile (%) H2O (%) 
0 10 90 
5 30 70 
14 30 70 
15 10 90 
21 10 90 
 
MS conditions consist of using a SQ 6130 MS system (Agilent) in positive ionization 
(electrospray ionization (ESI+), single quadrupole MS detector, drying gas flow: 11 L/min, 
drying gas temperature: 325 °C, nebulizer pressure: 30 psi, capillary voltage: 4000 V, SCAN 
range (m/z): 100 – 900 (40%), fragmentor: 100 V. 
Table 5.2 Reference masses used to follow the transglycosylation reaction. 
Channel Compound SIM ion  
2 Lacto-N-biose 
 
384 [M+H]+; 406 [M+Na]+ 
3 p-NP-Lacto-N-biose 
Lactose 
 
360 [M+NH4]+, 365 [M+Na]+ 
522 [M+NH4]+, 527 [M+Na]+ 
4 Lacto-N-tetraose 708 [M+H]+; 730 [M+Na]+ 
 
The validation of the method was done using Lacto-N-tetraose as standard. The limit of 
detection (LOD) and the limit of quantification (LOQ) were 2.5 µM and 5 µM respectively, and 
coefficient of variation was less than 15 %.   
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5.3 RESULTS AND DISCUSSION 
With the aim of engineering Bifidibacterium bifidum Lacto-N-biosidase (LnbB) to modulate 
transglycosylation/hydrolysis ratio for the synthesis of Lacto-N-tetraose (type 1 HMO core), 
two rational-design strategies were evaluated.  
5.3.1 Glycosynthase-like strategy  
In the substrate-assisted mechanism, a conserved Asn or Asp residue play a role in orientating 
the 2-acetamido group and ultimately promoting the nucleophilic attack of the 2-acetamido 
group at the anomeric position to form the oxazolinium ion intermediate in the hydrolase 
mechanism. The first glycosynthase from retaining GHs acting via substrate-assisted catalysis 
was the endo-β-N-acetylhexosaminidase from Mucor hiemalis (Endo-M) (Umekawa et al., 
2008). It belongs to family GH85 enzymes which are endo-β-N-acetylhexosaminidases that 
cleave the chitobiose core (GlcNAcβ-1,4GlcNAc) of N-linked glycans. Asn175 residue of Endo-M 
assists the appropriate orientation of the 2-acetamido group of the substrate for catalysis. Its 
mutation to alanine abolishes the hydrolytic activity, but is able to take the sugar oxazoline as 
donor substrate for transglycosylation, acting like a glycosynthase. The methodology has been 
extended to other GH85 enzymes (Endo-A, Endo-D) for the chemoenzymatic synthesis of N-
glycoproteins (Wang and Huang, 2009; Yamamoto, 2013). In addition, family GH18 enzymes, 
which comprise chitinases and endo-β-N-acetylglucosaminidases, also operate by substrate-
assisted catalysis and were also successfully converted to glycosynthases (Huang et al., 2012; 
Martinez et al., 2012). 
Since Asp320 of LnbB was identified as the assisting residue and D320A mutated protein was 
3100 times less hydrolytically active than the wild type (see Chapter 3), D320A mutant is 
proposed as the glycosynthase-like LnbB biocatalyst.  
Glycosynthase reaction of D320A was studied using Lacto-N-biose oxazoline derivative (oxa-
LNB) as donor and p-NP-lactose as acceptor to yield p-NP-Lacto-N-tetraose (Figure 5.2). 
 
Figure 5.2 Glycosynthase reaction to produce Lacto-N-tetraose using Lacto-N-biosidase mutant protein. 
 
Although pH 4.5 corresponds to the maximum hydrolytic activity of the LnbB wild-type, 
glycosynthase reactions will be explored at pH higher than 6 to guarantee the stability of 
oxazoline derivative donor (see Chapter 2). Similarly to D320A, the equivalent mutant of SpHex 
(D313A) also had a reduced hydrolytic activity and interestingly, the optimum pH for hydrolytic 
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activity was shifted from pH 4.5 to pH 7.0 (Williams et al., 2002). Consequently, LnbB 
glycosynthase experiments were performed under different pH conditions: pHs 6, 7 and 8. 
Final conditions involved 1 mM of LNB-oxa (donor), 2 mM of lactose and 1 µM of protein. The 
reactions took place in 50mM of citrate-phosphate buffer at different pH and at 30 °C. At 
different times, reactions were stopped by adding 4-fold volumes of 1-propanol (50% in 
water), and then, were analysed using HPLC-UV. 
The use of 1-propanol to stop the enzymatic reaction instead of 1.5 M glycine buffer at pH 11 
was due to the hydrolysis of the LNT product when it was incubated at basic conditions. 
Moreover, glycine buffer was not suitable for further analysis using MS equipment. Different 
stopping methods were tried, and the final conditions involved adding 4 volumes of 1-
propanol to the reaction aliquots prior to HPLC-MS analysis.  
Unfortunately, at the conditions tested, no synthetic activity was detected. LNT was not 
formed in any of the reactions. The fact that the hydrolytic activity was not completely 
abolished by the mutation of the assisting residue suggested that hydrolysis of oxa-LNB donor 
could occur, and prevent LNT formation.  
In retaining glycosynthases with two essential residues, the removal of the nucleophilic residue 
renders completely inactive enzymes. Thus, when performing glycosynthase reaction, the 
corresponding activated fluoride donor transfer to an acceptor is kinetically favoured over 
hydrolysis. The synthesised product is no longer hydrolysed because of the lack of the 
nucleophile, and it renders high transglycosylation yields (Planas et al., 2015). The initial 
concept of glycosynthase preparation based on mutated glycosidases at catalytic nucleophile 
and the use of glycosyl fluoride donor appears to be, in principle, a simple strategy. However, 
this has not led to a large variety of different enzymes, since, nowadays, the glycosynthases 
available are, so far, limited to 16 glycoside families out of the more than 100 glycosidase 
families described in Cazy database (Cantarel et al., 2009; Cobucci-Ponzano et al., 2008). 
The additional fact that, to date, there is no glycosynthase acting enzyme from family GH20, 
suggests a more complex strategy. More research is needed to unravel whether LnbB can 
become a glycosynthase, and in that sense, synthesise the added-value oligosaccharide, lacto-
N-tetraose. 
5.3.2 Enhanced transglycosylation strategy 
In order to explore transglycosylation activity of LnbB, Endo-M protein was also used as 
reference. Umekawa et al. generated two more interesting mutants with superior 
transglycosidase activity; N175Q and Y217F. The N175Q mutant was found to possess 
enhanced transglycosidase-like activity with “natural” N-glycan compared to the wild type (3-
fold higher), and even higher glycosynthase-like activity with sugar oxazoline in comparison 
with N175A. Authors suggested that the extension of the side-chain from Asn to Gln by one 
carbon might hindered the hydrogen bonding between the amide group of the assisting 
residue (Asn or Gln) and the acetamide of the GlcNAc of the substrate. These results also 
implicated the significance of amide side-chain in the Asp175 of Endo-M for promoting 
oxazoline transglycosylation in the second step of the catalysis (Umekawa et al., 2010). Finally, 
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the authors mutated the residue Tyr217 to Phe. Tyr217 is located in the active-site, is a highly 
conserved residue among GH85, and was found to be essential for transglycosylation activity, 
but not for hydrolytic activity of the wild type Endo-M. The Y217F mutant catalysed the 
transglycosylation reaction more efficiently than the wild type Endo-M (5-fold higher). Besides, 
the removal of the hydroxyl group of Tyr residue resulted in a diminished hydrolysis activity. 
Moreover, replacement of Tyr217 to other amino acids than Phe, resulted in abolishment of 
both activities, hydrolysis and transglycosylation. These results suggested that the phenyl 
group at this position is important for, both, acceptor recognition and for the catalysis and may 
be involved in the activation of a water molecule for hydrolysis (Umekawa et al., 2008, 2010). 
Accordingly, two mutated proteins of LnbB were generated: D320E and Y419F. Asp320 was 
substituted by Glu since this longer side-chain might allow more favourable interaction to 
facilitate oxazoline substrate processing similarly to Endo-M. Finally, Tyr419, which is highly 
conserved in GH20 enzymes, was changed to Phe to improve acceptor recognition. It is known 
that the role of the residues located in positives subsites are important for transglycosylation 
activity by contributing to higher binding free energy of the incoming acceptor (Bissaro et al., 
2015).  
Again, the genes of the corresponding mutants were successfully obtained by site-directed 
mutagenesis using wild type Full-length pET24b construct as template (C-terminal His-tagged). 
Mutations were confirmed by DNA sequencing and the final constructs were used to transform 
E. coli BL21 (DE3) cells for the expression and purification of mutant recombinant proteins (see 
Chapter 3 (material and methods section). 
The protein concentration was determined by Bradford (Bradford, 1976) using BSA as 
standard. Yields of 3-7 mg of proteins per litre of culture were obtained. All proteins were 
considered to be >90% pure by Coomassie staining after SDS-PAGE (Figure 5.3, lane 4 and 5). 
 
Figure 5.3 SDS-PAGE analysis of the wild type and mutant LnbB proteins. 
Lane 1: full-length protein, M: marker, Lane 2: D320A protein, Lane 3: D320E protein, Lane 4: Y419F protein. 
Molecular masses in kDa. 
 
The hydrolytic activity of the mutated proteins was evaluated. In addition, a new batch of wild 
type LnbB was obtained and analysed as the control. Briefly, the hydrolytic activity of the 
soluble proteins was performed in a reaction mixture containing p-NP-LNB as substrate and 
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citrate-phosphate buffer at pH 4.5. The reaction was stopped at different interval times and 
the release of p-NP was measured (see Chapter 3, materials and methods). 
Table 5.3 Kinetic parameters of the hydrolytic reaction of wild type and mutant LnbB proteins. The reactions were 
done at 20 nM of proteins, 0.25 mM of substrate, 30 °C in buffer C at pH 4.5. 
 
Protein Specific activity (s-1) 
Wild type 31 
D320E 0.24  
Y419F 0.23  
 
Both mutated proteins showed similar decreased hydrolytic activity (130-fold decrease) 
compared to the wild type enzyme (Table 5.3). In the case of the D320E mutant, the 
introduction of a longer side-chain seemed to disturb the interaction with the 2-acetamido 
group of the substrate, although the mutated enzyme showed residual activity. Similarly, in 
Y419F mutant, the removal of the hydroxyl group showed a worsening of the hydrolytic 
capacity, possibly due to a loss of an hydrogen bond with the substrate. As both mutants were 
designed to evaluate its possible enhanced transglycosylation activity compared to the wild 
type LnbB, the decreased but not abolished hydrolytic activity, postulated them as good 
candidates. 
Condensation reactions between p-NP-LNB (donor) and lactose (acceptor) were performed in 
order to study the transglycosylation activity of D320E and Y419 mutants, as well as the wild 
type LnbB. In addition to LNT formation, other side reactions such as the hydrolysis of the 
donor p-NP-LNB to yield LNB and p-NP, and the hydrolysis of the product LNT to LNB and 
lactose could occur (Figure 5.4). 
 
Figure 5.4 Trasnglycosylation reaction of LnbB to synthesise Lacto-N-tetraose (19). 
 
Transglycosylation reaction catalysed by LnbB was followed using HPLC-MS in order to identify 
LNT formation. HPLC-MS method was set up to follow the three reactions monitoring LNT 
((m/z) 708 [M+H]+ and 730 [M+Na]+), LNB (384 [M+H]+ and 406 [M+Na]+), p-NP-LNB (360 
[M+NH4]+ and 365 [M+Na]+) and lactose (522 [M+NH4]+ and 527 [M+Na]+). The procedure 
involved an Acquity UPLC BEH Amide Column and a gradient with acetonitrile/water with 0.1% 
formic acid. The mass spectrometer was used in positive ionization (electrospray ionization 
(ESI+) with a single quadrupole MS detector). 
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Figure 5.5 MS spectrum of LNT.  
 
 
 
Figure 5.6 Chromatogram of LNT. 
 
The method was validated with LNT. It was determined that the limit of detection (LOD) and 
the limit of quantification (LOQ) were 2.5 µM and 5 µM respectively, and coefficient of 
variation was less than 15 %. Figure 5.5 shows the mass spectrum and the HPLC-MS 
chromatogram of LNT. As is observed, LNT elutes at 12.7 min. LNT standard was used in each 
reaction and the corresponding response factor was applied of 3.7·106± 5.8·104 mM-1 with a 
relative error of 1.6%).  
5.3.2.1 Synthesis of LNT by transglycosylation reaction 
With the aim of enhancing the transglycosylation/hydrolysis ratio, an excess of acceptor 
(compared to donor) was used to minimise the presence of water molecules within the active 
centre of the protein. In addition, an organic solvent was added (Dimethylsulfoxide, DMSO) to 
reduce water activity. 
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Figure 5.7 DMSO tolerance of LnbB. 
Reaction mixtures containing 20 nM of LnbB, 0.25 mM of p-NP-LNB, 0-15 % DMSO and 50mM of citrate-phosphate 
buffer pH 4.5 (Buffer C) in a final volume of 100 µL, were incubated at 30 °C. At different interval times, the 
different reactions were stopped by adding 150 µL of Glycine buffer pH 11, and released p-nitrophenol was 
measured at 400 nm in a plate reader spectrophotometer. 
 
Since, in some cases, the use of hydro-organic solvents in enzymatic reactions faces with the 
instability of enzymes in those organic solvents, the DMSO tolerance of LnbB was analysed in 
the hydrolytic activity of wild type enzyme with p-NP-LNB as substrate. As observed in Figure 
5.7, the hydrolytic activity of LnbB was not affected by a range of 0-15 % of DMSO, therefore, 
15 % DMSO was used for transglycosylation reaction. 
Transglycosylation reaction catalysed by the wild type LnbB and D320E and Y419F mutants was 
analysed. Initial conditions were as follows: p-NP-LNB and lactose at donor:acceptor ratio of 
1:5 or 1:10, 200 nM of protein, in 50mM of citrate-phosphate buffer, citrate-phosphate buffer 
at pH 4.5 with 15% of DMSO at 30 °C. Since very low yields of LNT were obtained using wild 
type LnbB at these conditions, new reactions were done with a molar excess of 100-fold 
acceptor compared to donor and also with higher amount of protein. Final reactions were 
performed at 2.5 mM of p-NP-LNB (donor), 0.25 M of lactose and 500 nM of protein. At 
different times, reactions were stopped by adding 4-fold volumes of 1-propanol (50% in 
water), and then, were injected into the amide column for HPLC-MS analysis. 
The wild type LnbB showed transglycosylation activity, however, the LNT synthesis were too 
low to quantify it and in less than 10 min it quickly disappeared by hydrolysis. Similar results 
were reported by Wada and coworkers (Wada et al., 2008). 
LNT formation by transglycosylation occurred when Y419F mutant was used as biocatalyst in 
the same conditions. Figure 5.8 shows that peak at 12.7 min corresponding to LNT evolved 
during the course of the reaction. From 60 min to 90 min of reaction, LNT increased to a 
maximum of 0.24 mM (0.9% yield), and from then, it decreased to its completely hydrolysis 
(Figure 5.9A). 
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Figure 5.8 Progression of the transglycosylation reaction of Y419F mutant followed using HPLC-MS. 
Transglycosylation at different times of reaction: Blue: 60 min, Red: 90, Green: 120 min, and Pink: 180 min. 
 
D320E mutant showed higher transglycosylation activity. The progress curve of the reaction 
was very similar to Y419F, but, in this case, LNT was synthesised in higher yields. As observed 
in Figure 5.9B, at time 0 min, LNT was already formed. The maximum production was at 90 min 
with 3.3% yield. From then, LNT concentration was decreased till 16 h that LNT was completely 
hydrolysed. 
 
 
 
Figure 5.9 LNT synthesis by transglycosylation of (A) Y419F protein and (B) D320E protein.  
Values were calculated using a response factor of 3.7·106± 5.8·104 mM-1with a relative error of 1.6%.  
 
The analysis of p-NP-LNB revealed that it was under its quantification limit in all reactions, 
which indicates that the hydrolysis of the p-NP-LNB substrate was the main reaction 
accomplished when transglycosylation was performed.  
 
These results, although being unpretentious, position LnbB as an interesting protein for further 
engineering studies in order to synthesise LNT. And, a second generation of mutants are 
proposed for future research. 
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Recently, Bissaro et al. studied the molecular basis of transglycosylation in engineering 
retaining glycosidases, mainly exo-acting enzymes. They observed that mutations of conserved 
negative subsite residues (donor subsites) produce retention time prolongation of the donor 
glycosyl moiety, and thus, enhance the transglycosylation activity (Bissaro et al., 2015).  
 
 
Figure 5.10 Stereoviews of LNB (A) and LNB-thiazoline (B) bound to the active site of LnbB. 
Catalytic residues, residues forming hydrogen bonds, and residues forming hydrophobic interactions are shown in 
magenta, green, and white, respectively. Hydrogen bonds are shown as red dashed lines. Images from Ito et a., 
2013. PDB entry (A) 4H04 (B) 4JAW. 
 
We have identified some conserved residues among GH20 proteins with the aim of favouring 
transglycosylation over hydrolysis ratio of LnbB. His263 which establishes hydrophobic 
interactions with the galactose moiety of LNB (Figure 5.10). Trp373, Trp394 and Trp465 also 
form hydrophobic interactions with both, Gal and GlcNAc, of LNB. Asp467 which is also 
hydrogen bonding with the O4- and O6-hydroxyl groups of the GlcNAc residue. Gln190 (which 
corresponds to Arg in others GH20 enzymes) forms hydrogen bonds with the O4- hydroxyl 
group of Gal and defines the characteristic -2 subsite of LnbB. And finally, Asn259, which is 
hydrogen binding the galactose unit of LNB according to the crystal structure (Ito et al., 2013). 
  
Then, His263, Trp373, Trp394, Trp465, Gln190, Asn259 and Asp467 residues are proposed for 
future work as a rational starting point for enzyme engineering to enhance transglycosylation 
activity of LnbB. These residues are interacting with the donor substrate and their mutations 
could result in the modulation of transglycosylation/hydrolysis ratio of LnbB. 
 
 
  
A B
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5.4 CONCLUSIONS 
The first generation of mutants for the synthesis of LNT were designed: D320A, D320E and 
Y419F. These mutants showed decreased hydrolytic activity compared to the wild type 
enzyme, but in any case, the activity was abolished.  
 
The glycosynthase reaction with D320A mutant in the presence of the oxazoline derivative 
lacto-N-bioside and lactose did not occur. Mutation of the assisting residue is not enough to 
redesign the catalytic activity of LnbB as a glycosynthase-like biocatalyst.  
 
By contrast, the transglycosylation reactions between of p-NP-lacto-N-bioside and lactose 
using D320E and Y419F mutants showed an increased transglycosylation yield compared to the 
wild type LnbB. However, future protein engineering is proposed for both glycosynthase and 
transglycosylation approaches to be able to enhance the transglycosylation/hydrolysis ratio.  
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 CONCLUSIONS 
1. Lacto-N-biose (LNB), synthesised using Bacillus circulans β-Gal-3 enzyme, was used as 
starting compound for the synthesis of the substrates of Bifidobacterium bifidum 
Lacto-N-biosidase (LnbB). A three steps method was performed to synthesise p-NP-
LNB. It involved the peracetylation and chlorination of the anomeric carbon of LNB, 
glycosylation with p-NP, and final deacetylation. The synthesis of oxa-LNB was 
achieved via oxazoline ring formation using CDMBI. The study of different 
methodologies, which are extensively used in carbohydrate synthesis, suggested a high 
lability of the β-1,3 linkage when an acetamide group is located in position C-2. 
 
2. The kinetic characterization of the recombinant B. bifidum LnbB showed optimum 
catalytic efficiency at pH 4.5, and hydrolytic activity followed saturation kinetics. By 
sequence alignment analysis of GH20 enzymes, Asp320 and Glu321 of LnbB were 
studied, and their mutations supported their role as catalytic residues. 
 
3. After the structural-functional analysis of GH20 enzymes, two models of organization 
were identified: model A with GH20b-GH20-α architecture, and model B with the 
single catalytic GH20 domain alone.  
 
4. B. bifidum LnbB protein belongs to Model A domain organization. Truncated forms of 
LnbB showed that model A enzymes cannot be reduced to model B, since GH20b 
domain is a structural requirement in the N-terminus of GH20 to assure protein 
stability.  
 
5. Model A architecture (GH20b-GH20-α) is not always the minimal functional unit. 
Important interactions in the substrate binding cavity of the catalytic GH20 domain are 
provided by a remote element in all structures, which must be preserved to ensure a 
proper definition of the active site. The remote element can directly be provided by a 
long loop 2 of the GH20 domain itself. In this case, GH20b-GH20-α can act as a minimal 
functional unit, and large multidomain enzymes can be engineered to reduced forms 
with a minimal model A architecture. In other circumstances, when loop 2 is short, 
proteins dimerize or present an accompanying domain in the C-terminus of GH20 that 
provide this remote element. In the latter cases, protein engineering of these enzymes 
must be designed maintaining the accompanying domains. 
 
6. The remote element in B. bifidum LnbB is provided by the lectin domain, which is an 
accompanying domain in the C-terminus. The hydrolytic activity recovery of the 
inactive truncated form of LnbB in the presence of the lectin domain confirmed that 
the lectin domain assists in the definition of the active site and thus, is essential for 
catalysis. 
 
7. The results of D320A mutant as glycosynthase suggested that mutation of the assisting 
residue is not enough to redesign the catalytic activity of B. bifidum LnbB to behave as 
glycosynthase-like biocatalyst. By contrast, the ability of D320E and Y419F mutants to 
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 perform synthesis of LNT by transglycosylation provides a rational starting point in 
order to modulate the transglycosylation/hydrolysis activity ratio of in B. bifidum LnbB. 
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Table A1.1. Monosaccharide building blocks for HMO. 
Glycan structures are depicted according to the recommendations of the Consortium of Functional Glycomics 
(http://www.functionalglycomics.org). 
 
Monosaccharide Abbreviation Symbol Structure 
Glucose Glc 
 
OHO
HO
HO
HO
OH
 
Galactose Gal 
 
O
OH
HO
OH
OH
OH
 
N-Acetylglucosamine GlcNAc 
 
O
HO
HO
HN
HO
OH
O
H3C  
Fucose Fuc 
 
OH3C
OH
OH
OH
OH
 
 
N-Acetylneuraminic acid Neu5Ac 
 
O
HO
CO2H
OH
H
NH3C
O
HO
OH OH
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Table A1.2. Twelve glycosidic Linkages that constitute HMO. 
 
Glycosidic linkages Structure 
Galactosidic bonds Galβ1-4Glc 
               3GlcNAc 
Galβ1 
Galβ1-4GlcNAc 
N-Acetyl-glucosaminidic bonds                     3Galβ1      
GlcNAcβ1 
GlcNAcβ1 
                     6βGal 
Fucosidic bonds    Gal2 
 
Fucα1 
               3Glc 
Fucα1 
               3GlcNAc 
Fucα1 
Fucα1-4GlcNAc 
Sialidic bonds                       3Gal 
Neu5Acα2 
Neu5Acα2                    
                      6Gal 
Neu5Acα2 
                      6GlcNAc 
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Table A1.3. Core structures that occur in HMO. 
 
Oligosaccharide  Structure 
Lacto-N-tetraose LNT 
         3Galβ1-4Glc            
                                         3GlcNAcβ1  
                         Galβ1  
 
Lacto-N-neotetraose LNnT 
          3Galβ1-4Glc 
                            3Galβ1-4GlcNAcβ1  
  
 
Lacto-N-hexaose LNH 
Galβ1-4GlcNAcβ1  
    3/6Galβ1-4Glc 
  3GlcNAcβ1  
                          Galβ1  
 
Lacto-N-neohexaose LNnH 
Galβ1-4GlcNAcβ1  
    3/6Galβ1-4Glc 
Galβ1-4GlcNAcβ1  
 
para-Lacto-N-hexaose pLNH 
     3Galβ1-4Glc 
                                           3Galβ1-4GlcNAcβ1  
                       3GlcNAcβ1  
     Galβ1  
 
para-Lacto-N-
neohexaose pLNnH 
 3Galβ1-4Glc 
3Galβ1-4GlcNAcβ1  
         Galβ1-4GlcNAcβ1  
 
Lacto-N-octaose LNO 
  
                                                       3Galβ1-4GlcNAcβ1  
                    Galβ1-4GlcNAcβ1 3/6Galβ1-4Glc 
                                                                  3GlcNACβ1  
                  Galβ1  
 
Lacto-N-neooctaose LNnO 
   
                                          3Galβ1-4GlcNAcβ1  
                   3GlcNAcβ1   3/6Galβ1-4Glc 
                        Galβ1                              Galβ1-4GlcNACβ1  
   
 
iso-Lacto-N-octaose iLNO 
   
                             3Galβ1-4GlcNAcβ1  
     3GlcNAcβ1   3/6Galβ1-4Glc 
                   Galβ1                                         3GlcNACβ1  
                       Galβ1                                
 
para-Lacto-N-octaose pLNO 
  3Galβ1-4Glc 
       3Galβ1-4GlcNAcβ1  
   3Galβ1-4GlcNAcβ1  
           3GlcNAcβ1   
    Galβ1           
 
para-Lacto-N-
neooctaose pLNnO 
  3Galβ1-4Glc 
                                     3Galβ1-4GlcNAcβ1  
 3Galβ1-4GlcNAβ1  
   Galβ1-GlcNAβ1     
 
Lacto-N-decaose LND 
Galβ1-4GlcNAcβ1   
 3/6Galβ1-4GlcNAcβ1  
3GlcNAc β1       3/6Galβ1-4Glc 
                    Galβ1                    3GlcNAcβ1  
  Galβ1  
 
Lacto-N-neodecaose LNnD 
                         Galβ1-4GlcNAcβ1   
    3/6Galβ1-4GlcNAcβ1  
                       Galβ1-4GlcNAc β1  3/6Galβ1-4Glc 
 3GlcNAcβ1  
   Galβ1  
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Table A1.4. Structures of HMO that appear in this thesis (I). 
 
Oligosaccharide  Structure 
Lactose Lac                                                                           Galβ1-4Glc 
Lacto-N-triose LNT-II          3Galβ1-4Glc                                                     GlcNAcβ1  
 
2’-Fucosyllactose 2’FL 
 2Galβ1-4Glc 
 
  Fucα1 
 
3’-Fucosylalactose 3’FL 
 Galβ1-4Glc 
                         3 
        Fucα1 
           
 
Lactodifucotetratose LDFT 
 2Galβ1-4Glc 
                          3   
Fucα1               
           Fucα1 
 
3’-sialyllactose 3’SL 
Galβ1-4Glc 
                         3 
Neu5Acα2 
           
 
6’-sialyllactose 6’SL 
Neu5Acα2 
 
          6Galβ1-4Glc 
 
3’-Sialyl-3-fucosyllactose 3’S3FL 
3Galβ1-4Glc 
                                     3 
Neu5Acα2               
                     Fucα1 
 
Lacto-N-tetraose LNT 
         3Galβ1-4Glc            
                                         3GlcNAcβ1  
                         Galβ1  
 
Lacto-N-neotetraose LNnT 
          3Galβ1-4Glc 
                             Galβ1-4GlcNAcβ1  
  
 
Lacto-N-fucopentaose I LNFP I 
         3Galβ1-4Glc            
                                         3GlcNAcβ1  
                       2Galβ1  
                
              Fucα1 
 
 
Lacto-N-fucopentaose II LNFP II 
         3Galβ1-4Glc            
                           Fucα1- 4GlcNAcβ1  
                                            3  
                         Galβ1  
 
Lacto-N-fucopentaose III LNFP III 
 3Galβ1-4Glc 
Galβ1-4Glcβ1  
                      3                                                      
Fucα1 
 
  
 
Lacto-N-fucopentaose V LNFP V 
         3Galβ1-4Glc            
                                         3GlcNAcβ1            3 
                         Galβ1     Fucα1 
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Table A1.5. Structures of HMO that appear in this thesis (II). 
 
Oligosaccharide  Structure 
Lacto-N-difuco-hexaose I LNDFH I 
         3Galβ1-4Glc            
                    Fucα1-4GlcNAcβ1  
                          3  
                       2Galβ1  
                
              Fucα1 
 
 
Lacto-N-difuco-hexaose II LNDFH II 
         3Galβ1-4Glc            
                           Fucα1-4GlcNAcβ1            3 
                             3      Fucα1 
                        Galβ1  
 
Sialyllacto-N-tetraose a LSTa 
         3Galβ1-4Glc            
                                         3GlcNAcβ1  
                       3Galβ1  
Neu5Acα2  
 
Sialyllacto-N-tetraose b LSTb 
               Neu5Acα2  
                            6         3Galβ1-4Glc            
                                         3GlcNAcβ1  
                         Galβ1  
 
Disialyllacto-N-tetraose DSLNT 
               Neu5Acα2  
                            6         3Galβ1-4Glc            
                                         3GlcNAcβ1  
                       3Galβ1  
Neu5Acα2  
 
Lacto-N-hexaose LNH 
Galβ1-4GlcNAcβ1  
    3/6Galβ1-4Glc 
   3GlcNAcβ1  
                        Galβ1  
 
Fucosyllacto-N-hexaose I FLNH I 
Galβ1-4GlcNAcβ1  
    3/6Galβ1-4Glc 
   3GlcNAcβ1  
                        2Galβ1  
            
               Fucα1 
 
 
Fucosyllacto-N-hexaose II FLNH II 
Galβ1-4GlcNAcβ1  
                     3    6 
Fucα1    3Galβ1-4Glc 
   3GlcNAcβ1  
                        Galβ1  
 
Lacto-N-neohexaose LNnH 
Galβ1-4GlcNAcβ1  
    3/6Galβ1-4Glc 
Galβ1-4GlcNAcβ1  
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Figure A2.1. Chemical structures of the molecules appeared in Chapter 2. 
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Compound 3  
2-Acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-glucopyranose (Lacto-N-biose) 
 
Figure A2.2. 1H NMR of 2-Acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-glucopyranose.  
 
 
Figure A2.3. 13C NMR of 2-Acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-glucopyranose. 
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Compound 16 
4-Nitrophenyl 2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-
D-glucopyranoside 
 
Figure A2.4. 1H NMR of 4-Nitrophenyl 2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-β-D-glucopyranoside. 
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Figure A2.5 13C NMR of 4-Nitrophenyl 2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-β-D-glucopyranoside. 
 
Figure A2.6 HSQC of 4-Nitrophenyl 2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-β-D-glucopyranoside. 
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Compound 9 
2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride  
 
 
Figure A2.7. 1H NMR of 2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride. 
 
Compound 10 
2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl acetate 
 
Figure A2.8. 1H NMR of 2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl acetate. 
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Compound 11 
4-Nitrophenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside 
 
 
Figure A2.9. 1H NMR of 4-Nitrophenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside. 
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Compound 8 
4-Nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside 
 
Figure A2.10. 1H NMR of 4-Nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside. 
 
 
Figure A2.11. HSQC of 4-Nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside. 
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Compound 7 
4-nitrophenyl 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-glucopyranoside 
 
Figure A2.12. 1H NMR of 4-nitrophenyl 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-glucopyranoside. 
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Compound 12 
Per-O-acetated N-acetyl-D-glucosamine  
 
Figure A2.13. 1H NMR of Per-O-acetated N-acetyl-D-glucosamine.  
 
 
Figure A2.14. HSQC of Per-O-acetated N-acetyl-D-glucosamine. 
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Compound 13 
Per-O-acetated 1,2-ozaxoline derivative of N-acetyl-D-glucosamine  
 
Figure A2.15. 1H NMR of per-O-acetated 1,2-ozaxoline derivative of N-acetyl-D-glucosamine.  
 
 
Figure A2.16. 13C NMR of per-O-acetated 1,2-ozaxoline derivative of N-acetyl-D-glucosamine. 
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Compound 14 
1,2-ozaxoline derivative of N-acetyl-D-glucosamine  
 
Figure A2.17. 1H NMR of 1,2-ozaxoline derivative of N-acetyl-D-glucosamine. 
 
 
Figure A2.18. 13C NMR of 1,2-ozaxoline derivative of N-acetyl-D-glucosamine. 
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Compound 15 
1,2-ozaxoline derivative of 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-glucopyranose 
(Lacto-N-biose)  
 
Figure A2.19. 1H NMR of 1,2-ozaxoline derivative of 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-β-D-
glucopyranose. 
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Figure A3.1. Prediction of the secondary structure of full length LnbB using JPred3. 
QUERY shows the amino acidic sequence of the protein. Jnetpred shows the prediction of the secondary structure. 
JNETCONF indicates de probability of the prediction 
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Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta       1  MKH--------EKQQ-----RFSIRKYAVGAASVLIGFAFQAQTVAADGVTPTTTENQPTIHTVSDSPQS   57 
tr_Q8DRL6_Q8DRL6_STRR6_Be       1  MKH--------EKQQ-----RFSIRKYAVGAASVLIGFAFQAQTVAADGVTPTTTENQPTIHTVSDSPQS   57 
tr_D2KW09_D2KW09_9BACL_He       1  -----------------------------MMS--------------------------------------    3 
tr_O85361_O85361_STRPL_B-       1  MT--------------------------TGAA--------------------------------------    6 
tr_B3TLD6_B3TLD6_BIFBI_La       1  MEK--------SSNR-----RFGVRTVAAIVAGLMVGGMCTAMTA-------------------------   32 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito       1  MN--------------------AFKLSALARLTATMGFLGGMGSAMADQQLVDQLSQLKLNVKMLDNRAG   50 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-       1  MA--------------------------------------------------------------------    2 
tr_Q06GJ0_Q06GJ0_OSTFU_N-       1  MW---------------------SRRIPLFIFGVLVLILSVAAE------------DVVWRWSCDNGKCV   37 
sp_P07686_HEXB_HUMAN_Beta       1  MELCGLGLPRPPMLLALLLATLLAAMLALLTQVALVVQVAEA----------------------------   42 
sp_P06865_HEXA_HUMAN_Beta       1  MT-----------------------SSRLWFSLLL-----------------------------------   12 
Consensus_ss:                                                       hh                                    
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta      58  SENRTEETPKAVLQPEAPKTVETETPATDKVASLPKTEEKPQEEVSSTPSDKAEVVTPTSAEKETANKKA  127 
tr_Q8DRL6_Q8DRL6_STRR6_Be      58  SENRTEETPKAELQPEAPKTVETETPATDKVASLPKTEEKPQEEVSSTPSDKAEVVTPTSAEKETANKKE  127 
tr_D2KW09_D2KW09_9BACL_He          ----------------------------------------------------------------------      
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La          ----------------------------------------------------------------------      
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito      51  ENGVDCAALGADWASCNRVLFTLSNDGQAIDGKDWVIYFHSPRQTLRVDNDQFKIAHLTGDLYKLEPTAK  120 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-      38  K---------------------------------------------------------------------   38 
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta     128  EEASPKKEEAKEVDSKESNTDKTDKDKPAKKDEAKAEADKPATEAGKERAATVNEKLAKKKIVSIDAGRK  197 
tr_Q8DRL6_Q8DRL6_STRR6_Be     128  EEASPKKEEAKEVDSKESNTDKTDKDKPAKKDEAKAEADKPETETGKERAATVNEKLAKKKIVSIDAGRK  197 
tr_D2KW09_D2KW09_9BACL_He          ----------------------------------------------------------------------      
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La          ----------------------------------------------------------------------      
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito     121  FSGFPAGKAVEIPVVAEYWQLFRNDFLPRWYATSGDAKPKMLANTDTENLDQFVAPFTGDQWKRTKDDKN  190 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta     198  YFSPEQLKEIIDKAKHYGYTDLHLLVGNDGLRFMLDDMSITANGKTYASDDVKRAIEKGTNDYYNDPNGN  267 
tr_Q8DRL6_Q8DRL6_STRR6_Be     198  YFSPEQLKEIIDKAKHYGYTDLHLLVGNDGLRFMLDDMSITANGKTYASDDVKRAIEKGTNDYYNDPNGN  267 
tr_D2KW09_D2KW09_9BACL_He       4  ------------FIPESASASTS-----------------------------------------------   14 
tr_O85361_O85361_STRPL_B-       7  ------------PDRKAPVRPTP-----------------------------------------------   17 
tr_B3TLD6_B3TLD6_BIFBI_La      33  ----SAADDSAAGYSATAPVNLT-----------------------------------------------   51 
tr_A1RBZ5_A1RBZ5_ARTAT_Be       1  --------------------MSA-----------------------------------------------    3 
sp_Q54468_CHB_SERMA_Chito     191  ILMTPASRFVSNADLQTLPAGAL-----------------------------------------------  213 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-      39  LKNDPRSSEPALSLEACKMFCNE-----------------------------------------------   61 
sp_P07686_HEXB_HUMAN_Beta      43  -------------ARAPSVSAKP-----------------------------------------------   52 
sp_P06865_HEXA_HUMAN_Beta      13  ----------------AAAFAGR-----------------------------------------------   19 
Consensus_ss:                                                                                             
 
 
Conservation:                                            9 6                                              
sp_P49610_STRH_STRPN_Beta     268  HLTESQMTDLINYAKDKGIGLIPTVNSPGHMDAILNAMKELGIQNPNFSYFGKKSARTVDL---------  328 
tr_Q8DRL6_Q8DRL6_STRR6_Be     268  HLTESQMTDLINYAKDKGIGLIPTVNSPGHMDAILNAMKELGIQNPNFSYFGKKSARTVDL---------  328 
tr_D2KW09_D2KW09_9BACL_He      15  -----------------QPSILPKPVS-------------YTVGSGQFVLT-KNASIFVAGNNV---GET   50 
tr_O85361_O85361_STRPL_B-      18  -----------------LDRVIPAPAS-------------VDPGGAPYRIT-RGTHIRVDDS--------   48 
tr_B3TLD6_B3TLD6_BIFBI_La      52  -----------------RPATVPSMDG-------------WTDGTGAWTLG-EGTRVVSSD---------   81 
tr_A1RBZ5_A1RBZ5_ARTAT_Be       4  -----------------FHQLIPAPWS-------------FSAGTGELELD-AGTSVGADP---------   33 
sp_Q54468_CHB_SERMA_Chito     214  -----------------RGKIVPTPMQ-------------VKVHAQDADLR-KGVALDLST---------  243 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-       3  -----------------------------------------TFLGLSSKQE-KALVRLDK----------   20 
tr_Q06GJ0_Q06GJ0_OSTFU_N-      62  -----------------YGLLWPRPTG-------------EADLGNFLSKI-NLNSIEVKILKK--GATD   98 
sp_P07686_HEXB_HUMAN_Beta      53  -----------------GPALWPLPLS-------------VKMTPNLLHLA-PENFYISHSPN-------   84 
sp_P06865_HEXA_HUMAN_Beta      20  -----------------ATALWPWPQN-------------FQTSDQRYVLY-PNNFQFQYDVSSAAQPGC   58 
Consensus_ss:                                                e             eee   eeee    eeeeee           
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta     329  -DNEQAVAFTKALIDKYAAYFAKKTEIFNIGLDEYANDATDAKGWSVLQADKYYPNEGYPVKGYEKFIAY  397 
tr_Q8DRL6_Q8DRL6_STRR6_Be     329  -DNEQAVAFTKALIDKYAAYFAKKTEIFNIGLDEYANDATDAKGWSVLQADKYYPNEGYPVKGYEKFIAY  397 
tr_D2KW09_D2KW09_9BACL_He      51  DELFNIGQALAKKLNASTGYT-------------------------------------------------   71 
tr_O85361_O85361_STRPL_B-      49  REARRVGDYLADLLRPATGYR-------------------------------------------------   69 
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tr_B3TLD6_B3TLD6_BIFBI_La      82  -ALAARAQSLASELTKFTDVD-------------------------------------------------  101 
tr_A1RBZ5_A1RBZ5_ARTAT_Be      34  -ELRGPRRWLTRALGGATGWD-------------------------------------------------   53 
sp_Q54468_CHB_SERMA_Chito     244  -LVKPAADVVSQRFALLGVPV-------------------------------------------------  263 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-      99  DLMEAAAKRFKEQVSLAIPRG-------------------------------------------------  119 
sp_P07686_HEXB_HUMAN_Beta      85  STAGPSCTLLEEAFRRYHGYI-------------------------------------------------  105 
sp_P06865_HEXA_HUMAN_Beta      59  SVLDEAFQRYRDLLFGSGSWP-------------------------------------------------   79 
Consensus_ss:                       hhhhhhhhhhhhhhhhh                                                     
 
 
Conservation:                                                           5                                 
sp_P49610_STRH_STRPN_Beta     398  ANDLARIVKSHGLKPMAFND-GIYYNSDTSFGSFDKDIIVSMWTGGWGGYDVASSKLLAEKGHQILNTND  466 
tr_Q8DRL6_Q8DRL6_STRR6_Be     398  ANDLARIVKSHGLKPMAFND-GIYYNSDTSFGSFDKDIIVSMWTGGWGGYDVASSKLLAEKGHQILNTND  466 
tr_D2KW09_D2KW09_9BACL_He      72  -------ISV-------VKSN----------QPTAGSIYLTTVG--------------------------   91 
tr_O85361_O85361_STRPL_B-      70  -------LPV-------TAHG-------------HGGIRLRLAG--------------------------   86 
tr_B3TLD6_B3TLD6_BIFBI_La     102  -------IKA-------ATGS-----------ATGKDISLTLDA--------------------------  120 
tr_A1RBZ5_A1RBZ5_ARTAT_Be      54  -------LAP-------APAR-------------EAGIRLLLDP--------------------------   70 
sp_Q54468_CHB_SERMA_Chito     264  -------QTN-------GYP---------------IKTDIQPGK--------------------------  278 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-      21  ------------------YLN-------------LGEIAVSLVT--------------------------   33 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     120  -------STP-------KLTG-------------KAVDVYLVNEN-------------------------  137 
sp_P07686_HEXB_HUMAN_Beta     106  -------FGFYKWHHEPAEFQAKTQ--------VQQLLVSITLQS-------------------------  135 
sp_P06865_HEXA_HUMAN_Beta      80  -------RPY-------LTGKRHTL--------EKNVLVVSVVTP-------------------------  102 
Consensus_ss:                                                           eeeee                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta     467  AWYYVLGRNADGQGWYNLDQGLNGIKNTPITSVPKTEGADIPIIGGMVAAWADTPSARYSPSRLFKLMRH  536 
tr_Q8DRL6_Q8DRL6_STRR6_Be     467  AWCYVLGRNADGQGWYNLDQGLNGIKNTPITSVPKTEGADIPIIGGMVAAWADTPSARYSPSHLFKLMRH  536 
tr_D2KW09_D2KW09_9BACL_He          ----------------------------------------------------------------------      
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La          ----------------------------------------------------------------------      
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                               6 5 6                    7    
sp_P49610_STRH_STRPN_Beta     537  FANANAEYFAADYESAEQALNEVPKDLNRYTAESVTAVKEAEKAIRSLDS-----NLSRAQQDTIDQAIA  601 
tr_Q8DRL6_Q8DRL6_STRR6_Be     537  FANANAEYFAADYESAEQALNEVPKDLNRYTAESVAAVKEAEKAIRSLDS-----NLSRAQQDTIDQAIA  601 
tr_D2KW09_D2KW09_9BACL_He      92  ----------------------------------GNAALGNEGYDLITTS-----NQVTLTANKPEGVFR  122 
tr_O85361_O85361_STRPL_B-      87  ------------------------------------GPYGDEGYRLDSGP-----AGVTITARKAAGLFH  115 
tr_B3TLD6_B3TLD6_BIFBI_La     121  ---------------------------------SKKAELGDEGFKLNIGS-----KGLEVIGATDIGVFY  152 
tr_A1RBZ5_A1RBZ5_ARTAT_Be      71  -------------------------------------SLDAEAYRLEVS------DAVVISAGGAAGAFY   97 
sp_Q54468_CHB_SERMA_Chito     279  ---------------------------------FKGAMAVSGAYELKIGK-----KEAQVIGFDQAGVFY  310 
tr_Q840G9_Q840G9_AGGAC_Ds       1  --------------------------------------------------------NCCVKGN-------    7 
tr_Q6ST21_Q6ST21_STRGN_N-      34  --------------------------------------DSATSIKVEGRQ-----GYYQVSYKQPHQLYR   60 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     138  ------------------------------PNEKAFSLEMDESYGLRVSPSGADRVNATITANSFFGMRH  177 
sp_P07686_HEXB_HUMAN_Beta     136  ------------------------------ECDAFPNISSDESYTLLVKE-----PVAVLKANRVWGALR  170 
sp_P06865_HEXA_HUMAN_Beta     103  ------------------------------GCNQLPTLESVENYTLTIND-----DQCLLLSETVWGALR  137 
Consensus_ss:                                                                 eeeee        eeeeee  hhhhhh 
 
 
Conservation:                      6     556                          5    55  68  8         55 56  7  6  
sp_P49610_STRH_STRPN_Beta     602  KLQETVNNLTLTP---------EAQKEEEAKREVEKLAKNKVISIDAGRK-YFTLNQLKRIVDKASELGY  661 
tr_Q8DRL6_Q8DRL6_STRR6_Be     602  KLQETVNNLTLTP---------EAQKEEEAKREVEKLAKNKVISIDAGRK-YFTLDQLKRIVDKASELGY  661 
tr_D2KW09_D2KW09_9BACL_He     123  GNQTLLQLLPAGIEKNT-VVSGVQWVIPHSNISDKPEYEYRGLMLDVARH-FFTVDEVKRQIDLASQYKI  190 
tr_O85361_O85361_STRPL_B-     116  GVQTLRQLLPPAVEKDS--AQPGPWLVAGGTIEDTPRYAWRSAMLDVSRH-FFGVDEVKRYIDRVARYKY  182 
tr_B3TLD6_B3TLD6_BIFBI_La     153  GTRSVSQMLRQG-----------QLTLPAGTVATKPKYKERGATLCACQI-NISTDWIDRFLSDMADLRL  210 
tr_A1RBZ5_A1RBZ5_ARTAT_Be      98  GAQTLLQLLGPAALRQAPVVAVEGWSVPRVSVEDKPRFGYRGTMLDVARH-FMPKDNVLRFIEVMAMHKL  166 
sp_Q54468_CHB_SERMA_Chito     311  GLQSILSLVPSDG----------SGKIATLDASDAPRFPYRGIFLDVARN-FHKKDAVLRLLDQMAAYKL  369 
tr_Q840G9_Q840G9_AGGAC_Ds       8  -----------------------------SIYPQKTSTKQTGLMLDIARH-FYSPEVIKSFIDTISLSGG   47 
tr_Q6ST21_Q6ST21_STRGN_N-      61  ALALLSAALRSG--------------QDEVQIEEEAAYEDLAYMADCSRNAVLNLSSAKKMIEVLALMGY  116 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     178  GLETLSQLFVFDDIR------DHLLMVRDVNISDKPVYPYRGILLDTARN-YYSIESIKRTIEAMAAVKL  240 
sp_P07686_HEXB_HUMAN_Beta     171  GLETFSQLVYQDSY--------GTFTINESTIIDSPRFSHRGILIDTSRH-YLPVKIILKTLDAMAFNKF  231 
sp_P06865_HEXA_HUMAN_Beta     138  GLETFSQLVWKSAE--------GTFFINKTEIEDFPRFPHRGLLLDTSRH-YLPLSSILDTLDVMAYNKL  198 
Consensus_ss:                      hhhhhhhhh               eee  eeeee       eeeee        hhhhhhhhhhhhh    
 
 
Conservation:                      7 5655  6           6                   6                           67 
sp_P49610_STRH_STRPN_Beta     662  SDVHLLLGNDG-LRFLLDDMTITANGKTYASDDVKKAIIEGTKAYY---------------DDPNGTALT  715 
tr_Q8DRL6_Q8DRL6_STRR6_Be     662  SDVHLLLGNDG-LRFLLNDMTITANGKTYASDDVKKAIIEGTKAYY---------------DDPNGTALT  715 
tr_D2KW09_D2KW09_9BACL_He     191  NKFHMHLSDDQGWRIEIKSWPDLIE--------------IGSKGQV---------------GGGPGGYYT  231 
tr_O85361_O85361_STRPL_B-     183  NKLHLHLSDDQGWRIAIDSWPRLAT--------------YGGSTEV---------------GGGPGGYYT  223 
tr_B3TLD6_B3TLD6_BIFBI_La     211  NYVLLEMKLKP----------EEDN--------------TKKAA--------------------TWSYYT  236 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     167  NVLHLHLTDDQGWRMQINRYPKLTE--------------TGAWRRESSLGSW---RAGVFDGRPHGGFYT  219 
sp_Q54468_CHB_SERMA_Chito     370  NKFHFHLSDDEGWRIEIPGLPELTE--------------VGGQRCHDLSETTCLLPQYGQGPDVYGGFFS  425 
tr_Q840G9_Q840G9_AGGAC_Ds      48  NFLHLHFSDHENYAIESHLLNQRAE--------------NAVQGKDGIY----------INPYTGKPFLS   93 
tr_Q6ST21_Q6ST21_STRGN_N-     117  STFELYMEDTYEIE----NQPYF---------------------------------------GYFRGRYT  143 
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tr_Q06GJ0_Q06GJ0_OSTFU_N-     241  NTFHWHITDSQSFPFVTTKRPNLYK--------------FGALS--------------------PQKVYT  276 
sp_P07686_HEXB_HUMAN_Beta     232  NVLHWHIVDDQSFPYQSITFPELSN--------------KGSYS--------------------LSHVYT  267 
sp_P06865_HEXA_HUMAN_Beta     199  NVFHWHLVDDPSFPYESFTFPELMR--------------KGSYN-------------------PVTHIYT  235 
Consensus_ss:                       eeeeeee            hhhhh              h                               
 
 
Conservation:                           5   68  5 5 658666 869  5                                         
sp_P49610_STRH_STRPN_Beta     716  QAEVTELIEYAKSKDIGLIPAINSPGHMDAMLVAMEKLG----IKNP------------------QAHFD  763 
tr_Q8DRL6_Q8DRL6_STRR6_Be     716  QAEVTELIEYAKSKDIGLIPAINSPGHMDAMLVAMEKLG----IKNP------------------QAHFD  763 
tr_D2KW09_D2KW09_9BACL_He     232  QEQFKDIVSYAAERYIEVIPEIDMPGHTNAALASYGELN----PDGKR---------------KAMRTDT  282 
tr_O85361_O85361_STRPL_B-     224  KAEYKEIVRYAASRHLEVVPEIDMPGHTNAALASYAELN----CDGVA---------------PPLYTGT  274 
tr_B3TLD6_B3TLD6_BIFBI_La     237  RDDVKKFVKKANNYGIDVIPEINSPGHMNVWLENYPEYQ----LADN---------------------SG  281 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     220  QDDLREIVAFAADRHITVIPEIDVPGHSQAAIAAYPELG----AGPADG------------SSPVEVWTR  273 
sp_Q54468_CHB_SERMA_Chito     426  RQDYIDIIKYAQARQIEVIPEIDMPAHARAAVVSMEARYKKLHAAGKEQEANEFRLVDPTDTSNTTSVQF  495 
tr_Q840G9_Q840G9_AGGAC_Ds      94  YRQLDDIKAYAKAKGIELIPELDSPNHMTAIFKLVQKDR----GVKY-----------------LQGLKS  142 
tr_Q6ST21_Q6ST21_STRGN_N-     144  VAELQEIEDYAADFDMSFVPCIQTLAHLSAFVKWGIKEV----------------------------QEL  185 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     277  KAAIREVVRFGLERGVRVLPEFDAPAHVGEGWQDTDLTV----CFKAE---------------PWKSYCV  327 
sp_P07686_HEXB_HUMAN_Beta     268  PNDVRMVIEYARLRGIRVLPEFDTPGHTLSWGKGQKDLL----TPCY------------------SRQNK  315 
sp_P06865_HEXA_HUMAN_Beta     236  AQDVKEVIEYARLRGIRVLAEFDTPGHTLSWGPGIPGLL----TPCY------------------SGSEP  283 
Consensus_ss:                      hhhhhhhhhhhhh   eeee    hhhhhhhhhh hhh                                 
 
 
Conservation:                                      6      5    5          6 9599                          
sp_P49610_STRH_STRPN_Beta     764  KVSKTTMDLKNEEAMNFVKALIGKYMDFFAG---KTKIFNFGTDEYAND---------------------  809 
tr_Q8DRL6_Q8DRL6_STRR6_Be     764  KVSKTTMDLKNEEAMNFVKALIGKYMDFFAG---KTKIFNFGTDEYAND---------------------  809 
tr_D2KW09_D2KW09_9BACL_He     283  AVGYSTLMPRAEITYQFVEDVISELAAISP-----SPYIHLGGDESNA----------------------  325 
tr_O85361_O85361_STRPL_B-     275  KVGFSSLCVDKDVTYDFVDDVIGELAALTP-----GRYLHIGGDEAHS----------------------  317 
tr_B3TLD6_B3TLD6_BIFBI_La     282  RKDPNKLDISNPEAVKFYKTLIDEYDGVFT-----TKYWHMGADEYMIG---------------------  325 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     274  WGINETVLEVSETSLEFYRNVLDEVVEIFP-----SPWISLGGDEVPLT---------------------  317 
sp_Q54468_CHB_SERMA_Chito     496  FNRQSYLNPCLDSSQRFVDKVIGEIAQMHKEAGQPIKTWHFGGDEAKNIRLGAGYTDKAKPEPGKGIIDQ  565 
tr_Q840G9_Q840G9_AGGAC_Ds     143  RQVDDEIDITNADSITFMQSLMSEVIDIFGD---TSQHFHIGGDEFGYS---------------------  188 
tr_Q6ST21_Q6ST21_STRGN_N-     186  RDVEDILLIGEEKVYDLIEGMFQTMAHLHT------RKINIGMDEAHL----------------------  227 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     328  EPPCGQLNPTKDELYQYLEDIYSDMAEVFD----TTDIFHMGGDEVSEA---------------------  372 
sp_P07686_HEXB_HUMAN_Beta     316  LDSFGPINPTLNTTYSFLTTFFKEISEVFP-----DQFIHLGGDEVEFK---------------------  359 
sp_P06865_HEXA_HUMAN_Beta     284  SGTFGPVNPSLNNTYEFMSTFFLEVSSVFP-----DFYLHLGGDEVDFT---------------------  327 
Consensus_ss:                                 hhhhhhhhhhhhhhhhh         eeeee                             
 
 
Conservation:                                                         5             6      8              
sp_P49610_STRH_STRPN_Beta     810  ---------ATSAQGWYYLKW-----YQLYGKFAEYANTLAAMAKE--RGL-QPMAFNDGFYYEDKD---  859 
tr_Q8DRL6_Q8DRL6_STRR6_Be     810  ---------ATSAQGWYYLKW-----YQLYGKFAEYANTLAAMAKE--RGL-QPMAFNDGFYYEDKD---  859 
tr_D2KW09_D2KW09_9BACL_He     326  ---------------------------TSAADYDYFFGRVTAIANS--YGK-KVVGWDPSDTSS------  359 
tr_O85361_O85361_STRPL_B-     318  ---------------------------TPKADFVAFMKRVQPIVAK--YGK-TVVGWHQLAGAE------  351 
tr_B3TLD6_B3TLD6_BIFBI_La     326  -----TSFDNYSKLKTFAEKQYGA-GATPNDAFTGFINDIDKYVKA--KGK-QLRIWNDGIVNTK-----  381 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     318  -----QWQASAQAQAKAAELGL----DDVSGLHSWFVGQLALHLKH--HGR-ATSVWDEIGDGG------  369 
sp_Q54468_CHB_SERMA_Chito     566  SNEDKPWAKSQVCQTMIKEGKV----ADMEHLPSYFGQEVSKLVKA--HGIDRMQAWQDGLKDAESS---  626 
tr_Q840G9_Q840G9_AGGAC_Ds     189  -----VES---------------------NHEFITYANKLSYFLEK--KGL-KTRMWNDGLIKNT-----  224 
tr_Q6ST21_Q6ST21_STRGN_N-     228  ----------VGLGRYLIKHGF----QNRSLLMCQHLERVLDIADK--YGF-NCQMWSDMFFKLMSADGQ  280 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     373  -----CWNSSDSIQNFMMQNRWDLDKESFLKLWNYFQQKAQDKAYKAFGKKLPLILWTSTLTNYKHI---  434 
sp_P07686_HEXB_HUMAN_Beta     360  -----CWESNPKIQDFMRQKGFG---TDFKKLESFYIQKVLDIIAT--INK-GSIVWQEVFDDK------  412 
sp_P06865_HEXA_HUMAN_Beta     328  -----CWKSNPEIQDFMRKKGFG---EDFKQLESFYIQTLLDIVSS--YGK-GYVVWQEVFDNK------  380 
Consensus_ss:                                hhhhhhhhh         hhhhhhhhhhhhhhhhhh      eeeee  hh          
 
 
Conservation:                                             5  9                            8           5   
sp_P49610_STRH_STRPN_Beta     860  --------------DVQFDKDVLISYWSKGWWG----------YNLASPQYLASKGYKFLNTNGDWYYIL  905 
tr_Q8DRL6_Q8DRL6_STRR6_Be     860  --------------DVQFDKDVLISYWSKGWWG----------YNLASPQYLASKGYKFLNTNGDWYYVI  905 
tr_D2KW09_D2KW09_9BACL_He     360  ----------------GATSDSVLQNWTCS---------------ASTGTAAKAKGMKVIVSP-ANAYLD  397 
tr_O85361_O85361_STRPL_B-     352  -----------------PVEGALVQYWGLDRTG---------DAEKAEVAEAARNGTGLILSPADRTYLD  395 
tr_B3TLD6_B3TLD6_BIFBI_La     382  --------------NVSLNKDIVIEYWYGA---------------GRKPQELVQDGYTLMNAT-QALYWS  421 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     370  -----------------LPDGALVASWRG----------------YEGGIDALRKGYDVVMCPEHKLYLD  406 
sp_Q54468_CHB_SERMA_Chito     627  --------------KAFATSRVGVNFWDTLYW-----------GGFDSVNDWANKGYEVVVSNPDYVYMD  671 
tr_Q840G9_Q840G9_AGGAC_Ds     225  --------------FEQINPNIEITYWSYDGDTQDKNEAAERRDMRVSLPELLAKGFTVLNYNSYYLYIV  280 
tr_Q6ST21_Q6ST21_STRGN_N-     281  YDRDVEIPEETRVYLDRLKERVTLVYWDYY---------------QDSEEKYNRNFQ-NHHKISQDIAFA  334 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     435  -------------DDYLNKDDYIIQVWTTGV--------------DPQIKGLLEKGYRLIMSNYDALYFD  477 
sp_P07686_HEXB_HUMAN_Beta     413  ---------------AKLAPGTIVEVWKDSA-------------YPEELSRVTASGFPVILSAPWYLDLI  454 
sp_P06865_HEXA_HUMAN_Beta     381  ---------------VKIQPDTIIQVWREDIPV----------NYMKELELVTKAGFRALLSAPWYLNRI  425 
Consensus_ss:                                           eeeeee                  hhhhhhhhh    eee    h eee 
 
 
Conservation:                                                                                 8     9 7   
sp_P49610_STRH_STRPN_Beta     906  GQKPEDGGGFL---KKAI-ENTGKTPFNQLAS----------------TKYPEVDLPTVGSMLSIWADRP  955 
tr_Q8DRL6_Q8DRL6_STRR6_Be     906  GNHKQDEAYPL---SKAV-ENSGKVPFNQLAS----------------TKYPEVDLPTVGSMLSIWADRP  955 
tr_D2KW09_D2KW09_9BACL_He     398  MKYYSDSPIGL--QWRGFVNTNRAYNWDPTD--------------------CIKGANIYGVESTLWTETF  445 
tr_O85361_O85361_STRPL_B-     396  MKYTKDTPLGL--SWAGYVEVQRSYDWDPAG-----------------YLPGAPADAVRGVEAPLWTETL  446 
tr_B3TLD6_B3TLD6_BIFBI_La     422  RSAQVYKVNAA-------RLYNNNWNVGTFDGG---------------RQIDKNYDKLTGAKVSIWPDSS  469 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     407  HRQADGDDEPV--PVGFVTTLQAVYEFEPLPG----------------VEGTDFPGRLLGAQANIWSEHL  458 
sp_Q54468_CHB_SERMA_Chito     672  FPYEVNPDERGYYWGTRFSDERKVFSFAPDNMPQNAETSVDRDGNHFNAKSDKPWPGAYGLSAQLWSETQ  741 
tr_Q840G9_Q840G9_AGGAC_Ds     281  PKASPTFSQDAAFAAKDVIKNWDLGVWDGRNT----------------KNRVQNTHEIAGAALSIWGEDA  334 
tr_Q6ST21_Q6ST21_STRGN_N-     335  GGA---------------WKWIGFTPHNHFSRLVA-----------IEANKACRKNQVKEVIVTGWGDNG  378 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     478  CGYGAWVGAGNN-WCSPYIGWQKVYDNSPAV------------------IALEHRDQVLGGEAALWSEQS  528 
sp_P07686_HEXB_HUMAN_Beta     455  SYG---------------QDWRKYYKVEPLDF----------------GGTQKQKQLFIGGEACLWGEYV  493 
sp_P06865_HEXA_HUMAN_Beta     426  SYG---------------PDWKDFYIVEPLAF----------------EGTPEQKALVIGGEACMWGEYV  464 
Consensus_ss:                                          hhh                             hhh  eeeeeeeee     
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Conservation:                         5         5     56  5                                               
sp_P49610_STRH_STRPN_Beta     956  ---SAEYKEEEIFELMTAFADHNKDYFRA----------------------NYNALREELAKIPT-NLEG  999 
tr_Q8DRL6_Q8DRL6_STRR6_Be     956  ---SAEYKEEEIFELMTAFADHNKDYFRA----------------------NYNALREELAKIPT-NLEG  999 
tr_D2KW09_D2KW09_9BACL_He     446  V--TQDHLDYMLYPKLLSNAEVGWTARG------------------------DRNWDDFKERLIE-HTPR  488 
tr_O85361_O85361_STRPL_B-     447  S--DPDQLDYMAFPRLPGVAELGWSPAS------------------------THDWDTYKVRLAA-QAPY  489 
tr_B3TLD6_B3TLD6_BIFBI_La     470  YFQTENEVEKEIFDGMRFISQMTWSDSR-----------------------PWATWNDMKADIDK-IGYP  515 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     459  D--SPRRVQFAAFPRLSAISEVFWSNPA------------------------GRDYDEFLTRLTGAHLAR  502 
sp_Q54468_CHB_SERMA_Chito     742  R--TDPQMEYMIFPRALSVAERSWHRAGWEQDYRAGREYKGGETHFVDTQALEKDWLRFANILGQRELAK  809 
tr_Q840G9_Q840G9_AGGAC_Ds     335  ----KALKDETIQKNTKSLLEAVIHKTN------------------------GDE---------------  361 
tr_Q6ST21_Q6ST21_STRGN_N-     379  ----GETSQFSVLPALQIWAELAYRNDL------------------------KKVSEHFLVSTGL-DFDD  419 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     529  ---DTSTLDGRLWPRAAALAERLWAEPA-------------------------TSWQDAEYRMLH-IRER  569 
sp_P07686_HEXB_HUMAN_Beta     494  ---DATNLTPRLWPRASAVGERLWSSKD------------------------VRDMDDAYDRLTR-HRCR  535 
sp_P06865_HEXA_HUMAN_Beta     465  ---DNTNLVPRLWPRAGAVAERLWSNKL------------------------TSDLTFAYERLSH-FRCE  506 
Consensus_ss:                          hhhhhhhhhhhhhhhhhhhh                               hhhhhhhhhh hhhh 
 
 
Conservation:                          5                                                                  
sp_P49610_STRH_STRPN_Beta    1000  YSKESLEALDAAKTALNYNLNRNKQAELDTLVANLKAALQGLKPAVTHSGSLDENEVAANVETRPELITR 1069 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1000  YSKESLEALDAAKTALNYNLNRNKQAELDTLVANLKAALQGLKPAATHSGSLDENEVAANVETRPELITR 1069 
tr_D2KW09_D2KW09_9BACL_He     489  LQNKGIKFFADPIVWELP----------------------------------------------------  506 
tr_O85361_O85361_STRPL_B-     490  WEAAGIDFYRSPQVPWT-----------------------------------------------------  506 
tr_B3TLD6_B3TLD6_BIFBI_La     516  LDIREYDYTPVDAGIYDI----------------------------------------------------  533 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     503  LEAMGVEYRPLSGPAPWQ----------------------------------------------------  520 
sp_Q54468_CHB_SERMA_Chito     810  LDKGGVAYRLPVPGARVAA---------------------------------------------------  828 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-     420  FMKIDLANLLPD----------------------------------------------------------  431 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     570  LVRMGIQAESLQPEWCYQ----------------------------------------------------  587 
sp_P07686_HEXB_HUMAN_Beta     536  MVERGIAAQPLYAGYCNH----------------------------------------------------  553 
sp_P06865_HEXA_HUMAN_Beta     507  LLRRGVQAQPLNVGFCEQ----------------------------------------------------  524 
Consensus_ss:                      hhh                                                                    
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta    1070  TEEIPFEVIKKENPNLPAGQENIITAGVKGERTHYISVLTENGKTTETV-------------LDS----- 1121 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1070  TEEIPFEVIKKENPNLPAGQENIITAGVKGERTHYISVLTENGKTTETV-------------LDS----- 1121 
tr_D2KW09_D2KW09_9BACL_He     507  -----------------------------------IVQIN---------SEWKMDEGTGTVVKDTSGYLN  532 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La     534  -----------------------------------PQLKS---------ISKGPWELITTPDGYYQMKDT  559 
tr_A1RBZ5_A1RBZ5_ARTAT_Be     521  ----------------------------------QRPGVEGWKRDYDAEQLVRN----------------  540 
sp_Q54468_CHB_SERMA_Chito     829  ------------------------------GKLEANIALPGLGIEYSTDGGK------------------  850 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-     432  -----------------------------------LPDNL---------SGINPNRYVLYQDVL------  451 
tr_Q06GJ0_Q06GJ0_OSTFU_N-     588  -----------------------------------NEGYCYS----------------------------  594 
sp_P07686_HEXB_HUMAN_Beta     554  -----------------------------------ENM--------------------------------  556 
sp_P06865_HEXA_HUMAN_Beta     525  -----------------------------------EFEQT------------------------------  529 
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta          ----------------------------------------------------------------------      
tr_Q8DRL6_Q8DRL6_STRR6_Be          ----------------------------------------------------------------------      
tr_D2KW09_D2KW09_9BACL_He     533  GTLVGGA---------------------------------------------------------------  539 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La     560  VSGKCLALFTGSKHLDVVTQVGARPELRNCADVSVGQDQRNTANERNTQKWQIRADKDGKYTISPALTQQ  629 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta          ----------------------------------------------------------------------      
tr_Q8DRL6_Q8DRL6_STRR6_Be          ----------------------------------------------------------------------      
tr_D2KW09_D2KW09_9BACL_He          ----------------------------------------------------------------------      
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La     630  RLAIATGNEQNIDLETHRPAAGTVAQFPADLVSDNALFTLTGHMGMSATVDSKTVNPASPSKITVKVRAA  699 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta    1122  --------------------------------------------------------------QVTK---- 1125 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1122  --------------------------------------------------------------QVTK---- 1125 
tr_D2KW09_D2KW09_9BACL_He     540  -------------------------------------------------KWTAGKQGNGVSFDGSSGYIN  560 
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tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La     700  SNANTGDVTVTPVVPEGWEIKPGSVSLKSIPAGKAAIAYFNVVNTTGTGDATVQFKLTNTKTGEELGTTS  769 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito     851  --------------------------------------------------------------QWQRYDAK  858 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta    1126  EVINQVVEVGAPVTHKGDESGLAPTTEVKPRLDIQEEEIPFTTVTCENPLLLK--------------GKT 1181 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1126  EVINQVVEVGSPVTHKGDESGLAPTTEVKPRLDIQEEEIPFTTVTRENPLLLK--------------GKT 1181 
tr_D2KW09_D2KW09_9BACL_He     561  LGGQDITGNWTAAVWVYGQPNTTNNETLLSGTTSAIKINQYNKTGKVGITIYGTKDYTYNYSIPSNKWTH  630 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La     770  VALTGSLTKDVEASDYAASSQETTGEHAPVGNAFDKNANTFWHSKYSNPSANL--------------PHW  825 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta    1182  QVITK--------------------------------------GVNGHRSNFYSVSTSADGKEV------ 1207 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1182  QVITK--------------------------------------GVNGHRSNFYSVSTSADGKEV------ 1207 
tr_D2KW09_D2KW09_9BACL_He     631  LTFVGTSTGTALYENGVLKETIAAKMNGPMALVGAEKTGGSGDLTSYFRGSLDELKIFNRALS-------  693 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La     826  LAFKASPGEGNK-----------------------IAAITHLYRQDKLNGPAKNVAVYVVAASDANSVAD  872 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-     452  ------------------------------------------------------CPLLEQHIR-------  460 
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta          ----------------------------------------------------------------------      
tr_Q8DRL6_Q8DRL6_STRR6_Be          ----------------------------------------------------------------------      
tr_D2KW09_D2KW09_9BACL_He     694  --ASEVVELAKS----------------------------------------------------------  703 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La     873  VTNWGEPVATAEFPYTKELQTIALPNTIPSGDVYVKFQINDAWGLTETSAGVTWAAVAELAATAKATPVE  942 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-     461  --PEKDKQHFAS----------------------------------------------------------  470 
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta          ----------------------------------------------------------------------      
tr_Q8DRL6_Q8DRL6_STRR6_Be          ----------------------------------------------------------------------      
tr_D2KW09_D2KW09_9BACL_He          ----------------------------------------------------------------------      
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La     943  LTEPEQPKDNPEVTETPEATGVTVSGDGVANGALSLKKGTTAQLTAKVAPDDADQAVTWASSDDKVVTVD 1012 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta          ----------------------------------------------------------------------      
tr_Q8DRL6_Q8DRL6_STRR6_Be          ----------------------------------------------------------------------      
tr_D2KW09_D2KW09_9BACL_He     704  ----PAPKASLTGPQSANPGQSFDVKMGLSDVSPSEFGQMYAQDWTINYDSAKLQLDSITSLQDKFQVID  769 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La    1013  KTGKVTAVAKGVAKVTATTANGKSASVTVTV--------------------------------------- 1043 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito     859  ----AKPAVSGEVQVRSVSPDGKRYSRAEKV---------------------------------------  885 
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
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tr_Q6ST21_Q6ST21_STRGN_N-     471  ----SAQQLGEISKRAGEYAYIFETQAQL-----------------------------------------  495 
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta    1208  KTLVNSVVAQEAVTQIVEVGTMVTHVGDENGQAAIAEEKPKLEIPSQPAPSTAPAEESKVLPQDPAPVVT 1277 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1208  KTLVNSVVAQEAVTQIVEVGTMVTHVGDENGQAAIAEEKPKLEIPSQPAPSTAPAEESKALPQDPAPVVT 1277 
tr_D2KW09_D2KW09_9BACL_He     770  QKELAPGQIRIVAANAAANQGVTPQGDLFAFKFTVKAGTDVKTTISADHIVIGNAQGKELEIAGATHEIQ  839 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La    1044  TEDSEVPGPTGPTEPTKPGTEKPTTKPTTKPNDGKLSAT------------------------------- 1082 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta    1278  EKKLPETGTHDSAGLV------------------------------------------------------ 1293 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1278  EKKLPETGTHDSAELV------------------------------------------------------ 1293 
tr_D2KW09_D2KW09_9BACL_He     840  VSIPVDKSQLNVLIANAQAKHDAAVEGNEDGLYAAGSKAQLQTAIHTAKAVADNSNASQQQVDSAKSALE  909 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La    1083  ----------GADTAV------------------------------------------------------ 1088 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-     496  -------------NAL------------------------------------------------------  498 
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta    1294  ------------------------------------------------------VAGLMSTLAAY----- 1304 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1294  ------------------------------------------------------VAGLMSTLAAY----- 1304 
tr_D2KW09_D2KW09_9BACL_He     910  EAVQVFESKKISADVNGDGQVSIGDLAIIAGAYGKEEGQAGWNKKADVNHDGKVDIIDLTIVAKA-----  974 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La    1089  ------------------------------------------------------LATIAALFALA----- 1099 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-     499  ------------------------------------------------------LALKISITSGIQKAYR  514 
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
sp_P49610_STRH_STRPN_Beta          ----------------------------------------------------------------------      
tr_Q8DRL6_Q8DRL6_STRR6_Be          ----------------------------------------------------------------------      
tr_D2KW09_D2KW09_9BACL_He          ----------------------------------------------------------------------      
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La          ----------------------------------------------------------------------      
tr_A1RBZ5_A1RBZ5_ARTAT_Be          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          ----------------------------------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-     515  NGDKEHLSALAEKDFPQLYQMVEDFSDQFSRQWQQENKIFGLDTIDIRFGGLLKRIKRAQERLEQFISGQ  584 
tr_Q06GJ0_Q06GJ0_OSTFU_N-          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                  
sp_P49610_STRH_STRPN_Beta    1305  ----------GLTK---------RKED---------------- 1312 
tr_Q8DRL6_Q8DRL6_STRR6_Be    1305  ----------GLTK---------RKED---------------- 1312 
tr_D2KW09_D2KW09_9BACL_He     975  ----------ILQI-----------------------------  978 
tr_O85361_O85361_STRPL_B-          -------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La    1100  ----------GGAVV------AVRRRSVR-------------- 1112 
tr_A1RBZ5_A1RBZ5_ARTAT_Be          -------------------------------------------      
sp_Q54468_CHB_SERMA_Chito          -------------------------------------------      
tr_Q840G9_Q840G9_AGGAC_Ds          -------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-     585  IDCVEELEQEILPFNDFYKDQGLTATTANQWHLIATASTIYTT  627 
tr_Q06GJ0_Q06GJ0_OSTFU_N-          -------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          -------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          -------------------------------------------      
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Figure A3.2. Promals alignment of LnbB and crystallized GH20 family proteins.  
B3TLD6: B. bifidum Lacto-N-biosidase (LnbB) 
O85361: S. plicatus B-N-acetylhexosaminidase (HexSp)  
Q5446Z: Serratia marcenesis Chitobiase  
P0686:  HEXA_HUMAN Beta-hexosaminidase subunit alpha  
P0768:  HEXB_HUMAN Beta-hexosaminidase subunit beta  
Q6ST21: Streptococcus gordonii N-acetyl-beta-D-glucosaminidase  
A1RBZ5: Arthrobacter aurescens Beta-N-acetylhexosaminidase  
D2KW09: Paenibacillus sp. Hexosaminidase Hex1t 
Q840G9: Aggregatibacter actinomycetemcomitans DspB (Fragment)  
Q8DRL6: Streptococcus pneumoniae (strain R6)Beta-N-acetyl-hexosaminidase  
P4961:  Streptococcus pneumoniae serotype 4 (TIGR4)Beta-N-acetylhexosaminidase  
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Conservation:                      9                                                                      
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito       1  MN------------------AFKLSALARLTATMGFLGGMGSAMADQQLVDQLSQLKLNVKMLDNRAGEN   52 
tr_O85361_O85361_STRPL_B-       1  MT--------------------------------------------------------------------    2 
tr_B3TLD6_B3TLD6_BIFBI_La       1  MEK--------SSNR-----RFGVRTVAAIVAGLMVGGMCTA----------------------------   29 
sp_P07686_HEXB_HUMAN_Beta       1  MELCGLGLPRPPMLLALLLATLLAAMLALLTQVALVVQVA------------------------------   40 
sp_P06865_HEXA_HUMAN_Beta       1  MT-----------------------SSRLWFSLLLAA---------------------------------   14 
tr_Q6ST21_Q6ST21_STRGN_N-       1  MA--------------------------------------------------------------------    2 
Consensus_ss:                                                       hhhh                                  
 
 
Conservation:                                                                                             
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito      53  GVDCAALGADWASCNRVLFTLSNDGQAIDGKDWVIYFHSPRQTLRVDNDQFKIAHLTGDLYKLEPTAKFS  122 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La          ----------------------------------------------------------------------      
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                                                             
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito     123  GFPAGKAVEIPVVAEYWQLFRNDFLPRWYATSGDAKPKMLANTDTENLDQFVAPFTGDQWKRTKDDKNIL  192 
tr_O85361_O85361_STRPL_B-          ----------------------------------------------------------------------      
tr_B3TLD6_B3TLD6_BIFBI_La      30  ---------------------------------------------------------------------M   30 
sp_P07686_HEXB_HUMAN_Beta          ----------------------------------------------------------------------      
sp_P06865_HEXA_HUMAN_Beta          ----------------------------------------------------------------------      
tr_Q6ST21_Q6ST21_STRGN_N-          ----------------------------------------------------------------------      
Consensus_ss:                                                                                             
 
 
Conservation:                                                              5                              
tr_Q840G9_Q840G9_AGGAC_Ds          ----------------------------------------------------------------------      
sp_Q54468_CHB_SERMA_Chito     193  MTPASRFVSNADLQTLPAGALRGKIVPTPMQVKVHAQDADLRKGVALDLST----------LVKPAADVV  252 
tr_O85361_O85361_STRPL_B-       3  ------TGAAPDRKAPVRPTPLDRVIPAPASVDPGGAPYRITRGTHIRVDDSR--------EARRVGDYL   58 
tr_B3TLD6_B3TLD6_BIFBI_La      31  TASAADDSAAGYSATAPVNLTRPATVPSMDGWTDGTGAWTLGEGTRVVSSD----------ALAARAQSL   90 
sp_P07686_HEXB_HUMAN_Beta      41  ---------EAARAPSVSAKPGPALWPLPLSVKMTPNLLHLAPENFYISHSPNS-------TAGPSCTLL   94 
sp_P06865_HEXA_HUMAN_Beta      15  ----------------AFAGRATALWPWPQNFQTSDQRYVLYPNNFQFQYDVSSAAQPGCSVLDEAFQRY   68 
tr_Q6ST21_Q6ST21_STRGN_N-       3  --------------------------------TFLGLSSKQEKALVRLDKYLN-----------------   23 
Consensus_ss:                                                    eeee   eeee   eeeee            hhhhhhhhh 
 
 
Conservation:                                                                          5 5 7        5     
tr_Q840G9_Q840G9_AGGAC_Ds       1  --------------------------------------------------------------NCCVKGN-    7 
sp_Q54468_CHB_SERMA_Chito     253  SQRFALLGVP-------VQTNGYP--------IKTDIQPG---KFKGAMAVSGAYELKIGKKEAQVIGFD  304 
tr_O85361_O85361_STRPL_B-      59  ADLLRPATGY-------RLPVTAHG------HGGIRLRLA------GGPYGDEGYRLDSGPAGVTITARK  109 
tr_B3TLD6_B3TLD6_BIFBI_La      91  ASELTKFTDV-------DIKAATGS----ATGKDISLTLD---ASKKAELGDEGFKLNIGSKGLEVIGAT  146 
sp_P07686_HEXB_HUMAN_Beta      95  EEAFRRYHGYIFGFYKWHHEPAEFQAKTQVQQLLVSITLQSECDAFPNISSDESYTLLVKEPVAVLKANR  164 
sp_P06865_HEXA_HUMAN_Beta      69  RDLLFGSGSW-------PRPYLTGKRHTLEKNVLVVSVVTPGCNQLPTLESVENYTLTINDDQCLLLSET  131 
tr_Q6ST21_Q6ST21_STRGN_N-      24  -----------------------------LGEIAVSLVTD----------SATSIKVEGRQGYYQVSYKQ   54 
Consensus_ss:                      hhhhhhh                         eeeeeee               eeeee   eeeeee   
 
 
Conservation:                        7   75   5556                        5    55  57  7            65  7 
tr_Q840G9_Q840G9_AGGAC_Ds       8  ---------------------------------SIYPQKTSTKQTGLMLDIARH-FYSPEVIKSFIDTIS   43 
sp_Q54468_CHB_SERMA_Chito     305  QAGVFYGLQSILSLVPSDG--------SGKIATLDASDAPRFPYRGIFLDVARN-FHKKDAVLRLLDQMA  365 
tr_O85361_O85361_STRPL_B-     110  AAGLFHGVQTLRQLLPPAVEKDSAQPGPWLVAGGTIEDTPRYAWRSAMLDVSRH-FFGVDEVKRYIDRVA  178 
tr_B3TLD6_B3TLD6_BIFBI_La     147  DIGVFYGTRSVSQMLRQG---------QLTLPAGTVATKPKYKERGATLCACQI-NISTDWIDRFLSDMA  206 
sp_P07686_HEXB_HUMAN_Beta     165  VWGALRGLETFSQLVYQDSY------GTFTINESTIIDSPRFSHRGILIDTSRH-YLPVKIILKTLDAMA  227 
sp_P06865_HEXA_HUMAN_Beta     132  VWGALRGLETFSQLVWKSAE------GTFFINKTEIEDFPRFPHRGLLLDTSRH-YLPLSSILDTLDVMA  194 
tr_Q6ST21_Q6ST21_STRGN_N-      55  PHQLYRALALLSAALRS------------GQDEVQIEEEAAYEDLAYMADCSRNAVLNLSSAKKMIEVLA  112 
Consensus_ss:                      hhhhhhhhhhhhhhh              eeeeeeeee       eeeee        hhhhhhhhhhhh 
 
 
Conservation:                          7  555  7            55   5                           56         7 
tr_Q840G9_Q840G9_AGGAC_Ds      44  LSGGNFLHLHFSDHENYAIESHLLNQRAENAVQGKDGIYI----------NPYTGKPFLSYRQLDDIKAY  103 
sp_Q54468_CHB_SERMA_Chito     366  AYKLNKFHFHLSDDEGWRIEIPGLPELTEVGGQRCHDLSETTCLLPQYGQGPDVYGGFFSRQDYIDIIKY  435 
tr_O85361_O85361_STRPL_B-     179  RYKYNKLHLHLSDDQGWRIAIDSWPRLATYGGSTEVG---------------GGPGGYYTKAEYKEIVRY  233 
tr_B3TLD6_B3TLD6_BIFBI_La     207  DLRLNYVLLEMKLKP----------EEDNTKKAA--------------------TWSYYTRDDVKKFVKK  246 
sp_P07686_HEXB_HUMAN_Beta     228  FNKFNVLHWHIVDDQSFPYQSITFPELSNKGSYS--------------------LSHVYTPNDVRMVIEY  277 
sp_P06865_HEXA_HUMAN_Beta     195  YNKLNVFHWHLVDDPSFPYESFTFPELMRKGSYNP-------------------VTHIYTAQDVKEVIEY  245 
tr_Q6ST21_Q6ST21_STRGN_N-     113  LMGYSTFELYMEDTYEIENQPY---------FGY--------------------FRGRYTVAELQEIEDY  153 
Consensus_ss:                      h    eeeeeee             hhhhh                              hhhhhhhhhh 
 
 
Conservation:                      9    5 5 77 5 7 9                                                      
tr_Q840G9_Q840G9_AGGAC_Ds     104  AKAKGIELIPELDSPNHMTAIFKLVQKDR----GVKYL-----------------QGLKSRQVDDEIDIT  152 
sp_Q54468_CHB_SERMA_Chito     436  AQARQIEVIPEIDMPAHARAAVVSMEARYKKLHAAGKEQEANEFRLVDPTDTSNTTSVQFFNRQSYLNPC  505 
tr_O85361_O85361_STRPL_B-     234  AASRHLEVVPEIDMPGHTNAALASYAELN----CDGVAP---------------PLYTGTKVGFSSLCVD  284 
tr_B3TLD6_B3TLD6_BIFBI_La     247  ANNYGIDVIPEINSPGHMNVWLENYPEYQ----LADN---------------------SGRKDPNKLDIS  291 
sp_P07686_HEXB_HUMAN_Beta     278  ARLRGIRVLPEFDTPGHTLSWGKGQKDLL----TPCYS------------------RQNKLDSFGPINPT  325 
sp_P06865_HEXA_HUMAN_Beta     246  ARLRGIRVLAEFDTPGHTLSWGPGIPGLL----TPCYS------------------GSEPSGTFGPVNPS  293 
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tr_Q6ST21_Q6ST21_STRGN_N-     154  AADFDMSFVPCIQTLAHLSAFVKWGIKEV----------------------------QELRDVEDILLIG  195 
Consensus_ss:                      hhh   eeee    hhhhhhhhhh hhh                                           
 
 
Conservation:                            7      7               7 9599                                    
tr_Q840G9_Q840G9_AGGAC_Ds     153  NADSITFMQSLMSEVIDIFGD---TSQHFHIGGDEFGYS--------------------------VES--  191 
sp_Q54468_CHB_SERMA_Chito     506  LDSSQRFVDKVIGEIAQMHKEAGQPIKTWHFGGDEAKNIRLGAGYTDKAKPEPGKGIIDQSNEDKPWAKS  575 
tr_O85361_O85361_STRPL_B-     285  KDVTYDFVDDVIGELAALTP-----GRYLHIGGDEAHS--------------------------------  317 
tr_B3TLD6_B3TLD6_BIFBI_La     292  NPEAVKFYKTLIDEYDGVFT-----TKYWHMGADEYMIG--------------------------TSFDN  330 
sp_P07686_HEXB_HUMAN_Beta     326  LNTTYSFLTTFFKEISEVFP-----DQFIHLGGDEVEFK--------------------------CWESN  364 
sp_P06865_HEXA_HUMAN_Beta     294  LNNTYEFMSTFFLEVSSVFP-----DFYLHLGGDEVDFT--------------------------CWKSN  332 
tr_Q6ST21_Q6ST21_STRGN_N-     196  EEKVYDLIEGMFQTMAHLHT------RKINIGMDEAHLV-------------------------------  228 
Consensus_ss:                       hhhhhhhhhhhhhhhhh         eeeee                                       
 
 
Conservation:                                                          7      9 5                         
tr_Q840G9_Q840G9_AGGAC_Ds     192  ------------------NHEFITYANKLSYFLEKKGL-KTRMWNDGLIKNT------------------  224 
sp_Q54468_CHB_SERMA_Chito     576  QVCQTMIKEGKV---ADMEHLPSYFGQEVSKLVKAHGIDRMQAWQDGLKDAESS----------------  626 
tr_O85361_O85361_STRPL_B-     318  ----------------TPKADFVAFMKRVQPIVAKYGK-TVVGWHQLAGA--------------------  350 
tr_B3TLD6_B3TLD6_BIFBI_La     331  YSKLKTFAEKQYGAGATPNDAFTGFINDIDKYVKAKGK-QLRIWNDGIVNTK------------------  381 
sp_P07686_HEXB_HUMAN_Beta     365  PKIQDFMRQKGFG--TDFKKLESFYIQKVLDIIATINK-GSIVWQEVFDDK-------------------  412 
sp_P06865_HEXA_HUMAN_Beta     333  PEIQDFMRKKGFG--EDFKQLESFYIQTLLDIVSSYGK-GYVVWQEVFDNK-------------------  380 
tr_Q6ST21_Q6ST21_STRGN_N-     229  -GLGRYLIKHGF---QNRSLLMCQHLERVLDIADKYGF-NCQMWSDMFFKLMSADGQYDRDVEIPEETRV  293 
Consensus_ss:                      hhhhhhhhh        hhhhhhhhhhhhhhhhhh    eeeeee hh                       
 
 
Conservation:                                  59                               7                         
tr_Q840G9_Q840G9_AGGAC_Ds     225  -FEQINPNIEITYWSYDGDTQDKNEAAERRDMRVSLPELLA---KGFTVLNYNSYYLYIVPKASPTFSQD  290 
sp_Q54468_CHB_SERMA_Chito     627  -KAFATSRVGVNFWDTLY-----------WGGFDSVNDWAN---KGYEVVVSNPDYVYMDFPYEVNPDER  681 
tr_O85361_O85361_STRPL_B-     351  ---EPVEGALVQYWGLDRT---------GDAEKAEVAEAAR---NGTGLILSPADRTYLDMKYTKDTPLG  405 
tr_B3TLD6_B3TLD6_BIFBI_La     382  -NVSLNKDIVIEYWYGA---------------GRKPQELVQ---DGYTLMNAT-QALYWSRSAQVYKVNA  431 
sp_P07686_HEXB_HUMAN_Beta     413  --AKLAPGTIVEVWKDSA-------------YPEELSRVTA---SGFPVILSAPWYLDLISYG-------  457 
sp_P06865_HEXA_HUMAN_Beta     381  --VKIQPDTIIQVWREDI----------PVNYMKELELVTK---AGFRALLSAPWYLNRISYG-------  428 
tr_Q6ST21_Q6ST21_STRGN_N-     294  YLDRLKERVTLVYWDYYQ-----------DSEEKYNRNFQNHHKISQDIAFAGGAWKWIGFTP-------  345 
Consensus_ss:                              eeeeee                  hhhhhhhhh       eee  hhh               
 
 
Conservation:                                        6                              7     9 6             
tr_Q840G9_Q840G9_AGGAC_Ds     291  AAFAAKDVIKNWDLGVWDGRNT----------------KNRVQNTHEIAGAALSIWGEDA----KALKDE  340 
sp_Q54468_CHB_SERMA_Chito     682  GYYWGTRFSDERKVFSFAPDNMPQNAETSVDRDGNHFNAKSDKPWPGAYGLSAQLWSETQR--TDPQMEY  749 
tr_O85361_O85361_STRPL_B-     406  LSW--AGYVEVQRSYDWDPAG-----------------YLPGAPADAVRGVEAPLWTETLS--DPDQLDY  454 
tr_B3TLD6_B3TLD6_BIFBI_La     432  ARLY----NNNWNVGTFDGGR------------------QIDKNYDKLTGAKVSIWPDSSYFQTENEVEK  479 
sp_P07686_HEXB_HUMAN_Beta     458  --------QDWRKYYKVEPLDF----------------GGTQKQKQLFIGGEACLWGEYV---DATNLTP  500 
sp_P06865_HEXA_HUMAN_Beta     429  --------PDWKDFYIVEPLAF----------------EGTPEQKALVIGGEACMWGEYV---DNTNLVP  471 
tr_Q6ST21_Q6ST21_STRGN_N-     346  -----HNHFSRLVAIE----------------------ANKACRKNQVKEVIVTGWGDNG----GETSQF  384 
Consensus_ss:                                hhhh                           hhhh  eeeeeeeee        hhhhhh 
 
 
Conservation:                         5      7  5                                               
tr_Q840G9_Q840G9_AGGAC_Ds     341  TIQKNTKSLLEAVIHKTNG-DE--------------------------------------  361 
sp_Q54468_CHB_SERMA_Chito     750  MIFPRALSVAERSWHRAGW-EQDYRAGREYKGG-------ETH-----------------  784 
tr_O85361_O85361_STRPL_B-     455  MAFPRLPGVAELGWSPAST-HDWDTYKVRLAAQAPYWEAAGIDFYRSPQVPWT-------  506 
tr_B3TLD6_B3TLD6_BIFBI_La     480  EIFDGMRFISQMTWSDSRPWATWNDMKADIDKIGYPLDIREYDYTPVD-AGIYDI-----  533 
sp_P07686_HEXB_HUMAN_Beta     501  RLWPRASAVGERLWSSKDV-RDMDDAYDRLTRHRCRMVERGIAAQPLY-AGYCNHENM--  556 
sp_P06865_HEXA_HUMAN_Beta     472  RLWPRAGAVAERLWSNKLT-SDLTFAYERLSHFRCELLRRGVQAQPLN-VGFCEQEFEQT  529 
tr_Q6ST21_Q6ST21_STRGN_N-     385  SVLPALQIWAELAYRNDLK-KVSEHFLVSTGLDFDDFMKIDLANLLPDLP----------  433 
Consensus_ss:                      hhhhhhhhhhhhhh        hhhhhhhhhhhhhhhhh                      
 
Figure A3.3. Promals alignment of the GH20 domains of LnbB and crystallized GH20 family proteins. 
B3TLD6: B. bifidum Lacto-N-biosidase (LnbB) 
O85361: S. plicatus B-N-acetylhexosaminidase (HexSp)  
Q5446Z: Serratia marcenesis Chitobiase  
P0686:  HEXA_HUMAN Beta-hexosaminidase subunit alpha  
P0768:  HEXB_HUMAN Beta-hexosaminidase subunit beta  
Q6ST21: Streptococcus gordonii N-acetyl-beta-D-glucosaminidase  
Q840G9: Aggregatibacter actinomycetemcomitans DspB (Fragment)  
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Figure A3.4. Prediction of transmembrane helices in proteins using TMHMM Server v. 2.0. 
 
 
 
Figure A3.5. Graphic map of pET24b vector with LnbB C-terminal His-tagged protein. 
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Figure A3.6. Graphic map of pET28a+ vector with LnbB N-terminal His-tagged protein.    
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Figure A4.1. Multiple sequence alignment of β-N-acetylhexosaminidases of known structure from family GH20.  
Domains distribution is shown as coloured boxes on top. Accompanying domains are not shown. Conserved arginine 
and glutamate/aspartate sites are marked with a star. Sequences were downloaded from UniProt entry names: 
SpHex (O85361_STRPL), ScHex (Q9L068), Bf3009 (Q5LAT3) NahA (A1RBZ5_ARTAT), Hex1T (D2KW09_9BACL), SmCHB 
(CHB_SERMA), LnbB B3TLD6_BIFBI), HexA (HEXA_HUMAN), HexB (HEXB_HUMAN), OfHex1 (Q06GJ0_OSTFU), GcnA 
(Q6ST21_STRGN), DspB (Q840G9_AGGAC), StrH_R6 (Q8DRL6_STRR6), StrH_TIGR4 (STRH_STRPN). Alignment was 
performed with PROMALS. Conserved positions are coloured according to ClustalW colour scheme. Only the 
sequence fragments covering GH20b, GH20 domains and extra α-helix were considered in this alignment. 
 
 
Figure A4.2. Graphic map of pET28a+ vector with Construct A N-terminal His-tagged protein. 
 
 
Figure A4.3. Graphic map of pET28a+ vector with Construct B N-terminal His-tagged protein.  
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Figure A4.4 Graphic map of pET28a+ vector with Construct Bα N-terminal His-tagged protein. 
 
 
Figure A4.5 Graphic map of pET28a+ vector with Construct D C-terminal His-tagged protein. 
 
 
 
Figure A4.6 Graphic map of pET28a+ vector with Construct F C-terminal His-tagged protein.  
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Structural-Functional Analysis Reveals a
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GH20 Hexosaminidases
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Abstract
Hexosaminidases are involved in important biological processes catalyzing the hydrolysis
of N-acetyl-hexosaminyl residues in glycosaminoglycans and glycoconjugates. The GH20
enzymes present diverse domain organizations for which we propose two minimal model
architectures: Model A containing at least a non-catalytic GH20b domain and the catalytic
one (GH20) always accompanied with an extra α-helix (GH20b-GH20-α), and Model B with
only the catalytic GH20 domain. The large Bifidobacterium bifidum lacto-N-biosidase was
used as a model protein to evaluate the minimal functional unit due to its interest and struc-
tural complexity. By expressing different truncated forms of this enzyme, we show that
Model A architectures cannot be reduced to Model B. In particular, there are two structural
requirements general to GH20 enzymes with Model A architecture. First, the non-catalytic
domain GH20b at the N-terminus of the catalytic GH20 domain is required for expression
and seems to stabilize it. Second, the substrate-binding cavity at the GH20 domain always
involves a remote element provided by a long loop from the catalytic domain itself or, when
this loop is short, by an element from another domain of the multidomain structure or from
the dimeric partner. Particularly, the lacto-N-biosidase requires GH20b and the lectin-like
domain at the N- and C-termini of the catalytic GH20 domain to be fully soluble and function-
al. The lectin domain provides this remote element to the active site. We demonstrate resto-
ration of activity of the inactive GH20b-GH20-α construct (model A architecture) by a
complementation assay with the lectin-like domain. The engineering of minimal functional
units of multidomain GH20 enzymes must consider these structural requirements.
Introduction
N-acetyl-β-hexosaminidases are widely distributed in nature participating in many biological
processes [1,2]. They catalyze the hydrolysis of N-acetyl-hexosaminyl residues in glycoproteins,
glycosaminoglycans, chitin, and glycolipids, and are classified in CAZY families GH3, GH20
and GH84 (Carbohydrate Active Enzymes database, www.cazy.org [3]). GH20 hexosaminidases
are found in crustaceans, insects and fungi, participating in the degradation of chitin, and in
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bacteria, where they are involved in the catabolism of oligosaccharides that serve as nitrogen
and carbon sources. From the biotechnological point of view, hexosaminidases, together with
chitinases, are important enzymes for industrial chitin degradation, the most abundant polysac-
charide after cellulose [2]. They are also powerful insect and fungal control agents as biopesti-
cides. In humans, the two lysosomal hexosaminidases HexA and HexB are responsible for the
hydrolysis of GlcNAc and GalNAc residues of glycosphingolipids such as ganglioside GM2 and
their dysfunction is linked to neurodegenerative disorders known as Tay-Sachs and Sandhoff
diseases [4,5]. In addition, some bacterial hexosaminidases contribute to the virulence of some
infections in humans as in the case of Actinobacillus actinomycetemcomitans that colonizes the
human oral cavity and causes periodontitis and Streptococcus pneumoniae infections [2].
GH20 enzymes comprise not only β-N-acetylhexosaminidases (EC.3.2.1.52), catalyzing the
removal of terminal non-reducing N-acetylhexosamine residues, but also lacto-N-biosidases
(EC.3.2.1.140), hydrolyzing the terminal lacto-N-biosyl residues from the non-reducing end of
oligosaccharides such as human milk oligosaccharides (HMOs). HMOs play an important role
in the development of intestinal flora and in the modulation of the immune system of breast-
fed infants [6–8]. HMOs are constituted by two core tetrasaccharide structures: the lacto-N-tet-
raose (type 1) characterized by lacto-N-biose (Galβ1,3GlcNAc) and lactose units linked by a β-
1,3 glycosidic bond, and lacto-neo-N-tetraose (type 2) formed by β-1,3-linked N-acetyllactosa-
mine (Galβ1,4GlcNAc) and lactose. They are elongated to different isomers of lacto-N-hexa-,
octa- and decaose and then, decorated with fucose and sialic residues via α-1,2/3/4 linkages
and α-2,3/6 respectively [9,10]. Bifidobacteria have a unique metabolism on HMO resulting in
their predominant proliferation in the colon of breast-fed infants [7]. Specifically, Bifidobacter-
ium bifidummetabolizes type 1 human milk oligosaccharides by the action of extracellular sia-
lidases, fucosidases and lacto-N-biosidase.
To date, the structures of thirteen GH20 enzymes are known. Their domain organization is di-
verse and several accompanying domains are present apart from the catalytic GH20 domain. In
addition, some of them exist as dimeric proteins. We aimed at defining the minimal functional do-
main architecture for enzymatic activity in these GH20 family enzymes. We chose the large B. bifi-
dum lacto-N-biosidase (LnbB) as a model protein because of its complex domain organization
among GH20 enzymes and its significance in the metabolism of humanmilk oligosaccharides.
The LnbB gene encodes for a membrane-anchored extracellular enzyme of 1112 amino acid resi-
dues. Recently, it was cloned and the recombinant full length protein was characterized confirm-
ing that this enzyme catalyzes the hydrolysis of the tetrasaccharide Galβ1,3GlcNAcβ1,3Galβ1,4Glc
to lacto-N-biose (Galβ1,3GlcNAc) and lactose (Fig 1) [11,12]. LnbB is a retaining exo-enzyme
that acts by substrate-assisted catalysis, which is a common feature of GH20 enzymes.
By means of structural and sequence analysis of GH20 enzymes of known structure, we
have established two levels of domains organization in this family, and further engineered
LnbB in different truncated forms according to these models. We report the structural require-
ments for functionality, of this and the other GH20 enzymes, to obtain a minimal functional
unit that retains the enzymatic activities. The importance of a remote element in the active site
such as loop 2 seen in some GH20 enzymes is analyzed in all structures. It is shown that the iso-
lated GH20 catalytic domain in LnbB is inactive and requires a remote element provided by
Fig 1. Hydrolytic reaction of lacto-N-tetraose catalyzed byB. bifidum lacto-N-biosidase.
doi:10.1371/journal.pone.0128075.g001
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the adjacent lectin domain for activity, as observed in a complementation experiment. This
structural and functional analysis provides new insights for further enzyme engineering for
biotechnological and biomedical applications.
Materials and Methods
Cloning, expression and purification of Lacto-N-biosidase enzyme from
Escherichia coli
Two synthetic genes of Lacto-N-biosidase from Bifidobacterium bifidum (LnbB), codon-opti-
mized for the expression in Escherichia coli were produced by GenScript (GenScript, NJ, USA).
The LnbB gene (37–1064) was cloned into the pET24b plasmid (Novagen, Madison, WI, USA)
using the restriction sites NdeI and XhoI, and the construct A gene (40–528) into the pET28a
+ vector using NdeI and Bpu1102. Constructs B (176–497) and Bα (176–528) genes were ob-
tained by PCR reaction using construct A as template, and constructs D (40–776) and F (546–
776) genes using the full length LnbB gene. The following forward and reverse primers were used
(restriction site are underlined): P1 (5’-GGAATTCCATATGAAGCCGAAATATAAAGAACGT-
3’) and P2 (5’-TAATAGCTCAGCGGCGTCAAC-3’) for construct B; P1 and P3 (5’-TAA
TAGCTCAGCACGGGAGTCACTCCA-3’) for construct Bα; P4 (5’-GCGTATCCATGGCTGAT
GACTCCGCAGCAGGCTA-3’) and P5 (5’-GCGTATCTCGAGCAGGCTGCCGGTCAGC-3’) for
construct D, and P6 (5’-GCGTATCCATGGTGGATGCGGGTATC-3’) and P5 for construct F.
All constructs were cloned into the pET28a+ vector. E. coliDH5 cells were transformed and posi-
tive transformants were verified by DNA sequencing.
Expression and purification of the full length protein and constructs were carried out as fol-
lows: recombinant cultures of E. coli BL21 (DE3) star cells were grown following an autoinduc-
tion protocol [13] in LB medium with 30 μgmL-1 kanamycin, 25mMNa2HPO4, 25mM
K2HPO4, 50mM NH4Cl, 5mMNa2SO4, 2mMMgSO4, 0.5% glycerol, 0.05% glucose and 0.2%
lactose at 250 rpm and 30°C for 24 h. The full length protein and constructs A, B and Bα were
also obtained using 1 mM IPTG induction after 16 h of growth at 37°C in LB medium with
kanamycin achieving similar results. Cells were harvested by centrifugation (4000g, 15 min,
4°C), resuspended in buffer A (Na2HPO4 20mM, NaCl 150mM, pH 7.5) and disrupted in a cell
disrupter (20000 psi). After centrifugation (20000g, 4°C, 2 h), the supernatant was loaded into
a 1mL Ni2+-charged HiTrap chelating column chromatography. Proteins were purified to ho-
mogeneity by a linear gradient of Buffer B (Na2HPO4 20 mM, NaCl 150 mM, imidazole
500mM, pH 7.5). Collected fractions were analyzed by SDS-PAGE and fractions containing
the proteins were combined and dialyzed against buffer A with a 30 kDa cut-off membrane. All
proteins were purified further using an XK16/60 Superdex 200 column (GE Healthcare), pree-
quilibrated with buffer A. Fractions were pooled, concentrated with a Centricon YM-10 unit
(Merk Millipore) and stored at 4°C. Protein concentrations were determined spectrophotomet-
rically by the BCA method measuring A590 nm using BSA as standard [14].
Protein size was determined using dynamic light scattering in a Nano ZS Nanosizer (Mal-
vern Instruments Ltd., UK) with a laser light wavelength of 632.8 nm and a scattering angle of
173 degrees. Temperature was set at 25°C. Protein solutions in buffer A were measured without
previous dilution. Full length protein showed a single peak for monodisperse particles of 10
nm and PDI 0.30, which is consistent with monomeric form.
Kinetics of the hydrolase activity
Lacto-N-biosidase activity assays with p-nitrophenyl β-lacto-N-bioside (Toronto Research
Chemicals Inc.) were performed at 30°C in a volume of 0.1 mL using 96-wells microtiter plates
Domain Organization in Family GH20 Hexosaminidases
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measuring p-nitrophenol concentration at 405 nm. Enzymatic reactions were performed in a
reaction mixture containing 0.25 mM substrate and 50mM of citrate-phosphate buffer (pH
4.5). After pre-incubation for 5 min, reactions were initiated by addition of the enzyme (20 nM
of full length protein and construct D, 20 nM-4 μM of construct A). At regular time intervals,
reactions were quenched by the addition of 0.15 mL of quenching buffer (0.5 M of glycine, pH
10) and p-nitrophenol release was measured by absorbance at 400 nm with a microplate-reader
MRX (Cultek). Triplicate measurements at each concentration were performed.
Complementation assays
Enzymatic reactions with constructs A and F were performed using standard conditions in a
Bravo liquid handling Robot (Agilent). After pre-incubation of construct A (50 nM) and F (25
nM-500 nM) for 5 minutes, addition of the substrate initiated the reaction. Triplicate measure-
ments at each concentration were performed. The complex of constructs A and F was also
characterized using gel filtration chromatography. The mixture of construct A (42 μM) with
excess of construct F (245 μM) was loaded to the Superdex 200 column pre-equilibrated with
buffer A and calibrated with protein standards. Fractions were further analyzed by SDS-PAGE
and their hydrolase activity was determined. This purification was performed by duplicate.
Enzymatic activities of construct A (50 nM) in the presence of BSA at 1:1, 1:4 and 1:10 ratio
were analyzed using standard conditions.
GH20 structures and sequences retrieval and analysis
The list of currently available 3D structures of GH20 enzymes was retrieved from CAZY data-
base (http://www.cazy.org, [3]). Protein structures were downloaded from the Protein Data
Bank (http://www.pdb.org). Protein sequences were retrieved from UniProt (http://www.
uniprot.org). Assignment of protein domains were obtained from different databases (Pfam,
Superfamily, SCOP, PSI-BLAST and CAZY) and the consensus domain organizations are re-
ported in Table 1. Protein structures were analysed and visualized with VMD [15]. Structure
alignment was performed with MultiSeq [16] restricting the alignment region to GH20b and
GH20 domains only. Sequence alignment was performed with PROMALS [17] with default op-
tions. Only the sequence fragments covering GH20b, GH20 domains and extra α-helix
were considered.
Results and Discussion
1. Structural domains organization of GH20 proteins
According to CAZY classification [3], GH20 family is mainly composed of both prokaryotic
and eukaryotic β-N-acetylhexosaminidases with different substrate specificities. Using data in-
tegration from different databases (Pfam, Superfamily, SCOP, PSI-BLAST and CAZY data-
bases), we report in Table 1 the consensus domains organization in GH20 proteins of known
structure. The catalytic activity in this family of enzymes is assigned to the GH20 domain
(PFAM code PF00728) which typically folds into a (β/α)8-barrel topology. Except for dispersin
B from A. actinomycetemcomitans that presents only a single GH20 domain, the rest of struc-
tures show the catalytic domain accompanied by several domains with quite diverse functional-
ities: a non-catalytic domain, commonly named as GH20b, which is conserved in most GH20
enzymes although with unknown function, several lectin domains, carbohydrate binding do-
mains, and other domains of unknown function.
Due to this diversity in domain organization, different questions come out: are all the ac-
companying domains essential for activity? Would the GH20 catalytic domain alone be
Domain Organization in Family GH20 Hexosaminidases
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functional? Which is the importance of GH20b? Several studies on the structure-function rela-
tionships at the active site have been performed [18–22] but only few have addressed the struc-
tural organization of these enzymes [23–25].
Regardless of the number of accompanying domains, we propose two different models of
organization (Table 1): Model A, comprising proteins with at least both GH20b and GH20 do-
mains, which is characterized by a GH20b-GH20-α architecture, where GH20 is always accom-
panied by GH20b at the N-terminus and followed by an extra α-helix after the GH20 (β/α)8-
barrel, and Model B with proteins that only present the GH20 domain without GH20b.
Table 1. Domain organization of GH20 β-N-acetylhexosaminidases.
Model A
Enzyme Organism Length
(aa)
PDB Domains1 GH20b-GH20-α
location
Monomeric
β-N-acetylhexosaminidase (SpHex) Streptomyces plicatus 506 1HP5[A] GH20b-GH20-α 19–494
β-N-acetylhexosaminidase (ScHex) Streptomyces coelicolor A3(2) 535 4C7G[A] GH20b-GH20-α 11–511
β-N-acetylhexosaminidase (Hex1T) Paenibacillus sp. 978 3GH5[A] GH20b-GH20-α-Lectin-CBD 15–493
Chitobiase (SmCHB) Serratia marcescens 885 1QBB[A] CHB_HEX-GH20b-GH20-α-
CHB_HEX_C
215–814
Lacto-N-biosidase (LnbB) Biﬁdobacterium biﬁdum 1112 4JAW[A,B] GH20b-GH20-α-Lectin-
CBM32-Ig like
34–515
β-N-acetylhexosaminidase (NahA)* Arthrobacter aurescens 540 3RCN[A] GH20b-GH20- 5–506
β-N-acetylhexosaminidase
(Bf3009*)
Bacteroides fragilis 518 4PYS[A,B] GH20b-GH20-α 21–498
Heterodimeric
β-N-acetylhexosaminidase (HexA) Homo sapiens 529/556 2GK1 [A,B,C,
D,E,F,G]
GH20b-GH20-α α:23–510 β:56–
540
Homodimeric
β-N-acetylhexosaminidase (HexB) Homo sapiens 556/556 1NP0[A,B] GH20b-GH20-α 56–540
β-N-acetylhexosaminidase (OfHex1) Ostrinia furnacalis 593/593 3OZO[A] GH20b-GH20-α 65–574
β-N-acetylhexosaminidase (GcnA) Streptococcus gordonii 627/627 2EPN[A,B] GH20b-GH20-α-Domain III 2–414
Model B
Enzyme Organism Length
(aa)
PDB Domains1 GH20 domain
location
Monomeric
β-1,6-N acetylglucosaminidase
Dispersin B (DspB)
Aggregatibacter
actinomycetemcomitans
361 1YHT[A] GH20 20–342
β-N-acetylhexosaminidase (StrH) Streptococcus pneumoniae R6 1312 3RPM[A,B] GH20-GH20-G5-G5 190–538 635–
972
Streptococcus pneumoniae
TIGR4
1312 2YL8[A] GH20-GH20-G5-G5 190–538
2YL9[A,B,C,
D]
GH20-GH20-G5-G5 635–972
Data obtained using integration from different databases (Pfam, Superfamily, SCOP, PSI-BLAST and CAZY databases). PDB structure accession code
and chain identiﬁer used for structural analysis are indicated and domains actually present in the PDB structure are underlined.
1 Domains: domain nomenclature according to the consensus domain organization by integrating Pfam, Superfamily, SCOP, PSI-BLAST and CAZY
databases. Preferentially CAZY annotation is used, if available. CBD: carbohydrate binding domain, CBM32: carbohydrate binding module family 32,
CHB_HEX: chitobiose hexosaminidase accompanying domain in the N-terminus, CHB_HEX_C: chitobiose hexosaminidase C-terminal accompanying
domain, Lectin: lectin-like domain according to PSI-BLAST, Ig like: Immunoglobulin-like fold domain, Domain III: C-terminal domain needed to dimerize
according to authors, G5: accompanying domain of carbohydrate metabolism enzymes.
*: Oligomerization state in solution is unknown
doi:10.1371/journal.pone.0128075.t001
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To date, eleven of the thirteen GH20 enzymes structures fit into Model A (Fig 2A). As sum-
marized in Table 1, five of them are monomeric proteins in solution (SpHex, ScHex, Hex1T,
SmCHB, and LnbB), whereas other four are dimeric proteins (HexA, Hex B, OfHex1, and
GcnA). The oligomerization state of the Arthrobacter aurescens (NahA) and Bacteroides fragilis
(Bf3009) enzymes remains unknown.
For the monomeric proteins, SpHex and ScHex structures, which share 94% sequence identi-
ty, comprise the GH20b domain followed by the catalytic GH20 domain [26,27]. Hex1T consists
of four domains, GH20b and GH20, and domains III and IV which are described as concanava-
lin A-like lectin and cellulose-binding domains respectively, according to Superfamily database
(Supfam). The Hex1T crystal structure is a truncated form (residues 1–502), with only the
GH20b and GH20 domains [25]. SmCHB is also constituted by four domains, where the N-
terminal domain (CHB_HEX) is annotated as a carbohydrate binding module although its
Fig 2. Crystal structures of GH20 β-N-acetylhexosaminidases. (A) Structures according to model A architecture. (B) Structures according to model B
architecture. GH20b domains are colored in orange, GH20 domains in blue, α-helix in green, and the rest of accompanying domains in yellow and purple.
Loop 2 from GH20 domain is in red. Dimer counterparts follow the same coloring scheme but with lower intensity.
doi:10.1371/journal.pone.0128075.g002
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function remains unknown, and the C-terminal domain (CHB_HEX_C) as an immunoglobu-
lin-like fold domain (Supfam). The central domains correspond to GH20b and GH20 domains
[21]. LnbB is formed by five domains. Domains I and II are the GH20b and GH20 ones, Domain
III (residues 546–700) is similar to a lectin domain according to a PSI-Blast search, Domain IV
(784–932) has sequence homology to CBM32 (Supfam), and domain V (962–1041) is described
as a Immunoglobulin-like domain in PFam. The recent crystal structure of this enzyme corre-
sponds to a C-terminal truncated form (41–663) with the GH20b, GH20 and part of the lectin-
like domain [23]. Finally, NahA and Bf3009, with unknown oligomerization states but included
in the group of monomeric proteins in Table 1, present only the GH20b and GH20 domains.
For the dimeric proteins, each subunit of HexA, HexB [28,29] and OfHex1 [30] have only
the two domains, GH20b and GH20, while the GcnA structure contains an additional domain
III, which is predominantly α-helical and is reported to form a significant part of the dimer in-
terface [31]. In general, these accompanying domains are non-catalytic domains involved in
binding and substrate specificity but still the mechanism by which this occurs remains uncer-
tain [32,33].
The remaining two GH20 enzymes present structures that are assigned to Model B (Fig 2B):
dispersin B from Aggregatibacter actinomycetemcomitans (DspB) and the β-hexosaminidases
from Streptococcus pneumoniae (StrH). Both are monomeric proteins in solution where DspB
presents only one domain, the unique GH20 domain [34], and StrH consists of four domains,
where the N-terminus is a tandem repeat of two GH20 domains, designated as GH20-1 and
GH20-2, and the C-terminus is a tandem repeat of two domains tentatively designated as G5
with unknown function (Pfam). Truncated forms containing a single GH20-1 and GH20-2 do-
mains of S. pneumoniae were crystallized [24]. The GH20-1 and GH20-2 domains are quite
similar although specific features confer differential substrate specificities.
2. B. bifidum lacto-N-biosidase truncated forms
The full length protein was truncated according to the two different models of structure organi-
zation we propose, and three different truncated proteins were designed: construct A, B and Bα
(Fig 3).
Construct A (residues 40–528) follows the architecture organization of Model A enzymes
and is composed of the GH20b and GH20 domains always followed by the extra α-helix. This
construct would be expected to be active since several enzymes of model A exhibit just these
two domains alone in the wild-type protein (such as SpHex structure and HexA, HexB and
OfHex1 subunits). Furthermore, a truncated form of Hex1T (encoding the GH20b-GH20-α
domains alone) is reported to be active [25]. However, a previous work by Ito et al. (2013) in
which different LnbB truncated forms were designed, revealed that a truncated protein (37–
520) equivalent to construct A exhibits no catalytic activity. A longer truncated protein (37–
663) composed by GH20b-GH20-α and a part of the lectin-like domain was reported to be as
active as the full length. These data indicate that the GH20b-GH20-α architecture is not the
minimal functional unit for LnbB, as it is for the rest of the model A GH20 enzymes. Further
studies are presented to determine the details of the minimum requirement for LnbB to be
catalytically active.
Construct B (residues 176–497) mimics Model B enzymes and is formed by the single cata-
lytic GH20 domain alone. Lastly, construct Bα (residues 176–528) was designed to tackle the
open question whether the accompanying GH20b domain can be removed in Model A en-
zymes. This construct encodes the catalytic GH20 domain with the extra α-helix at the C-ter-
minus. Both constructs, B and Bα, were designed for the study of the behaviour of the GH20
catalytic domain in model A proteins.
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Engineered proteins of LnbB enzyme were cloned and expressed in E. coli. The full length pro-
tein (37–1064), without the signal peptide andmembrane anchor regions, was expressed as C-ter-
minal His6-Tagged protein. Constructs A, B and Bα were expressed as N-terminal His6-Tagged
proteins. Cultures were grown at 30°C for 24 h with autoinduction medium. The full length pro-
tein and construct A were obtained as soluble intracellular proteins with yields of 16 and 27 mg/L
of culture respectively. SDS-PAGE analysis and MALDI-TOFmass spectrometry confirmed the
theoretical 112 kDa of the full length protein and 57 kDa of Construct A. Further characterization
by gel filtration chromatography showed that the full length protein is monomeric with particle
size of about 10 nm by dynamic light scattering, whereas Construct A is mainly dimeric in solu-
tion (Fig 4). The full length protein was also expressed as N-terminal His6-Tagged protein to eval-
uate the effect of the N-terminal tag. Both, C-terminal and N-terminal His6-Tagged full length
proteins, were soluble and had the same specific activity (data not shown).
On the other hand, constructs B and Bα were only present in the insoluble pellet and no sol-
uble protein was achieved after different expression conditions such as autoinduction or IPTG
induction at different temperatures (data not shown). This seems to indicate that the single
GH20 catalytic domain of LnbB, with or without the extra α-helix, is not stable enough and
yields insoluble aggregates. Thus, GH20b domain at the N-terminus of GH20 is required for
LnbB expression and stability. This domain is present in all model A enzymes being the relative
orientation of GH20b and GH20 catalytic domain the same in all structures (Fig 2). The num-
ber of β-strands of the GH20b domain varies (for example five in GcnA, six in HexA and HexB
and seven in SpHEx and LnbB) but the interface between both domains is well conserved: two
loops (residues 54–60 of loop 1 and residues 127–130 of loop 4 in LnbB) and three helices (resi-
dues 82–99, 146–163 and the extra α-helix of the GH20 domain which is oriented toward an
hydrophobic pocket). GH20b domain is not only found in GH20 enzymes but also in some
GH84 hexosaminidases and GH67 glucoronidases annotated in Pfam as GH20b and GH67N
Fig 3. Truncated forms of B.bifidum Lacto-N-biosidase.
doi:10.1371/journal.pone.0128075.g003
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[35], respectively, always located at the N-terminus of the catalytic domain. Considering this
scenario, we conclude that GH20b-GH20-α architecture of model A enzymes cannot be re-
duced to that of model B.
The hydrolytic activity of the soluble constructs was assayed using p-nitrophenyl β-lacto-N-
bioside as substrate at pH 4.5 and 30°C. Full length protein showed a specific activity of
27.2 ± 3.5 s-1, but construct A was inactive, as expected according to previous studies [23]. The
GH20b-GH20-α architecture of LnbB is enough to guarantee protein expression, but this ar-
chitecture does not correspond to the minimal functional unit maybe requiring other accom-
panying domains from the C-terminus for the enzyme to be active.
3. Structural requirements in the GH20 domain for functionality
While this minimal GH20b-GH20-α architecture assures the activity of SpHex and Hex1T
[25,36] and also of dimeric proteins such as HexA, HexB and OfHex1 [30,37,38], it is not
enough for LnbB. The crystal structure of LnbB (residues 41–663) in complex with the cyclic
intermediate analogue lacto-N-biose-thiazoline [23] consisting of three out of the five domains
(GH20b, GH20 and part of the lectin-like domain) was active. The accompanying lectin do-
main resulted to be the missing element required in our construct A to be fully active. We have
carefully analyzed the interaction of the catalytic GH20 domain with other C-terminus do-
mains in all crystallized protein structures of model A (Fig 5). Exploring the structure, impor-
tant structural features can be assigned. The lectin domain interacts with the catalytic GH20
domain, providing a remote element that folds on the active site (Fig 5A). This element (resi-
dues 570–578) consists of a beta-turn, in which Leu574 completes the substrate binding cavity
favouring a hydrophobic interaction with the hydroxymethyl group of the galactose moiety of
the substrate. In addition, Leu574 is positioned between two conserved amino acids Gln190
and Asp467 of subsites -1 and -2 forming further interactions between this turn and the active
site (Fig 5A). For instance, through a water mediated hydrogen bond, the backbone nitrogen
atom of Leu574 favours the orientation of Gln190 towards the O4 of the galactose unit of the
Fig 4. Size exclusion chromatography of the full length protein and different constructs of Lacto-N-biosidase from B.bifidum. (A) Chromatogram of
the full length protein (FL) and constructs A, D and F. (B) SDS-PAGE of the eluted proteins. M: broad range protein molecular weight marker (200, 116.2,
97.4, 66.2, 45, 31 kDa).
doi:10.1371/journal.pone.0128075.g004
Domain Organization in Family GH20 Hexosaminidases
PLOS ONE | DOI:10.1371/journal.pone.0128075 May 29, 2015 9 / 17
disaccharide ligand. Engineered forms of LnbB in which part of the C-terminus of the lectin
domain were even shorter [23] or completely removed as in our construct A, showed an impor-
tant decrease in activity of the enzyme, indicating that the interactions we observe in the struc-
ture between the remote lectin domain and the substrate binding site are essential for catalysis.
Fig 5. Remote elements and their key residues that complement the active site of GH20 β-N-
acetylhexosaminidases. (A) B. bifidum lacto-N-biosidase. (B) S. plicatus. (C) S. gordonii N-
acetylhexosaminidases. Dot lines represent interactions between residues of the remote element and the
active site as indicated in Table 2.
doi:10.1371/journal.pone.0128075.g005
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Interestingly, we have detected that this pattern is reproduced in all proteins of model A:
there is always a remote element assisting in the definition of the substrate binding cavity by
means of direct interactions with conserved amino acids directly involved in protein—sub-
strate interactions. Table 2 summarizes the exact localization of these remote elements for each
member of model A and the interactions it forms with conserved active site residues. In gener-
al, this remote element is provided by a long loop of the GH20 domain itself (loop 2). In the
cases where this loop is too short, the remote element comes from an accompanying domain
(such as the lectin domain in the case of LnbB) or from the C-terminus of the other monomer
in the case of dimeric proteins. In detail, structures of SpHex, ScHex, NahA, Bf3009, SmCHB
and Hex1T present this remote element coming from the extended loop 2 of the GH20 domain
itself (Fig 5B). This loop positions a hydrophobic residue, such as Val214 in SpHex (equivalent
to Leu574 in LnbB), into the second shell of the subsite -1 cavity just behind the conserved argi-
nine and aspartate in all known GH20 hexosaminidases, Arg 162 and Asp444 (equivalent to
Gln190 and Asp467 in LnbB, see alignment in Fig 6). These amino acid residues can form hy-
drophobic interactions between their side chains and also, a hydrogen bond between the
Table 2. Remote element and conserved interactions with the active site of model A GH20 β-N-acteylhexosaminidases.
Enzyme Loop 2 length Remote element GH20 conserved Arg/Asp or Glu at
subsite −1
Remote element interactions with
conserved Arg/Asp
non-polar
interactions
polar
interactions
SpHex Long G209-T223 Loop 2 R162 V214 V214
E444 V214 -
ScHex Long G238-T252 Loop 2 R191 V243 V243
E473 V243 -
NahA Long G193-T219 Loop 2 R146 - R196
E456 - -
Bf3009 Long G200-S214 Loop 2 R153 - Q209
D450 -
Hex1T Long G217-T231 Loop 2 R170 V222 V222
E443 V222 -
SmCHB Long G396-S425 Loop 2 R349 Y413 R399
E739 Y413 -
LnbB Short T231-T236 Lectin G570-T578 Q190* L574 S233
D467 L574 -
HexA Short αG225-
αT235
C-terminus subunit β
A543-N552
αR178 βA548 βG549
αE462 βY547 -
HexA Short βG258-
βT267
C-terminus subunit α
A514-E523
βR211 αV519 αG520
βE491 αV519 -
HexB Short G258-T267 C-terminus dimer A514-E523 R211 A548 G549
E491 Y547 -
OfHex1 Short G267-T276 C-terminus dimer A577-S594 R220 P582 E583
E526 P582 -
GcnA Short G136-T143 C-terminus dimer S622-T627 R95 - T627
D376 T627 -
*Residue in LnbB substituting the function of the conserved arginine but in subsite -2.
doi:10.1371/journal.pone.0128075.t002
Domain Organization in Family GH20 Hexosaminidases
PLOS ONE | DOI:10.1371/journal.pone.0128075 May 29, 2015 11 / 17
backbone NH group of Val214 and the carbonyl group of the backbone of Arg162 (Fig 5B).
These interactions between residues of the remote element and the conserved arginine and as-
partate of subsite -1, are present in all the structures with long loop 2 (Table 2). ScHex presents
Val243 of loop2 next to Arg191 and Asp473 in the same way. NahA and SmCHB show the lon-
gest loops 2 as seen in the alignment. They provide the remote elements next to the corre-
sponding arginines, Arg146 and Arg349, and aspartates, Asp456 and Asp739 respectively. One
arginine of the remote element, Arg196 in NahA and Arg399 in SmCHB, is hydrogen-bonded
to the backbone of the active site arginine. Similarly, Bf3009 presents Gln209 of loop2 next to
Arg153 and Asp450. In Hex1T, Val222 from the remote element is positioned behind Arg170
and Asp443 and the backbone NH group of this valine donates a hydrogen bond to the argi-
nine carbonyl oxygen atom. Interestingly, a truncated form of Hex1T with only the GH20b
and GH20 domains has been reported to be active [25]. Consistently with our explanations,
Fig 6. Multiple sequence alignment of β-N-acetylhexosaminidases of known structure from family GH20.Domains distribution is shown as colored
boxes on top. Accompanying domains are not shown. Conserved arginine and glutamate/aspartate sites are marked with a star. Sequences were
downloaded from UniProt entry names: SpHex (O85361_STRPL), ScHex (Q9L068), Bf3009 (Q5LAT3) NahA (A1RBZ5_ARTAT), Hex1T
(D2KW09_9BACL), SmCHB (CHB_SERMA), LnbB (B3TLD6_BIFBI), HexA (HEXA_HUMAN), HexB (HEXB_HUMAN), OfHex1 (Q06GJ0_OSTFU), GcnA
(Q6ST21_STRGN), DspB (Q840G9_AGGAC), StrH_R6 (Q8DRL6_STRR6), StrH_TIGR4 (STRH_STRPN). Alignment was performed with PROMALS [17].
Conserved positions are coloured according to ClustalW colour scheme.
doi:10.1371/journal.pone.0128075.g006
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this truncated form does not affect the definition of the active site, because this construct keeps
the long loop 2 in the GH20 domain.
By contrast, when loop 2 is short, this remote element comes from the accompanying do-
mains, as in LnbB, or from the C-terminus domains of the other monomer in dimeric struc-
tures, such as, GcnA, HexA, HexB and OfHex1. For example, in the homodimeric structure of
GcnA, domain III forms a significant part of the dimer interface [31]. The C-terminus of do-
main III of chain B (622–627) winds back into the structure and contacts the catalytic GH20 of
chain A (Fig 5C). Specifically, the C-terminus amino acid residue Thr627 projects into subsite
-1 and it is adjacent to the conserved arginine and aspartate (Arg95, Asp376) and is part of the
active-site pocket of the dimer partner. Besides, the carboxyl group of this C-terminal Thr627
and the Arg95 side chain are at less than 3 Å distance, establishing electrostatic interactions. As
in LnbB, any truncated form of this C-terminus domain III is believed to be inactive. In the di-
meric structures of HexA, HexB and OfHex1 [28–30], dimerization occurs exclusively between
the GH20 catalytic domains. Dimerization is essential for catalysis since residues of one subunit
structurally complete the active site of the other one. For example, Tyr456 of subunit β is part
of the active site of subunit α in HexA. In addition, the C-terminus of subunit β provides this
remote element very close to the subsite-binding cavity of subunit α and vice versa (Table 2).
Particularly, the hydrophobic residue Ala548 (subunit β) of this element in HexA forms part of
the second shell of the cavity behind the conserved Arg178 (subunit α) and Asp462 (subunit
α), and the backbone nitrogen atom of Gly549 (subunit β) interacts by hydrogen bond with the
carbonyl oxygen atom of Arg178 (subunit α). The equivalent interactions between subunits are
also seen in HexB and OfHex1 crystal structures (Table 2).
Therefore, all GH20 structures of model A clearly show the presence of a remote element
folding on the substrate-binding cavity providing amino acid residues that either complete the
active site, as in the extended subsite -1 of the S. gordonii hexosaminidase or in subsite -2 of the
LnbB, or participate in the second shell of this cavity behind the conserved arginine and aspar-
tate residues in subsite -1 of hexosaminidases.
To provide experimental evidence of the requirement of this remote element in LnbB, a
complementation assay was designed. If Construct A (composed of the GH20b and GH20-α
domains) is inactive because of the lack of the remote element, would addition of the lectin do-
main (as a single protein) reconstitute the active site and restore activity? Toward this end,
Construct F (the single lectin domain, Fig 3) to assay complementation with Construct A, as
well as Construct D (Fig 3), which contains the non-catalytic GH20b domain, the catalytic
GH20 domain and the lectin domain, were expressed. The C-terminal His6-Tagged proteins
were purified and analyzed by SDS-PAGE and MALDI-TOF, confirming the corresponding
theoretical molecular masses of 83 and 28 kDa for constructs D and F, respectively. Gel filtra-
tion chromatography showed that both proteins were monomers in solution (Fig 4). Construct
D was active with the same specific activity than the full length enzyme on p-nitrophenyl β-lac-
tobioside (27 s-1). Therefore, both C-terminal domains in LnbB, the CBM32 and Ig like do-
mains are not important for the catalytic activity, and construct D is the minimal functional
unit of LnbB. Next, a complementation experiment was assayed by adding Construct F (the
single lectin domain) on the inactive Construct A. Activity was restored in a concentration-de-
pendent manner when increasing the concentrations of Construct F (Fig 7). At a molar ratio of
1:6 activity levels off at 11% of the hydrolytic activity of the full length enzyme. The interaction
between constructs A and F at a 1:6 molar ratio was analyzed by gel filtration chromatography
(Fig 8). Fractions L1–L2 correspond to the excess of Construct F, the lectin domain with molec-
ular weight of 28 kDa, and fractions C1–C6 to proteins with molecular weight of 74 kDa that
could be the dimer of construct A (as in Fig 4) and the complex between A and F with theoreti-
cal molecular mass of 85 kDa. The hydrolase activity of Fractions C1–C6 and the presence of
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Fig 7. Complementation assay of construct A with construct F at different molar ratios.Conditions: 50 nM construct A, 25 nM-500 nM construct F, 0.25
mM p-nitrophenyl β-lacto-N-bioside, 25 mM citrate-25 mM phosphate buffer, pH 4.5, 30°C. The relative standard deviation did not overcome 2% except at 6
and 10 molar ratio that was lower than 15%.
doi:10.1371/journal.pone.0128075.g007
Fig 8. Size exclusion chromatography of the complementation assay in a ratio 1:6 of constructs A and F. (A) Chromatogram of the eluted fractions:
absorbance at 280nm (-), hydrolase activity (•••). (B) SDS-PAGE of different fractions. M: broad range protein molecular weight marker (200, 116.2, 97.4,
66.2, 45, 31 kDa); A: construct A Standard, fractions C1–C6, fractions L1–L2. The relative standard deviations for the molecular weights and activities were
less than 2% and 15% respectively.
doi:10.1371/journal.pone.0128075.g008
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lectin in these fractions seen in SDS-PAGE (Fig 8) demonstrate that the complex between A
and F is formed and active. As it is observed in Fig 8, not all construct A protein is complexed
with construct F. By densitometry analysis we determined that the lectin represents 10% of
total protein in the mixture. Assuming a 1:1 interaction, 10% of Construct A is in complex with
Construct F and therefore the specific activity of the complex is similar to that of the full length
protein. To exclude non-specific interactions, complementation assay was performed with
Construct A and BSA at different concentration ratios and no activity recovery was found
(data not shown).
Conclusions
This structural-functional analysis allows us to come to different conclusions. First, we identi-
fied two levels of domain organization in GH20 enzymes: model A with GH20b-GH20-α ar-
chitecture and model B with the single catalytic GH20 domain alone. As LnbB constructs
show, model A enzymes cannot be reduced to model B, since GH20b domain is a structural re-
quirement in the N-terminus of GH20 to assure protein stability. Secondly, GH20b-GH20-α
architecture is not always the minimal functional unit. For the LnbB enzyme here studied, the
isolated GH20b-GH20-α domain is inactive and requires the lectin domain which provides an
essential loop to shape the active site. Based on these results and analysis of the structures of
GH20 enzymes, we propose a broader mechanism by which important interactions in the sub-
strate binding cavity of the catalytic GH20 domain are provided by a remote element in all
structures, which must be preserved to ensure a proper definition of the active site. The remote
element can directly be provided by a long loop 2 of the GH20 domain itself. In this case,
GH20b-GH20-α can act as a minimal functional unit, and large multidomain enzymes can be
engineered to reduced forms with a minimal model A architecture. In other circumstances,
when loop 2 is short, proteins dimerize or present an accompanying domain in the C-terminus
of GH20 that provide this remote element. In the latter cases, protein engineering of these en-
zymes must be designed maintaining the accompanying domains. The proposed model can
stimulate further studies on other members of the superfamily.
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